Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,2748541,clearance,Theophylline clearance was reduced from 126 to 98 ml/hr/kg (22.2%) whereas the steady state volume of distribution of the drug increased from 461 to 550 ml/kg (19.3%).,Inhibition of theophylline elimination in rabbits by verapamil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2748541/),[ml] / [h·kg],126 to 98,719,DB00661,Verapamil
,2748541,steady state volume of distribution,Theophylline clearance was reduced from 126 to 98 ml/hr/kg (22.2%) whereas the steady state volume of distribution of the drug increased from 461 to 550 ml/kg (19.3%).,Inhibition of theophylline elimination in rabbits by verapamil. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2748541/),[ml] / [kg],461 to 550,720,DB00661,Verapamil
,2748541,terminal half-life,The terminal half-life of theophylline increased from 2.7 to 4.0 hr (49.8%).,Inhibition of theophylline elimination in rabbits by verapamil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2748541/),h,2.7,721,DB00661,Verapamil
,2748541,terminal half-life,The terminal half-life of theophylline increased from 2.7 to 4.0 hr (49.8%).,Inhibition of theophylline elimination in rabbits by verapamil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2748541/),h,4.0,722,DB00661,Verapamil
,1417461,relative bioavailability,A mean relative bioavailability of 127% for the test preparation was found.,Bioavailability study of two different verapamil formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1417461/),%,127,1622,DB00661,Verapamil
,29976060,bioavailability,Pharmacokinetic studies in rats showed an increase in the bioavailability of peptide 12 > 70-fold (from 0.58 ± 0.11% to 43.8 ± 14.9%) after applying the LPCM method to peptide 12 and converting it to the prodrug 12P.,Enhancing Oral Bioavailability of Cyclic RGD Hexa-peptides by the Lipophilic Prodrug Charge Masking Approach: Redirection of Peptide Intestinal Permeability from a Paracellular to Transcellular Pathway. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29976060/),%,0.58,1759,DB00661,Verapamil
,29976060,bioavailability,Pharmacokinetic studies in rats showed an increase in the bioavailability of peptide 12 > 70-fold (from 0.58 ± 0.11% to 43.8 ± 14.9%) after applying the LPCM method to peptide 12 and converting it to the prodrug 12P.,Enhancing Oral Bioavailability of Cyclic RGD Hexa-peptides by the Lipophilic Prodrug Charge Masking Approach: Redirection of Peptide Intestinal Permeability from a Paracellular to Transcellular Pathway. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29976060/),%,43.8,1760,DB00661,Verapamil
,25650380,"V(max,met1)","After correction for the adsorption of 10%-25% dose verapamil and norverapamil onto Tygon tubing and binding to albumin and red blood cell, fitting of verapamil and formed and preformed norverapamil data with ADAPT5 revealed nonlinearity for protein binding, N-demethylation (V(max,met1)(VER --> NOR) = 96.6 ± 33.4 nmol/min; K(m,met1)(VER --> NOR) = 10.4 ± 4.1 μM), formation of other metabolites (V(max,met2(VER -->others) 288 ± 51 nmol/min; K(m.met2)(VER -->others )= 14.1 ± 4.9 μM), as well as biliary excretion (V(max,sec)(VER)= 0.911 ± 0.505 nmol/min; K(m,sec)(VER) = 4.75 ± 2.29 μM).",PBPK modeling to unravel nonlinear pharmacokinetics of verapamil to estimate the fractional clearance for verapamil N-demethylation in the recirculating rat liver preparation. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25650380/),[nM] / [min],96.6,2033,DB00661,Verapamil
,25650380,"K(m,met1)","After correction for the adsorption of 10%-25% dose verapamil and norverapamil onto Tygon tubing and binding to albumin and red blood cell, fitting of verapamil and formed and preformed norverapamil data with ADAPT5 revealed nonlinearity for protein binding, N-demethylation (V(max,met1)(VER --> NOR) = 96.6 ± 33.4 nmol/min; K(m,met1)(VER --> NOR) = 10.4 ± 4.1 μM), formation of other metabolites (V(max,met2(VER -->others) 288 ± 51 nmol/min; K(m.met2)(VER -->others )= 14.1 ± 4.9 μM), as well as biliary excretion (V(max,sec)(VER)= 0.911 ± 0.505 nmol/min; K(m,sec)(VER) = 4.75 ± 2.29 μM).",PBPK modeling to unravel nonlinear pharmacokinetics of verapamil to estimate the fractional clearance for verapamil N-demethylation in the recirculating rat liver preparation. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25650380/),μM,10.4,2034,DB00661,Verapamil
,25650380,"V(max,met2","After correction for the adsorption of 10%-25% dose verapamil and norverapamil onto Tygon tubing and binding to albumin and red blood cell, fitting of verapamil and formed and preformed norverapamil data with ADAPT5 revealed nonlinearity for protein binding, N-demethylation (V(max,met1)(VER --> NOR) = 96.6 ± 33.4 nmol/min; K(m,met1)(VER --> NOR) = 10.4 ± 4.1 μM), formation of other metabolites (V(max,met2(VER -->others) 288 ± 51 nmol/min; K(m.met2)(VER -->others )= 14.1 ± 4.9 μM), as well as biliary excretion (V(max,sec)(VER)= 0.911 ± 0.505 nmol/min; K(m,sec)(VER) = 4.75 ± 2.29 μM).",PBPK modeling to unravel nonlinear pharmacokinetics of verapamil to estimate the fractional clearance for verapamil N-demethylation in the recirculating rat liver preparation. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25650380/),[nM] / [min],288,2035,DB00661,Verapamil
,25650380,K(m.met2),"After correction for the adsorption of 10%-25% dose verapamil and norverapamil onto Tygon tubing and binding to albumin and red blood cell, fitting of verapamil and formed and preformed norverapamil data with ADAPT5 revealed nonlinearity for protein binding, N-demethylation (V(max,met1)(VER --> NOR) = 96.6 ± 33.4 nmol/min; K(m,met1)(VER --> NOR) = 10.4 ± 4.1 μM), formation of other metabolites (V(max,met2(VER -->others) 288 ± 51 nmol/min; K(m.met2)(VER -->others )= 14.1 ± 4.9 μM), as well as biliary excretion (V(max,sec)(VER)= 0.911 ± 0.505 nmol/min; K(m,sec)(VER) = 4.75 ± 2.29 μM).",PBPK modeling to unravel nonlinear pharmacokinetics of verapamil to estimate the fractional clearance for verapamil N-demethylation in the recirculating rat liver preparation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25650380/),μM,14.1,2036,DB00661,Verapamil
,25650380,"V(max,sec)","After correction for the adsorption of 10%-25% dose verapamil and norverapamil onto Tygon tubing and binding to albumin and red blood cell, fitting of verapamil and formed and preformed norverapamil data with ADAPT5 revealed nonlinearity for protein binding, N-demethylation (V(max,met1)(VER --> NOR) = 96.6 ± 33.4 nmol/min; K(m,met1)(VER --> NOR) = 10.4 ± 4.1 μM), formation of other metabolites (V(max,met2(VER -->others) 288 ± 51 nmol/min; K(m.met2)(VER -->others )= 14.1 ± 4.9 μM), as well as biliary excretion (V(max,sec)(VER)= 0.911 ± 0.505 nmol/min; K(m,sec)(VER) = 4.75 ± 2.29 μM).",PBPK modeling to unravel nonlinear pharmacokinetics of verapamil to estimate the fractional clearance for verapamil N-demethylation in the recirculating rat liver preparation. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25650380/),[nM] / [min],0.911,2037,DB00661,Verapamil
,25650380,"K(m,sec)","After correction for the adsorption of 10%-25% dose verapamil and norverapamil onto Tygon tubing and binding to albumin and red blood cell, fitting of verapamil and formed and preformed norverapamil data with ADAPT5 revealed nonlinearity for protein binding, N-demethylation (V(max,met1)(VER --> NOR) = 96.6 ± 33.4 nmol/min; K(m,met1)(VER --> NOR) = 10.4 ± 4.1 μM), formation of other metabolites (V(max,met2(VER -->others) 288 ± 51 nmol/min; K(m.met2)(VER -->others )= 14.1 ± 4.9 μM), as well as biliary excretion (V(max,sec)(VER)= 0.911 ± 0.505 nmol/min; K(m,sec)(VER) = 4.75 ± 2.29 μM).",PBPK modeling to unravel nonlinear pharmacokinetics of verapamil to estimate the fractional clearance for verapamil N-demethylation in the recirculating rat liver preparation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25650380/),μM,4.75,2038,DB00661,Verapamil
,25650380,hepatic clearance of verapamil (CL(L)(VER),"The hepatic clearance of verapamil (CL(L)(VER) decreased with the dose (8.16-10.2 ml/min), with values remaining high relative to perfusate blood flow rate among the doses.",PBPK modeling to unravel nonlinear pharmacokinetics of verapamil to estimate the fractional clearance for verapamil N-demethylation in the recirculating rat liver preparation. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25650380/),[ml] / [min],8.16-10.2,2039,DB00661,Verapamil
,25650380,hepatic clearance,"The hepatic clearance of preformed norverapamil (11 ml/min) remained unchanged for the concentrations studied and approximated perfusate blood flow rate, suggesting a high norverapamil extraction ratio.",PBPK modeling to unravel nonlinear pharmacokinetics of verapamil to estimate the fractional clearance for verapamil N-demethylation in the recirculating rat liver preparation. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25650380/),[ml] / [min],11,2040,DB00661,Verapamil
,7648767,oral clearance,"Marked enantiospecific disposition of verapamil occurred, with oral clearance values of 40.8, 25.3, and 121 ml/min/kg for the total verapamil, R-verapamil, and S-verapamil, respectively.","Verapamil stereoisomerism: enantiomeric ratios in plasma dependent on peak concentrations, oral input rate, or both. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648767/),[ml] / [kg·min],40.8,2385,DB00661,Verapamil
,7648767,oral clearance,"Marked enantiospecific disposition of verapamil occurred, with oral clearance values of 40.8, 25.3, and 121 ml/min/kg for the total verapamil, R-verapamil, and S-verapamil, respectively.","Verapamil stereoisomerism: enantiomeric ratios in plasma dependent on peak concentrations, oral input rate, or both. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648767/),[ml] / [kg·min],25.3,2386,DB00661,Verapamil
,7648767,oral clearance,"Marked enantiospecific disposition of verapamil occurred, with oral clearance values of 40.8, 25.3, and 121 ml/min/kg for the total verapamil, R-verapamil, and S-verapamil, respectively.","Verapamil stereoisomerism: enantiomeric ratios in plasma dependent on peak concentrations, oral input rate, or both. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648767/),[ml] / [kg·min],121,2387,DB00661,Verapamil
,7648767,peak concentration [Cmax],"Wide input-rate differences also occurred between the immediate- and sustained-release formulations (mean [% coefficient of variation]; peak concentration [Cmax] [total], 327 [44%] versus 73 [58%] ng/ml; time to reach Cmax [total], 1.71 [36%] versus 10.8 [62%] hours).","Verapamil stereoisomerism: enantiomeric ratios in plasma dependent on peak concentrations, oral input rate, or both. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648767/),[ng] / [ml],327,2388,DB00661,Verapamil
,7648767,peak concentration [Cmax],"Wide input-rate differences also occurred between the immediate- and sustained-release formulations (mean [% coefficient of variation]; peak concentration [Cmax] [total], 327 [44%] versus 73 [58%] ng/ml; time to reach Cmax [total], 1.71 [36%] versus 10.8 [62%] hours).","Verapamil stereoisomerism: enantiomeric ratios in plasma dependent on peak concentrations, oral input rate, or both. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648767/),[ng] / [ml],73,2389,DB00661,Verapamil
,7648767,time to reach Cmax,"Wide input-rate differences also occurred between the immediate- and sustained-release formulations (mean [% coefficient of variation]; peak concentration [Cmax] [total], 327 [44%] versus 73 [58%] ng/ml; time to reach Cmax [total], 1.71 [36%] versus 10.8 [62%] hours).","Verapamil stereoisomerism: enantiomeric ratios in plasma dependent on peak concentrations, oral input rate, or both. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648767/),h,1.71,2390,DB00661,Verapamil
,7648767,time to reach Cmax,"Wide input-rate differences also occurred between the immediate- and sustained-release formulations (mean [% coefficient of variation]; peak concentration [Cmax] [total], 327 [44%] versus 73 [58%] ng/ml; time to reach Cmax [total], 1.71 [36%] versus 10.8 [62%] hours).","Verapamil stereoisomerism: enantiomeric ratios in plasma dependent on peak concentrations, oral input rate, or both. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648767/),h,10.8,2391,DB00661,Verapamil
,7648767,bioavailability,The mean extent of total verapamil bioavailability from the sustained-release formulation was 73.3% of the immediate-release formulation.,"Verapamil stereoisomerism: enantiomeric ratios in plasma dependent on peak concentrations, oral input rate, or both. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648767/),%,73.3,2392,DB00661,Verapamil
excess,1587055,t 1/2 beta,Amlodipine is an exception with a t 1/2 beta in excess of 30h.,Clinical pharmacokinetics of calcium antagonists. An update. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587055/),h,30,2483,DB00661,Verapamil
,6540109,absolute bioavailability,The absolute bioavailability of the buccal preparation (37%) was slightly greater than the oral capsule (33%) and both had higher bioavailability than observed in earlier studies on verapamil dragees (10-20%).,"Verapamil disposition and effect on PQ-intervals after buccal, oral and intravenous administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6540109/),%,37,2678,DB00661,Verapamil
,6540109,absolute bioavailability,The absolute bioavailability of the buccal preparation (37%) was slightly greater than the oral capsule (33%) and both had higher bioavailability than observed in earlier studies on verapamil dragees (10-20%).,"Verapamil disposition and effect on PQ-intervals after buccal, oral and intravenous administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6540109/),%,33,2679,DB00661,Verapamil
,6540109,bioavailability,The absolute bioavailability of the buccal preparation (37%) was slightly greater than the oral capsule (33%) and both had higher bioavailability than observed in earlier studies on verapamil dragees (10-20%).,"Verapamil disposition and effect on PQ-intervals after buccal, oral and intravenous administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6540109/),%,10-20,2680,DB00661,Verapamil
less,6540109,bioavailability,"Thus, although the buccal tablet was alkalinised and had a rapid disintegration in vitro, characteristics thought to increase buccal uptake, the bioavailability is still much less then 100%.","Verapamil disposition and effect on PQ-intervals after buccal, oral and intravenous administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6540109/),%,100,2681,DB00661,Verapamil
,3370742,peak plasma concentrations,"Verapamil, given according to this treatment schedule, reached peak plasma concentrations of 3 microM.",Effect of verapamil on doxorubicin activity and pharmacokinetics in mice bearing resistant and sensitive solid tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370742/),μM,3,3127,DB00661,Verapamil
,3370742,AUC,The resistance of the B16VDXR line was associated with the ability of the tumor to retain less doxorubicin (AUC = 83 micrograms h/g) than the sensitive tumor B16 (AUC = 204 micrograms h/g) in spite of similar initial levels.,Effect of verapamil on doxorubicin activity and pharmacokinetics in mice bearing resistant and sensitive solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370742/),[h·μg] / [g],83,3128,DB00661,Verapamil
,3370742,AUC,The resistance of the B16VDXR line was associated with the ability of the tumor to retain less doxorubicin (AUC = 83 micrograms h/g) than the sensitive tumor B16 (AUC = 204 micrograms h/g) in spite of similar initial levels.,Effect of verapamil on doxorubicin activity and pharmacokinetics in mice bearing resistant and sensitive solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370742/),[h·μg] / [g],204,3129,DB00661,Verapamil
,16640453,absolute bioavailability,The absolute bioavailability ranges from 35% to 50%.,Clinical pharmacokinetics of ranolazine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),%,35,3347,DB00661,Verapamil
,16640453,absolute bioavailability,The absolute bioavailability ranges from 35% to 50%.,Clinical pharmacokinetics of ranolazine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),%,50,3348,DB00661,Verapamil
,16640453,protein binding,Ranolazine protein binding is about 61-64% over the therapeutic concentration range.,Clinical pharmacokinetics of ranolazine. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),%,61-64,3349,DB00661,Verapamil
,16640453,Volume of distribution at steady state,Volume of distribution at steady state ranges from 85 to 180 L.,Clinical pharmacokinetics of ranolazine. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),l,85 to 180,3350,DB00661,Verapamil
,16640453,Elimination half-life,"Elimination half-life of ranolazine is 1.4-1.9 hours but is apparently prolonged, on average, to 7 hours for the ER formulation as a result of extended absorption (flip-flop kinetics).",Clinical pharmacokinetics of ranolazine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),h,1.4-1.9,3351,DB00661,Verapamil
,16640453,Elimination half-life,"Elimination half-life of ranolazine is 1.4-1.9 hours but is apparently prolonged, on average, to 7 hours for the ER formulation as a result of extended absorption (flip-flop kinetics).",Clinical pharmacokinetics of ranolazine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),h,7,3352,DB00661,Verapamil
,16640453,Oral plasma clearance,"Oral plasma clearance diminishes with dose from, on average, 45 L/h at 500 mg twice daily to 33 L/h at 1000 mg twice daily.",Clinical pharmacokinetics of ranolazine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),[l] / [h],45,3353,DB00661,Verapamil
,16640453,Oral plasma clearance,"Oral plasma clearance diminishes with dose from, on average, 45 L/h at 500 mg twice daily to 33 L/h at 1000 mg twice daily.",Clinical pharmacokinetics of ranolazine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640453/),[l] / [h],33,3354,DB00661,Verapamil
,19135530,area under the plasma concentration-time curve (AUC),"After oral irinotecan dosing, the mean area under the plasma concentration-time curve (AUC) was found to be 14.03+/-2.18 microgh/ml which was increased significantly, i.e. 61.71+/-15.0 microgh/ml when verapamil was co-administered (P<0.05).","Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19135530/),[μgh] / [ml],14.03,4808,DB00661,Verapamil
,19135530,area under the plasma concentration-time curve (AUC),"After oral irinotecan dosing, the mean area under the plasma concentration-time curve (AUC) was found to be 14.03+/-2.18 microgh/ml which was increased significantly, i.e. 61.71+/-15.0 microgh/ml when verapamil was co-administered (P<0.05).","Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19135530/),[μgh] / [ml],61.71,4809,DB00661,Verapamil
,19135530,maximum plasma concentration,"Similarly, the mean maximum plasma concentration of irinotecan increased from 2.93+/-0.37 microg/ml (without verapamil) to 10.75+/-1.0 microg/ml (with verapamil) (P<0.05).","Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19135530/),[μg] / [ml],2.93,4810,DB00661,Verapamil
,19135530,maximum plasma concentration,"Similarly, the mean maximum plasma concentration of irinotecan increased from 2.93+/-0.37 microg/ml (without verapamil) to 10.75+/-1.0 microg/ml (with verapamil) (P<0.05).","Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19135530/),[μg] / [ml],10.75,4811,DB00661,Verapamil
,19135530,AUC,"On the other hand, the intravenous irinotecan administration with verapamil resulted in small but statistically significant effect on AUC (10.76+/-2.0 to 23.3+/-3.8 microgh/ml; P<0.05) and systemic clearance (1206.4+/-159.7 to 713.5+/-78.2 ml/(hkg)).","Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19135530/),[μgh] / [ml],10.76,4812,DB00661,Verapamil
,19135530,AUC,"On the other hand, the intravenous irinotecan administration with verapamil resulted in small but statistically significant effect on AUC (10.76+/-2.0 to 23.3+/-3.8 microgh/ml; P<0.05) and systemic clearance (1206.4+/-159.7 to 713.5+/-78.2 ml/(hkg)).","Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19135530/),[μgh] / [ml],23.3,4813,DB00661,Verapamil
,19135530,systemic clearance,"On the other hand, the intravenous irinotecan administration with verapamil resulted in small but statistically significant effect on AUC (10.76+/-2.0 to 23.3+/-3.8 microgh/ml; P<0.05) and systemic clearance (1206.4+/-159.7 to 713.5+/-78.2 ml/(hkg)).","Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19135530/),[ml] / [hkg],1206.4,4814,DB00661,Verapamil
,19135530,systemic clearance,"On the other hand, the intravenous irinotecan administration with verapamil resulted in small but statistically significant effect on AUC (10.76+/-2.0 to 23.3+/-3.8 microgh/ml; P<0.05) and systemic clearance (1206.4+/-159.7 to 713.5+/-78.2 ml/(hkg)).","Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19135530/),[ml] / [hkg],713.5,4815,DB00661,Verapamil
,19135530,percent,"The mean percent of irinotecan excreted into bile over 5h following intravenous and oral administration was found to be 8% and 1%, respectively, which was further reduced to half when treated with verapamil.","Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19135530/),%,8,4816,DB00661,Verapamil
,19135530,percent,"The mean percent of irinotecan excreted into bile over 5h following intravenous and oral administration was found to be 8% and 1%, respectively, which was further reduced to half when treated with verapamil.","Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19135530/),%,1,4817,DB00661,Verapamil
,16949884,Area under the % effect-time curve,"Area under the % effect-time curve (% min) was 714+/-214 in Healthy/Placebo, 256+/-249 in Arthritis/Placebo, 1534+/-367 in Healthy/Statin, and 1713+/-393 in Arthritis/Statin.","Pravastatin reverses the down-regulating effect of inflammation on beta-adrenergic receptors: a disease-drug interaction between inflammation, pravastatin, and propranolol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16949884/),%·min,714,8258,DB00661,Verapamil
,16949884,Area under the % effect-time curve,"Area under the % effect-time curve (% min) was 714+/-214 in Healthy/Placebo, 256+/-249 in Arthritis/Placebo, 1534+/-367 in Healthy/Statin, and 1713+/-393 in Arthritis/Statin.","Pravastatin reverses the down-regulating effect of inflammation on beta-adrenergic receptors: a disease-drug interaction between inflammation, pravastatin, and propranolol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16949884/),%·min,256,8259,DB00661,Verapamil
,16949884,Area under the % effect-time curve,"Area under the % effect-time curve (% min) was 714+/-214 in Healthy/Placebo, 256+/-249 in Arthritis/Placebo, 1534+/-367 in Healthy/Statin, and 1713+/-393 in Arthritis/Statin.","Pravastatin reverses the down-regulating effect of inflammation on beta-adrenergic receptors: a disease-drug interaction between inflammation, pravastatin, and propranolol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16949884/),%·min,1534,8260,DB00661,Verapamil
,16949884,Area under the % effect-time curve,"Area under the % effect-time curve (% min) was 714+/-214 in Healthy/Placebo, 256+/-249 in Arthritis/Placebo, 1534+/-367 in Healthy/Statin, and 1713+/-393 in Arthritis/Statin.","Pravastatin reverses the down-regulating effect of inflammation on beta-adrenergic receptors: a disease-drug interaction between inflammation, pravastatin, and propranolol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16949884/),%·min,1713,8261,DB00661,Verapamil
,9126675,vascular/cardiac effect ratios,"The mean vascular/cardiac effect ratios of the first-generation CCBs-verapamil, nifedipine, and diltiazem-are relatively low and amount to approximately 3, 10, and 3, respectively.",Pharmacological aspects of calcium channel blockers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9126675/),,3,9816,DB00661,Verapamil
,9126675,vascular/cardiac effect ratios,"The mean vascular/cardiac effect ratios of the first-generation CCBs-verapamil, nifedipine, and diltiazem-are relatively low and amount to approximately 3, 10, and 3, respectively.",Pharmacological aspects of calcium channel blockers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9126675/),,10,9817,DB00661,Verapamil
,9126675,elimination half-lives,"The onset of action of verapamil, nifedipine, and diltiazem, at least in immediate-release formulations, is relatively fast (0.5-2 hours), and their elimination half-lives range from 2 to 7 hours.",Pharmacological aspects of calcium channel blockers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9126675/),h,2 to 7,9818,DB00661,Verapamil
,3802708,oral clearance,"Pretreatment with verapamil, 80 mg and 120 mg (every 8 hours for 3 days), reduced the oral clearance of quinidine from 17.0 L/hr to 11.6 and 11.3 L/hr, respectively (P less than 0.01).",The effect of coadministration of verapamil on the pharmacokinetics and metabolism of quinidine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802708/),[l] / [h],17.0,9894,DB00661,Verapamil
,3802708,oral clearance,"Pretreatment with verapamil, 80 mg and 120 mg (every 8 hours for 3 days), reduced the oral clearance of quinidine from 17.0 L/hr to 11.6 and 11.3 L/hr, respectively (P less than 0.01).",The effect of coadministration of verapamil on the pharmacokinetics and metabolism of quinidine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802708/),[l] / [h],11.6,9895,DB00661,Verapamil
,3802708,oral clearance,"Pretreatment with verapamil, 80 mg and 120 mg (every 8 hours for 3 days), reduced the oral clearance of quinidine from 17.0 L/hr to 11.6 and 11.3 L/hr, respectively (P less than 0.01).",The effect of coadministration of verapamil on the pharmacokinetics and metabolism of quinidine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3802708/),[l] / [h],11.3,9896,DB00661,Verapamil
,31613735,plasma protein binding,"In addition to lesinurad (plasma protein binding 98.2%), the matrix effects from special population plasma on the quantitation of verapamil (PPB 89.6%), allopurinol and oxypurinol (PPB negligible) were also investigated.",The Effects of Special Patient Population Plasma on Pharmacokinetic Quantifications Using LC-MS/MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31613735/),%,98.2,10887,DB00661,Verapamil
>,27420350,apparent permeability coefficient,Tryptanthrin displayed high permeability (apparent permeability coefficient > 32.0 × 10(-6) cm/s) across the cell monolayer.,Caco-2 Permeability Studies and In Vitro hERG Liability Assessment of Tryptanthrin and Indolinone. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27420350/),[cm] / [s],32.0 × 10(-6),11234,DB00661,Verapamil
below,27420350,efflux ratio,The efflux ratio below 2 (< 1.12) and unchanged apparent permeability coefficient values in the presence of the P-glycoprotein inhibitor verapamil (50 µM) indicated that tryptanthrin was not involved in P-glycoprotein interactions.,Caco-2 Permeability Studies and In Vitro hERG Liability Assessment of Tryptanthrin and Indolinone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27420350/),,2,11235,DB00661,Verapamil
<,27420350,efflux ratio,The efflux ratio below 2 (< 1.12) and unchanged apparent permeability coefficient values in the presence of the P-glycoprotein inhibitor verapamil (50 µM) indicated that tryptanthrin was not involved in P-glycoprotein interactions.,Caco-2 Permeability Studies and In Vitro hERG Liability Assessment of Tryptanthrin and Indolinone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27420350/),,1.12,11236,DB00661,Verapamil
>,27420350,IC50,Low human ether-a-go-go-related gene inhibition was found for tryptanthrin (IC50 > 10 µM) and indolinone (IC50 of 24.96 µM).,Caco-2 Permeability Studies and In Vitro hERG Liability Assessment of Tryptanthrin and Indolinone. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27420350/),μM,10,11237,DB00661,Verapamil
,27420350,IC50,Low human ether-a-go-go-related gene inhibition was found for tryptanthrin (IC50 > 10 µM) and indolinone (IC50 of 24.96 µM).,Caco-2 Permeability Studies and In Vitro hERG Liability Assessment of Tryptanthrin and Indolinone. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27420350/),μM,24.96,11238,DB00661,Verapamil
,9772689,Tmax,"The main pharmacokinetic parameters obtained were: Tmax, 5.9 +/- 1.6 h; Cmax, 118.9 +/- 37.2 micrograms.",[Pharmacokinetic and electocardiographic study of oral verapamil sustained-release tablet in 10 Chinese volunteers]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9772689/),h,5.9,12497,DB00661,Verapamil
,9772689,Cmax,"The main pharmacokinetic parameters obtained were: Tmax, 5.9 +/- 1.6 h; Cmax, 118.9 +/- 37.2 micrograms.",[Pharmacokinetic and electocardiographic study of oral verapamil sustained-release tablet in 10 Chinese volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9772689/),μg,118.9,12498,DB00661,Verapamil
,9772689,T1,"L-1; T1, 5.4 +/- 1.5 h; k0, 30.5 +/- 17.5 micrograms.",[Pharmacokinetic and electocardiographic study of oral verapamil sustained-release tablet in 10 Chinese volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9772689/),h,5.4,12499,DB00661,Verapamil
,9772689,k0,"L-1; T1, 5.4 +/- 1.5 h; k0, 30.5 +/- 17.5 micrograms.",[Pharmacokinetic and electocardiographic study of oral verapamil sustained-release tablet in 10 Chinese volunteers]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9772689/),μg,30.5,12500,DB00661,Verapamil
,9772689,T1/2,"L-1.h-1; T1/2, 10.8 +/- 4.9 h; MRT, 15.4 +/- 3.2 h and AUC. 1.96 +/- 0.82 mg.h.L-1.",[Pharmacokinetic and electocardiographic study of oral verapamil sustained-release tablet in 10 Chinese volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9772689/),h,10.8,12501,DB00661,Verapamil
,9772689,MRT,"L-1.h-1; T1/2, 10.8 +/- 4.9 h; MRT, 15.4 +/- 3.2 h and AUC. 1.96 +/- 0.82 mg.h.L-1.",[Pharmacokinetic and electocardiographic study of oral verapamil sustained-release tablet in 10 Chinese volunteers]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9772689/),h,15.4,12502,DB00661,Verapamil
,9772689,AUC.,"L-1.h-1; T1/2, 10.8 +/- 4.9 h; MRT, 15.4 +/- 3.2 h and AUC. 1.96 +/- 0.82 mg.h.L-1.",[Pharmacokinetic and electocardiographic study of oral verapamil sustained-release tablet in 10 Chinese volunteers]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9772689/),[h·mg] / [l],1.96,12503,DB00661,Verapamil
,9772689,EC50,"EC50, 64.6 +/- 16.9 micrograms.",[Pharmacokinetic and electocardiographic study of oral verapamil sustained-release tablet in 10 Chinese volunteers]. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9772689/),μg,64.6,12504,DB00661,Verapamil
,9772689,Emax,"L-1, Emax, 54 +/- 11 ms and s, 1.68 +/- 0.66.",[Pharmacokinetic and electocardiographic study of oral verapamil sustained-release tablet in 10 Chinese volunteers]. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9772689/),ms,54,12505,DB00661,Verapamil
,9772689,s,"L-1, Emax, 54 +/- 11 ms and s, 1.68 +/- 0.66.",[Pharmacokinetic and electocardiographic study of oral verapamil sustained-release tablet in 10 Chinese volunteers]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9772689/),,1.68,12506,DB00661,Verapamil
,28528287,Clearance,Clearance estimates (95% CI) were 84.9L/h (69.5-100.3) for oxcarbazepine and 2.0L/h (1.9-2.1) for both MHD enantiomers.,Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28528287/),[l] / [h],84.9,15058,DB00661,Verapamil
,28528287,Clearance,Clearance estimates (95% CI) were 84.9L/h (69.5-100.3) for oxcarbazepine and 2.0L/h (1.9-2.1) for both MHD enantiomers.,Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28528287/),[l] / [h],2.0,15059,DB00661,Verapamil
,28528287,volume of distribution,"The volume of distribution was much larger for oxcarbazepine (131L (97-165)) as compared to R-(-)- and S-(+)-MHD (23.6L (14.4-32.8) vs. 31.7L (22.5-40.9), respectively).",Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28528287/),l,131,15060,DB00661,Verapamil
,28528287,volume of distribution,"The volume of distribution was much larger for oxcarbazepine (131L (97-165)) as compared to R-(-)- and S-(+)-MHD (23.6L (14.4-32.8) vs. 31.7L (22.5-40.9), respectively).",Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28528287/),l,23.6,15061,DB00661,Verapamil
,28528287,volume of distribution,"The volume of distribution was much larger for oxcarbazepine (131L (97-165)) as compared to R-(-)- and S-(+)-MHD (23.6L (14.4-32.8) vs. 31.7L (22.5-40.9), respectively).",Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28528287/),l,31.7,15062,DB00661,Verapamil
,9696960,AUCv/AUCm ratio (AUCR),"The AUCv/AUCm ratio (AUCR) was slightly, but significantly, increased after GJ (1.67 vs 1.92).",The effect of grapefruit juice on the pharmacokinetics of orally administered verapamil. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9696960/),,1.67,15343,DB00661,Verapamil
,9696960,AUCv/AUCm ratio (AUCR),"The AUCv/AUCm ratio (AUCR) was slightly, but significantly, increased after GJ (1.67 vs 1.92).",The effect of grapefruit juice on the pharmacokinetics of orally administered verapamil. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9696960/),,1.92,15344,DB00661,Verapamil
,25590941,oral bioavailability,"Then the pharmacokinetics of PPI in rats was studied and the result revealed that PPI was slowly eliminated with low oral bioavailability (about 0.62%) at a dose of 50 mg/kg, and when co-administrated with verapamil (VPL) and cyclosporine A (CYA), the oral bioavailability of PPI could increase from 0.62% to 3.52% and 3.79% respectively.",Study on the pharmacokinetics profiles of polyphyllin I and its bioavailability enhancement through co-administration with P-glycoprotein inhibitors by LC-MS/MS method. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25590941/),%,0.62,18150,DB00661,Verapamil
,25590941,oral bioavailability,"Then the pharmacokinetics of PPI in rats was studied and the result revealed that PPI was slowly eliminated with low oral bioavailability (about 0.62%) at a dose of 50 mg/kg, and when co-administrated with verapamil (VPL) and cyclosporine A (CYA), the oral bioavailability of PPI could increase from 0.62% to 3.52% and 3.79% respectively.",Study on the pharmacokinetics profiles of polyphyllin I and its bioavailability enhancement through co-administration with P-glycoprotein inhibitors by LC-MS/MS method. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25590941/),%,3.52,18151,DB00661,Verapamil
,25590941,oral bioavailability,"Then the pharmacokinetics of PPI in rats was studied and the result revealed that PPI was slowly eliminated with low oral bioavailability (about 0.62%) at a dose of 50 mg/kg, and when co-administrated with verapamil (VPL) and cyclosporine A (CYA), the oral bioavailability of PPI could increase from 0.62% to 3.52% and 3.79% respectively.",Study on the pharmacokinetics profiles of polyphyllin I and its bioavailability enhancement through co-administration with P-glycoprotein inhibitors by LC-MS/MS method. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25590941/),%,3.79,18152,DB00661,Verapamil
,25590941,efflux ratio,"In addition, in vitro studies showed that with the presence of VPL and CYA in Caco-2 cells, the efflux ratio of PPI decreased from 12.5 to 2.96 and 2.22, and the intracellular concentrations increased 5.8- and 5.0-fold respectively.",Study on the pharmacokinetics profiles of polyphyllin I and its bioavailability enhancement through co-administration with P-glycoprotein inhibitors by LC-MS/MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25590941/),,12.5,18153,DB00661,Verapamil
,25590941,efflux ratio,"In addition, in vitro studies showed that with the presence of VPL and CYA in Caco-2 cells, the efflux ratio of PPI decreased from 12.5 to 2.96 and 2.22, and the intracellular concentrations increased 5.8- and 5.0-fold respectively.",Study on the pharmacokinetics profiles of polyphyllin I and its bioavailability enhancement through co-administration with P-glycoprotein inhibitors by LC-MS/MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25590941/),,2.96,18154,DB00661,Verapamil
,25590941,efflux ratio,"In addition, in vitro studies showed that with the presence of VPL and CYA in Caco-2 cells, the efflux ratio of PPI decreased from 12.5 to 2.96 and 2.22, and the intracellular concentrations increased 5.8- and 5.0-fold respectively.",Study on the pharmacokinetics profiles of polyphyllin I and its bioavailability enhancement through co-administration with P-glycoprotein inhibitors by LC-MS/MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25590941/),,2.22,18155,DB00661,Verapamil
,12545141,Apparent oral clearance,Apparent oral clearance of sustained-release verapamil was 23.8 +/- 2.3 mL/min per kilogram in women compared with 18.6 +/- 3.4 mL/min per kilogram in men.,"Population analyses of sustained-release verapamil in patients: effects of sex, race, and smoking. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12545141/),[ml] / [kg·min],23.8,18403,DB00661,Verapamil
,12545141,Apparent oral clearance,Apparent oral clearance of sustained-release verapamil was 23.8 +/- 2.3 mL/min per kilogram in women compared with 18.6 +/- 3.4 mL/min per kilogram in men.,"Population analyses of sustained-release verapamil in patients: effects of sex, race, and smoking. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12545141/),[ml] / [kg·min],18.6,18404,DB00661,Verapamil
,3358897,Cmax,2. The peak plasma concentrations (Cmax) and areas under the plasma concentration-time curves (AUC) of verapamil were similar during combined treatment with propranolol (mean +/- s.d.: Cmax = 491 +/- 397 ng ml-1; AUC = 2075 +/- 1524 ng ml-1 h) or atenolol (mean +/- s.d.: Cmax = 372 +/- 320 ng ml-1; AUC = 1985 +/- 1660 ng ml-1 h).,The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358897/),[ng] / [ml],491,18517,DB00661,Verapamil
,3358897,AUC,2. The peak plasma concentrations (Cmax) and areas under the plasma concentration-time curves (AUC) of verapamil were similar during combined treatment with propranolol (mean +/- s.d.: Cmax = 491 +/- 397 ng ml-1; AUC = 2075 +/- 1524 ng ml-1 h) or atenolol (mean +/- s.d.: Cmax = 372 +/- 320 ng ml-1; AUC = 1985 +/- 1660 ng ml-1 h).,The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358897/),[h·ng] / [ml],2075,18518,DB00661,Verapamil
,3358897,Cmax,2. The peak plasma concentrations (Cmax) and areas under the plasma concentration-time curves (AUC) of verapamil were similar during combined treatment with propranolol (mean +/- s.d.: Cmax = 491 +/- 397 ng ml-1; AUC = 2075 +/- 1524 ng ml-1 h) or atenolol (mean +/- s.d.: Cmax = 372 +/- 320 ng ml-1; AUC = 1985 +/- 1660 ng ml-1 h).,The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358897/),[ng] / [ml],372,18519,DB00661,Verapamil
,3358897,AUC,2. The peak plasma concentrations (Cmax) and areas under the plasma concentration-time curves (AUC) of verapamil were similar during combined treatment with propranolol (mean +/- s.d.: Cmax = 491 +/- 397 ng ml-1; AUC = 2075 +/- 1524 ng ml-1 h) or atenolol (mean +/- s.d.: Cmax = 372 +/- 320 ng ml-1; AUC = 1985 +/- 1660 ng ml-1 h).,The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358897/),[h·ng] / [ml],1985,18520,DB00661,Verapamil
,3358897,Cmax,3. No differences in Cmax and AUC were observed during verapamil monotherapy (mean +/- s.d.: Cmax = 287 +/- 105 ng ml-1; AUC = 1375 +/- 455 ng ml-1 h) vs combined treatment with propranolol (mean +/- s.d.: Cmax = 312 +/- 55 ng ml-1; AUC = 1566 +/- 486 ng ml-1 h).,The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358897/),[ng] / [ml],287,18521,DB00661,Verapamil
,3358897,AUC,3. No differences in Cmax and AUC were observed during verapamil monotherapy (mean +/- s.d.: Cmax = 287 +/- 105 ng ml-1; AUC = 1375 +/- 455 ng ml-1 h) vs combined treatment with propranolol (mean +/- s.d.: Cmax = 312 +/- 55 ng ml-1; AUC = 1566 +/- 486 ng ml-1 h).,The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358897/),[h·ng] / [ml],1375,18522,DB00661,Verapamil
,3358897,Cmax,3. No differences in Cmax and AUC were observed during verapamil monotherapy (mean +/- s.d.: Cmax = 287 +/- 105 ng ml-1; AUC = 1375 +/- 455 ng ml-1 h) vs combined treatment with propranolol (mean +/- s.d.: Cmax = 312 +/- 55 ng ml-1; AUC = 1566 +/- 486 ng ml-1 h).,The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358897/),[ng] / [ml],312,18523,DB00661,Verapamil
,3358897,AUC,3. No differences in Cmax and AUC were observed during verapamil monotherapy (mean +/- s.d.: Cmax = 287 +/- 105 ng ml-1; AUC = 1375 +/- 455 ng ml-1 h) vs combined treatment with propranolol (mean +/- s.d.: Cmax = 312 +/- 55 ng ml-1; AUC = 1566 +/- 486 ng ml-1 h).,The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358897/),[h·ng] / [ml],1566,18524,DB00661,Verapamil
,3358897,Cmax,"4. Treatment with verapamil increased the Cmax (mean +/- s.d.: 227 +/- 117 vs 116 +/- 62 ng ml-1, P less than 0.05) and AUC (1389 +/- 617 vs 837 +/- 316 ng ml-1 h, P = 0.0625) of propranolol in all subjects.",The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358897/),[ng] / [ml],227,18525,DB00661,Verapamil
,3358897,Cmax,"4. Treatment with verapamil increased the Cmax (mean +/- s.d.: 227 +/- 117 vs 116 +/- 62 ng ml-1, P less than 0.05) and AUC (1389 +/- 617 vs 837 +/- 316 ng ml-1 h, P = 0.0625) of propranolol in all subjects.",The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358897/),[ng] / [ml],116,18526,DB00661,Verapamil
,3358897,AUC,"4. Treatment with verapamil increased the Cmax (mean +/- s.d.: 227 +/- 117 vs 116 +/- 62 ng ml-1, P less than 0.05) and AUC (1389 +/- 617 vs 837 +/- 316 ng ml-1 h, P = 0.0625) of propranolol in all subjects.",The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358897/),[h·ng] / [ml],1389,18527,DB00661,Verapamil
,3358897,AUC,"4. Treatment with verapamil increased the Cmax (mean +/- s.d.: 227 +/- 117 vs 116 +/- 62 ng ml-1, P less than 0.05) and AUC (1389 +/- 617 vs 837 +/- 316 ng ml-1 h, P = 0.0625) of propranolol in all subjects.",The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358897/),[h·ng] / [ml],837,18528,DB00661,Verapamil
,3735134,Terminal elimination half-life,"Terminal elimination half-life was significantly prolonged in obese animals compared to lean (mean +/- S.D., 2.68 +/- 0.87 hr obese vs. 1.39 +/- 0.35 hr lean; P less than .01) due to the significantly increased total volume of distribution observed in the obese animals (1.62 +/- 0.28 liters obese vs. 0.83 +/- 0.14 liters lean; P less than .001).",Pharmacokinetics and dynamics of (+/-)-verapamil in lean and obese Zucker rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735134/),h,2.68,18605,DB00661,Verapamil
,3735134,Terminal elimination half-life,"Terminal elimination half-life was significantly prolonged in obese animals compared to lean (mean +/- S.D., 2.68 +/- 0.87 hr obese vs. 1.39 +/- 0.35 hr lean; P less than .01) due to the significantly increased total volume of distribution observed in the obese animals (1.62 +/- 0.28 liters obese vs. 0.83 +/- 0.14 liters lean; P less than .001).",Pharmacokinetics and dynamics of (+/-)-verapamil in lean and obese Zucker rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735134/),h,1.39,18606,DB00661,Verapamil
,3735134,total volume of distribution,"Terminal elimination half-life was significantly prolonged in obese animals compared to lean (mean +/- S.D., 2.68 +/- 0.87 hr obese vs. 1.39 +/- 0.35 hr lean; P less than .01) due to the significantly increased total volume of distribution observed in the obese animals (1.62 +/- 0.28 liters obese vs. 0.83 +/- 0.14 liters lean; P less than .001).",Pharmacokinetics and dynamics of (+/-)-verapamil in lean and obese Zucker rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735134/),l,1.62,18607,DB00661,Verapamil
,3735134,total volume of distribution,"Terminal elimination half-life was significantly prolonged in obese animals compared to lean (mean +/- S.D., 2.68 +/- 0.87 hr obese vs. 1.39 +/- 0.35 hr lean; P less than .01) due to the significantly increased total volume of distribution observed in the obese animals (1.62 +/- 0.28 liters obese vs. 0.83 +/- 0.14 liters lean; P less than .001).",Pharmacokinetics and dynamics of (+/-)-verapamil in lean and obese Zucker rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735134/),l,0.83,18608,DB00661,Verapamil
,3735134,total clearance,There was no significant difference in the total clearance (0.45 +/- 0.16 liters/hr obese vs. 0.43 +/- 0.10 liters/hr lean; NS) between lean and obese animals.,Pharmacokinetics and dynamics of (+/-)-verapamil in lean and obese Zucker rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735134/),[l] / [h],0.45,18609,DB00661,Verapamil
,3735134,total clearance,There was no significant difference in the total clearance (0.45 +/- 0.16 liters/hr obese vs. 0.43 +/- 0.10 liters/hr lean; NS) between lean and obese animals.,Pharmacokinetics and dynamics of (+/-)-verapamil in lean and obese Zucker rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735134/),[l] / [h],0.43,18610,DB00661,Verapamil
,3735134,Steady-state clearance,Steady-state clearance was similar between groups (0.349 +/- 0.095 liters/hr obese vs. 0.244 +/- 0.066 liters/hr lean; NS).,Pharmacokinetics and dynamics of (+/-)-verapamil in lean and obese Zucker rats. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735134/),[l] / [h],0.349,18611,DB00661,Verapamil
,3735134,Steady-state clearance,Steady-state clearance was similar between groups (0.349 +/- 0.095 liters/hr obese vs. 0.244 +/- 0.066 liters/hr lean; NS).,Pharmacokinetics and dynamics of (+/-)-verapamil in lean and obese Zucker rats. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735134/),[l] / [h],0.244,18612,DB00661,Verapamil
,3735134,concentration,Plasma verapamil concentration at the termination of steady-state infusion was similar between lean and obese rats (0.91 +/- 0.24 microgram/ml obese vs. 1.26 +/- 0.33 microgram/ml lean).,Pharmacokinetics and dynamics of (+/-)-verapamil in lean and obese Zucker rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735134/),[μg] / [ml],0.91,18613,DB00661,Verapamil
,3735134,concentration,Plasma verapamil concentration at the termination of steady-state infusion was similar between lean and obese rats (0.91 +/- 0.24 microgram/ml obese vs. 1.26 +/- 0.33 microgram/ml lean).,Pharmacokinetics and dynamics of (+/-)-verapamil in lean and obese Zucker rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3735134/),[μg] / [ml],1.26,18614,DB00661,Verapamil
,25466967,Km,"TC was shown to be a substrate of OATP1A2 (Km = 6.9 ± 1.3 μmol/L; Vmax = 41.6 ± 1.8 pmol/mg·min), OCT1 (Km = 106 ± 16 μmol/L; Vmax = 269 ± 18 pmol/mg·min), and P-gp (Km = 34.9 ± 7.5 μmol/L; Vmax = 105 ± 9.1 pmol/mg·min, lipovesicle assay).",Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25466967/),[μM] / [l],6.9,18726,DB00661,Verapamil
,25466967,Vmax,"TC was shown to be a substrate of OATP1A2 (Km = 6.9 ± 1.3 μmol/L; Vmax = 41.6 ± 1.8 pmol/mg·min), OCT1 (Km = 106 ± 16 μmol/L; Vmax = 269 ± 18 pmol/mg·min), and P-gp (Km = 34.9 ± 7.5 μmol/L; Vmax = 105 ± 9.1 pmol/mg·min, lipovesicle assay).",Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25466967/),[pM] / [mg·min],41.6,18727,DB00661,Verapamil
,25466967,Km,"TC was shown to be a substrate of OATP1A2 (Km = 6.9 ± 1.3 μmol/L; Vmax = 41.6 ± 1.8 pmol/mg·min), OCT1 (Km = 106 ± 16 μmol/L; Vmax = 269 ± 18 pmol/mg·min), and P-gp (Km = 34.9 ± 7.5 μmol/L; Vmax = 105 ± 9.1 pmol/mg·min, lipovesicle assay).",Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25466967/),[μM] / [l],106,18728,DB00661,Verapamil
,25466967,Vmax,"TC was shown to be a substrate of OATP1A2 (Km = 6.9 ± 1.3 μmol/L; Vmax = 41.6 ± 1.8 pmol/mg·min), OCT1 (Km = 106 ± 16 μmol/L; Vmax = 269 ± 18 pmol/mg·min), and P-gp (Km = 34.9 ± 7.5 μmol/L; Vmax = 105 ± 9.1 pmol/mg·min, lipovesicle assay).",Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25466967/),[pM] / [mg·min],269,18729,DB00661,Verapamil
,25466967,Km,"TC was shown to be a substrate of OATP1A2 (Km = 6.9 ± 1.3 μmol/L; Vmax = 41.6 ± 1.8 pmol/mg·min), OCT1 (Km = 106 ± 16 μmol/L; Vmax = 269 ± 18 pmol/mg·min), and P-gp (Km = 34.9 ± 7.5 μmol/L; Vmax = 105 ± 9.1 pmol/mg·min, lipovesicle assay).",Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25466967/),[μM] / [l],34.9,18730,DB00661,Verapamil
,25466967,Vmax,"TC was shown to be a substrate of OATP1A2 (Km = 6.9 ± 1.3 μmol/L; Vmax = 41.6 ± 1.8 pmol/mg·min), OCT1 (Km = 106 ± 16 μmol/L; Vmax = 269 ± 18 pmol/mg·min), and P-gp (Km = 34.9 ± 7.5 μmol/L; Vmax = 105 ± 9.1 pmol/mg·min, lipovesicle assay).",Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25466967/),[pM] / [mg·min],105,18731,DB00661,Verapamil
,25466967,Km,"TC was taken up into HBU cells (Km = 18.5 ± 4.8 μmol/L; Vmax = 106 ± 11.3 pmol/mg·min) by mechanisms that could be synergistically inhibited by naringin (IC50 = 10.8 (8.4; 13.8) μmol/L) and verapamil (IC50 = 4.6 (2.8; 7.5) μmol/L), inhibitors of OATP1A2 and OCT1, respectively.",Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25466967/),[μM] / [l],18.5,18732,DB00661,Verapamil
,25466967,Vmax,"TC was taken up into HBU cells (Km = 18.5 ± 4.8 μmol/L; Vmax = 106 ± 11.3 pmol/mg·min) by mechanisms that could be synergistically inhibited by naringin (IC50 = 10.8 (8.4; 13.8) μmol/L) and verapamil (IC50 = 4.6 (2.8; 7.5) μmol/L), inhibitors of OATP1A2 and OCT1, respectively.",Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25466967/),[pM] / [mg·min],106,18733,DB00661,Verapamil
,25466967,IC50,"TC was taken up into HBU cells (Km = 18.5 ± 4.8 μmol/L; Vmax = 106 ± 11.3 pmol/mg·min) by mechanisms that could be synergistically inhibited by naringin (IC50 = 10.8 (8.4; 13.8) μmol/L) and verapamil (IC50 = 4.6 (2.8; 7.5) μmol/L), inhibitors of OATP1A2 and OCT1, respectively.",Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25466967/),[μM] / [l],10.8,18734,DB00661,Verapamil
,25466967,IC50,"TC was taken up into HBU cells (Km = 18.5 ± 4.8 μmol/L; Vmax = 106 ± 11.3 pmol/mg·min) by mechanisms that could be synergistically inhibited by naringin (IC50 = 10.8 (8.4; 13.8) μmol/L) and verapamil (IC50 = 4.6 (2.8; 7.5) μmol/L), inhibitors of OATP1A2 and OCT1, respectively.",Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25466967/),[μM] / [l],4.6,18735,DB00661,Verapamil
,2954736,nonrenal,"Significant (P less than 0.05) reduction in nonrenal (7.01 +/- 1.97 to 4.00 +/- 1.86 L/hr) and total clearance (14.1 +/- 2.6 to 11.5 +/- 2.5 L/hr) were induced by verapamil, without change in renal clearance.",The comparative effects of verapamil and a new dihydropyridine calcium channel blocker on digoxin pharmacokinetics. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2954736/),[l] / [h],7.01,18768,DB00661,Verapamil
,2954736,nonrenal,"Significant (P less than 0.05) reduction in nonrenal (7.01 +/- 1.97 to 4.00 +/- 1.86 L/hr) and total clearance (14.1 +/- 2.6 to 11.5 +/- 2.5 L/hr) were induced by verapamil, without change in renal clearance.",The comparative effects of verapamil and a new dihydropyridine calcium channel blocker on digoxin pharmacokinetics. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2954736/),[l] / [h],4.00,18769,DB00661,Verapamil
,2954736,total clearance,"Significant (P less than 0.05) reduction in nonrenal (7.01 +/- 1.97 to 4.00 +/- 1.86 L/hr) and total clearance (14.1 +/- 2.6 to 11.5 +/- 2.5 L/hr) were induced by verapamil, without change in renal clearance.",The comparative effects of verapamil and a new dihydropyridine calcium channel blocker on digoxin pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2954736/),[l] / [h],14.1,18770,DB00661,Verapamil
,2954736,total clearance,"Significant (P less than 0.05) reduction in nonrenal (7.01 +/- 1.97 to 4.00 +/- 1.86 L/hr) and total clearance (14.1 +/- 2.6 to 11.5 +/- 2.5 L/hr) were induced by verapamil, without change in renal clearance.",The comparative effects of verapamil and a new dihydropyridine calcium channel blocker on digoxin pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2954736/),[l] / [h],11.5,18771,DB00661,Verapamil
,2954736,elimination half-life,A near-significant (P less than 0.1) increase in peripheral volume of distribution contributed to prolonged elimination half-life (23.1 +/- 4.4 to 34.3 +/- 9.7 hours).,The comparative effects of verapamil and a new dihydropyridine calcium channel blocker on digoxin pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2954736/),h,23.1,18772,DB00661,Verapamil
,2954736,elimination half-life,A near-significant (P less than 0.1) increase in peripheral volume of distribution contributed to prolonged elimination half-life (23.1 +/- 4.4 to 34.3 +/- 9.7 hours).,The comparative effects of verapamil and a new dihydropyridine calcium channel blocker on digoxin pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2954736/),h,34.3,18773,DB00661,Verapamil
,16013069,AUC,"With naringin, the AUC of verapamil was significantly greater (28.4 versus 18.4 microg min/ml).","Effects of naringin on the pharmacokinetics of verapamil and one of its metabolites, norverapamil, in rabbits. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013069/),[min·μg] / [ml],28.4,19260,DB00661,Verapamil
,16013069,AUC,"With naringin, the AUC of verapamil was significantly greater (28.4 versus 18.4 microg min/ml).","Effects of naringin on the pharmacokinetics of verapamil and one of its metabolites, norverapamil, in rabbits. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013069/),[min·μg] / [ml],18.4,19261,DB00661,Verapamil
,16013069,AUC(verapamil)/AUC(,"Although, the AUC values of norverapamil were not significantly different between groups without and with naringin, the AUC(verapamil)/AUC(norverapamil) ratio was considerably greater (1.49 versus 1.11) with naringin.","Effects of naringin on the pharmacokinetics of verapamil and one of its metabolites, norverapamil, in rabbits. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013069/),,1.49,19262,DB00661,Verapamil
,16013069,AUC(verapamil)/AUC(,"Although, the AUC values of norverapamil were not significantly different between groups without and with naringin, the AUC(verapamil)/AUC(norverapamil) ratio was considerably greater (1.49 versus 1.11) with naringin.","Effects of naringin on the pharmacokinetics of verapamil and one of its metabolites, norverapamil, in rabbits. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16013069/),,1.11,19263,DB00661,Verapamil
,432439,half-lives of distribution (T 1/2 alpha),The half-lives of distribution (T 1/2 alpha) and elimination (T 1/2 beta) phases showed 0.23 hour and 4.21 hour on an average respectively.,Pharmacokinetics of verapamil in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/432439/),h,0.23,19578,DB00661,Verapamil
,432439,elimination (T 1/2 beta),The half-lives of distribution (T 1/2 alpha) and elimination (T 1/2 beta) phases showed 0.23 hour and 4.21 hour on an average respectively.,Pharmacokinetics of verapamil in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/432439/),h,4.21,19579,DB00661,Verapamil
,432439,apparent volume of distribution [Vd (area)],The apparent volume of distribution [Vd (area)] showed 2.51 1/kg and body clearance (C1b) showed 500.64 ml/min on an average.,Pharmacokinetics of verapamil in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/432439/),[1] / [kg],2.51,19580,DB00661,Verapamil
,432439,body clearance (C1b),The apparent volume of distribution [Vd (area)] showed 2.51 1/kg and body clearance (C1b) showed 500.64 ml/min on an average.,Pharmacokinetics of verapamil in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/432439/),[ml] / [min],500.64,19581,DB00661,Verapamil
,432439,time to reach peak blood level (Tmax),"After oral administration, the time to reach peak blood level (Tmax) was reached within 1.84 hour and the peak serum concentration showed 219.09 ng/ml on an average.",Pharmacokinetics of verapamil in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/432439/),h,1.84,19582,DB00661,Verapamil
,432439,peak serum concentration,"After oral administration, the time to reach peak blood level (Tmax) was reached within 1.84 hour and the peak serum concentration showed 219.09 ng/ml on an average.",Pharmacokinetics of verapamil in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/432439/),[ng] / [ml],219.09,19583,DB00661,Verapamil
,432439,bioavailability,The bioavailability was only 22.47% on an average.,Pharmacokinetics of verapamil in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/432439/),%,22.47,19584,DB00661,Verapamil
,26444334,t1/2,"The pharmacokinetic parameters of i.v. and i.m. administration routes were as follows (i.v. vs i.m.): t1/2 15.73 vs 17.24h, Tmax 0.06 vs 0.26h, AUC0-t 69.35 vs 67.90hng/mL, AUC0-inf 78.24 vs 79.67hng/mL, Cmax 37.5 vs 9.1ng/mL, Ae0-24h 22.7 vs 25.21μg.",Development and validation of an improved HPLC-MS/MS method for comparative pharmacokinetics of penehyclidine hydrochloride following a single intravenous or intramuscular injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26444334/),h,15.73,20413,DB00661,Verapamil
,26444334,t1/2,"The pharmacokinetic parameters of i.v. and i.m. administration routes were as follows (i.v. vs i.m.): t1/2 15.73 vs 17.24h, Tmax 0.06 vs 0.26h, AUC0-t 69.35 vs 67.90hng/mL, AUC0-inf 78.24 vs 79.67hng/mL, Cmax 37.5 vs 9.1ng/mL, Ae0-24h 22.7 vs 25.21μg.",Development and validation of an improved HPLC-MS/MS method for comparative pharmacokinetics of penehyclidine hydrochloride following a single intravenous or intramuscular injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26444334/),h,17.24,20414,DB00661,Verapamil
,26444334,Tmax,"The pharmacokinetic parameters of i.v. and i.m. administration routes were as follows (i.v. vs i.m.): t1/2 15.73 vs 17.24h, Tmax 0.06 vs 0.26h, AUC0-t 69.35 vs 67.90hng/mL, AUC0-inf 78.24 vs 79.67hng/mL, Cmax 37.5 vs 9.1ng/mL, Ae0-24h 22.7 vs 25.21μg.",Development and validation of an improved HPLC-MS/MS method for comparative pharmacokinetics of penehyclidine hydrochloride following a single intravenous or intramuscular injection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26444334/),h,0.06,20415,DB00661,Verapamil
,26444334,Tmax,"The pharmacokinetic parameters of i.v. and i.m. administration routes were as follows (i.v. vs i.m.): t1/2 15.73 vs 17.24h, Tmax 0.06 vs 0.26h, AUC0-t 69.35 vs 67.90hng/mL, AUC0-inf 78.24 vs 79.67hng/mL, Cmax 37.5 vs 9.1ng/mL, Ae0-24h 22.7 vs 25.21μg.",Development and validation of an improved HPLC-MS/MS method for comparative pharmacokinetics of penehyclidine hydrochloride following a single intravenous or intramuscular injection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26444334/),h,0.26,20416,DB00661,Verapamil
,26444334,AUC0-t,"The pharmacokinetic parameters of i.v. and i.m. administration routes were as follows (i.v. vs i.m.): t1/2 15.73 vs 17.24h, Tmax 0.06 vs 0.26h, AUC0-t 69.35 vs 67.90hng/mL, AUC0-inf 78.24 vs 79.67hng/mL, Cmax 37.5 vs 9.1ng/mL, Ae0-24h 22.7 vs 25.21μg.",Development and validation of an improved HPLC-MS/MS method for comparative pharmacokinetics of penehyclidine hydrochloride following a single intravenous or intramuscular injection. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26444334/),[hng] / [ml],69.35,20417,DB00661,Verapamil
,26444334,AUC0-t,"The pharmacokinetic parameters of i.v. and i.m. administration routes were as follows (i.v. vs i.m.): t1/2 15.73 vs 17.24h, Tmax 0.06 vs 0.26h, AUC0-t 69.35 vs 67.90hng/mL, AUC0-inf 78.24 vs 79.67hng/mL, Cmax 37.5 vs 9.1ng/mL, Ae0-24h 22.7 vs 25.21μg.",Development and validation of an improved HPLC-MS/MS method for comparative pharmacokinetics of penehyclidine hydrochloride following a single intravenous or intramuscular injection. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26444334/),[hng] / [ml],67.90,20418,DB00661,Verapamil
,26444334,AUC0-inf,"The pharmacokinetic parameters of i.v. and i.m. administration routes were as follows (i.v. vs i.m.): t1/2 15.73 vs 17.24h, Tmax 0.06 vs 0.26h, AUC0-t 69.35 vs 67.90hng/mL, AUC0-inf 78.24 vs 79.67hng/mL, Cmax 37.5 vs 9.1ng/mL, Ae0-24h 22.7 vs 25.21μg.",Development and validation of an improved HPLC-MS/MS method for comparative pharmacokinetics of penehyclidine hydrochloride following a single intravenous or intramuscular injection. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26444334/),[hng] / [ml],78.24,20419,DB00661,Verapamil
,26444334,AUC0-inf,"The pharmacokinetic parameters of i.v. and i.m. administration routes were as follows (i.v. vs i.m.): t1/2 15.73 vs 17.24h, Tmax 0.06 vs 0.26h, AUC0-t 69.35 vs 67.90hng/mL, AUC0-inf 78.24 vs 79.67hng/mL, Cmax 37.5 vs 9.1ng/mL, Ae0-24h 22.7 vs 25.21μg.",Development and validation of an improved HPLC-MS/MS method for comparative pharmacokinetics of penehyclidine hydrochloride following a single intravenous or intramuscular injection. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26444334/),[hng] / [ml],79.67,20420,DB00661,Verapamil
,26444334,Cmax,"The pharmacokinetic parameters of i.v. and i.m. administration routes were as follows (i.v. vs i.m.): t1/2 15.73 vs 17.24h, Tmax 0.06 vs 0.26h, AUC0-t 69.35 vs 67.90hng/mL, AUC0-inf 78.24 vs 79.67hng/mL, Cmax 37.5 vs 9.1ng/mL, Ae0-24h 22.7 vs 25.21μg.",Development and validation of an improved HPLC-MS/MS method for comparative pharmacokinetics of penehyclidine hydrochloride following a single intravenous or intramuscular injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26444334/),[ng] / [ml],37.5,20421,DB00661,Verapamil
,26444334,Cmax,"The pharmacokinetic parameters of i.v. and i.m. administration routes were as follows (i.v. vs i.m.): t1/2 15.73 vs 17.24h, Tmax 0.06 vs 0.26h, AUC0-t 69.35 vs 67.90hng/mL, AUC0-inf 78.24 vs 79.67hng/mL, Cmax 37.5 vs 9.1ng/mL, Ae0-24h 22.7 vs 25.21μg.",Development and validation of an improved HPLC-MS/MS method for comparative pharmacokinetics of penehyclidine hydrochloride following a single intravenous or intramuscular injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26444334/),[ng] / [ml],9.1,20422,DB00661,Verapamil
,26444334,Ae0-24h,"The pharmacokinetic parameters of i.v. and i.m. administration routes were as follows (i.v. vs i.m.): t1/2 15.73 vs 17.24h, Tmax 0.06 vs 0.26h, AUC0-t 69.35 vs 67.90hng/mL, AUC0-inf 78.24 vs 79.67hng/mL, Cmax 37.5 vs 9.1ng/mL, Ae0-24h 22.7 vs 25.21μg.",Development and validation of an improved HPLC-MS/MS method for comparative pharmacokinetics of penehyclidine hydrochloride following a single intravenous or intramuscular injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26444334/),μg,22.7,20423,DB00661,Verapamil
,26444334,Ae0-24h,"The pharmacokinetic parameters of i.v. and i.m. administration routes were as follows (i.v. vs i.m.): t1/2 15.73 vs 17.24h, Tmax 0.06 vs 0.26h, AUC0-t 69.35 vs 67.90hng/mL, AUC0-inf 78.24 vs 79.67hng/mL, Cmax 37.5 vs 9.1ng/mL, Ae0-24h 22.7 vs 25.21μg.",Development and validation of an improved HPLC-MS/MS method for comparative pharmacokinetics of penehyclidine hydrochloride following a single intravenous or intramuscular injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26444334/),μg,25.21,20424,DB00661,Verapamil
,26444334,absolute bioavailability,"The mean absolute bioavailability of the i.m. administration route was 98.4% (95% confidence interval, 93.4-103.6%).",Development and validation of an improved HPLC-MS/MS method for comparative pharmacokinetics of penehyclidine hydrochloride following a single intravenous or intramuscular injection. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26444334/),%,98.4,20425,DB00661,Verapamil
,30638237,drug loading capability,"DTX-S-OA SNEDDS produced a uniform droplet size of about 30 nm and a significantly high drug loading capability (60 mg mL-1), compared with DTX SNEDDS (20 mg mL-1).",Formulating a single thioether-bridged oleate prodrug into a self-nanoemulsifying drug delivery system to facilitate oral absorption of docetaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30638237/),[mg] / [ml],60,20643,DB00661,Verapamil
,30638237,drug loading capability,"DTX-S-OA SNEDDS produced a uniform droplet size of about 30 nm and a significantly high drug loading capability (60 mg mL-1), compared with DTX SNEDDS (20 mg mL-1).",Formulating a single thioether-bridged oleate prodrug into a self-nanoemulsifying drug delivery system to facilitate oral absorption of docetaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30638237/),[mg] / [ml],20,20644,DB00661,Verapamil
,11377051,Extraction recovery,"Extraction recovery was 92.12% and 89.58% for V and N, respectively.",A validated method for the determination of verapamil and norverapamil in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11377051/),%,92.12,23174,DB00661,Verapamil
,11377051,Extraction recovery,"Extraction recovery was 92.12% and 89.58% for V and N, respectively.",A validated method for the determination of verapamil and norverapamil in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11377051/),%,89.58,23175,DB00661,Verapamil
,11377051,recovery,Its recovery was 82.50% on the average.,A validated method for the determination of verapamil and norverapamil in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11377051/),%,82.50,23176,DB00661,Verapamil
,11377051,Limit of detection,"Limit of detection was 0.924 ng/ml and limit of determination was 3,080 ng/ml for V, what corresponds concentration in plasma 1.232 ng/ml.",A validated method for the determination of verapamil and norverapamil in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11377051/),[ng] / [ml],0.924,23177,DB00661,Verapamil
,11377051,V,"Limit of detection was 0.924 ng/ml and limit of determination was 3,080 ng/ml for V, what corresponds concentration in plasma 1.232 ng/ml.",A validated method for the determination of verapamil and norverapamil in human plasma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11377051/),[ng] / [ml],"3,080",23178,DB00661,Verapamil
,11377051,V,"Limit of detection was 0.924 ng/ml and limit of determination was 3,080 ng/ml for V, what corresponds concentration in plasma 1.232 ng/ml.",A validated method for the determination of verapamil and norverapamil in human plasma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11377051/),[ng] / [ml],1.232,23179,DB00661,Verapamil
,11377051,limit of detection,"For N limit of detection was 0.030 ng/ml and limit of determination was 1.001 ng/ml what corresponds 0,4 ng/ml in plasma.",A validated method for the determination of verapamil and norverapamil in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11377051/),[ng] / [ml],0.030,23180,DB00661,Verapamil
,11377051,limit of determination,"For N limit of detection was 0.030 ng/ml and limit of determination was 1.001 ng/ml what corresponds 0,4 ng/ml in plasma.",A validated method for the determination of verapamil and norverapamil in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11377051/),[ng] / [ml],1.001,23181,DB00661,Verapamil
,11377051,limit of determination,"For N limit of detection was 0.030 ng/ml and limit of determination was 1.001 ng/ml what corresponds 0,4 ng/ml in plasma.",A validated method for the determination of verapamil and norverapamil in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11377051/),[ng] / [ml],"0,4",23182,DB00661,Verapamil
,17220245,systemic bioavailability,"The systemic bioavailability of glabridin was approximately 7.5% in rats, but increased when combined with verapamil.","Role of P-glycoprotein in the intestinal absorption of glabridin, an active flavonoid from the root of Glycyrrhiza glabra. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220245/),%,7.5,24804,DB00661,Verapamil
,17220245,IC(50),"Glabridin inhibited PgP-mediated transport of digoxin with an IC(50) value of 2.56 microM, but stimulated PgP/MDR1 ATPase activity with a K(m) of 25.1 microM.","Role of P-glycoprotein in the intestinal absorption of glabridin, an active flavonoid from the root of Glycyrrhiza glabra. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220245/),μM,2.56,24805,DB00661,Verapamil
,17220245,K(m),"Glabridin inhibited PgP-mediated transport of digoxin with an IC(50) value of 2.56 microM, but stimulated PgP/MDR1 ATPase activity with a K(m) of 25.1 microM.","Role of P-glycoprotein in the intestinal absorption of glabridin, an active flavonoid from the root of Glycyrrhiza glabra. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17220245/),μM,25.1,24806,DB00661,Verapamil
,22747744,distribution volume,"At baseline, substrate tracers such as R-[11C]verapamil display low brain concentrations with a distribution volume of around 1.",[11C]phenytoin revisited: synthesis by [11C]CO carbonylation and first evaluation as a P-gp tracer in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22747744/),,1,25546,DB00661,Verapamil
,2049795,detection limit,The detection limit for the quantitation by the present method is 0.09 ng/ml of plasma.,Determination of gallopamil in human plasma by selected ion monitoring. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2049795/),[ng] / [ml],0.09,25706,DB00661,Verapamil
,15708686,mobile phase flow rate,"Analysis of verapamil and internal standard, propranolol was performed with direct injection of 10 microl of rat plasma to the system and were eluted at 22 and 12 min, respectively, at a mobile phase flow rate of 0.5 (mobile phase A) and 0.15 ml/min (mobile phase B).",Direct determination of verapamil in rat plasma by coupled column microbore-HPLC method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15708686/),[ml] / [min],0.5,26025,DB00661,Verapamil
,15708686,mobile phase flow rate,"Analysis of verapamil and internal standard, propranolol was performed with direct injection of 10 microl of rat plasma to the system and were eluted at 22 and 12 min, respectively, at a mobile phase flow rate of 0.5 (mobile phase A) and 0.15 ml/min (mobile phase B).",Direct determination of verapamil in rat plasma by coupled column microbore-HPLC method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15708686/),[ml] / [min],0.15,26026,DB00661,Verapamil
,15708686,total run time,The peaks of verapamil and internal standard were good shapes and well separated from any interfering endogenous peaks during a total run time of 25 min.,Direct determination of verapamil in rat plasma by coupled column microbore-HPLC method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15708686/),min,25,26027,DB00661,Verapamil
,15708686,LOD,"The LOD and LOQ were 0.01 and 0.025 microg/ml, respectively, for verapamil using 10 microl of rat plasma.",Direct determination of verapamil in rat plasma by coupled column microbore-HPLC method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15708686/),[μg] / [ml],0.01,26028,DB00661,Verapamil
,15708686,LOQ,"The LOD and LOQ were 0.01 and 0.025 microg/ml, respectively, for verapamil using 10 microl of rat plasma.",Direct determination of verapamil in rat plasma by coupled column microbore-HPLC method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15708686/),[μg] / [ml],0.025,26029,DB00661,Verapamil
below,9210442,detection limit,"The detection limit is below 5 ng/ml for both compounds, and extraction recoveries close to 80%.",Simultaneous determination of verapamil and norverapamil in biological samples by high-performance liquid chromatography using ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210442/),[ng] / [ml],5,27566,DB00661,Verapamil
,9210442,extraction recoveries,"The detection limit is below 5 ng/ml for both compounds, and extraction recoveries close to 80%.",Simultaneous determination of verapamil and norverapamil in biological samples by high-performance liquid chromatography using ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210442/),%,80,27567,DB00661,Verapamil
,30739353,bioavailability,"The results showed that the bioavailability of olerciamide A using hepatic, gastric and intestinal routes were 92.16%, 84.88% and 5.76%, respectively.","Investigating the bioavailabilities of olerciamide A via the rat's hepatic, gastric and intestinal first-pass effect models. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30739353/),%,92.16,27840,DB00661,Verapamil
,30739353,bioavailability,"The results showed that the bioavailability of olerciamide A using hepatic, gastric and intestinal routes were 92.16%, 84.88% and 5.76%, respectively.","Investigating the bioavailabilities of olerciamide A via the rat's hepatic, gastric and intestinal first-pass effect models. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30739353/),%,84.88,27841,DB00661,Verapamil
,30739353,bioavailability,"The results showed that the bioavailability of olerciamide A using hepatic, gastric and intestinal routes were 92.16%, 84.88% and 5.76%, respectively.","Investigating the bioavailabilities of olerciamide A via the rat's hepatic, gastric and intestinal first-pass effect models. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30739353/),%,5.76,27842,DB00661,Verapamil
,29556829,relative oral bioavailability,"Thus, the relative oral bioavailability of BNPC-SD as well as BNPC-SD co-administered with verapamil was 156.33 and 202.46%, respectively, compared with the value for BN given alone.",Evaluation of Intestinal Absorption and Bioavailability of a Bergenin-Phospholipid Complex Solid Dispersion in Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29556829/),%,156.33,28851,DB00661,Verapamil
,29556829,relative oral bioavailability,"Thus, the relative oral bioavailability of BNPC-SD as well as BNPC-SD co-administered with verapamil was 156.33 and 202.46%, respectively, compared with the value for BN given alone.",Evaluation of Intestinal Absorption and Bioavailability of a Bergenin-Phospholipid Complex Solid Dispersion in Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29556829/),%,202.46,28852,DB00661,Verapamil
,7297027,area under the concentration-time curve (AUC) at steady state,"Steady state was reached by the seventh dose and the area under the concentration-time curve (AUC) at steady state (1999 +/- 435[SD] ng/ml . hr) was greater than that after the first dose (788 +/- 224, P less than 0.001).",Reduced verapamil clearance during long-term oral administration. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297027/),[ng] / [h·ml],1999,30207,DB00661,Verapamil
,7297027,area under the concentration-time curve (AUC) at steady state,"Steady state was reached by the seventh dose and the area under the concentration-time curve (AUC) at steady state (1999 +/- 435[SD] ng/ml . hr) was greater than that after the first dose (788 +/- 224, P less than 0.001).",Reduced verapamil clearance during long-term oral administration. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297027/),,788,30208,DB00661,Verapamil
,7297027,half-life (t1/2),This unexpected cumulation was associated with prolongation of verapamil half-life (t1/2) from 2.75 +/- 1.14 to 4.52 +/- 1.10 hr.,Reduced verapamil clearance during long-term oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297027/),h,2.75,30209,DB00661,Verapamil
,7297027,half-life (t1/2),This unexpected cumulation was associated with prolongation of verapamil half-life (t1/2) from 2.75 +/- 1.14 to 4.52 +/- 1.10 hr.,Reduced verapamil clearance during long-term oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297027/),h,4.52,30210,DB00661,Verapamil
,7297027,AUC,Norverapamil AUC also rose from 1225 +/- 405 to 2312 +/- 963 ng/ml/hr during the attainment of steady state.,Reduced verapamil clearance during long-term oral administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297027/),[ng] / [h·ml],1225,30211,DB00661,Verapamil
,7297027,AUC,Norverapamil AUC also rose from 1225 +/- 405 to 2312 +/- 963 ng/ml/hr during the attainment of steady state.,Reduced verapamil clearance during long-term oral administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297027/),[ng] / [h·ml],2312,30212,DB00661,Verapamil
,10080651,recoveries,The mean recoveries for human plasma were 95.4+/-3.1% for TMB and 89.4+/-4.1% for NDTMB.,"High-performance liquid chromatographic determination of trimebutine and its major metabolite, N-monodesmethyl trimebutine, in rat and human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10080651/),%,95.4,31318,DB00661,Verapamil
,10080651,recoveries,The mean recoveries for human plasma were 95.4+/-3.1% for TMB and 89.4+/-4.1% for NDTMB.,"High-performance liquid chromatographic determination of trimebutine and its major metabolite, N-monodesmethyl trimebutine, in rat and human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10080651/),%,89.4,31319,DB00661,Verapamil
,10080651,detection limits,"The detection limits of TMB and its metabolite, NDTMB, in human plasma were 1 and 5 ng/ml, respectively.","High-performance liquid chromatographic determination of trimebutine and its major metabolite, N-monodesmethyl trimebutine, in rat and human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10080651/),[ng] / [ml],1,31320,DB00661,Verapamil
,10080651,detection limits,"The detection limits of TMB and its metabolite, NDTMB, in human plasma were 1 and 5 ng/ml, respectively.","High-performance liquid chromatographic determination of trimebutine and its major metabolite, N-monodesmethyl trimebutine, in rat and human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10080651/),[ng] / [ml],5,31321,DB00661,Verapamil
more,24922060,efflux ratios,"The efflux ratios of ginsenoside Rb2, Rc, Rg2, Rg3, Rd and Rb1 were found more than 3.5 in L-MDR1 cells and can be decreased significantly by verapamil (a classical P-gp inhibitor).",Pharmacokinetic compatibility of ginsenosides and Schisandra Lignans in Shengmai-san: from the perspective of p-glycoprotein. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24922060/),,3.5,31880,DB00661,Verapamil
lower,24922060,efflux ratios,"Contrarily, the efflux ratios of other ginsenosides (Rh1, F1, Re, and Rg1) were lower than 2.0 and not affected by verapamil.",Pharmacokinetic compatibility of ginsenosides and Schisandra Lignans in Shengmai-san: from the perspective of p-glycoprotein. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24922060/),,2.0,31881,DB00661,Verapamil
,3186615,bioavailability,It can be concluded that verapamil sustained release tablets meet with the following requirements for these formulations: (1) a slower absorption with an acceptable bioavailability relative to conventional tablets (89%); (2) no initial high peak concentration; (3) little fluctuation in the plasma concentration compared to the conventional formulation; (4) no differences in the elimination half lives for the two formulations; (5) maintenance of a therapeutic plasma level for a longer period of time than for the conventional formulation; (6) no increase in unwanted side effects.,Pharmacokinetics of verapamil and norverapamil in patients with hypertension: a comparison of oral conventional and sustained release formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3186615/),%,89,31910,DB00661,Verapamil
,7295469,distribution half-life (alpha),3 Intravenous verapamil showed a mean distribution half-life (alpha) of 8.5 min and elimination half-life (beta) of 2.0 h.,Systemic availability of oral verapamil and effect on PR interval in man. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7295469/),min,8.5,32785,DB00661,Verapamil
,7295469,elimination half-life (beta),3 Intravenous verapamil showed a mean distribution half-life (alpha) of 8.5 min and elimination half-life (beta) of 2.0 h.,Systemic availability of oral verapamil and effect on PR interval in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7295469/),h,2.0,32786,DB00661,Verapamil
,7295469,volume of distribution,The volume of distribution was about 112.1.,Systemic availability of oral verapamil and effect on PR interval in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7295469/),,112.1,32787,DB00661,Verapamil
,7295469,elimination half-life,"Oral dosage gave an elimination half-life of 2.7 h, and a norverapamil half-life which averaged 4.6 h.",Systemic availability of oral verapamil and effect on PR interval in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7295469/),h,2.7,32788,DB00661,Verapamil
,7295469,half-life,"Oral dosage gave an elimination half-life of 2.7 h, and a norverapamil half-life which averaged 4.6 h.",Systemic availability of oral verapamil and effect on PR interval in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7295469/),h,4.6,32789,DB00661,Verapamil
,7295469,bioavailability,The bioavailability of the oral dose averaged 22% (17 to 29%).,Systemic availability of oral verapamil and effect on PR interval in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7295469/),%,22,32790,DB00661,Verapamil
,22490230,k(inact),"The inactivation kinetic parameter, k(inact), was most consistent across systems tested for clarithromycin, verapamil, and troleandomycin, with a high k(inact) of 0.91 min(-1) observed for mibefradil in HepaRG cells.",Time-dependent inhibition and estimation of CYP3A clinical pharmacokinetic drug-drug interactions using plated human cell systems. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22490230/),1/[min],0.91,32837,DB00661,Verapamil
,22490230,apparent K(I),The apparent K(I) estimates derived from the various systems displayed a range of variability from 3-fold for clarithromycin (5.4-17.7 μM) to 6-fold for verapamil (1.9-12.6 μM).,Time-dependent inhibition and estimation of CYP3A clinical pharmacokinetic drug-drug interactions using plated human cell systems. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22490230/),μM,5.4-17.7,32838,DB00661,Verapamil
,22490230,apparent K(I),The apparent K(I) estimates derived from the various systems displayed a range of variability from 3-fold for clarithromycin (5.4-17.7 μM) to 6-fold for verapamil (1.9-12.6 μM).,Time-dependent inhibition and estimation of CYP3A clinical pharmacokinetic drug-drug interactions using plated human cell systems. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22490230/),μM,1.9-12.6,32839,DB00661,Verapamil
,17479539,bioavailability,"The bioavailability of the new peroral retard formulation was (20.00 +/- 4.30)% and was in reasonable agreement with that determined for the already registered verapamil retard formulation, i.e. (19.46 +/- 4.02)%, thereby indicating bioequivalence.",Validation of the hepatic blood flow rate model for verapamil first-pass metabolism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17479539/),%,20.00,33165,DB00661,Verapamil
,17479539,bioavailability,"The bioavailability of the new peroral retard formulation was (20.00 +/- 4.30)% and was in reasonable agreement with that determined for the already registered verapamil retard formulation, i.e. (19.46 +/- 4.02)%, thereby indicating bioequivalence.",Validation of the hepatic blood flow rate model for verapamil first-pass metabolism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17479539/),%,19.46,33166,DB00661,Verapamil
,2467122,half-life,"It is water soluble and photostable, and has a long half-life of 35-50 h.",Pharmacokinetics of calcium antagonists. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2467122/),h,35-50,33986,DB00661,Verapamil
,31256062,oral bioavailability,The oral bioavailability of linagliptin is low (29.5%) due to its first pass metabolism in the intestine and liver.,Enhanced oral bioavailability of linagliptin by the influence of gallic acid and ellagic acid in male Wistar albino rats: involvement of p-glycoprotein inhibition. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31256062/),%,29.5,34852,DB00661,Verapamil
,27572343,net efflux ratio,"In MDCK-pAbcb1 cells, enrofloxacin was transported by P-gp with net efflux ratio of 2.48 and the efflux function was blocked by P-gp inhibitor verapamil.","Abcb1 in Pigs: Molecular cloning, tissues distribution, functional analysis, and its effect on pharmacokinetics of enrofloxacin. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27572343/),,2.48,36285,DB00661,Verapamil
>,12959634,bioavailability,The bioavailability of the oral formulation of oxcarbazepine is high (>95%).,Clinical pharmacokinetics of oxcarbazepine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959634/),%,95,36869,DB00661,Verapamil
,12959634,plasma protein binding,The plasma protein binding of MHD is about 40%.,Clinical pharmacokinetics of oxcarbazepine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959634/),%,40,36870,DB00661,Verapamil
,12959634,Elimination half-lives,Elimination half-lives in healthy volunteers are 1-5 hours for oxcarbazepine and 7-20 hours for MHD.,Clinical pharmacokinetics of oxcarbazepine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959634/),h,1-5,36871,DB00661,Verapamil
,12959634,Elimination half-lives,Elimination half-lives in healthy volunteers are 1-5 hours for oxcarbazepine and 7-20 hours for MHD.,Clinical pharmacokinetics of oxcarbazepine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12959634/),h,7-20,36872,DB00661,Verapamil
,8268824,recoveries,"Mean recoveries of 70 and 63% were obtained for verapamil and flecainide, respectively.",Measurement of plasma verapamil levels by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8268824/),%,70,36985,DB00661,Verapamil
,8268824,recoveries,"Mean recoveries of 70 and 63% were obtained for verapamil and flecainide, respectively.",Measurement of plasma verapamil levels by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8268824/),%,63,36986,DB00661,Verapamil
,8268824,area under the curve from 0 to 24 h (AUC[0-24]),"The mean values for the area under the curve from 0 to 24 h (AUC[0-24]), maximum achieved concentration (Cmax) and time to achieve the maximum concentration (Tmax) were 863 ng h-1 ml-1, 112 ng/ml and 4 h, respectively.",Measurement of plasma verapamil levels by high-performance liquid chromatography. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8268824/),[ng] / [h·ml],863,36987,DB00661,Verapamil
,8268824,maximum achieved concentration (Cmax),"The mean values for the area under the curve from 0 to 24 h (AUC[0-24]), maximum achieved concentration (Cmax) and time to achieve the maximum concentration (Tmax) were 863 ng h-1 ml-1, 112 ng/ml and 4 h, respectively.",Measurement of plasma verapamil levels by high-performance liquid chromatography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8268824/),[ng] / [ml],112,36988,DB00661,Verapamil
,8268824,time to achieve the maximum concentration (Tmax),"The mean values for the area under the curve from 0 to 24 h (AUC[0-24]), maximum achieved concentration (Cmax) and time to achieve the maximum concentration (Tmax) were 863 ng h-1 ml-1, 112 ng/ml and 4 h, respectively.",Measurement of plasma verapamil levels by high-performance liquid chromatography. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8268824/),h,4,36989,DB00661,Verapamil
,7128672,plasma clearance,"Following intravenous injection, the disposition of verapamil followed a biexponential pattern with a fast distribution phase and a slower elimination of phase (t 1/2 beta = 5.79 h), corresponding to a plasma clearance of 0.26 l/kg/h.",Clinical pharmacokinetics of verapamil in patients with atrial fibrillation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7128672/),[l] / [h·kg],0.26,37099,DB00661,Verapamil
,7128672,t 1/2 beta,"After oral administration, only an elimination phase was evident, with the same elimination rate (t 1/2 beta = 5.53 h).",Clinical pharmacokinetics of verapamil in patients with atrial fibrillation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7128672/),h,5.53,37100,DB00661,Verapamil
,7128672,oral bioavailability,The oral bioavailability was 10.5% +/- 7.5%.,Clinical pharmacokinetics of verapamil in patients with atrial fibrillation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7128672/),%,10.5,37101,DB00661,Verapamil
,7128672,plasma half-lives,"The norverapamil formed after i.v. and oral administration of verapamil had plasma half-lives of 5.86 h and 6.77 h, respectively.",Clinical pharmacokinetics of verapamil in patients with atrial fibrillation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7128672/),h,5.86,37102,DB00661,Verapamil
,7128672,plasma half-lives,"The norverapamil formed after i.v. and oral administration of verapamil had plasma half-lives of 5.86 h and 6.77 h, respectively.",Clinical pharmacokinetics of verapamil in patients with atrial fibrillation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7128672/),h,6.77,37103,DB00661,Verapamil
,17039785,lag time of release,In vitro the lag time of release profile of VH from VH-COERP was 5 h and then VH was extended release from VH-COERP in the following time.,[Preparation of verapamil hydrochloride controlled-onset extended-release pellets and its pharmacokinetics in dogs]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17039785/),h,5,38265,DB00661,Verapamil
,17039785,lag time,"Compared with the VH-DRP, VH-COERP in vivo has an obviously lag time (4 h) , Tmax was also delayed (8 h) and the relative bioavailability was (94.56 +/- 7.64)%.",[Preparation of verapamil hydrochloride controlled-onset extended-release pellets and its pharmacokinetics in dogs]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17039785/),h,4,38266,DB00661,Verapamil
,17039785,Tmax,"Compared with the VH-DRP, VH-COERP in vivo has an obviously lag time (4 h) , Tmax was also delayed (8 h) and the relative bioavailability was (94.56 +/- 7.64)%.",[Preparation of verapamil hydrochloride controlled-onset extended-release pellets and its pharmacokinetics in dogs]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17039785/),h,8,38267,DB00661,Verapamil
,17039785,relative bioavailability,"Compared with the VH-DRP, VH-COERP in vivo has an obviously lag time (4 h) , Tmax was also delayed (8 h) and the relative bioavailability was (94.56 +/- 7.64)%.",[Preparation of verapamil hydrochloride controlled-onset extended-release pellets and its pharmacokinetics in dogs]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17039785/),%,94.56,38268,DB00661,Verapamil
,8675249,area under the curve,"Mean nifedipine area under the curve values were greater with diltiazem than verapamil (1430 versus 1134 ng.h/mL, P = .026), with each greater than nifedipine alone (957 ng.h/mL).",Comparison of nifedipine alone and with diltiazem or verapamil in hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8675249/),[h·ng] / [ml],1430,38324,DB00661,Verapamil
,8675249,area under the curve,"Mean nifedipine area under the curve values were greater with diltiazem than verapamil (1430 versus 1134 ng.h/mL, P = .026), with each greater than nifedipine alone (957 ng.h/mL).",Comparison of nifedipine alone and with diltiazem or verapamil in hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8675249/),[h·ng] / [ml],1134,38325,DB00661,Verapamil
,8675249,area under the curve,"Mean nifedipine area under the curve values were greater with diltiazem than verapamil (1430 versus 1134 ng.h/mL, P = .026), with each greater than nifedipine alone (957 ng.h/mL).",Comparison of nifedipine alone and with diltiazem or verapamil in hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8675249/),[h·ng] / [ml],957,38326,DB00661,Verapamil
,21142292,influx rate constant [K(1)],"Most pharmacokinetic parameters of (R)- and (S)-verapamil as well as parameters describing exchange of radioactivity between plasma and brain (influx rate constant [K(1)] = 0.030 ± 0.003 and 0.031 ± 0.005 mL/mL/min and efflux rate constant [k(2)] = 0.099 ± 0.006 and 0.095 ± 0.008 min-1 for period 1 and 2, respectively) were not statistically different between the two periods although there was a trend for nonlinear pharmacokinetics for the (R)-enantiomer.",A combined accelerator mass spectrometry-positron emission tomography human microdose study with 14C- and 11C-labelled verapamil. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21142292/),[ml] / [min·ml],0.030,38695,DB00661,Verapamil
,21142292,influx rate constant [K(1)],"Most pharmacokinetic parameters of (R)- and (S)-verapamil as well as parameters describing exchange of radioactivity between plasma and brain (influx rate constant [K(1)] = 0.030 ± 0.003 and 0.031 ± 0.005 mL/mL/min and efflux rate constant [k(2)] = 0.099 ± 0.006 and 0.095 ± 0.008 min-1 for period 1 and 2, respectively) were not statistically different between the two periods although there was a trend for nonlinear pharmacokinetics for the (R)-enantiomer.",A combined accelerator mass spectrometry-positron emission tomography human microdose study with 14C- and 11C-labelled verapamil. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21142292/),[ml] / [min·ml],0.031,38696,DB00661,Verapamil
,21142292,efflux rate constant [k(2)],"Most pharmacokinetic parameters of (R)- and (S)-verapamil as well as parameters describing exchange of radioactivity between plasma and brain (influx rate constant [K(1)] = 0.030 ± 0.003 and 0.031 ± 0.005 mL/mL/min and efflux rate constant [k(2)] = 0.099 ± 0.006 and 0.095 ± 0.008 min-1 for period 1 and 2, respectively) were not statistically different between the two periods although there was a trend for nonlinear pharmacokinetics for the (R)-enantiomer.",A combined accelerator mass spectrometry-positron emission tomography human microdose study with 14C- and 11C-labelled verapamil. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21142292/),1/[min],0.099,38697,DB00661,Verapamil
,21142292,efflux rate constant [k(2)],"Most pharmacokinetic parameters of (R)- and (S)-verapamil as well as parameters describing exchange of radioactivity between plasma and brain (influx rate constant [K(1)] = 0.030 ± 0.003 and 0.031 ± 0.005 mL/mL/min and efflux rate constant [k(2)] = 0.099 ± 0.006 and 0.095 ± 0.008 min-1 for period 1 and 2, respectively) were not statistically different between the two periods although there was a trend for nonlinear pharmacokinetics for the (R)-enantiomer.",A combined accelerator mass spectrometry-positron emission tomography human microdose study with 14C- and 11C-labelled verapamil. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21142292/),1/[min],0.095,38698,DB00661,Verapamil
,17365275,apparent elimination half-life,[3H]BNP was eliminated with an apparent elimination half-life of 27.5 min after microinjection into the parietal cortex area 2 regions of the rat brain.,P-glycoprotein mediates brain-to-blood efflux transport of buprenorphine across the blood-brain barrier. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17365275/),min,27.5,39422,DB00661,Verapamil
,17365275,apparent efflux clearance,"The apparent efflux clearance of [3H]BNP across the BBB was 0.154 ml/min/g brain, which was calculated from the elimination rate constant (2.52 x 10- 2 min- 1) and the distribution volume in the brain (6.11 ml/g brain).",P-glycoprotein mediates brain-to-blood efflux transport of buprenorphine across the blood-brain barrier. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17365275/),[ml] / [brain·g·min],0.154,39423,DB00661,Verapamil
,17365275,elimination rate constant,"The apparent efflux clearance of [3H]BNP across the BBB was 0.154 ml/min/g brain, which was calculated from the elimination rate constant (2.52 x 10- 2 min- 1) and the distribution volume in the brain (6.11 ml/g brain).",P-glycoprotein mediates brain-to-blood efflux transport of buprenorphine across the blood-brain barrier. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17365275/),1·min-,2.52 x 10- 2,39424,DB00661,Verapamil
,17365275,distribution volume,"The apparent efflux clearance of [3H]BNP across the BBB was 0.154 ml/min/g brain, which was calculated from the elimination rate constant (2.52 x 10- 2 min- 1) and the distribution volume in the brain (6.11 ml/g brain).",P-glycoprotein mediates brain-to-blood efflux transport of buprenorphine across the blood-brain barrier. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17365275/),[ml] / [g],6.11,39425,DB00661,Verapamil
,8398588,peak plasma drug concentrations,4. Single doses of 500 and 1000 mg R-verapamil produced peak plasma drug concentrations in the range 1000-3000 ng ml-1.,"R-verapamil: pharmacokinetics and effects on PR interval, blood pressure and heart rate. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8398588/),[ng] / [ml],1000-3000,39767,DB00661,Verapamil
,11996900,Oral bioavailability,Oral bioavailability of M6G was 2.1%; 13% of oral M6G was deglucuronidated to morphine.,Verapamil decreases glucuronidase activity in the gut. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996900/),%,2.1,40433,DB00661,Verapamil
,11996900,Oral bioavailability,Oral bioavailability of M6G was 2.1%; 13% of oral M6G was deglucuronidated to morphine.,Verapamil decreases glucuronidase activity in the gut. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996900/),%,13,40434,DB00661,Verapamil
,11996900,IC(50),"In vitro experiments provided evidence that verapamil inhibits beta-glucuronidase from E. coli with an IC(50) of 30 microM, whereas no inhibition of the rat beta-glucuronidase from small intestine was seen.",Verapamil decreases glucuronidase activity in the gut. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996900/),μM,30,40435,DB00661,Verapamil
,19406953,elimination half-life (t(1/2)),"In the presence of topically instilled verapamil (1% w/v), elimination half-life (t(1/2)) (176 +/- 7 min), apparent elimination rate constant (lambda(z)) (0.0039 +/- 0.0001 min(-1)), and mean retention time (MRT) (143 +/- 30 min) of intravitreally administered quinidine were significantly different from those of the control (105 +/- 11 min, 0.0066 +/- 0.0007 min(-1), and 83 +/- 13 min, respectively).",Vitreal kinetics of quinidine in rabbits in the presence of topically coadministered P-glycoprotein substrates/modulators. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19406953/),min,176,40583,DB00661,Verapamil
,19406953,apparent elimination rate constant (lambda(z)),"In the presence of topically instilled verapamil (1% w/v), elimination half-life (t(1/2)) (176 +/- 7 min), apparent elimination rate constant (lambda(z)) (0.0039 +/- 0.0001 min(-1)), and mean retention time (MRT) (143 +/- 30 min) of intravitreally administered quinidine were significantly different from those of the control (105 +/- 11 min, 0.0066 +/- 0.0007 min(-1), and 83 +/- 13 min, respectively).",Vitreal kinetics of quinidine in rabbits in the presence of topically coadministered P-glycoprotein substrates/modulators. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19406953/),1/[min],0.0039,40584,DB00661,Verapamil
,19406953,mean retention time (MRT),"In the presence of topically instilled verapamil (1% w/v), elimination half-life (t(1/2)) (176 +/- 7 min), apparent elimination rate constant (lambda(z)) (0.0039 +/- 0.0001 min(-1)), and mean retention time (MRT) (143 +/- 30 min) of intravitreally administered quinidine were significantly different from those of the control (105 +/- 11 min, 0.0066 +/- 0.0007 min(-1), and 83 +/- 13 min, respectively).",Vitreal kinetics of quinidine in rabbits in the presence of topically coadministered P-glycoprotein substrates/modulators. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19406953/),min,143,40585,DB00661,Verapamil
,19406953,mean retention time (MRT),"In the presence of topically instilled verapamil (1% w/v), elimination half-life (t(1/2)) (176 +/- 7 min), apparent elimination rate constant (lambda(z)) (0.0039 +/- 0.0001 min(-1)), and mean retention time (MRT) (143 +/- 30 min) of intravitreally administered quinidine were significantly different from those of the control (105 +/- 11 min, 0.0066 +/- 0.0007 min(-1), and 83 +/- 13 min, respectively).",Vitreal kinetics of quinidine in rabbits in the presence of topically coadministered P-glycoprotein substrates/modulators. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19406953/),min,105,40586,DB00661,Verapamil
,19406953,mean retention time (MRT),"In the presence of topically instilled verapamil (1% w/v), elimination half-life (t(1/2)) (176 +/- 7 min), apparent elimination rate constant (lambda(z)) (0.0039 +/- 0.0001 min(-1)), and mean retention time (MRT) (143 +/- 30 min) of intravitreally administered quinidine were significantly different from those of the control (105 +/- 11 min, 0.0066 +/- 0.0007 min(-1), and 83 +/- 13 min, respectively).",Vitreal kinetics of quinidine in rabbits in the presence of topically coadministered P-glycoprotein substrates/modulators. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19406953/),min,83,40587,DB00661,Verapamil
,19406953,t(1/2),Intravitreal coadministration of quinidine and verapamil resulted in a significant increase in t(1/2) (159 +/- 9 min) and a decrease in lambda(z) (0.0043 +/- 0.0002 min(-1)) of quinidine.,Vitreal kinetics of quinidine in rabbits in the presence of topically coadministered P-glycoprotein substrates/modulators. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19406953/),min,159,40588,DB00661,Verapamil
,19406953,lambda(z),Intravitreal coadministration of quinidine and verapamil resulted in a significant increase in t(1/2) (159 +/- 9 min) and a decrease in lambda(z) (0.0043 +/- 0.0002 min(-1)) of quinidine.,Vitreal kinetics of quinidine in rabbits in the presence of topically coadministered P-glycoprotein substrates/modulators. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19406953/),1/[min],0.0043,40589,DB00661,Verapamil
,10778935,run times,"Separation of the eight analytes was achieved on a LUNA C8 analytical column (150x2 mm I.D., 5 microm particle size) with 5 mM ammonium acetate-acetonitrile as the mobile phase run with a gradient from 70:30 to 40:60 and run times of 15 min.","Rapid and highly sensitive method for the determination of verapamil, [2H7]verapamil and metabolites in biological fluids by liquid chromatography-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10778935/),min,15,40779,DB00661,Verapamil
,6362951,systemic bioavailability,The high hepatic extraction results in low systemic bioavailability (20%) after oral drug administration.,Clinical pharmacokinetics of verapamil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6362951/),%,20,41666,DB00661,Verapamil
,7955798,clearance,"S-Verapamil clearance was greater than R-verapamil clearance in all age groups (p < 0.001), and aging decreased S-verapamil (p < 0.05) and R-verapamil (p < 0.008) clearance (average +/- SD, S-verapamil clearance was 14.3 +/- 4.7, 13.4 +/- 5.2, and 11.7 +/- 5.2 ml/min/kg; R-verapamil clearance was 6.5 +/- 3.3, 5.6 +/- 2.8, and 4.5 +/- 1.6 ml/min/kg in young, middle-aged, and older subjects, respectively).",Verapamil stereoisomers during racemic verapamil administration: effects of aging and comparisons to administration of individual stereoisomers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955798/),[ml] / [kg·min],14.3,42545,DB00661,Verapamil
,7955798,clearance,"S-Verapamil clearance was greater than R-verapamil clearance in all age groups (p < 0.001), and aging decreased S-verapamil (p < 0.05) and R-verapamil (p < 0.008) clearance (average +/- SD, S-verapamil clearance was 14.3 +/- 4.7, 13.4 +/- 5.2, and 11.7 +/- 5.2 ml/min/kg; R-verapamil clearance was 6.5 +/- 3.3, 5.6 +/- 2.8, and 4.5 +/- 1.6 ml/min/kg in young, middle-aged, and older subjects, respectively).",Verapamil stereoisomers during racemic verapamil administration: effects of aging and comparisons to administration of individual stereoisomers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955798/),[ml] / [kg·min],13.4,42546,DB00661,Verapamil
,7955798,clearance,"S-Verapamil clearance was greater than R-verapamil clearance in all age groups (p < 0.001), and aging decreased S-verapamil (p < 0.05) and R-verapamil (p < 0.008) clearance (average +/- SD, S-verapamil clearance was 14.3 +/- 4.7, 13.4 +/- 5.2, and 11.7 +/- 5.2 ml/min/kg; R-verapamil clearance was 6.5 +/- 3.3, 5.6 +/- 2.8, and 4.5 +/- 1.6 ml/min/kg in young, middle-aged, and older subjects, respectively).",Verapamil stereoisomers during racemic verapamil administration: effects of aging and comparisons to administration of individual stereoisomers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955798/),[ml] / [kg·min],11.7,42547,DB00661,Verapamil
,7955798,clearance,"S-Verapamil clearance was greater than R-verapamil clearance in all age groups (p < 0.001), and aging decreased S-verapamil (p < 0.05) and R-verapamil (p < 0.008) clearance (average +/- SD, S-verapamil clearance was 14.3 +/- 4.7, 13.4 +/- 5.2, and 11.7 +/- 5.2 ml/min/kg; R-verapamil clearance was 6.5 +/- 3.3, 5.6 +/- 2.8, and 4.5 +/- 1.6 ml/min/kg in young, middle-aged, and older subjects, respectively).",Verapamil stereoisomers during racemic verapamil administration: effects of aging and comparisons to administration of individual stereoisomers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955798/),[ml] / [kg·min],6.5,42548,DB00661,Verapamil
,7955798,clearance,"S-Verapamil clearance was greater than R-verapamil clearance in all age groups (p < 0.001), and aging decreased S-verapamil (p < 0.05) and R-verapamil (p < 0.008) clearance (average +/- SD, S-verapamil clearance was 14.3 +/- 4.7, 13.4 +/- 5.2, and 11.7 +/- 5.2 ml/min/kg; R-verapamil clearance was 6.5 +/- 3.3, 5.6 +/- 2.8, and 4.5 +/- 1.6 ml/min/kg in young, middle-aged, and older subjects, respectively).",Verapamil stereoisomers during racemic verapamil administration: effects of aging and comparisons to administration of individual stereoisomers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955798/),[ml] / [kg·min],5.6,42549,DB00661,Verapamil
,7955798,clearance,"S-Verapamil clearance was greater than R-verapamil clearance in all age groups (p < 0.001), and aging decreased S-verapamil (p < 0.05) and R-verapamil (p < 0.008) clearance (average +/- SD, S-verapamil clearance was 14.3 +/- 4.7, 13.4 +/- 5.2, and 11.7 +/- 5.2 ml/min/kg; R-verapamil clearance was 6.5 +/- 3.3, 5.6 +/- 2.8, and 4.5 +/- 1.6 ml/min/kg in young, middle-aged, and older subjects, respectively).",Verapamil stereoisomers during racemic verapamil administration: effects of aging and comparisons to administration of individual stereoisomers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955798/),[ml] / [kg·min],4.5,42550,DB00661,Verapamil
,7955798,half-life,"A trend toward an age effect on elimination half-lives was seen (S-verapamil half-life, 281 +/- 116 versus 234 +/- 89 minutes in elderly versus young; R-verapamil half-life, 253 +/- 56 versus 199 +/- 58 minutes in elderly versus young, p = 0.08).",Verapamil stereoisomers during racemic verapamil administration: effects of aging and comparisons to administration of individual stereoisomers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955798/),min,281,42551,DB00661,Verapamil
,7955798,half-life,"A trend toward an age effect on elimination half-lives was seen (S-verapamil half-life, 281 +/- 116 versus 234 +/- 89 minutes in elderly versus young; R-verapamil half-life, 253 +/- 56 versus 199 +/- 58 minutes in elderly versus young, p = 0.08).",Verapamil stereoisomers during racemic verapamil administration: effects of aging and comparisons to administration of individual stereoisomers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955798/),min,234,42552,DB00661,Verapamil
,7955798,half-life,"A trend toward an age effect on elimination half-lives was seen (S-verapamil half-life, 281 +/- 116 versus 234 +/- 89 minutes in elderly versus young; R-verapamil half-life, 253 +/- 56 versus 199 +/- 58 minutes in elderly versus young, p = 0.08).",Verapamil stereoisomers during racemic verapamil administration: effects of aging and comparisons to administration of individual stereoisomers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955798/),min,253,42553,DB00661,Verapamil
,7955798,half-life,"A trend toward an age effect on elimination half-lives was seen (S-verapamil half-life, 281 +/- 116 versus 234 +/- 89 minutes in elderly versus young; R-verapamil half-life, 253 +/- 56 versus 199 +/- 58 minutes in elderly versus young, p = 0.08).",Verapamil stereoisomers during racemic verapamil administration: effects of aging and comparisons to administration of individual stereoisomers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7955798/),min,199,42554,DB00661,Verapamil
,33917412,flow rate,"The polar organic mobile phase composed of acetonitrile/methanol/trifluoroacetic acid/triethylamine (98:2:0.05: 0.025, v/v/v/v) and a flow rate of 0.5 mL/min was applied.",Development and Validation of a Chiral Liquid Chromatographic Assay for Enantiomeric Separation and Quantification of Verapamil in Rat Plasma: Stereoselective Pharmacokinetic Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33917412/),[ml] / [min],0.5,42615,DB00661,Verapamil
,33917412,recoveries,The intra- and inter-day precisions were not more than 11.6% and the recoveries of S-(-)- and R-(+)-VER at all quality control levels ranged from 92.3% to 98.2%.,Development and Validation of a Chiral Liquid Chromatographic Assay for Enantiomeric Separation and Quantification of Verapamil in Rat Plasma: Stereoselective Pharmacokinetic Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33917412/),%,92.3,42616,DB00661,Verapamil
,33917412,recoveries,The intra- and inter-day precisions were not more than 11.6% and the recoveries of S-(-)- and R-(+)-VER at all quality control levels ranged from 92.3% to 98.2%.,Development and Validation of a Chiral Liquid Chromatographic Assay for Enantiomeric Separation and Quantification of Verapamil in Rat Plasma: Stereoselective Pharmacokinetic Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33917412/),%,98.2,42617,DB00661,Verapamil
>,26429767,specific activity,"(R)- and (S)-[(11)C]EMP yields were ~30%, with specific activity>74 GBq/μmol and radiochemical purity>99%.",(R)-[¹¹C]Emopamil as a novel tracer for imaging enhanced P-glycoprotein function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26429767/),[gbq] / [μM],74,42704,DB00661,Verapamil
,7124631,Maintenance concentration,"Maintenance concentration remained between 77 and 156 ng/ml for all patients, and averaged 122 ng/ml.",Pharmacokinetics of verapamil: experience with a sustained intravenous infusion regimen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7124631/),[ng] / [ml],77 and 156,42926,DB00661,Verapamil
,7124631,Maintenance concentration,"Maintenance concentration remained between 77 and 156 ng/ml for all patients, and averaged 122 ng/ml.",Pharmacokinetics of verapamil: experience with a sustained intravenous infusion regimen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7124631/),[ng] / [ml],122,42927,DB00661,Verapamil
,3348317,coefficient of elimination,"After direct fetal digitalization we calculated that the coefficient of elimination for digoxin from the fetus was 0.0463 h-1, and digoxin elimination half-life was 15.9 hours.",Direct treatment of fetal supraventricular tachycardia after failed transplacental therapy. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3348317/),1/[h],0.0463,47668,DB00661,Verapamil
,3348317,elimination half-life,"After direct fetal digitalization we calculated that the coefficient of elimination for digoxin from the fetus was 0.0463 h-1, and digoxin elimination half-life was 15.9 hours.",Direct treatment of fetal supraventricular tachycardia after failed transplacental therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3348317/),h,15.9,47669,DB00661,Verapamil
,3348317,half,The latter time span is substantially less than the 50-hour half-life previously reported in newborn infants with low birth weight.,Direct treatment of fetal supraventricular tachycardia after failed transplacental therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3348317/),h,50,47670,DB00661,Verapamil
,3348317,f,The fetal/maternal concentration ratio of procainamide was 0.914.,Direct treatment of fetal supraventricular tachycardia after failed transplacental therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3348317/),,0.91,47671,DB00661,Verapamil
,3348317,concentration ratio,The fetal/maternal concentration ratio of procainamide was 0.914.,Direct treatment of fetal supraventricular tachycardia after failed transplacental therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3348317/),,0.91,47672,DB00661,Verapamil
,3348317,clearance,"However, maternal clearance of procainamide (9.7 ml/kg-1/min-1) was twice as long as the clearance reported for nonpregnant patients undergoing fast acetylation.",Direct treatment of fetal supraventricular tachycardia after failed transplacental therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3348317/),[ml] / [kg],9.7,47673,DB00661,Verapamil
,7248141,total plasma clearance,"2 After intravenous administration, plasma concentrations were much higher in the patient group such that the total plasma clearance was reduced from a mean of 1258 ml/min in normals to 616 ml/min in the patient group (P less than 0.0025).","Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7248141/),[ml] / [min],1258,48898,DB00661,Verapamil
,7248141,total plasma clearance,"2 After intravenous administration, plasma concentrations were much higher in the patient group such that the total plasma clearance was reduced from a mean of 1258 ml/min in normals to 616 ml/min in the patient group (P less than 0.0025).","Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7248141/),[ml] / [min],616,48899,DB00661,Verapamil
,7248141,apparent volume of distribution,"The apparent volume of distribution nearly doubled (6.76 v 12.05 l/kg, P less than 0.025) and the terminal half-life was prolonged four fold (3.7 v 14.2 h, P less than 0.001).","Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7248141/),[l] / [kg],6.76,48900,DB00661,Verapamil
,7248141,apparent volume of distribution,"The apparent volume of distribution nearly doubled (6.76 v 12.05 l/kg, P less than 0.025) and the terminal half-life was prolonged four fold (3.7 v 14.2 h, P less than 0.001).","Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7248141/),[l] / [kg],12.05,48901,DB00661,Verapamil
,7248141,terminal half-life,"The apparent volume of distribution nearly doubled (6.76 v 12.05 l/kg, P less than 0.025) and the terminal half-life was prolonged four fold (3.7 v 14.2 h, P less than 0.001).","Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7248141/),h,3.7,48902,DB00661,Verapamil
,7248141,terminal half-life,"The apparent volume of distribution nearly doubled (6.76 v 12.05 l/kg, P less than 0.025) and the terminal half-life was prolonged four fold (3.7 v 14.2 h, P less than 0.001).","Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7248141/),h,14.2,48903,DB00661,Verapamil
,7248141,absolute bioavailability,"The absolute bioavailability more than doubled (22.0% normals v 52.3% liver cirrhotics, P less than 0.001) and apparent oral clearance was reduced to only 20% of normal (6.38 v 1.30 l/min, P less than 0.001).","Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7248141/),%,22.0,48904,DB00661,Verapamil
,7248141,absolute bioavailability,"The absolute bioavailability more than doubled (22.0% normals v 52.3% liver cirrhotics, P less than 0.001) and apparent oral clearance was reduced to only 20% of normal (6.38 v 1.30 l/min, P less than 0.001).","Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7248141/),%,52.3,48905,DB00661,Verapamil
,7248141,apparent oral clearance,"The absolute bioavailability more than doubled (22.0% normals v 52.3% liver cirrhotics, P less than 0.001) and apparent oral clearance was reduced to only 20% of normal (6.38 v 1.30 l/min, P less than 0.001).","Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7248141/),[l] / [min],20,48906,DB00661,Verapamil
,7248141,apparent oral clearance,"The absolute bioavailability more than doubled (22.0% normals v 52.3% liver cirrhotics, P less than 0.001) and apparent oral clearance was reduced to only 20% of normal (6.38 v 1.30 l/min, P less than 0.001).","Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7248141/),[l] / [min],6.38,48907,DB00661,Verapamil
,7248141,apparent oral clearance,"The absolute bioavailability more than doubled (22.0% normals v 52.3% liver cirrhotics, P less than 0.001) and apparent oral clearance was reduced to only 20% of normal (6.38 v 1.30 l/min, P less than 0.001).","Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7248141/),[l] / [min],1.30,48908,DB00661,Verapamil
,10417494,inlet concentration,"The inlet concentration of (R/S)-verapamil was 120 mg l-1 in both periods, and ketoconazole was added at 40 mg l-1 in period 2.",The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10417494/),[mg] / [l],120,49074,DB00661,Verapamil
,9626462,trough,"The median trough dexverapamil plus norverapamil level on day 3 was 1110 ng/ml (range, 186-3385 ng/ml), and the median peak level was 2164 ng/ml (range, 964-8382 ng/ml).",Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626462/),[ng] / [ml],1110,50015,DB00661,Verapamil
,9626462,peak level,"The median trough dexverapamil plus norverapamil level on day 3 was 1110 ng/ml (range, 186-3385 ng/ml), and the median peak level was 2164 ng/ml (range, 964-8382 ng/ml).",Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626462/),[ng] / [ml],2164,50016,DB00661,Verapamil
,17910813,bioavailability,Co-administration with carvedilol increased ciclosporin bioavailability from 33% to 70%.,Carvedilol increases ciclosporin bioavailability by inhibiting P-glycoprotein-mediated transport. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17910813/),%,33,50838,DB00661,Verapamil
,17910813,bioavailability,Co-administration with carvedilol increased ciclosporin bioavailability from 33% to 70%.,Carvedilol increases ciclosporin bioavailability by inhibiting P-glycoprotein-mediated transport. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17910813/),%,70,50839,DB00661,Verapamil
,12779279,AUC,"[AUC: 3.09 mg/mL hr, Cmax: 203.95 microg/mL, Tmax: 8 hr].",Design and evaluation of matrix diffusion controlled transdermal patches of verapamil hydrochloride. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12779279/),[mg] / [h·ml],3.09,51357,DB00661,Verapamil
,12779279,Cmax,"[AUC: 3.09 mg/mL hr, Cmax: 203.95 microg/mL, Tmax: 8 hr].",Design and evaluation of matrix diffusion controlled transdermal patches of verapamil hydrochloride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12779279/),[μg] / [ml],203.95,51358,DB00661,Verapamil
,12779279,Tmax,"[AUC: 3.09 mg/mL hr, Cmax: 203.95 microg/mL, Tmax: 8 hr].",Design and evaluation of matrix diffusion controlled transdermal patches of verapamil hydrochloride. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12779279/),h,8,51359,DB00661,Verapamil
,2475689,bioavailability,"The mean bioavailability of the 120-mg tablet relative to the 240-mg tablet was 107%, with 95% confidence limits of 81 and 142%, indicating that the amount of verapamil available from the two tablets was similar.",Sustained-release verapamil: multiple-dose pharmacokinetic comparison of 120-mg and 240-mg tablets and the effect of halving a 240-mg tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2475689/),%,107,51887,DB00661,Verapamil
,2475689,bioavailability,"The mean bioavailability of the 120-mg tablet relative to the 240-mg tablet was 107%, with 95% confidence limits of 81 and 142%, indicating that the amount of verapamil available from the two tablets was similar.",Sustained-release verapamil: multiple-dose pharmacokinetic comparison of 120-mg and 240-mg tablets and the effect of halving a 240-mg tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2475689/),%,142,51888,DB00661,Verapamil
,8431970,Maximal concentrations,"Maximal concentrations of VPL and nor-VPL reached 705 +/- 473 and 308 +/- 122 ng/ml, respectively, with the steady-state concentrations being 265 +/- 42 ng/ml for VPL and 180 +/- 12 ng/ml for nor-VPL.",Effects of verapamil on the pharmacokinetics and metabolism of epirubicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8431970/),[ng] / [ml],705,51952,DB00661,Verapamil
,8431970,Maximal concentrations,"Maximal concentrations of VPL and nor-VPL reached 705 +/- 473 and 308 +/- 122 ng/ml, respectively, with the steady-state concentrations being 265 +/- 42 ng/ml for VPL and 180 +/- 12 ng/ml for nor-VPL.",Effects of verapamil on the pharmacokinetics and metabolism of epirubicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8431970/),[ng] / [ml],308,51953,DB00661,Verapamil
,8431970,steady-state concentrations,"Maximal concentrations of VPL and nor-VPL reached 705 +/- 473 and 308 +/- 122 ng/ml, respectively, with the steady-state concentrations being 265 +/- 42 ng/ml for VPL and 180 +/- 12 ng/ml for nor-VPL.",Effects of verapamil on the pharmacokinetics and metabolism of epirubicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8431970/),[ng] / [ml],265,51954,DB00661,Verapamil
,8431970,steady-state concentrations,"Maximal concentrations of VPL and nor-VPL reached 705 +/- 473 and 308 +/- 122 ng/ml, respectively, with the steady-state concentrations being 265 +/- 42 ng/ml for VPL and 180 +/- 12 ng/ml for nor-VPL.",Effects of verapamil on the pharmacokinetics and metabolism of epirubicin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8431970/),[ng] / [ml],180,51955,DB00661,Verapamil
,11697758,peak plasma concentration,"In steady-state conditions during combination treatment, a modest increase in mean (+/- SD) peak plasma concentration of dofetilide from 2.40 +/- 0.42 to 3.43 +/- 0.71 ng x ml(-1) (43% increase, p < 0.1) was noted.","Transient kinetic and dynamic interactions between verapamil and dofetilide, a class III antiarrhythmic. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11697758/),[ng] / [ml],2.40,52043,DB00661,Verapamil
,11697758,peak plasma concentration,"In steady-state conditions during combination treatment, a modest increase in mean (+/- SD) peak plasma concentration of dofetilide from 2.40 +/- 0.42 to 3.43 +/- 0.71 ng x ml(-1) (43% increase, p < 0.1) was noted.","Transient kinetic and dynamic interactions between verapamil and dofetilide, a class III antiarrhythmic. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11697758/),[ng] / [ml],3.43,52044,DB00661,Verapamil
,11697758,AUC,"During the combination period, for the first 4 hours, mean AUC values for D increased from 7.4 +/- 1.0 (D alone) to 9.2 +/- 1.4 ng x h x ml(-1) (26% increase, p <0.1).","Transient kinetic and dynamic interactions between verapamil and dofetilide, a class III antiarrhythmic. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11697758/),[h·ng] / [ml],7.4,52045,DB00661,Verapamil
,11697758,AUC,"During the combination period, for the first 4 hours, mean AUC values for D increased from 7.4 +/- 1.0 (D alone) to 9.2 +/- 1.4 ng x h x ml(-1) (26% increase, p <0.1).","Transient kinetic and dynamic interactions between verapamil and dofetilide, a class III antiarrhythmic. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11697758/),[h·ng] / [ml],9.2,52046,DB00661,Verapamil
,11697758,maximal,"The maximal mean increase in QT, over steady-state baseline values was 20 msec for D alone versus 26 msec during combination therapy.","Transient kinetic and dynamic interactions between verapamil and dofetilide, a class III antiarrhythmic. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11697758/),,20,52047,DB00661,Verapamil
,18816461,flow rate,The chromatographic separation was achieved using a 100 x 2 mm C(18) Waters Symmetry column combined with a gradient mobile phase composed of acetonitrile and 0.1% formic acid aqueous solution at a flow rate of 220 microL/min.,"Quantitative determination of capsaicin, a transient receptor potential channel vanilloid 1 agonist, by liquid chromatography quadrupole ion trap mass spectrometry: evaluation of in vitro metabolic stability. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18816461/),[μl] / [min],220,52506,DB00661,Verapamil
,18816461,T(1/2),"Results suggest very rapid degradation with T(1/2) ranging from 2.3 to 4.1 min and high clearance values suggesting that drug bioavailability will be considerably reduced, consequently affecting drug response and efficacy.","Quantitative determination of capsaicin, a transient receptor potential channel vanilloid 1 agonist, by liquid chromatography quadrupole ion trap mass spectrometry: evaluation of in vitro metabolic stability. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18816461/),min,2.3 to 4.1,52507,DB00661,Verapamil
,15848954,apparent elimination half-life,PTZ was eliminated with the apparent elimination half-life of 13.0 min after microinjection into the parietal cortex area 2 region of the rat brain.,In vivo evidence for the efflux transport of pentazocine from the brain across the blood-brain barrier using the brain efflux index method. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848954/),min,13.0,53252,DB00661,Verapamil
,15848954,apparent efflux clearance,"The apparent efflux clearance of PTZ across the BBB was 137 microl/min/g brain, which was calculated from the elimination rate constant (5.35 x 10(-2) min(-1) and the distribution volume in the brain (2.56 ml/g brain).",In vivo evidence for the efflux transport of pentazocine from the brain across the blood-brain barrier using the brain efflux index method. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848954/),[μl] / [brain·g·min],137,53253,DB00661,Verapamil
,15848954,elimination rate constant,"The apparent efflux clearance of PTZ across the BBB was 137 microl/min/g brain, which was calculated from the elimination rate constant (5.35 x 10(-2) min(-1) and the distribution volume in the brain (2.56 ml/g brain).",In vivo evidence for the efflux transport of pentazocine from the brain across the blood-brain barrier using the brain efflux index method. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848954/),1/[min],5.35 x 10(-2),53254,DB00661,Verapamil
,15848954,distribution volume,"The apparent efflux clearance of PTZ across the BBB was 137 microl/min/g brain, which was calculated from the elimination rate constant (5.35 x 10(-2) min(-1) and the distribution volume in the brain (2.56 ml/g brain).",In vivo evidence for the efflux transport of pentazocine from the brain across the blood-brain barrier using the brain efflux index method. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848954/),[ml] / [brain·g],2.56,53255,DB00661,Verapamil
,21206135,apparent permeability coefficients,"PDE-310 exhibited high Caco-2 cell permeability in the absorptive direction (apparent permeability coefficients, ∼20 × 10(-6) cm/s), with higher transport in the secretory direction, giving efflux ratios of 3.9 and 2.6 at 5 and 10 µM, respectively.","Preclinical pharmacokinetics of PDE-310, a novel PDE4 inhibitor. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21206135/),,∼20 × 10(-6),53461,DB00661,Verapamil
,21206135,efflux ratios,"PDE-310 exhibited high Caco-2 cell permeability in the absorptive direction (apparent permeability coefficients, ∼20 × 10(-6) cm/s), with higher transport in the secretory direction, giving efflux ratios of 3.9 and 2.6 at 5 and 10 µM, respectively.","Preclinical pharmacokinetics of PDE-310, a novel PDE4 inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21206135/),,3.9,53462,DB00661,Verapamil
,21206135,efflux ratios,"PDE-310 exhibited high Caco-2 cell permeability in the absorptive direction (apparent permeability coefficients, ∼20 × 10(-6) cm/s), with higher transport in the secretory direction, giving efflux ratios of 3.9 and 2.6 at 5 and 10 µM, respectively.","Preclinical pharmacokinetics of PDE-310, a novel PDE4 inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21206135/),,2.6,53463,DB00661,Verapamil
,21206135,K(m),"Following intravenous administration, nonlinear elimination of PDE-310 was observed at the tested dose ranges (K(m), 0.87 µg/mL; V(max), 0.3 mg·h(-1)·kg(-1)).","Preclinical pharmacokinetics of PDE-310, a novel PDE4 inhibitor. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21206135/),[μg] / [ml],0.87,53464,DB00661,Verapamil
,21206135,V(max),"Following intravenous administration, nonlinear elimination of PDE-310 was observed at the tested dose ranges (K(m), 0.87 µg/mL; V(max), 0.3 mg·h(-1)·kg(-1)).","Preclinical pharmacokinetics of PDE-310, a novel PDE4 inhibitor. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21206135/),[mg] / [h·kg],0.3,53465,DB00661,Verapamil
>,21206135,oral bioavailability,PDE-310 exhibited high oral bioavailability (>70%) and was distributed well to various tissues except brain and testis.,"Preclinical pharmacokinetics of PDE-310, a novel PDE4 inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21206135/),%,70,53466,DB00661,Verapamil
,11263576,extraction recovery,The extraction recovery averaged 59% for rocuronium and 83% for the internal standard.,Quantitative determination of rocuronium in human plasma by liquid chromatography-electrospray ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11263576/),%,59,53798,DB00661,Verapamil
,11263576,extraction recovery,The extraction recovery averaged 59% for rocuronium and 83% for the internal standard.,Quantitative determination of rocuronium in human plasma by liquid chromatography-electrospray ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11263576/),%,83,53799,DB00661,Verapamil
,11263576,limit of quantification (LOQ),"The limit of quantification (LOQ), using 500 microl of plasma, was 25 ng/ml.",Quantitative determination of rocuronium in human plasma by liquid chromatography-electrospray ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11263576/),[ng] / [ml],25,53800,DB00661,Verapamil
>,8201390,absolute neutrophil count [ANC],"In more than 600 patient-treatments, bone marrow toxicity was negligible (mean absolute neutrophil count [ANC] > 2.0 x 10(9)/L).","Results of a clinical trial in humans with refractory cancer of the intracellular histamine antagonist, N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine-HCl, in combination with various single antineoplastic agents. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8201390/),,2.0,53802,DB00661,Verapamil
,9661014,half-life,"The concentration of ITZ in liver tissue declined in parallel with the plasma ITZ concentration until 24 h after intravenous injection of the drug (half-life, 5 h); however, the ITZ in brain tissue rapidly disappeared (half-life, 0.4 h).",P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661014/),h,5,56069,DB00661,Verapamil
,9661014,half-life,"The concentration of ITZ in liver tissue declined in parallel with the plasma ITZ concentration until 24 h after intravenous injection of the drug (half-life, 5 h); however, the ITZ in brain tissue rapidly disappeared (half-life, 0.4 h).",P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661014/),h,0.4,56070,DB00661,Verapamil
,26299424,absolute oral bioavailability,"The absolute oral bioavailability of pristimerin is 28.4% at a dose of 1 mg·kg(-1), and the bioavailability was poor.",Absorption and metabolism characteristics of pristimerin as determined by a sensitive and reliable LC-MS/MS method. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26299424/),%,28.4,56116,DB00661,Verapamil
,26299424,half-life,"Pristimerin was stable in S9 fractions but metabolized in HLM with a half-life of 20.4 min, which indicated that pristimerin could be mainly metabolized by phase I enzymes.",Absorption and metabolism characteristics of pristimerin as determined by a sensitive and reliable LC-MS/MS method. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26299424/),min,20.4,56117,DB00661,Verapamil
,2631477,absolute bioavailability,"Despite its almost complete absorption following oral administration, gallopamil has an absolute bioavailability of only 15% due to an extensive hepatic first-pass metabolism.",[Pharmacokinetics and metabolism of gallopamil]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2631477/),%,15,57672,DB00661,Verapamil
,2631477,bioavailability,During multiple oral dosing bioavailability increases to approximately 25% indicating a partial saturation of first-pass metabolism.,[Pharmacokinetics and metabolism of gallopamil]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2631477/),%,25,57673,DB00661,Verapamil
,2631477,half-life time,Since the half-life time of gallopamil is on average 3-6 h a minimum of three times daily dosing of the instant-release 50 mg tablet is required in order to maintain therapeutic plasma concentrations.,[Pharmacokinetics and metabolism of gallopamil]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2631477/),h,3-6,57674,DB00661,Verapamil
,17973928,oral bioavailability,The oral bioavailability of verapamil was 32.9% in normal rats and 34.4% in rats with liver fibrosis.,Effects of liver fibrosis on verapamil pharmacokinetics in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17973928/),%,32.9,58066,DB00661,Verapamil
,17973928,oral bioavailability,The oral bioavailability of verapamil was 32.9% in normal rats and 34.4% in rats with liver fibrosis.,Effects of liver fibrosis on verapamil pharmacokinetics in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17973928/),%,34.4,58067,DB00661,Verapamil
,24075962,terminal half-life,FEX had a terminal half-life of 1.7h and a liver extraction of 3%.,Effects of verapamil on the pharmacokinetics and hepatobiliary disposition of fexofenadine in pigs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24075962/),h,1.7,58641,DB00661,Verapamil
,24075962,liver extraction,FEX had a terminal half-life of 1.7h and a liver extraction of 3%.,Effects of verapamil on the pharmacokinetics and hepatobiliary disposition of fexofenadine in pigs. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24075962/),%,3,58642,DB00661,Verapamil
,2501057,plasma clearance,"Verapamil slightly decreased the plasma clearance of flecainide (7.78 +/- 0.60 ml/kg/min for flecainide alone, 7.34 +/- 0.48 ml/kg/min for flecainide and verapamil together, p less than 0.05).",The pharmacodynamic and pharmacokinetic interaction between single doses of flecainide acetate and verapamil: effects on cardiac function and drug clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2501057/),[ml] / [kg·min],7.78,59211,DB00661,Verapamil
,2501057,plasma clearance,"Verapamil slightly decreased the plasma clearance of flecainide (7.78 +/- 0.60 ml/kg/min for flecainide alone, 7.34 +/- 0.48 ml/kg/min for flecainide and verapamil together, p less than 0.05).",The pharmacodynamic and pharmacokinetic interaction between single doses of flecainide acetate and verapamil: effects on cardiac function and drug clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2501057/),[ml] / [kg·min],7.34,59212,DB00661,Verapamil
,11958560,bioavailability (F),"Following oral administration, the bioavailability (F) of I (17%) was much higher than that of II (1%).","Differences in the absorption, metabolism and biliary excretion of a diastereomeric pair of alphavbeta3-antagonists in rat: limited role of P-glycoprotein. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11958560/),%,17,59734,DB00661,Verapamil
,11958560,bioavailability (F),"Following oral administration, the bioavailability (F) of I (17%) was much higher than that of II (1%).","Differences in the absorption, metabolism and biliary excretion of a diastereomeric pair of alphavbeta3-antagonists in rat: limited role of P-glycoprotein. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11958560/),%,1,59735,DB00661,Verapamil
,15304428,intestinal,"The intestinal and hepatic extraction of VL, calculated directly from area under the curve measurements, were 79% and 92%, respectively, and are in contrast to our previous dog results that showed VL intestinal extraction to be negligible.",Differentiation of gut and hepatic first-pass loss of verapamil in intestinal and vascular access-ported (IVAP) rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15304428/),%,79,60353,DB00661,Verapamil
,15304428,hepatic extraction,"The intestinal and hepatic extraction of VL, calculated directly from area under the curve measurements, were 79% and 92%, respectively, and are in contrast to our previous dog results that showed VL intestinal extraction to be negligible.",Differentiation of gut and hepatic first-pass loss of verapamil in intestinal and vascular access-ported (IVAP) rabbits. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15304428/),%,92,60354,DB00661,Verapamil
,29988733,Papp[BL-AP],"Compared to raw BBR and physical mixture, BBR-BS20-NCs facilitated the dissolution rate and extent of release of BBR in aqueous solution, and further increased the absorption of BBR in MDCK-MDR1 monolayer by overcoming the Pgp-mediated secretory transport (Papp[BL-AP] values of 2.85 ± 0.04 × 10-6 cm/s, 2.21 ± 0.14 × 10-6 cm/s, and 2.00 ± 0.07 × 10-6 cm/s for pure BBR, physical mixture, and BBR-BS20-NCs, respectively).",Dual-functional Brij-S20-modified nanocrystal formulation enhances the intestinal transport and oral bioavailability of berberine. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29988733/),[cm] / [s],2.85,60490,DB00661,Verapamil
,29988733,Papp[BL-AP],"Compared to raw BBR and physical mixture, BBR-BS20-NCs facilitated the dissolution rate and extent of release of BBR in aqueous solution, and further increased the absorption of BBR in MDCK-MDR1 monolayer by overcoming the Pgp-mediated secretory transport (Papp[BL-AP] values of 2.85 ± 0.04 × 10-6 cm/s, 2.21 ± 0.14 × 10-6 cm/s, and 2.00 ± 0.07 × 10-6 cm/s for pure BBR, physical mixture, and BBR-BS20-NCs, respectively).",Dual-functional Brij-S20-modified nanocrystal formulation enhances the intestinal transport and oral bioavailability of berberine. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29988733/),[cm] / [s],2.21,60491,DB00661,Verapamil
,29988733,Papp[BL-AP],"Compared to raw BBR and physical mixture, BBR-BS20-NCs facilitated the dissolution rate and extent of release of BBR in aqueous solution, and further increased the absorption of BBR in MDCK-MDR1 monolayer by overcoming the Pgp-mediated secretory transport (Papp[BL-AP] values of 2.85 ± 0.04 × 10-6 cm/s, 2.21 ± 0.14 × 10-6 cm/s, and 2.00 ± 0.07 × 10-6 cm/s for pure BBR, physical mixture, and BBR-BS20-NCs, respectively).",Dual-functional Brij-S20-modified nanocrystal formulation enhances the intestinal transport and oral bioavailability of berberine. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29988733/),[cm] / [s],2.00,60492,DB00661,Verapamil
,29988733,relative bioavailability,"Significant improvements in the maximum concentration observed (Cmax) and area under drug concentration-time curve (AUC0-t) of BBR-BS20-NCs were obtained in pharmacokinetic studies compared to pure BBR, and the relative bioavailability of BBR-BS20-NCs to pure BBR was 404.1%.",Dual-functional Brij-S20-modified nanocrystal formulation enhances the intestinal transport and oral bioavailability of berberine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29988733/),%,404.1,60493,DB00661,Verapamil
,3803414,apparent oral clearance,"The apparent oral clearance of verapamil was decreased after both the twice and thrice daily dosage regimens (1.38 and 1.841/min, respectively) as compared to the single dose (4.391/min).",Pharmacokinetics of verapamil in patients with hypertension. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3803414/),1/[min],1.38,61810,DB00661,Verapamil
,3803414,apparent oral clearance,"The apparent oral clearance of verapamil was decreased after both the twice and thrice daily dosage regimens (1.38 and 1.841/min, respectively) as compared to the single dose (4.391/min).",Pharmacokinetics of verapamil in patients with hypertension. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3803414/),1/[min],1.841,61811,DB00661,Verapamil
,3803414,apparent oral clearance,"The apparent oral clearance of verapamil was decreased after both the twice and thrice daily dosage regimens (1.38 and 1.841/min, respectively) as compared to the single dose (4.391/min).",Pharmacokinetics of verapamil in patients with hypertension. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3803414/),1/[min],4.391,61812,DB00661,Verapamil
,3803414,plasma half-life,The plasma half-life of verapamil was increased from 3.34 h (single dose) to 4.65 h (b.i.d.).,Pharmacokinetics of verapamil in patients with hypertension. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3803414/),h,3.34,61813,DB00661,Verapamil
,3803414,plasma half-life,The plasma half-life of verapamil was increased from 3.34 h (single dose) to 4.65 h (b.i.d.).,Pharmacokinetics of verapamil in patients with hypertension. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3803414/),h,4.65,61814,DB00661,Verapamil
,3803414,AUC,"Decreased elimination of norverapamil was also found after multiple doses of verapamil, as shown by an increase in the adjusted AUC of norverapamil (adjusted to a verapamil dose of 80 mg), namely from 574.9 h X ng X ml-1 (single dose) to 1172 h X ng X ml-1 (b.d.) and to 841 h X ng X ml-1 (t.d.s.).",Pharmacokinetics of verapamil in patients with hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3803414/),[h·ng] / [ml],574.9,61815,DB00661,Verapamil
,3803414,AUC,"Decreased elimination of norverapamil was also found after multiple doses of verapamil, as shown by an increase in the adjusted AUC of norverapamil (adjusted to a verapamil dose of 80 mg), namely from 574.9 h X ng X ml-1 (single dose) to 1172 h X ng X ml-1 (b.d.) and to 841 h X ng X ml-1 (t.d.s.).",Pharmacokinetics of verapamil in patients with hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3803414/),[h·ng] / [ml],1172,61816,DB00661,Verapamil
,3803414,AUC,"Decreased elimination of norverapamil was also found after multiple doses of verapamil, as shown by an increase in the adjusted AUC of norverapamil (adjusted to a verapamil dose of 80 mg), namely from 574.9 h X ng X ml-1 (single dose) to 1172 h X ng X ml-1 (b.d.) and to 841 h X ng X ml-1 (t.d.s.).",Pharmacokinetics of verapamil in patients with hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3803414/),[h·ng] / [ml],841,61817,DB00661,Verapamil
,3803414,plasma half-life,The plasma half-life of norverapamil increase from 5.68 h to 7.34 h during twice daily dosing.,Pharmacokinetics of verapamil in patients with hypertension. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3803414/),h,5.68,61818,DB00661,Verapamil
,3803414,plasma half-life,The plasma half-life of norverapamil increase from 5.68 h to 7.34 h during twice daily dosing.,Pharmacokinetics of verapamil in patients with hypertension. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3803414/),h,7.34,61819,DB00661,Verapamil
,15637133,peak-area ratios,The peak-area ratios (drugs/internal standard) were linked to concentrations (6.4-1282 microg/L for T3; 6.5-1309.8 microg/L for T4; 20-2000 microg/L for TE4c) according to a quadratic equation.,Quantification of antimalarial bisthiazolium compounds and their neutral bioprecursors in plasma by liquid chromatography-electrospray mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15637133/),μ,6.4-1282,63885,DB00661,Verapamil
,15637133,peak-area ratios,The peak-area ratios (drugs/internal standard) were linked to concentrations (6.4-1282 microg/L for T3; 6.5-1309.8 microg/L for T4; 20-2000 microg/L for TE4c) according to a quadratic equation.,Quantification of antimalarial bisthiazolium compounds and their neutral bioprecursors in plasma by liquid chromatography-electrospray mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15637133/),μ,6.5-1309.8,63886,DB00661,Verapamil
,15637133,peak-area ratios,The peak-area ratios (drugs/internal standard) were linked to concentrations (6.4-1282 microg/L for T3; 6.5-1309.8 microg/L for T4; 20-2000 microg/L for TE4c) according to a quadratic equation.,Quantification of antimalarial bisthiazolium compounds and their neutral bioprecursors in plasma by liquid chromatography-electrospray mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15637133/),[μg] / [l],20-2000,63887,DB00661,Verapamil
,15637133,extraction recoveries,"The mean extraction recoveries were 87%, 98%, and 80% for T3, T4, and TE4c, respectively.",Quantification of antimalarial bisthiazolium compounds and their neutral bioprecursors in plasma by liquid chromatography-electrospray mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15637133/),%,87,63888,DB00661,Verapamil
,15637133,extraction recoveries,"The mean extraction recoveries were 87%, 98%, and 80% for T3, T4, and TE4c, respectively.",Quantification of antimalarial bisthiazolium compounds and their neutral bioprecursors in plasma by liquid chromatography-electrospray mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15637133/),%,98,63889,DB00661,Verapamil
,15637133,extraction recoveries,"The mean extraction recoveries were 87%, 98%, and 80% for T3, T4, and TE4c, respectively.",Quantification of antimalarial bisthiazolium compounds and their neutral bioprecursors in plasma by liquid chromatography-electrospray mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15637133/),%,80,63890,DB00661,Verapamil
,20538723,bioavailability (F),The bioavailability (F) of talinolol after high-dose administration to the stomach was significantly greater than that achieved by the low dose (approximately 18 versus 2%).,Role of p-glycoprotein in region-specific gastrointestinal absorption of talinolol in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20538723/),%,18,64134,DB00661,Verapamil
,20538723,bioavailability (F),The bioavailability (F) of talinolol after high-dose administration to the stomach was significantly greater than that achieved by the low dose (approximately 18 versus 2%).,Role of p-glycoprotein in region-specific gastrointestinal absorption of talinolol in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20538723/),%,2,64135,DB00661,Verapamil
,7636539,MTD,"The MTD of dexverapamil was 150 mg/m2 every 4 hours (900 mg/m2/d), and hypotension was the principal dose-limiting toxicity.",Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7636539/),[mg] / [m2],150,64149,DB00661,Verapamil
,25854676,C max,"When the rats were pretreated with verapamil, the C max of triptolide increased from 423.01 ± 19.59 to 565.33 ± 20.27 ng/mL (33.6 %), and the AUC0-6 h increased by approximately 57 % when co-administered with verapamil.",Influence of Verapamil on Pharmacokinetics of Triptolide in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25854676/),[ng] / [ml],423.01,64841,DB00661,Verapamil
,25854676,C max,"When the rats were pretreated with verapamil, the C max of triptolide increased from 423.01 ± 19.59 to 565.33 ± 20.27 ng/mL (33.6 %), and the AUC0-6 h increased by approximately 57 % when co-administered with verapamil.",Influence of Verapamil on Pharmacokinetics of Triptolide in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25854676/),[ng] / [ml],565.33,64842,DB00661,Verapamil
,19881252,areas under drug concentration-time curve (AUC) ratios,"In vivo animal experiments, the time-courses of the concentrations of TEL in ELF and AMs following oral administration of TEL solution (50 mg/4 mL/kg) to rats were markedly higher than in plasma, and areas under drug concentration-time curve (AUC) ratios of ELF/plasma and AMs/plasma were 2.4 and 65.3, respectively.","Distribution characteristics of telithromycin, a novel ketolide antimicrobial agent applied for treatment of respiratory infection, in lung epithelial lining fluid and alveolar macrophages. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19881252/),,2.4,65311,DB00661,Verapamil
,19881252,areas under drug concentration-time curve (AUC) ratios,"In vivo animal experiments, the time-courses of the concentrations of TEL in ELF and AMs following oral administration of TEL solution (50 mg/4 mL/kg) to rats were markedly higher than in plasma, and areas under drug concentration-time curve (AUC) ratios of ELF/plasma and AMs/plasma were 2.4 and 65.3, respectively.","Distribution characteristics of telithromycin, a novel ketolide antimicrobial agent applied for treatment of respiratory infection, in lung epithelial lining fluid and alveolar macrophages. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19881252/),,65.3,65312,DB00661,Verapamil
,27620464,entrapment efficiency,"The entrapment efficiency of VRP in the vesicles ranged from 24 to 64%, with best physical stability displayed with transfersomal vesicles prepared using sodium deoxycholate.",Composite chitosan-transfersomal vesicles for improved transnasal permeation and bioavailability of verapamil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27620464/),%,24 to 64,65313,DB00661,Verapamil
,27620464,absolute bioavailability,The chitosan composite transfersomal formulation exhibited absolute bioavailability of 81.83% compared to the oral solution which displayed only 13.04%.,Composite chitosan-transfersomal vesicles for improved transnasal permeation and bioavailability of verapamil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27620464/),%,81.83,65314,DB00661,Verapamil
,27620464,absolute bioavailability,The chitosan composite transfersomal formulation exhibited absolute bioavailability of 81.83% compared to the oral solution which displayed only 13.04%.,Composite chitosan-transfersomal vesicles for improved transnasal permeation and bioavailability of verapamil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27620464/),%,13.04,65315,DB00661,Verapamil
,32710209,bioavailability,"In contrast, the predicted bioavailability of posaconazole, a poorly soluble drug, decreased from 12% pre-RYGBS to 5% post-RYGBS.",PBPK modeling of CYP3A and P-gp substrates to predict drug-drug interactions in patients undergoing Roux-en-Y gastric bypass surgery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32710209/),%,12,65654,DB00661,Verapamil
,32710209,bioavailability,"In contrast, the predicted bioavailability of posaconazole, a poorly soluble drug, decreased from 12% pre-RYGBS to 5% post-RYGBS.",PBPK modeling of CYP3A and P-gp substrates to predict drug-drug interactions in patients undergoing Roux-en-Y gastric bypass surgery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32710209/),%,5,65655,DB00661,Verapamil
,33957192,inhibition constants,"Experiments in vitro indicated that CLZ competitively inhibited the conversion of RIS to 9-hydroxy-RIS with the inhibition constants of 1.36 and 3.0 μM in rat and human liver microsomes, respectively.",Clozapine affects the pharmacokinetics of risperidone and inhibits its metabolism and P-glycoprotein-mediated transport in vivo and in vitro: A safety attention to antipsychotic polypharmacy with clozapine and risperidone. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33957192/),μM,1.36,66266,DB00661,Verapamil
,33957192,inhibition constants,"Experiments in vitro indicated that CLZ competitively inhibited the conversion of RIS to 9-hydroxy-RIS with the inhibition constants of 1.36 and 3.0 μM in rat and human liver microsomes, respectively.",Clozapine affects the pharmacokinetics of risperidone and inhibits its metabolism and P-glycoprotein-mediated transport in vivo and in vitro: A safety attention to antipsychotic polypharmacy with clozapine and risperidone. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33957192/),μM,3.0,66267,DB00661,Verapamil
,26514967,AUC(0-12),The kinetic disposition of MHD was enantioselective with plasma accumulation (AUC(0-12) S-(+)/R-(-) ratio of 4.38) and lower fraction unbound (0.37 vs 0.42) of the S-(+)-MHD enantiomer.,Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),,4.38,66710,DB00661,Verapamil
,26514967,fraction unbound,The kinetic disposition of MHD was enantioselective with plasma accumulation (AUC(0-12) S-(+)/R-(-) ratio of 4.38) and lower fraction unbound (0.37 vs 0.42) of the S-(+)-MHD enantiomer.,Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),,0.37,66711,DB00661,Verapamil
,26514967,fraction unbound,The kinetic disposition of MHD was enantioselective with plasma accumulation (AUC(0-12) S-(+)/R-(-) ratio of 4.38) and lower fraction unbound (0.37 vs 0.42) of the S-(+)-MHD enantiomer.,Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),,0.42,66712,DB00661,Verapamil
,26514967,mean residence time,Treatment with verapamil reduced the OXC mean residence time (4.91 vs 4.20 h) and apparent volume of distribution (4.72 vs 3.15 L/kg).,Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),h,4.91,66713,DB00661,Verapamil
,26514967,mean residence time,Treatment with verapamil reduced the OXC mean residence time (4.91 vs 4.20 h) and apparent volume of distribution (4.72 vs 3.15 L/kg).,Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),h,4.20,66714,DB00661,Verapamil
,26514967,apparent volume of distribution,Treatment with verapamil reduced the OXC mean residence time (4.91 vs 4.20 h) and apparent volume of distribution (4.72 vs 3.15 L/kg).,Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[l] / [kg],4.72,66715,DB00661,Verapamil
,26514967,apparent volume of distribution,Treatment with verapamil reduced the OXC mean residence time (4.91 vs 4.20 h) and apparent volume of distribution (4.72 vs 3.15 L/kg).,Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[l] / [kg],3.15,66716,DB00661,Verapamil
,26514967,C max total,"Verapamil also increased for both MHD enantiomers C max total [R-(-)-MHD: 2.65 vs 2.98 μg/mL and S-(+)-MHD: 10.15 vs 11.60 μg/mL], C average [R-(-)-MHD: 1.98 vs 2.18 μg/mL and S-(+)-MHD: 8.10 vs 8.83 μg/mL], and AUC(0-12) [R-(-)-MHD: 23.79 vs 26.19 μg h/mL and S-(+)-MHD: 97.87 vs 108.35 μg h/mL].",Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[μg] / [ml],2.65,66717,DB00661,Verapamil
,26514967,C max total,"Verapamil also increased for both MHD enantiomers C max total [R-(-)-MHD: 2.65 vs 2.98 μg/mL and S-(+)-MHD: 10.15 vs 11.60 μg/mL], C average [R-(-)-MHD: 1.98 vs 2.18 μg/mL and S-(+)-MHD: 8.10 vs 8.83 μg/mL], and AUC(0-12) [R-(-)-MHD: 23.79 vs 26.19 μg h/mL and S-(+)-MHD: 97.87 vs 108.35 μg h/mL].",Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[μg] / [ml],2.98,66718,DB00661,Verapamil
,26514967,C max total,"Verapamil also increased for both MHD enantiomers C max total [R-(-)-MHD: 2.65 vs 2.98 μg/mL and S-(+)-MHD: 10.15 vs 11.60 μg/mL], C average [R-(-)-MHD: 1.98 vs 2.18 μg/mL and S-(+)-MHD: 8.10 vs 8.83 μg/mL], and AUC(0-12) [R-(-)-MHD: 23.79 vs 26.19 μg h/mL and S-(+)-MHD: 97.87 vs 108.35 μg h/mL].",Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[μg] / [ml],10.15,66719,DB00661,Verapamil
,26514967,C max total,"Verapamil also increased for both MHD enantiomers C max total [R-(-)-MHD: 2.65 vs 2.98 μg/mL and S-(+)-MHD: 10.15 vs 11.60 μg/mL], C average [R-(-)-MHD: 1.98 vs 2.18 μg/mL and S-(+)-MHD: 8.10 vs 8.83 μg/mL], and AUC(0-12) [R-(-)-MHD: 23.79 vs 26.19 μg h/mL and S-(+)-MHD: 97.87 vs 108.35 μg h/mL].",Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[μg] / [ml],11.60,66720,DB00661,Verapamil
,26514967,C average,"Verapamil also increased for both MHD enantiomers C max total [R-(-)-MHD: 2.65 vs 2.98 μg/mL and S-(+)-MHD: 10.15 vs 11.60 μg/mL], C average [R-(-)-MHD: 1.98 vs 2.18 μg/mL and S-(+)-MHD: 8.10 vs 8.83 μg/mL], and AUC(0-12) [R-(-)-MHD: 23.79 vs 26.19 μg h/mL and S-(+)-MHD: 97.87 vs 108.35 μg h/mL].",Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[μg] / [ml],1.98,66721,DB00661,Verapamil
,26514967,C average,"Verapamil also increased for both MHD enantiomers C max total [R-(-)-MHD: 2.65 vs 2.98 μg/mL and S-(+)-MHD: 10.15 vs 11.60 μg/mL], C average [R-(-)-MHD: 1.98 vs 2.18 μg/mL and S-(+)-MHD: 8.10 vs 8.83 μg/mL], and AUC(0-12) [R-(-)-MHD: 23.79 vs 26.19 μg h/mL and S-(+)-MHD: 97.87 vs 108.35 μg h/mL].",Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[μg] / [ml],2.18,66722,DB00661,Verapamil
,26514967,C average,"Verapamil also increased for both MHD enantiomers C max total [R-(-)-MHD: 2.65 vs 2.98 μg/mL and S-(+)-MHD: 10.15 vs 11.60 μg/mL], C average [R-(-)-MHD: 1.98 vs 2.18 μg/mL and S-(+)-MHD: 8.10 vs 8.83 μg/mL], and AUC(0-12) [R-(-)-MHD: 23.79 vs 26.19 μg h/mL and S-(+)-MHD: 97.87 vs 108.35 μg h/mL].",Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[μg] / [ml],8.10,66723,DB00661,Verapamil
,26514967,C average,"Verapamil also increased for both MHD enantiomers C max total [R-(-)-MHD: 2.65 vs 2.98 μg/mL and S-(+)-MHD: 10.15 vs 11.60 μg/mL], C average [R-(-)-MHD: 1.98 vs 2.18 μg/mL and S-(+)-MHD: 8.10 vs 8.83 μg/mL], and AUC(0-12) [R-(-)-MHD: 23.79 vs 26.19 μg h/mL and S-(+)-MHD: 97.87 vs 108.35 μg h/mL].",Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[μg] / [ml],8.83,66724,DB00661,Verapamil
,26514967,AUC(0-12),"Verapamil also increased for both MHD enantiomers C max total [R-(-)-MHD: 2.65 vs 2.98 μg/mL and S-(+)-MHD: 10.15 vs 11.60 μg/mL], C average [R-(-)-MHD: 1.98 vs 2.18 μg/mL and S-(+)-MHD: 8.10 vs 8.83 μg/mL], and AUC(0-12) [R-(-)-MHD: 23.79 vs 26.19 μg h/mL and S-(+)-MHD: 97.87 vs 108.35 μg h/mL].",Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[h·μg] / [ml],23.79,66725,DB00661,Verapamil
,26514967,AUC(0-12),"Verapamil also increased for both MHD enantiomers C max total [R-(-)-MHD: 2.65 vs 2.98 μg/mL and S-(+)-MHD: 10.15 vs 11.60 μg/mL], C average [R-(-)-MHD: 1.98 vs 2.18 μg/mL and S-(+)-MHD: 8.10 vs 8.83 μg/mL], and AUC(0-12) [R-(-)-MHD: 23.79 vs 26.19 μg h/mL and S-(+)-MHD: 97.87 vs 108.35 μg h/mL].",Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[h·μg] / [ml],26.19,66726,DB00661,Verapamil
,26514967,AUC(0-12),"Verapamil also increased for both MHD enantiomers C max total [R-(-)-MHD: 2.65 vs 2.98 μg/mL and S-(+)-MHD: 10.15 vs 11.60 μg/mL], C average [R-(-)-MHD: 1.98 vs 2.18 μg/mL and S-(+)-MHD: 8.10 vs 8.83 μg/mL], and AUC(0-12) [R-(-)-MHD: 23.79 vs 26.19 μg h/mL and S-(+)-MHD: 97.87 vs 108.35 μg h/mL].",Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[h·μg] / [ml],97.87,66727,DB00661,Verapamil
,26514967,AUC(0-12),"Verapamil also increased for both MHD enantiomers C max total [R-(-)-MHD: 2.65 vs 2.98 μg/mL and S-(+)-MHD: 10.15 vs 11.60 μg/mL], C average [R-(-)-MHD: 1.98 vs 2.18 μg/mL and S-(+)-MHD: 8.10 vs 8.83 μg/mL], and AUC(0-12) [R-(-)-MHD: 23.79 vs 26.19 μg h/mL and S-(+)-MHD: 97.87 vs 108.35 μg h/mL].",Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26514967/),[h·μg] / [ml],108.35,66728,DB00661,Verapamil
,9862055,alpha half life,"Pharmacokinetics were similar with both infusion schedules with a mean alpha half life of 11.3 and 13.2 minutes, for the 30-minute and 150-minute infusion, and a terminal half life of 13.5 and 15 hours, respectively.",Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9862055/),min,11.3,67530,DB00661,Verapamil
,9862055,alpha half life,"Pharmacokinetics were similar with both infusion schedules with a mean alpha half life of 11.3 and 13.2 minutes, for the 30-minute and 150-minute infusion, and a terminal half life of 13.5 and 15 hours, respectively.",Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9862055/),min,13.2,67531,DB00661,Verapamil
,9862055,terminal half life,"Pharmacokinetics were similar with both infusion schedules with a mean alpha half life of 11.3 and 13.2 minutes, for the 30-minute and 150-minute infusion, and a terminal half life of 13.5 and 15 hours, respectively.",Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9862055/),h,13.5,67532,DB00661,Verapamil
,9862055,terminal half life,"Pharmacokinetics were similar with both infusion schedules with a mean alpha half life of 11.3 and 13.2 minutes, for the 30-minute and 150-minute infusion, and a terminal half life of 13.5 and 15 hours, respectively.",Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9862055/),h,15,67533,DB00661,Verapamil
,3378854,hepatic clearance,"The verapamil hepatic clearance was 423 +/- 92 ml/m, the hepatic plasma flow was 819 +/- 318 ml/m, and the verapamil intrinsic clearance was 1431 +/- 961 ml/m.",Verapamil pharmacokinetics and liver function in patients with cirrhosis. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378854/),[ml] / [m],423,71936,DB00661,Verapamil
,3378854,hepatic plasma flow,"The verapamil hepatic clearance was 423 +/- 92 ml/m, the hepatic plasma flow was 819 +/- 318 ml/m, and the verapamil intrinsic clearance was 1431 +/- 961 ml/m.",Verapamil pharmacokinetics and liver function in patients with cirrhosis. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378854/),[ml] / [m],819,71937,DB00661,Verapamil
,3378854,intrinsic clearance,"The verapamil hepatic clearance was 423 +/- 92 ml/m, the hepatic plasma flow was 819 +/- 318 ml/m, and the verapamil intrinsic clearance was 1431 +/- 961 ml/m.",Verapamil pharmacokinetics and liver function in patients with cirrhosis. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378854/),[ml] / [m],1431,71938,DB00661,Verapamil
,30553305,drug loading capacity,"The drug loading capacity and entrapment efficiency of PTX-loaded CR PMs were 35.24 ± 1.58% and 86.99 ± 12.26%, respectively.",Preparation and evaluation of carboxymethyl chitosan-rhein polymeric micelles with synergistic antitumor effect for oral delivery of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30553305/),%,35.24,71977,DB00661,Verapamil
,30553305,entrapment efficiency,"The drug loading capacity and entrapment efficiency of PTX-loaded CR PMs were 35.24 ± 1.58% and 86.99 ± 12.26%, respectively.",Preparation and evaluation of carboxymethyl chitosan-rhein polymeric micelles with synergistic antitumor effect for oral delivery of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30553305/),%,86.99,71978,DB00661,Verapamil
,1829915,steady state plasma concentration,"Bepridil was administered in a continuous 36 h infusion at 22 mg/kg/36 h, with a dose scheme which should result in a steady state plasma concentration of approximately 5 mumol/l, able to reverse anthracycline resistance in vitro.",Bepridil in combination with anthracyclines to reverse anthracycline resistance in cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829915/),[μM] / [l],5,74555,DB00661,Verapamil
,1829915,plasma concentration,"Pharmacokinetic studies demonstrated a median bepridil plasma concentration of 5.3 mumol/l (range 2.6-19.3 mumol/l), at the time of administration of the anthracycline.",Bepridil in combination with anthracyclines to reverse anthracycline resistance in cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1829915/),[μM] / [l],5.3,74556,DB00661,Verapamil
,18242899,efflux ratio,"Over a range from 0.03 to 0.3%, pluronic F68 increased apical-to-basolateral permeability (AP-BL) and decreased basolateral-to-apical permeability (BL-AP) of the P-gp substrate CEL in Caco-2 cell monolayer with the efflux ratio values of 2.8+/-0.3 (0.03%), 2.6+/-0.3 (0.1%), 2.3+/-0.2 (0.3%), respectively.",Effect of pluronic F68 block copolymer on P-glycoprotein transport and CYP3A4 metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18242899/),,2.8,75380,DB00661,Verapamil
,18242899,efflux ratio,"Over a range from 0.03 to 0.3%, pluronic F68 increased apical-to-basolateral permeability (AP-BL) and decreased basolateral-to-apical permeability (BL-AP) of the P-gp substrate CEL in Caco-2 cell monolayer with the efflux ratio values of 2.8+/-0.3 (0.03%), 2.6+/-0.3 (0.1%), 2.3+/-0.2 (0.3%), respectively.",Effect of pluronic F68 block copolymer on P-glycoprotein transport and CYP3A4 metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18242899/),,2.6,75381,DB00661,Verapamil
,18242899,efflux ratio,"Over a range from 0.03 to 0.3%, pluronic F68 increased apical-to-basolateral permeability (AP-BL) and decreased basolateral-to-apical permeability (BL-AP) of the P-gp substrate CEL in Caco-2 cell monolayer with the efflux ratio values of 2.8+/-0.3 (0.03%), 2.6+/-0.3 (0.1%), 2.3+/-0.2 (0.3%), respectively.",Effect of pluronic F68 block copolymer on P-glycoprotein transport and CYP3A4 metabolism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18242899/),,2.3,75382,DB00661,Verapamil
,18242899,IC(50),"Furthermore, CYP3A4-catalyzed formation of 1'-hydroxymidazolam was inhibited by pluronic F68 with IC(50) and K(i) values of 0.11 and 0.16 mg/ml, respectively.",Effect of pluronic F68 block copolymer on P-glycoprotein transport and CYP3A4 metabolism. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18242899/),[mg] / [ml],0.11,75383,DB00661,Verapamil
,18242899,K(i),"Furthermore, CYP3A4-catalyzed formation of 1'-hydroxymidazolam was inhibited by pluronic F68 with IC(50) and K(i) values of 0.11 and 0.16 mg/ml, respectively.",Effect of pluronic F68 block copolymer on P-glycoprotein transport and CYP3A4 metabolism. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18242899/),[mg] / [ml],0.16,75384,DB00661,Verapamil
,2429094,terminal phase half-life (t1/2),"On the rest day, the terminal phase half-life (t1/2) of verapamil averaged 161 +/- 23 min after i.v. injection of the drug.",Influence of prolonged submaximal exercise on the pharmacokinetics of verapamil in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2429094/),min,161,75712,DB00661,Verapamil
,2429094,total clearance,"The total clearance was 772 +/- 125 ml/min, and the area volume of distribution was 198 +/- 53 L.",Influence of prolonged submaximal exercise on the pharmacokinetics of verapamil in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2429094/),[ml] / [min],772,75713,DB00661,Verapamil
,2429094,area volume of distribution,"The total clearance was 772 +/- 125 ml/min, and the area volume of distribution was 198 +/- 53 L.",Influence of prolonged submaximal exercise on the pharmacokinetics of verapamil in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2429094/),l,198,75714,DB00661,Verapamil
,6725618,areas under the plasma concentration-time curve,The areas under the plasma concentration-time curve after the final dose were greater than after the first dose for both tiapamil (+53 per cent) and its metabolite (+24 per cent).,"Pharmacokinetics and hemodynamic effects of tiapamil: exercise performance, thallium stress scintigraphy, and radionuclide ventriculography. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6725618/),%,53,75984,DB00661,Verapamil
,6725618,areas under the plasma concentration-time curve,The areas under the plasma concentration-time curve after the final dose were greater than after the first dose for both tiapamil (+53 per cent) and its metabolite (+24 per cent).,"Pharmacokinetics and hemodynamic effects of tiapamil: exercise performance, thallium stress scintigraphy, and radionuclide ventriculography. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6725618/),%,24,75985,DB00661,Verapamil
,1283570,trough verapamil concentrations (Cmin),Comparable trough verapamil concentrations (Cmin) were observed with verapamil IR (98 micrograms/L) and SR (81 micrograms/L); morning Cmin verapamil concentrations were higher than daytime Cmin values.,"Comparative efficacy, safety and pharmacokinetics of verapamil SR vs verapamil IR in hypertensive patients. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1283570/),[μg] / [l],98,76929,DB00661,Verapamil
,1283570,trough verapamil concentrations (Cmin),Comparable trough verapamil concentrations (Cmin) were observed with verapamil IR (98 micrograms/L) and SR (81 micrograms/L); morning Cmin verapamil concentrations were higher than daytime Cmin values.,"Comparative efficacy, safety and pharmacokinetics of verapamil SR vs verapamil IR in hypertensive patients. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1283570/),[μg] / [l],81,76930,DB00661,Verapamil
,26169402,maximal relative efficacy (E max),"GSK1322322 demonstrated a uniform activity against the intracellular forms of all S. aureus strains tested, disregarding their resistance phenotypes, with a maximal relative efficacy (E max) of a 0.5 to 1 log10 CFU decrease compared to the original inoculum within 24 h and a static concentration (C s) close to its MIC in broth.",Cellular pharmacokinetics and intracellular activity of the novel peptide deformylase inhibitor GSK1322322 against Staphylococcus aureus laboratory and clinical strains with various resistance phenotypes: studies with human THP-1 monocytes and J774 murine macrophages. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26169402/),cfu,0.5 to 1,77391,DB00661,Verapamil
,29326490,half-life (T½),"Paromomycin showed good PK properties after intravenous dose in male BALB/c mice which included low plasma clearance, i.e., <10% of hepatic blood flow in mice, high volume of distribution (Vd), and half-life (T½) of 2.6 h.","Investigation of in vitro absorption, distribution, metabolism, and excretion and in vivo pharmacokinetics of paromomycin: Influence on oral bioavailability. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29326490/),h,2.6,79471,DB00661,Verapamil
,29326490,oral bioavailability,"Following per oral dose, it exhibits low oral bioavailability (0.3%) with carboxymethyl cellulose formulation.","Investigation of in vitro absorption, distribution, metabolism, and excretion and in vivo pharmacokinetics of paromomycin: Influence on oral bioavailability. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29326490/),%,0.3,79472,DB00661,Verapamil
up to,29326490,oral bioavailability,"Comparatively significant increase in oral plasma exposure of paromomycin was observed with an alternative oral formulation approach, use of P-gp and CYP inhibitors resulting in improved oral bioavailability up to 16%.","Investigation of in vitro absorption, distribution, metabolism, and excretion and in vivo pharmacokinetics of paromomycin: Influence on oral bioavailability. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29326490/),%,16,79473,DB00661,Verapamil
,3230150,Cmax,"The mean Cmax, tmax, AUC, apparent plasma clearance, and terminal t 1/2 were 190 +/- 108 ng/mL, 0.6 +/- 0.2 hour, 676 +/- 443 ng.hr/mL, 3926 +/- 1933 mL/min, and 11.4 +/- 4.0 hr, respectively, on the nonhemodialysis day.","An evaluation of the pharmacokinetics, pharmacodynamics, and dialyzability of verapamil in chronic hemodialysis patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3230150/),[ng] / [ml],190,79768,DB00661,Verapamil
,3230150,terminal t 1/2,"The mean Cmax, tmax, AUC, apparent plasma clearance, and terminal t 1/2 were 190 +/- 108 ng/mL, 0.6 +/- 0.2 hour, 676 +/- 443 ng.hr/mL, 3926 +/- 1933 mL/min, and 11.4 +/- 4.0 hr, respectively, on the nonhemodialysis day.","An evaluation of the pharmacokinetics, pharmacodynamics, and dialyzability of verapamil in chronic hemodialysis patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3230150/),h,11.4,79769,DB00661,Verapamil
,3230150,t 1/2,"The t 1/2 during hemodialysis was 3.6 +/- 1.1 hr, compared with 3.4 +/- 0.7 hr during the same period of time postdose on the nonhemodialysis day (NS, P greater than .05).","An evaluation of the pharmacokinetics, pharmacodynamics, and dialyzability of verapamil in chronic hemodialysis patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3230150/),h,3.6,79770,DB00661,Verapamil
,3230150,t 1/2,"The t 1/2 during hemodialysis was 3.6 +/- 1.1 hr, compared with 3.4 +/- 0.7 hr during the same period of time postdose on the nonhemodialysis day (NS, P greater than .05).","An evaluation of the pharmacokinetics, pharmacodynamics, and dialyzability of verapamil in chronic hemodialysis patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3230150/),h,3.4,79771,DB00661,Verapamil
,4084670,Bioavailability,Bioavailability (corrected for dose and elimination rate constant) following intranasal administration (36% +/- 7%) was approximately 3 fold that after oral administration (13% +/- 3%).,Pharmacodynamics of acute intranasal administration of verapamil: comparison with i.v. and oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4084670/),%,36,79924,DB00661,Verapamil
,4084670,Bioavailability,Bioavailability (corrected for dose and elimination rate constant) following intranasal administration (36% +/- 7%) was approximately 3 fold that after oral administration (13% +/- 3%).,Pharmacodynamics of acute intranasal administration of verapamil: comparison with i.v. and oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4084670/),%,13,79925,DB00661,Verapamil
,4084670,absorption half-life,Absorption from the nasal cavity appeared instantaneous compared to an absorption half-life of 50 +/- 6 min after oral administration.,Pharmacodynamics of acute intranasal administration of verapamil: comparison with i.v. and oral administration. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4084670/),min,50,79926,DB00661,Verapamil
,9849746,oral bioavailability,Concomitant intake of rifampicin (600 mg/die) induced especially the presystemic (prehepatic) metabolism of verapamil so that oral bioavailability approached zero and PD effects almost diminished.,Effect of age on pharmacokinetics and pharmacodynamics in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9849746/),,zero,80042,DB00661,Verapamil
,2903820,oral bioavailability,"The oral bioavailability of bisoprolol is high (90%) and the drug has a long elimination half-life which allows once-daily administration; in addition, it is hepatically and renally cleared in equal proportions.","Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2903820/),%,90,81252,DB00661,Verapamil
>,19229957,m/z,VER and NOR enantiomers in rat plasma was analyzed by LC-MS/MS (m/z = 441.3 > 165.5 for the NOR and m/z 455.3 > 165.5 for the VER enantiomers) using a Chiralpak AD column.,Influence of N-hexane inhalation on the enantioselective pharmacokinetics and metabolism of verapamil in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19229957/),,441.3,82289,DB00661,Verapamil
>,19229957,m/z,VER and NOR enantiomers in rat plasma was analyzed by LC-MS/MS (m/z = 441.3 > 165.5 for the NOR and m/z 455.3 > 165.5 for the VER enantiomers) using a Chiralpak AD column.,Influence of N-hexane inhalation on the enantioselective pharmacokinetics and metabolism of verapamil in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19229957/),,165.5,82290,DB00661,Verapamil
>,19229957,m/z,VER and NOR enantiomers in rat plasma was analyzed by LC-MS/MS (m/z = 441.3 > 165.5 for the NOR and m/z 455.3 > 165.5 for the VER enantiomers) using a Chiralpak AD column.,Influence of N-hexane inhalation on the enantioselective pharmacokinetics and metabolism of verapamil in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19229957/),,455.3,82291,DB00661,Verapamil
>,19229957,m/z,VER and NOR enantiomers in rat plasma was analyzed by LC-MS/MS (m/z = 441.3 > 165.5 for the NOR and m/z 455.3 > 165.5 for the VER enantiomers) using a Chiralpak AD column.,Influence of N-hexane inhalation on the enantioselective pharmacokinetics and metabolism of verapamil in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19229957/),,165.5,82292,DB00661,Verapamil
,19229957,AUC(0-infinity),"The pharmacokinetics of VER was enantioselective in control rats, with higher plasma proportions of the (-)-(S)-VER eutomer (AUC(0-infinity) = 250.8 vs. 120.4 ng/ml/h; P < or = 0.05, Wilcoxon test).",Influence of N-hexane inhalation on the enantioselective pharmacokinetics and metabolism of verapamil in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19229957/),[ng] / [h·ml],250.8,82293,DB00661,Verapamil
,19229957,AUC(0-infinity),"The pharmacokinetics of VER was enantioselective in control rats, with higher plasma proportions of the (-)-(S)-VER eutomer (AUC(0-infinity) = 250.8 vs. 120.4 ng/ml/h; P < or = 0.05, Wilcoxon test).",Influence of N-hexane inhalation on the enantioselective pharmacokinetics and metabolism of verapamil in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19229957/),[ng] / [h·ml],120.4,82294,DB00661,Verapamil
,19229957,AUC(0-infinity) ratio,"The (S)-NOR metabolite was also found to accumulate in plasma of control animals, with an S/R AUC(0-infinity) ratio of 1.5.",Influence of N-hexane inhalation on the enantioselective pharmacokinetics and metabolism of verapamil in rats. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19229957/),,1.5,82295,DB00661,Verapamil
,11393715,run time,The run time was 2.6 min.,Rapid determination of citalopram in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11393715/),min,2.6,83879,DB00661,Verapamil
,11393715,limit of quant,The limit of quantitation was 0.96 ng/ml using 1 ml of plasma.,Rapid determination of citalopram in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11393715/),[ng] / [ml],0.96,83880,DB00661,Verapamil
,12565199,clearance rate,Toxicokinetics parameters showed verapamil could increase clearance rate from 20.8+/-1.51 to 44.3+/-7.0 ml kg(-1)s(-1) and reduce AUC of P(-)soman from 2.08+/-0.151 to 0.996+/-0.172 mg s l(-1).,Effects of pretreatment with verapamil on the toxicokinetics of soman in rabbits and distribution in mouse brain and diaphragm. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12565199/),[ml] / [kg],20.8,84472,DB00661,Verapamil
,12565199,clearance rate,Toxicokinetics parameters showed verapamil could increase clearance rate from 20.8+/-1.51 to 44.3+/-7.0 ml kg(-1)s(-1) and reduce AUC of P(-)soman from 2.08+/-0.151 to 0.996+/-0.172 mg s l(-1).,Effects of pretreatment with verapamil on the toxicokinetics of soman in rabbits and distribution in mouse brain and diaphragm. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12565199/),[ml] / [kg],44.3,84473,DB00661,Verapamil
,12565199,AUC,Toxicokinetics parameters showed verapamil could increase clearance rate from 20.8+/-1.51 to 44.3+/-7.0 ml kg(-1)s(-1) and reduce AUC of P(-)soman from 2.08+/-0.151 to 0.996+/-0.172 mg s l(-1).,Effects of pretreatment with verapamil on the toxicokinetics of soman in rabbits and distribution in mouse brain and diaphragm. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12565199/),[mg·s] / [l],2.08,84474,DB00661,Verapamil
,12565199,AUC,Toxicokinetics parameters showed verapamil could increase clearance rate from 20.8+/-1.51 to 44.3+/-7.0 ml kg(-1)s(-1) and reduce AUC of P(-)soman from 2.08+/-0.151 to 0.996+/-0.172 mg s l(-1).,Effects of pretreatment with verapamil on the toxicokinetics of soman in rabbits and distribution in mouse brain and diaphragm. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12565199/),[mg·s] / [l],0.996,84475,DB00661,Verapamil
,7102502,elimination half-lives (t 1/2's),"Significant increases (p less than 0.01) were seen in the elimination half-lives (t 1/2's) of both verapamil (6.4 +/- 3.5 to 12 +/- 5 hours, mean +/- SD) and norverapamil (10.3 +/- 6 to 16.5 +/- 7 hours) during chronic oral verapamil administration.",Prolongation of verapamil elimination kinetics during chronic oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7102502/),h,6.4,84518,DB00661,Verapamil
,7102502,elimination half-lives (t 1/2's),"Significant increases (p less than 0.01) were seen in the elimination half-lives (t 1/2's) of both verapamil (6.4 +/- 3.5 to 12 +/- 5 hours, mean +/- SD) and norverapamil (10.3 +/- 6 to 16.5 +/- 7 hours) during chronic oral verapamil administration.",Prolongation of verapamil elimination kinetics during chronic oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7102502/),h,12,84519,DB00661,Verapamil
,7102502,elimination half-lives (t 1/2's),"Significant increases (p less than 0.01) were seen in the elimination half-lives (t 1/2's) of both verapamil (6.4 +/- 3.5 to 12 +/- 5 hours, mean +/- SD) and norverapamil (10.3 +/- 6 to 16.5 +/- 7 hours) during chronic oral verapamil administration.",Prolongation of verapamil elimination kinetics during chronic oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7102502/),h,10.3,84520,DB00661,Verapamil
,7102502,elimination half-lives (t 1/2's),"Significant increases (p less than 0.01) were seen in the elimination half-lives (t 1/2's) of both verapamil (6.4 +/- 3.5 to 12 +/- 5 hours, mean +/- SD) and norverapamil (10.3 +/- 6 to 16.5 +/- 7 hours) during chronic oral verapamil administration.",Prolongation of verapamil elimination kinetics during chronic oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7102502/),h,16.5,84521,DB00661,Verapamil
,9569055,area under the plasma concentration-time curve (AUC),"In nine intrapatient comparisons, the area under the plasma concentration-time curve (AUC) of epirubicin was significantly reduced by dexverapamil (mean 2968 vs 1901 microg ml[-1] h[-1], P= 0.02).",Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9569055/),[μg] / [h·ml],2968,84831,DB00661,Verapamil
,9569055,area under the plasma concentration-time curve (AUC),"In nine intrapatient comparisons, the area under the plasma concentration-time curve (AUC) of epirubicin was significantly reduced by dexverapamil (mean 2968 vs 1901 microg ml[-1] h[-1], P= 0.02).",Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9569055/),[μg] / [h·ml],1901,84832,DB00661,Verapamil
,9569055,trough plasma levels,The mean trough plasma levels of dexverapamil and its major metabolite nor-dexverapamil were 1.2 and 1.5 microM respectively.,Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9569055/),μM,1.2,84833,DB00661,Verapamil
,9569055,trough plasma levels,The mean trough plasma levels of dexverapamil and its major metabolite nor-dexverapamil were 1.2 and 1.5 microM respectively.,Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9569055/),μM,1.5,84834,DB00661,Verapamil
,10456485,area under the concentration time-curve (AUC),"CyA markedly increased the area under the concentration time-curve (AUC) of both IDA [558.26 (197.25) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); P < 0.01] and IDAOL [2896.60 (736.38) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.001] when coadministered as a single modulator, due to a lower total body clearance (CL) [83.51 (52.44) l x h(-1) x m(-2) vs 139.65 (69.45) l x h(-1) x m(-2); NS].",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[h·μg] / [l],558.26,85527,DB00661,Verapamil
,10456485,area under the concentration time-curve (AUC),"CyA markedly increased the area under the concentration time-curve (AUC) of both IDA [558.26 (197.25) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); P < 0.01] and IDAOL [2896.60 (736.38) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.001] when coadministered as a single modulator, due to a lower total body clearance (CL) [83.51 (52.44) l x h(-1) x m(-2) vs 139.65 (69.45) l x h(-1) x m(-2); NS].",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[h·μg] / [l],315.44,85528,DB00661,Verapamil
,10456485,area under the concentration time-curve (AUC),"CyA markedly increased the area under the concentration time-curve (AUC) of both IDA [558.26 (197.25) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); P < 0.01] and IDAOL [2896.60 (736.38) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.001] when coadministered as a single modulator, due to a lower total body clearance (CL) [83.51 (52.44) l x h(-1) x m(-2) vs 139.65 (69.45) l x h(-1) x m(-2); NS].",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[h·μg] / [l],2896.60,85529,DB00661,Verapamil
,10456485,area under the concentration time-curve (AUC),"CyA markedly increased the area under the concentration time-curve (AUC) of both IDA [558.26 (197.25) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); P < 0.01] and IDAOL [2896.60 (736.38) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.001] when coadministered as a single modulator, due to a lower total body clearance (CL) [83.51 (52.44) l x h(-1) x m(-2) vs 139.65 (69.45) l x h(-1) x m(-2); NS].",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[h·μg] / [l],1028.49,85530,DB00661,Verapamil
,10456485,total body clearance (CL),"CyA markedly increased the area under the concentration time-curve (AUC) of both IDA [558.26 (197.25) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); P < 0.01] and IDAOL [2896.60 (736.38) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.001] when coadministered as a single modulator, due to a lower total body clearance (CL) [83.51 (52.44) l x h(-1) x m(-2) vs 139.65 (69.45) l x h(-1) x m(-2); NS].",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[l] / [(m)^2·h],83.51,85531,DB00661,Verapamil
,10456485,total body clearance (CL),"CyA markedly increased the area under the concentration time-curve (AUC) of both IDA [558.26 (197.25) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); P < 0.01] and IDAOL [2896.60 (736.38) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.001] when coadministered as a single modulator, due to a lower total body clearance (CL) [83.51 (52.44) l x h(-1) x m(-2) vs 139.65 (69.45) l x h(-1) x m(-2); NS].",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[l] / [(m)^2·h],139.65,85532,DB00661,Verapamil
,10456485,exposure,"When patients received two MDR modulators simultaneously (D-Ver plus CyA), IDA exposure was essentially the same as in those of the no inhibitor group [331.29 (95.49) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); NS], whereas the IDAOL total body exposure was greater than in the no inhibitor group [2030.32 (401.11) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.01], even if less than in patients receiving CyA as a single MDR modulator (IDA + CyA group) [AUC 2030.32 (401.11) microg x h x l(-1) vs 2896.60 (736.38) microg x h x l(-1); P < 0.05], suggesting an antagonistic effect against those of CyA on IDA and IDAOL elimination and/or an unpredictable redistribution.",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[h·μg] / [l],331.29,85533,DB00661,Verapamil
,10456485,exposure,"When patients received two MDR modulators simultaneously (D-Ver plus CyA), IDA exposure was essentially the same as in those of the no inhibitor group [331.29 (95.49) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); NS], whereas the IDAOL total body exposure was greater than in the no inhibitor group [2030.32 (401.11) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.01], even if less than in patients receiving CyA as a single MDR modulator (IDA + CyA group) [AUC 2030.32 (401.11) microg x h x l(-1) vs 2896.60 (736.38) microg x h x l(-1); P < 0.05], suggesting an antagonistic effect against those of CyA on IDA and IDAOL elimination and/or an unpredictable redistribution.",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[h·μg] / [l],315.44,85534,DB00661,Verapamil
,10456485,total body exposure,"When patients received two MDR modulators simultaneously (D-Ver plus CyA), IDA exposure was essentially the same as in those of the no inhibitor group [331.29 (95.49) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); NS], whereas the IDAOL total body exposure was greater than in the no inhibitor group [2030.32 (401.11) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.01], even if less than in patients receiving CyA as a single MDR modulator (IDA + CyA group) [AUC 2030.32 (401.11) microg x h x l(-1) vs 2896.60 (736.38) microg x h x l(-1); P < 0.05], suggesting an antagonistic effect against those of CyA on IDA and IDAOL elimination and/or an unpredictable redistribution.",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[h·μg] / [l],2030.32,85535,DB00661,Verapamil
,10456485,total body exposure,"When patients received two MDR modulators simultaneously (D-Ver plus CyA), IDA exposure was essentially the same as in those of the no inhibitor group [331.29 (95.49) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); NS], whereas the IDAOL total body exposure was greater than in the no inhibitor group [2030.32 (401.11) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.01], even if less than in patients receiving CyA as a single MDR modulator (IDA + CyA group) [AUC 2030.32 (401.11) microg x h x l(-1) vs 2896.60 (736.38) microg x h x l(-1); P < 0.05], suggesting an antagonistic effect against those of CyA on IDA and IDAOL elimination and/or an unpredictable redistribution.",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[h·μg] / [l],1028.49,85536,DB00661,Verapamil
,10456485,AUC,"When patients received two MDR modulators simultaneously (D-Ver plus CyA), IDA exposure was essentially the same as in those of the no inhibitor group [331.29 (95.49) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); NS], whereas the IDAOL total body exposure was greater than in the no inhibitor group [2030.32 (401.11) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.01], even if less than in patients receiving CyA as a single MDR modulator (IDA + CyA group) [AUC 2030.32 (401.11) microg x h x l(-1) vs 2896.60 (736.38) microg x h x l(-1); P < 0.05], suggesting an antagonistic effect against those of CyA on IDA and IDAOL elimination and/or an unpredictable redistribution.",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[h·μg] / [l],2030.32,85537,DB00661,Verapamil
,10456485,AUC,"When patients received two MDR modulators simultaneously (D-Ver plus CyA), IDA exposure was essentially the same as in those of the no inhibitor group [331.29 (95.49) microg x h x l(-1) vs 315.44 (158.28) microg x h x l(-1); NS], whereas the IDAOL total body exposure was greater than in the no inhibitor group [2030.32 (401.11) microg x h x l(-1) vs 1028.49 (603.95) microg x h x l(-1); P < 0.01], even if less than in patients receiving CyA as a single MDR modulator (IDA + CyA group) [AUC 2030.32 (401.11) microg x h x l(-1) vs 2896.60 (736.38) microg x h x l(-1); P < 0.05], suggesting an antagonistic effect against those of CyA on IDA and IDAOL elimination and/or an unpredictable redistribution.",Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10456485/),[h·μg] / [l],2896.60,85538,DB00661,Verapamil
,11707062,V1,"Final pharmacokinetic parameters were: CL (L/h) = (0.036 x TBW + 0.112 x CL(CR)) x 0.77SPI x 0.784CCB, V1 = 1.83 L/kg, V2 = 22.6 L/kg and Q = 0.629 L/h/kg, where CL is total body clearance, V1 and V2 are the apparent volumes of distribution in the central and peripheral compartments, Q is intercompartmental clearance, TBW is total bodyweight (in kg), CL(CR) is creatinine clearance (in ml/min), SPI = 1 for concomitant administration of spironolactone (and zero otherwise) and CCB = 1 for concomitant administration of calcium antagonists (and zero otherwise).",Population pharmacokinetics of digoxin in Japanese patients: a 2-compartment pharmacokinetic model. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707062/),[l] / [kg],1.83,85950,DB00661,Verapamil
,11707062,V2,"Final pharmacokinetic parameters were: CL (L/h) = (0.036 x TBW + 0.112 x CL(CR)) x 0.77SPI x 0.784CCB, V1 = 1.83 L/kg, V2 = 22.6 L/kg and Q = 0.629 L/h/kg, where CL is total body clearance, V1 and V2 are the apparent volumes of distribution in the central and peripheral compartments, Q is intercompartmental clearance, TBW is total bodyweight (in kg), CL(CR) is creatinine clearance (in ml/min), SPI = 1 for concomitant administration of spironolactone (and zero otherwise) and CCB = 1 for concomitant administration of calcium antagonists (and zero otherwise).",Population pharmacokinetics of digoxin in Japanese patients: a 2-compartment pharmacokinetic model. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707062/),[l] / [kg],22.6,85951,DB00661,Verapamil
,11707062,Q,"Final pharmacokinetic parameters were: CL (L/h) = (0.036 x TBW + 0.112 x CL(CR)) x 0.77SPI x 0.784CCB, V1 = 1.83 L/kg, V2 = 22.6 L/kg and Q = 0.629 L/h/kg, where CL is total body clearance, V1 and V2 are the apparent volumes of distribution in the central and peripheral compartments, Q is intercompartmental clearance, TBW is total bodyweight (in kg), CL(CR) is creatinine clearance (in ml/min), SPI = 1 for concomitant administration of spironolactone (and zero otherwise) and CCB = 1 for concomitant administration of calcium antagonists (and zero otherwise).",Population pharmacokinetics of digoxin in Japanese patients: a 2-compartment pharmacokinetic model. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11707062/),[l] / [h·kg],0.629,85952,DB00661,Verapamil
,971476,half-lives,"Plasma concentrations of verapamil, which were determined by mass fragmentography, declined bi-exponentially with half-lives of the chi-phase ranging from 18 to 35 min and of the beta-phase from 170 to 440 min.",Physiological disposition of verapamil in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/971476/),min,18 to 35,87523,DB00661,Verapamil
,971476,half-lives,"Plasma concentrations of verapamil, which were determined by mass fragmentography, declined bi-exponentially with half-lives of the chi-phase ranging from 18 to 35 min and of the beta-phase from 170 to 440 min.",Physiological disposition of verapamil in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/971476/),min,170 to 440,87524,DB00661,Verapamil
,971476,apparent volume of distribution,The apparent volume of distribution ranged from 270 to 460 litre and plasma clearance from 730 to 1980 ml/min.,Physiological disposition of verapamil in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/971476/),l,270 to 460,87525,DB00661,Verapamil
,971476,plasma clearance,The apparent volume of distribution ranged from 270 to 460 litre and plasma clearance from 730 to 1980 ml/min.,Physiological disposition of verapamil in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/971476/),[ml] / [min],730 to 1980,87526,DB00661,Verapamil
,971476,bioavailability,Despite its almost complete absorption after oral administration verapamil was shown to undergo extensive first pass metabolism as the bioavailability was only 10 to 22%.,Physiological disposition of verapamil in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/971476/),%,10 to 22,87527,DB00661,Verapamil
,24066110,Cmax,"Pharmacokinetic analysis revealed that the 8 week-old broilers, when orally administrated enrofloxacin, exhibited significantly higher Cmax (1.97 vs. 0.98 μg • ml(-1), P=0.009), AUC(14.54 vs. 9.35 μg • ml(-1) • h, P=0.005) and Ka (1.38 vs. 0.43 h(-1), P=0.032), as well as lower Tpeak (1.78 vs. 3.28 h, P=0.048) and T1/2 ka (0.6 vs. 1.64 h, P=0.012) than the 4 week-old broilers.",Age-related P-glycoprotein expression in the intestine and affecting the pharmacokinetics of orally administered enrofloxacin in broilers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24066110/),[μg] / [ml],1.97,87691,DB00661,Verapamil
,24066110,Cmax,"Pharmacokinetic analysis revealed that the 8 week-old broilers, when orally administrated enrofloxacin, exhibited significantly higher Cmax (1.97 vs. 0.98 μg • ml(-1), P=0.009), AUC(14.54 vs. 9.35 μg • ml(-1) • h, P=0.005) and Ka (1.38 vs. 0.43 h(-1), P=0.032), as well as lower Tpeak (1.78 vs. 3.28 h, P=0.048) and T1/2 ka (0.6 vs. 1.64 h, P=0.012) than the 4 week-old broilers.",Age-related P-glycoprotein expression in the intestine and affecting the pharmacokinetics of orally administered enrofloxacin in broilers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24066110/),[μg] / [ml],0.98,87692,DB00661,Verapamil
,24066110,AUC,"Pharmacokinetic analysis revealed that the 8 week-old broilers, when orally administrated enrofloxacin, exhibited significantly higher Cmax (1.97 vs. 0.98 μg • ml(-1), P=0.009), AUC(14.54 vs. 9.35 μg • ml(-1) • h, P=0.005) and Ka (1.38 vs. 0.43 h(-1), P=0.032), as well as lower Tpeak (1.78 vs. 3.28 h, P=0.048) and T1/2 ka (0.6 vs. 1.64 h, P=0.012) than the 4 week-old broilers.",Age-related P-glycoprotein expression in the intestine and affecting the pharmacokinetics of orally administered enrofloxacin in broilers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24066110/),[h·μg] / [ml],14.54,87693,DB00661,Verapamil
,24066110,AUC,"Pharmacokinetic analysis revealed that the 8 week-old broilers, when orally administrated enrofloxacin, exhibited significantly higher Cmax (1.97 vs. 0.98 μg • ml(-1), P=0.009), AUC(14.54 vs. 9.35 μg • ml(-1) • h, P=0.005) and Ka (1.38 vs. 0.43 h(-1), P=0.032), as well as lower Tpeak (1.78 vs. 3.28 h, P=0.048) and T1/2 ka (0.6 vs. 1.64 h, P=0.012) than the 4 week-old broilers.",Age-related P-glycoprotein expression in the intestine and affecting the pharmacokinetics of orally administered enrofloxacin in broilers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24066110/),[h·μg] / [ml],9.35,87694,DB00661,Verapamil
,24066110,Ka,"Pharmacokinetic analysis revealed that the 8 week-old broilers, when orally administrated enrofloxacin, exhibited significantly higher Cmax (1.97 vs. 0.98 μg • ml(-1), P=0.009), AUC(14.54 vs. 9.35 μg • ml(-1) • h, P=0.005) and Ka (1.38 vs. 0.43 h(-1), P=0.032), as well as lower Tpeak (1.78 vs. 3.28 h, P=0.048) and T1/2 ka (0.6 vs. 1.64 h, P=0.012) than the 4 week-old broilers.",Age-related P-glycoprotein expression in the intestine and affecting the pharmacokinetics of orally administered enrofloxacin in broilers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24066110/),1/[h],1.38,87695,DB00661,Verapamil
,24066110,Ka,"Pharmacokinetic analysis revealed that the 8 week-old broilers, when orally administrated enrofloxacin, exhibited significantly higher Cmax (1.97 vs. 0.98 μg • ml(-1), P=0.009), AUC(14.54 vs. 9.35 μg • ml(-1) • h, P=0.005) and Ka (1.38 vs. 0.43 h(-1), P=0.032), as well as lower Tpeak (1.78 vs. 3.28 h, P=0.048) and T1/2 ka (0.6 vs. 1.64 h, P=0.012) than the 4 week-old broilers.",Age-related P-glycoprotein expression in the intestine and affecting the pharmacokinetics of orally administered enrofloxacin in broilers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24066110/),1/[h],0.43,87696,DB00661,Verapamil
,24066110,Tpeak,"Pharmacokinetic analysis revealed that the 8 week-old broilers, when orally administrated enrofloxacin, exhibited significantly higher Cmax (1.97 vs. 0.98 μg • ml(-1), P=0.009), AUC(14.54 vs. 9.35 μg • ml(-1) • h, P=0.005) and Ka (1.38 vs. 0.43 h(-1), P=0.032), as well as lower Tpeak (1.78 vs. 3.28 h, P=0.048) and T1/2 ka (0.6 vs. 1.64 h, P=0.012) than the 4 week-old broilers.",Age-related P-glycoprotein expression in the intestine and affecting the pharmacokinetics of orally administered enrofloxacin in broilers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24066110/),h,1.78,87697,DB00661,Verapamil
,24066110,Tpeak,"Pharmacokinetic analysis revealed that the 8 week-old broilers, when orally administrated enrofloxacin, exhibited significantly higher Cmax (1.97 vs. 0.98 μg • ml(-1), P=0.009), AUC(14.54 vs. 9.35 μg • ml(-1) • h, P=0.005) and Ka (1.38 vs. 0.43 h(-1), P=0.032), as well as lower Tpeak (1.78 vs. 3.28 h, P=0.048) and T1/2 ka (0.6 vs. 1.64 h, P=0.012) than the 4 week-old broilers.",Age-related P-glycoprotein expression in the intestine and affecting the pharmacokinetics of orally administered enrofloxacin in broilers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24066110/),h,3.28,87698,DB00661,Verapamil
,24066110,T1/2 ka,"Pharmacokinetic analysis revealed that the 8 week-old broilers, when orally administrated enrofloxacin, exhibited significantly higher Cmax (1.97 vs. 0.98 μg • ml(-1), P=0.009), AUC(14.54 vs. 9.35 μg • ml(-1) • h, P=0.005) and Ka (1.38 vs. 0.43 h(-1), P=0.032), as well as lower Tpeak (1.78 vs. 3.28 h, P=0.048) and T1/2 ka (0.6 vs. 1.64 h, P=0.012) than the 4 week-old broilers.",Age-related P-glycoprotein expression in the intestine and affecting the pharmacokinetics of orally administered enrofloxacin in broilers. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24066110/),h,0.6,87699,DB00661,Verapamil
,24066110,T1/2 ka,"Pharmacokinetic analysis revealed that the 8 week-old broilers, when orally administrated enrofloxacin, exhibited significantly higher Cmax (1.97 vs. 0.98 μg • ml(-1), P=0.009), AUC(14.54 vs. 9.35 μg • ml(-1) • h, P=0.005) and Ka (1.38 vs. 0.43 h(-1), P=0.032), as well as lower Tpeak (1.78 vs. 3.28 h, P=0.048) and T1/2 ka (0.6 vs. 1.64 h, P=0.012) than the 4 week-old broilers.",Age-related P-glycoprotein expression in the intestine and affecting the pharmacokinetics of orally administered enrofloxacin in broilers. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24066110/),h,1.64,87700,DB00661,Verapamil
,8181195,clearance,S-Verapamil clearance decreased in an age-related manner (15.7 +/- 3.5 ml/min/kg in young women versus 12 +/- 1.5 ml/min/kg in elderly women; p < 0.0004) and elimination half-life values increased in an age-related manner from 347 +/- 97 minutes in young women to 453 +/- 153 minutes in elderly women (p < 0.05).,Aging of women alters S-verapamil pharmacokinetics and pharmacodynamics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8181195/),[ml] / [kg·min],15.7,87739,DB00661,Verapamil
,8181195,clearance,S-Verapamil clearance decreased in an age-related manner (15.7 +/- 3.5 ml/min/kg in young women versus 12 +/- 1.5 ml/min/kg in elderly women; p < 0.0004) and elimination half-life values increased in an age-related manner from 347 +/- 97 minutes in young women to 453 +/- 153 minutes in elderly women (p < 0.05).,Aging of women alters S-verapamil pharmacokinetics and pharmacodynamics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8181195/),[ml] / [kg·min],12,87740,DB00661,Verapamil
,8181195,elimination half-life,S-Verapamil clearance decreased in an age-related manner (15.7 +/- 3.5 ml/min/kg in young women versus 12 +/- 1.5 ml/min/kg in elderly women; p < 0.0004) and elimination half-life values increased in an age-related manner from 347 +/- 97 minutes in young women to 453 +/- 153 minutes in elderly women (p < 0.05).,Aging of women alters S-verapamil pharmacokinetics and pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8181195/),min,347,87741,DB00661,Verapamil
,8181195,elimination half-life,S-Verapamil clearance decreased in an age-related manner (15.7 +/- 3.5 ml/min/kg in young women versus 12 +/- 1.5 ml/min/kg in elderly women; p < 0.0004) and elimination half-life values increased in an age-related manner from 347 +/- 97 minutes in young women to 453 +/- 153 minutes in elderly women (p < 0.05).,Aging of women alters S-verapamil pharmacokinetics and pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8181195/),min,453,87742,DB00661,Verapamil
,1303922,steady state concentration,Verapamil in a dose of 2 x 80 mg/day induced average steady state concentration in range of 40.6 +/- 7.8 ng/ml to 134.2 +/- 56.9 ng/ml and in a dose of 3 x 40 mg/day 28.9 +/- 5.1 ng/ml to 69.8 +/- 11.2 ng/ml.,[Pharmacokinetic investigations of verapamil used as a concomitant drug in treatment of premature labor]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1303922/),[ng] / [ml],40.6,88354,DB00661,Verapamil
,1303922,steady state concentration,Verapamil in a dose of 2 x 80 mg/day induced average steady state concentration in range of 40.6 +/- 7.8 ng/ml to 134.2 +/- 56.9 ng/ml and in a dose of 3 x 40 mg/day 28.9 +/- 5.1 ng/ml to 69.8 +/- 11.2 ng/ml.,[Pharmacokinetic investigations of verapamil used as a concomitant drug in treatment of premature labor]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1303922/),[ng] / [ml],134.2,88355,DB00661,Verapamil
,1303922,steady state concentration,Verapamil in a dose of 2 x 80 mg/day induced average steady state concentration in range of 40.6 +/- 7.8 ng/ml to 134.2 +/- 56.9 ng/ml and in a dose of 3 x 40 mg/day 28.9 +/- 5.1 ng/ml to 69.8 +/- 11.2 ng/ml.,[Pharmacokinetic investigations of verapamil used as a concomitant drug in treatment of premature labor]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1303922/),[ng] / [ml],28.9,88356,DB00661,Verapamil
,1303922,steady state concentration,Verapamil in a dose of 2 x 80 mg/day induced average steady state concentration in range of 40.6 +/- 7.8 ng/ml to 134.2 +/- 56.9 ng/ml and in a dose of 3 x 40 mg/day 28.9 +/- 5.1 ng/ml to 69.8 +/- 11.2 ng/ml.,[Pharmacokinetic investigations of verapamil used as a concomitant drug in treatment of premature labor]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1303922/),[ng] / [ml],69.8,88357,DB00661,Verapamil
,21466921,Area under the concentration-time curve (AUC) truncated at 2 days (AUC(2)),"Area under the concentration-time curve (AUC) truncated at 2 days (AUC(2)) was 15 and 28 μg day/L for group IVM and IVM+VER, respectively.",Influence of P-glycoprotein inhibition on secretion of ivermectin and doramectin by milk in lactating sheep. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466921/),[d·μg] / [l],15,88828,DB00661,Verapamil
,21466921,Area under the concentration-time curve (AUC) truncated at 2 days (AUC(2)),"Area under the concentration-time curve (AUC) truncated at 2 days (AUC(2)) was 15 and 28 μg day/L for group IVM and IVM+VER, respectively.",Influence of P-glycoprotein inhibition on secretion of ivermectin and doramectin by milk in lactating sheep. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466921/),[d·μg] / [l],28,88829,DB00661,Verapamil
,21466921,apparent plasma clearance (Cl/F),"With co-administration of VER, apparent plasma clearance (Cl/F) and mean residence time (MRT) of IVM decreased from 135 to 116 L/day and from 5.8 to 3.8 days, respectively.",Influence of P-glycoprotein inhibition on secretion of ivermectin and doramectin by milk in lactating sheep. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466921/),[l] / [d],135,88830,DB00661,Verapamil
,21466921,mean residence time (MRT),"With co-administration of VER, apparent plasma clearance (Cl/F) and mean residence time (MRT) of IVM decreased from 135 to 116 L/day and from 5.8 to 3.8 days, respectively.",Influence of P-glycoprotein inhibition on secretion of ivermectin and doramectin by milk in lactating sheep. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466921/),d,5.8 to 3.8,88831,DB00661,Verapamil
,21466921,AUC(,Similar trends were observed for DOR (AUC(2) 48 vs.,Influence of P-glycoprotein inhibition on secretion of ivermectin and doramectin by milk in lactating sheep. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466921/),,48,88832,DB00661,Verapamil
,21466921,Cl/F,"68 μg day/L, Cl/F 61 vs. 46 L/day, and MRT 5.6 vs. 4.4 days for groups DOR and DOR+VER, respectively).",Influence of P-glycoprotein inhibition on secretion of ivermectin and doramectin by milk in lactating sheep. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466921/),[l] / [d],61,88833,DB00661,Verapamil
,21466921,Cl/F,"68 μg day/L, Cl/F 61 vs. 46 L/day, and MRT 5.6 vs. 4.4 days for groups DOR and DOR+VER, respectively).",Influence of P-glycoprotein inhibition on secretion of ivermectin and doramectin by milk in lactating sheep. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466921/),[l] / [d],46,88834,DB00661,Verapamil
,21466921,MRT,"68 μg day/L, Cl/F 61 vs. 46 L/day, and MRT 5.6 vs. 4.4 days for groups DOR and DOR+VER, respectively).",Influence of P-glycoprotein inhibition on secretion of ivermectin and doramectin by milk in lactating sheep. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466921/),d,5.6,88835,DB00661,Verapamil
,21466921,MRT,"68 μg day/L, Cl/F 61 vs. 46 L/day, and MRT 5.6 vs. 4.4 days for groups DOR and DOR+VER, respectively).",Influence of P-glycoprotein inhibition on secretion of ivermectin and doramectin by milk in lactating sheep. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466921/),d,4.4,88836,DB00661,Verapamil
,8884718,systemic clearance,"The mean systemic clearance and apparent volume of distribution of i.v. diltiazem were 15.0 mL/min/kg and 2.70 L/kg, respectively.",Pharmacokinetic and pharmacodynamic properties of conventional and CD-formulated diltiazem in cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8884718/),[ml] / [kg·min],15.0,90305,DB00661,Verapamil
,8884718,apparent volume of distribution,"The mean systemic clearance and apparent volume of distribution of i.v. diltiazem were 15.0 mL/min/kg and 2.70 L/kg, respectively.",Pharmacokinetic and pharmacodynamic properties of conventional and CD-formulated diltiazem in cats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8884718/),[l] / [kg],2.70,90306,DB00661,Verapamil
,8884718,elimination half-life,The elimination half-life of diltiazem after i.v. and p.o. DLT administration were approximately 120 minutes.,Pharmacokinetic and pharmacodynamic properties of conventional and CD-formulated diltiazem in cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8884718/),min,120,90307,DB00661,Verapamil
,8884718,terminal half-life,"In contrast, the terminal half-life of CD was 460 minutes.",Pharmacokinetic and pharmacodynamic properties of conventional and CD-formulated diltiazem in cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8884718/),min,460,90308,DB00661,Verapamil
,8884718,apparent bioavailability,"The mean apparent bioavailability of DLT p.o. was 71%, which was significantly higher than that observed with CD (36%).",Pharmacokinetic and pharmacodynamic properties of conventional and CD-formulated diltiazem in cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8884718/),%,71,90309,DB00661,Verapamil
,8884718,apparent bioavailability,"The mean apparent bioavailability of DLT p.o. was 71%, which was significantly higher than that observed with CD (36%).",Pharmacokinetic and pharmacodynamic properties of conventional and CD-formulated diltiazem in cats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8884718/),%,36,90310,DB00661,Verapamil
,32187961,maximum plasma concentration (Cmax),The maximum plasma concentration (Cmax) of repaglinide increased from 70.80 ± 7.98 ng/mL to 124.71 ± 9.02 ng/mL and the area under the plasma concentration-time curve (AUC) increased from 134.89 ± 13.65 μg·h/L to 245.95 ± 7.24 μg·h/L.,Molecular pharmacokinetic mechanism of the drug-drug interaction between genistein and repaglinide mediated by P-gp. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32187961/),[ng] / [ml],70.80,90327,DB00661,Verapamil
,32187961,maximum plasma concentration (Cmax),The maximum plasma concentration (Cmax) of repaglinide increased from 70.80 ± 7.98 ng/mL to 124.71 ± 9.02 ng/mL and the area under the plasma concentration-time curve (AUC) increased from 134.89 ± 13.65 μg·h/L to 245.95 ± 7.24 μg·h/L.,Molecular pharmacokinetic mechanism of the drug-drug interaction between genistein and repaglinide mediated by P-gp. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32187961/),[ng] / [ml],124.71,90328,DB00661,Verapamil
,32187961,area under the plasma concentration-time curve (AUC),The maximum plasma concentration (Cmax) of repaglinide increased from 70.80 ± 7.98 ng/mL to 124.71 ± 9.02 ng/mL and the area under the plasma concentration-time curve (AUC) increased from 134.89 ± 13.65 μg·h/L to 245.95 ± 7.24 μg·h/L.,Molecular pharmacokinetic mechanism of the drug-drug interaction between genistein and repaglinide mediated by P-gp. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32187961/),[h·μg] / [l],134.89,90329,DB00661,Verapamil
,32187961,area under the plasma concentration-time curve (AUC),The maximum plasma concentration (Cmax) of repaglinide increased from 70.80 ± 7.98 ng/mL to 124.71 ± 9.02 ng/mL and the area under the plasma concentration-time curve (AUC) increased from 134.89 ± 13.65 μg·h/L to 245.95 ± 7.24 μg·h/L.,Molecular pharmacokinetic mechanism of the drug-drug interaction between genistein and repaglinide mediated by P-gp. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32187961/),[h·μg] / [l],245.95,90330,DB00661,Verapamil
,32187961,net efflux ratio,"The transepithelial transport rate of repaglinide from basolateral-to-apical in MDR1-MDCK cells was 3.6-fold higher than the apical-to-basolateral rate with a net efflux ratio of 1.92 compared with mock-MDCK cells, which was significantly decreased following co-administration with genistein or Ver.",Molecular pharmacokinetic mechanism of the drug-drug interaction between genistein and repaglinide mediated by P-gp. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32187961/),,1.92,90331,DB00661,Verapamil
,19740397,AUC(last),"AUC(last) was significantly lower among individuals with the 2677TT/3435TT (159.5 +/- 79.0 ng ml(-1) h) and 2677GT/3435CT (189.3 +/- 73.1 ng ml(-1) h) genotypes than those with the 2677GG/3435CC genotype (303.1 +/- 83.7 ng ml(-1) h) (P= 0.004 and P= 0.008, respectively).",Influence of ABCB1 gene polymorphisms on the pharmacokinetics of verapamil among healthy Chinese Han ethnic subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740397/),[h·ng] / [ml],159.5,91829,DB00661,Verapamil
,19740397,AUC(last),"AUC(last) was significantly lower among individuals with the 2677TT/3435TT (159.5 +/- 79.0 ng ml(-1) h) and 2677GT/3435CT (189.3 +/- 73.1 ng ml(-1) h) genotypes than those with the 2677GG/3435CC genotype (303.1 +/- 83.7 ng ml(-1) h) (P= 0.004 and P= 0.008, respectively).",Influence of ABCB1 gene polymorphisms on the pharmacokinetics of verapamil among healthy Chinese Han ethnic subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740397/),[h·ng] / [ml],189.3,91830,DB00661,Verapamil
,19740397,AUC(last),"AUC(last) was significantly lower among individuals with the 2677TT/3435TT (159.5 +/- 79.0 ng ml(-1) h) and 2677GT/3435CT (189.3 +/- 73.1 ng ml(-1) h) genotypes than those with the 2677GG/3435CC genotype (303.1 +/- 83.7 ng ml(-1) h) (P= 0.004 and P= 0.008, respectively).",Influence of ABCB1 gene polymorphisms on the pharmacokinetics of verapamil among healthy Chinese Han ethnic subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740397/),[h·ng] / [ml],303.1,91831,DB00661,Verapamil
,19740397,CL/F,"However, the CL/F value was higher among subjects with the 2677TT/3435TT (523.0 +/- 173.7 l h(-1)) genotype than those with the 2677GT/3435CT (452.2 +/- 188.6 l h(-1)) or 2677GG/3435CC (265.4 +/- 72.8 l h(-1)) genotypes.",Influence of ABCB1 gene polymorphisms on the pharmacokinetics of verapamil among healthy Chinese Han ethnic subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740397/),[l] / [h],523.0,91832,DB00661,Verapamil
,19740397,CL/F,"However, the CL/F value was higher among subjects with the 2677TT/3435TT (523.0 +/- 173.7 l h(-1)) genotype than those with the 2677GT/3435CT (452.2 +/- 188.6 l h(-1)) or 2677GG/3435CC (265.4 +/- 72.8 l h(-1)) genotypes.",Influence of ABCB1 gene polymorphisms on the pharmacokinetics of verapamil among healthy Chinese Han ethnic subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740397/),[l] / [h],452.2,91833,DB00661,Verapamil
,19740397,CL/F,"However, the CL/F value was higher among subjects with the 2677TT/3435TT (523.0 +/- 173.7 l h(-1)) genotype than those with the 2677GT/3435CT (452.2 +/- 188.6 l h(-1)) or 2677GG/3435CC (265.4 +/- 72.8 l h(-1)) genotypes.",Influence of ABCB1 gene polymorphisms on the pharmacokinetics of verapamil among healthy Chinese Han ethnic subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740397/),[l] / [h],265.4,91834,DB00661,Verapamil
,19740397,C(max),"In addition, the C(max) tended to be higher among subjects with the 2677GG/3435CC genotype than those with the 2677GT/3435CT or 2677TT/3435TT genotypes (42.2 +/- 3.9 vs 32.2 +/- 16.2 vs 38.1 +/- 13.7 ng ml(-1)).",Influence of ABCB1 gene polymorphisms on the pharmacokinetics of verapamil among healthy Chinese Han ethnic subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740397/),[ng] / [ml],42.2,91835,DB00661,Verapamil
,19740397,C(max),"In addition, the C(max) tended to be higher among subjects with the 2677GG/3435CC genotype than those with the 2677GT/3435CT or 2677TT/3435TT genotypes (42.2 +/- 3.9 vs 32.2 +/- 16.2 vs 38.1 +/- 13.7 ng ml(-1)).",Influence of ABCB1 gene polymorphisms on the pharmacokinetics of verapamil among healthy Chinese Han ethnic subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740397/),[ng] / [ml],32.2,91836,DB00661,Verapamil
,19740397,C(max),"In addition, the C(max) tended to be higher among subjects with the 2677GG/3435CC genotype than those with the 2677GT/3435CT or 2677TT/3435TT genotypes (42.2 +/- 3.9 vs 32.2 +/- 16.2 vs 38.1 +/- 13.7 ng ml(-1)).",Influence of ABCB1 gene polymorphisms on the pharmacokinetics of verapamil among healthy Chinese Han ethnic subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19740397/),[ng] / [ml],38.1,91837,DB00661,Verapamil
,22584255,C-K's efflux ratio,"To define the mechanisms responsible for this low bioavailability, two P-glycoprotein (P-gp) inhibitors, verapamil and cyclosporine A, were used, and their presence substantially decreased C-K's efflux ratio in Caco-2 cells (from 26.6 to <3) and significantly increased intracellular concentrations (by as much as 40-fold).","Inhibition of P-glycoprotein leads to improved oral bioavailability of compound K, an anticancer metabolite of red ginseng extract produced by gut microflora. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22584255/),,26.6,93100,DB00661,Verapamil
<,22584255,C-K's efflux ratio,"To define the mechanisms responsible for this low bioavailability, two P-glycoprotein (P-gp) inhibitors, verapamil and cyclosporine A, were used, and their presence substantially decreased C-K's efflux ratio in Caco-2 cells (from 26.6 to <3) and significantly increased intracellular concentrations (by as much as 40-fold).","Inhibition of P-glycoprotein leads to improved oral bioavailability of compound K, an anticancer metabolite of red ginseng extract produced by gut microflora. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22584255/),,3,93101,DB00661,Verapamil
,15692829,half-life,"Acute hypoxia did not alter the pharmacokinetics of theophylline [half-life+/-SD: 9.29+/-1.77 versus 9.39+/-1.40 (hypoxia)], 1,3-dimethyluric acid (12.9+/-4.72 versus 15.1+/-8.59), verapamil (2.00+/-0.98 versus 1.79+/-0.58), or norverapamil (7.98+/-2.94 versus 9.91+/-6.40).","Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692829/),,9.29,93165,DB00661,Verapamil
,15692829,half-life,"Acute hypoxia did not alter the pharmacokinetics of theophylline [half-life+/-SD: 9.29+/-1.77 versus 9.39+/-1.40 (hypoxia)], 1,3-dimethyluric acid (12.9+/-4.72 versus 15.1+/-8.59), verapamil (2.00+/-0.98 versus 1.79+/-0.58), or norverapamil (7.98+/-2.94 versus 9.91+/-6.40).","Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692829/),,9.39,93166,DB00661,Verapamil
,15692829,half-life,"Acute hypoxia did not alter the pharmacokinetics of theophylline [half-life+/-SD: 9.29+/-1.77 versus 9.39+/-1.40 (hypoxia)], 1,3-dimethyluric acid (12.9+/-4.72 versus 15.1+/-8.59), verapamil (2.00+/-0.98 versus 1.79+/-0.58), or norverapamil (7.98+/-2.94 versus 9.91+/-6.40).","Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692829/),,12.9,93167,DB00661,Verapamil
,15692829,half-life,"Acute hypoxia did not alter the pharmacokinetics of theophylline [half-life+/-SD: 9.29+/-1.77 versus 9.39+/-1.40 (hypoxia)], 1,3-dimethyluric acid (12.9+/-4.72 versus 15.1+/-8.59), verapamil (2.00+/-0.98 versus 1.79+/-0.58), or norverapamil (7.98+/-2.94 versus 9.91+/-6.40).","Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692829/),,15.1,93168,DB00661,Verapamil
,15692829,half-life,"Acute hypoxia did not alter the pharmacokinetics of theophylline [half-life+/-SD: 9.29+/-1.77 versus 9.39+/-1.40 (hypoxia)], 1,3-dimethyluric acid (12.9+/-4.72 versus 15.1+/-8.59), verapamil (2.00+/-0.98 versus 1.79+/-0.58), or norverapamil (7.98+/-2.94 versus 9.91+/-6.40).","Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692829/),,2.00,93169,DB00661,Verapamil
,15692829,half-life,"Acute hypoxia did not alter the pharmacokinetics of theophylline [half-life+/-SD: 9.29+/-1.77 versus 9.39+/-1.40 (hypoxia)], 1,3-dimethyluric acid (12.9+/-4.72 versus 15.1+/-8.59), verapamil (2.00+/-0.98 versus 1.79+/-0.58), or norverapamil (7.98+/-2.94 versus 9.91+/-6.40).","Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692829/),,1.79,93170,DB00661,Verapamil
,15692829,half-life,"Acute hypoxia did not alter the pharmacokinetics of theophylline [half-life+/-SD: 9.29+/-1.77 versus 9.39+/-1.40 (hypoxia)], 1,3-dimethyluric acid (12.9+/-4.72 versus 15.1+/-8.59), verapamil (2.00+/-0.98 versus 1.79+/-0.58), or norverapamil (7.98+/-2.94 versus 9.91+/-6.40).","Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692829/),,7.98,93171,DB00661,Verapamil
,15692829,half-life,"Acute hypoxia did not alter the pharmacokinetics of theophylline [half-life+/-SD: 9.29+/-1.77 versus 9.39+/-1.40 (hypoxia)], 1,3-dimethyluric acid (12.9+/-4.72 versus 15.1+/-8.59), verapamil (2.00+/-0.98 versus 1.79+/-0.58), or norverapamil (7.98+/-2.94 versus 9.91+/-6.40).","Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15692829/),,9.91,93172,DB00661,Verapamil
,17981422,total chromatographic run time,"Transitions 456>166 for VER enantiomers, 441>166 for NOR enantiomers and 330>193 for the internal standard were monitored and the method had a total chromatographic run time of 12 min.",Simultaneous analysis of the enantiomers of verapamil and norverapamil in rat plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17981422/),min,12,94549,DB00661,Verapamil
,17981422,AUC ratio (-)/(+),"The concentration of (-)-(S)-VER was three folds higher than (+)-(R)-VER, with an AUC ratio (-)/(+) of 2.66.",Simultaneous analysis of the enantiomers of verapamil and norverapamil in rat plasma by liquid chromatography-tandem mass spectrometry. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17981422/),,2.66,94550,DB00661,Verapamil
,17981422,Oral clearance,"Oral clearance values were 12.17 and 28.77 L/h/kg for (-)-(S)-VER and (+)-(R)-VER, respectively.",Simultaneous analysis of the enantiomers of verapamil and norverapamil in rat plasma by liquid chromatography-tandem mass spectrometry. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17981422/),[l] / [h·kg],12.17,94551,DB00661,Verapamil
,17981422,Oral clearance,"Oral clearance values were 12.17 and 28.77 L/h/kg for (-)-(S)-VER and (+)-(R)-VER, respectively.",Simultaneous analysis of the enantiomers of verapamil and norverapamil in rat plasma by liquid chromatography-tandem mass spectrometry. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17981422/),[l] / [h·kg],28.77,94552,DB00661,Verapamil
,26452875,flow rate,Chromatographic separation was performed on a Waters BEH C18 column with gradient elution using a mobile phase composed of acetonitrile and water (containing 0.1% formic acid) at a flow rate of 0.3 mL/min.,A sensitive and selective UPLC-MS/MS method for simultaneous determination of 10 alkaloids from Rhizoma Menispermi in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26452875/),[ml] / [min],0.3,95015,DB00661,Verapamil
more,26452875,extraction recoveries,The mean extraction recoveries of analytes and IS from rat plasma were all more than 77%.,A sensitive and selective UPLC-MS/MS method for simultaneous determination of 10 alkaloids from Rhizoma Menispermi in rat plasma and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26452875/),%,77,95016,DB00661,Verapamil
,26797108,Intrinsic clearance,Intrinsic clearance mediated by P-gp was 1.9 μL/min while passive diffusion clearance was 0.31 μL/min.,Blockade of P-Glycoprotein Decreased the Disposition of Phenformin and Increased Plasma Lactate Level. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26797108/),[μl] / [min],1.9,95379,DB00661,Verapamil
,26797108,passive diffusion clearance,Intrinsic clearance mediated by P-gp was 1.9 μL/min while passive diffusion clearance was 0.31 μL/min.,Blockade of P-Glycoprotein Decreased the Disposition of Phenformin and Increased Plasma Lactate Level. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26797108/),[μl] / [min],0.31,95380,DB00661,Verapamil
,4028631,t1/2,"After intravenous doses, the t1/2 (means +/- SE: control, 3.60 +/- 0.40 hours; cimetidine trial, 4.30 +/- 0.60 hours), volume of distribution (5.8 +/- 0.6 vs. 6.6 +/- 0.9 L/kg), and total clearance (19.2 +/- 1.5 vs. 18.4 +/- 1.6 ml/min/kg) did not change during cimetidine dosing.",Lack of interaction between verapamil and cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),h,3.60,95919,DB00661,Verapamil
,4028631,t1/2,"After intravenous doses, the t1/2 (means +/- SE: control, 3.60 +/- 0.40 hours; cimetidine trial, 4.30 +/- 0.60 hours), volume of distribution (5.8 +/- 0.6 vs. 6.6 +/- 0.9 L/kg), and total clearance (19.2 +/- 1.5 vs. 18.4 +/- 1.6 ml/min/kg) did not change during cimetidine dosing.",Lack of interaction between verapamil and cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),h,4.30,95920,DB00661,Verapamil
,4028631,volume of distribution,"After intravenous doses, the t1/2 (means +/- SE: control, 3.60 +/- 0.40 hours; cimetidine trial, 4.30 +/- 0.60 hours), volume of distribution (5.8 +/- 0.6 vs. 6.6 +/- 0.9 L/kg), and total clearance (19.2 +/- 1.5 vs. 18.4 +/- 1.6 ml/min/kg) did not change during cimetidine dosing.",Lack of interaction between verapamil and cimetidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),[l] / [kg],5.8,95921,DB00661,Verapamil
,4028631,volume of distribution,"After intravenous doses, the t1/2 (means +/- SE: control, 3.60 +/- 0.40 hours; cimetidine trial, 4.30 +/- 0.60 hours), volume of distribution (5.8 +/- 0.6 vs. 6.6 +/- 0.9 L/kg), and total clearance (19.2 +/- 1.5 vs. 18.4 +/- 1.6 ml/min/kg) did not change during cimetidine dosing.",Lack of interaction between verapamil and cimetidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),[l] / [kg],6.6,95922,DB00661,Verapamil
,4028631,total clearance,"After intravenous doses, the t1/2 (means +/- SE: control, 3.60 +/- 0.40 hours; cimetidine trial, 4.30 +/- 0.60 hours), volume of distribution (5.8 +/- 0.6 vs. 6.6 +/- 0.9 L/kg), and total clearance (19.2 +/- 1.5 vs. 18.4 +/- 1.6 ml/min/kg) did not change during cimetidine dosing.",Lack of interaction between verapamil and cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),[ml] / [kg·min],19.2,95923,DB00661,Verapamil
,4028631,total clearance,"After intravenous doses, the t1/2 (means +/- SE: control, 3.60 +/- 0.40 hours; cimetidine trial, 4.30 +/- 0.60 hours), volume of distribution (5.8 +/- 0.6 vs. 6.6 +/- 0.9 L/kg), and total clearance (19.2 +/- 1.5 vs. 18.4 +/- 1.6 ml/min/kg) did not change during cimetidine dosing.",Lack of interaction between verapamil and cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),[ml] / [kg·min],18.4,95924,DB00661,Verapamil
,4028631,t1/2,"After oral doses, the t1/2 (4.25 +/- 0.57 vs.",Lack of interaction between verapamil and cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),,4.25,95925,DB00661,Verapamil
,4028631,plasma AUC,"4.60 +/- 0.70 hours), plasma AUC (585 +/- 113 vs. 506 +/- 82 ng/ml X hr) and absolute bioavailability (35% +/- 7% vs. 30% +/- 5%) did not differ between control and cimetidine trials, respectively.",Lack of interaction between verapamil and cimetidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),[ng] / [h·ml],585,95926,DB00661,Verapamil
,4028631,plasma AUC,"4.60 +/- 0.70 hours), plasma AUC (585 +/- 113 vs. 506 +/- 82 ng/ml X hr) and absolute bioavailability (35% +/- 7% vs. 30% +/- 5%) did not differ between control and cimetidine trials, respectively.",Lack of interaction between verapamil and cimetidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),[ng] / [h·ml],506,95927,DB00661,Verapamil
,4028631,absolute bioavailability,"4.60 +/- 0.70 hours), plasma AUC (585 +/- 113 vs. 506 +/- 82 ng/ml X hr) and absolute bioavailability (35% +/- 7% vs. 30% +/- 5%) did not differ between control and cimetidine trials, respectively.",Lack of interaction between verapamil and cimetidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),%,35,95928,DB00661,Verapamil
,4028631,absolute bioavailability,"4.60 +/- 0.70 hours), plasma AUC (585 +/- 113 vs. 506 +/- 82 ng/ml X hr) and absolute bioavailability (35% +/- 7% vs. 30% +/- 5%) did not differ between control and cimetidine trials, respectively.",Lack of interaction between verapamil and cimetidine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),%,30,95929,DB00661,Verapamil
,4028631,clearance,"Lidocaine clearance fell (665 +/- 216 vs. 527 +/- 134 ml/min; P less than 0.05) during cimetidine therapy, resulting in a trend toward a longer t1/2 (1.81 +/- 0.41 vs. 2.44 +/- 0.42 hours; 0.1 greater than P greater than 0.05) with no change in volume of distribution (1.77 +/- 0.66 vs. 1.99 +/- 0.81 L/kg).",Lack of interaction between verapamil and cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),[ml] / [min],665,95930,DB00661,Verapamil
,4028631,clearance,"Lidocaine clearance fell (665 +/- 216 vs. 527 +/- 134 ml/min; P less than 0.05) during cimetidine therapy, resulting in a trend toward a longer t1/2 (1.81 +/- 0.41 vs. 2.44 +/- 0.42 hours; 0.1 greater than P greater than 0.05) with no change in volume of distribution (1.77 +/- 0.66 vs. 1.99 +/- 0.81 L/kg).",Lack of interaction between verapamil and cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),[ml] / [min],527,95931,DB00661,Verapamil
,4028631,t1/2,"Lidocaine clearance fell (665 +/- 216 vs. 527 +/- 134 ml/min; P less than 0.05) during cimetidine therapy, resulting in a trend toward a longer t1/2 (1.81 +/- 0.41 vs. 2.44 +/- 0.42 hours; 0.1 greater than P greater than 0.05) with no change in volume of distribution (1.77 +/- 0.66 vs. 1.99 +/- 0.81 L/kg).",Lack of interaction between verapamil and cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),h,1.81,95932,DB00661,Verapamil
,4028631,t1/2,"Lidocaine clearance fell (665 +/- 216 vs. 527 +/- 134 ml/min; P less than 0.05) during cimetidine therapy, resulting in a trend toward a longer t1/2 (1.81 +/- 0.41 vs. 2.44 +/- 0.42 hours; 0.1 greater than P greater than 0.05) with no change in volume of distribution (1.77 +/- 0.66 vs. 1.99 +/- 0.81 L/kg).",Lack of interaction between verapamil and cimetidine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),h,2.44,95933,DB00661,Verapamil
,4028631,volume of distribution,"Lidocaine clearance fell (665 +/- 216 vs. 527 +/- 134 ml/min; P less than 0.05) during cimetidine therapy, resulting in a trend toward a longer t1/2 (1.81 +/- 0.41 vs. 2.44 +/- 0.42 hours; 0.1 greater than P greater than 0.05) with no change in volume of distribution (1.77 +/- 0.66 vs. 1.99 +/- 0.81 L/kg).",Lack of interaction between verapamil and cimetidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),[l] / [kg],1.77,95934,DB00661,Verapamil
,4028631,volume of distribution,"Lidocaine clearance fell (665 +/- 216 vs. 527 +/- 134 ml/min; P less than 0.05) during cimetidine therapy, resulting in a trend toward a longer t1/2 (1.81 +/- 0.41 vs. 2.44 +/- 0.42 hours; 0.1 greater than P greater than 0.05) with no change in volume of distribution (1.77 +/- 0.66 vs. 1.99 +/- 0.81 L/kg).",Lack of interaction between verapamil and cimetidine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),[l] / [kg],1.99,95935,DB00661,Verapamil
,4028631,heart rate,A decrease in mean arterial pressure (8 +/- 1 vs. 9 +/- 2 mm Hg) and a reflex increase in heart rate (14 +/- 3 vs. 17 +/- 2 bpm) were no different in the control and cimetidine trials.,Lack of interaction between verapamil and cimetidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),bpm,14,95936,DB00661,Verapamil
,4028631,heart rate,A decrease in mean arterial pressure (8 +/- 1 vs. 9 +/- 2 mm Hg) and a reflex increase in heart rate (14 +/- 3 vs. 17 +/- 2 bpm) were no different in the control and cimetidine trials.,Lack of interaction between verapamil and cimetidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028631/),bpm,17,95937,DB00661,Verapamil
,8135031,elimination-half-life,"Therefore the Ca-antagonists of the so-called 2nd generation (e.g. Amlodipine, Felodipine, Isradipine, Nitrendipine, Nicardipine, Nimodipine, Nisoldipine) tend to longer elimination-half-lives; Amlodipin is an exception with an elimination-half-life of 30 hours on the average.",[Principles of the pharmacokinetics and pharmacodynamics of calcium antagonists]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8135031/),h,30,96381,DB00661,Verapamil
,2359015,area under the plasma concentration vs. time curve,Coadministration of cimetidine led to a significant increase in the area under the plasma concentration vs. time curve of S-verapamil (29.2 +/- 31.8 min x nmol x ml-1 vs. 41.2 +/- 33.7 min x nmol x ml-1; P less than .003) and R-verapamil (124.7 +/- 112.2 min x nmol x ml-1 vs. 156.8 +/- 105.0 min x nmol x ml-1; P less than .01).,"Interaction of verapamil and cimetidine: stereochemical aspects of drug metabolism, drug disposition and drug action. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2359015/),[min·nM] / [ml],29.2,96485,DB00661,Verapamil
,2359015,area under the plasma concentration vs. time curve,Coadministration of cimetidine led to a significant increase in the area under the plasma concentration vs. time curve of S-verapamil (29.2 +/- 31.8 min x nmol x ml-1 vs. 41.2 +/- 33.7 min x nmol x ml-1; P less than .003) and R-verapamil (124.7 +/- 112.2 min x nmol x ml-1 vs. 156.8 +/- 105.0 min x nmol x ml-1; P less than .01).,"Interaction of verapamil and cimetidine: stereochemical aspects of drug metabolism, drug disposition and drug action. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2359015/),[min·nM] / [ml],41.2,96486,DB00661,Verapamil
,2359015,area under the plasma concentration vs. time curve,Coadministration of cimetidine led to a significant increase in the area under the plasma concentration vs. time curve of S-verapamil (29.2 +/- 31.8 min x nmol x ml-1 vs. 41.2 +/- 33.7 min x nmol x ml-1; P less than .003) and R-verapamil (124.7 +/- 112.2 min x nmol x ml-1 vs. 156.8 +/- 105.0 min x nmol x ml-1; P less than .01).,"Interaction of verapamil and cimetidine: stereochemical aspects of drug metabolism, drug disposition and drug action. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2359015/),[min·nM] / [ml],124.7,96487,DB00661,Verapamil
,2359015,area under the plasma concentration vs. time curve,Coadministration of cimetidine led to a significant increase in the area under the plasma concentration vs. time curve of S-verapamil (29.2 +/- 31.8 min x nmol x ml-1 vs. 41.2 +/- 33.7 min x nmol x ml-1; P less than .003) and R-verapamil (124.7 +/- 112.2 min x nmol x ml-1 vs. 156.8 +/- 105.0 min x nmol x ml-1; P less than .01).,"Interaction of verapamil and cimetidine: stereochemical aspects of drug metabolism, drug disposition and drug action. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2359015/),[min·nM] / [ml],156.8,96488,DB00661,Verapamil
,2359015,Tu,Tubular secretion of S-D-617 was inhibited by cimetidine (342 +/- 104 vs. 238 +/- 52 ml x min-1; P less than .05) whereas secretion of the R-enantiomer remained unchanged (276 +/- 91 vs. 222 +/- 43 ml x min-1).,"Interaction of verapamil and cimetidine: stereochemical aspects of drug metabolism, drug disposition and drug action. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2359015/),[ml] / [min],342,96489,DB00661,Verapamil
,2359015,secretion,Tubular secretion of S-D-617 was inhibited by cimetidine (342 +/- 104 vs. 238 +/- 52 ml x min-1; P less than .05) whereas secretion of the R-enantiomer remained unchanged (276 +/- 91 vs. 222 +/- 43 ml x min-1).,"Interaction of verapamil and cimetidine: stereochemical aspects of drug metabolism, drug disposition and drug action. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2359015/),[ml] / [min],342,96490,DB00661,Verapamil
,2359015,secretion,Tubular secretion of S-D-617 was inhibited by cimetidine (342 +/- 104 vs. 238 +/- 52 ml x min-1; P less than .05) whereas secretion of the R-enantiomer remained unchanged (276 +/- 91 vs. 222 +/- 43 ml x min-1).,"Interaction of verapamil and cimetidine: stereochemical aspects of drug metabolism, drug disposition and drug action. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2359015/),[ml] / [min],238,96491,DB00661,Verapamil
,2359015,secretion,Tubular secretion of S-D-617 was inhibited by cimetidine (342 +/- 104 vs. 238 +/- 52 ml x min-1; P less than .05) whereas secretion of the R-enantiomer remained unchanged (276 +/- 91 vs. 222 +/- 43 ml x min-1).,"Interaction of verapamil and cimetidine: stereochemical aspects of drug metabolism, drug disposition and drug action. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2359015/),[ml] / [min],276,96492,DB00661,Verapamil
,2359015,secretion,Tubular secretion of S-D-617 was inhibited by cimetidine (342 +/- 104 vs. 238 +/- 52 ml x min-1; P less than .05) whereas secretion of the R-enantiomer remained unchanged (276 +/- 91 vs. 222 +/- 43 ml x min-1).,"Interaction of verapamil and cimetidine: stereochemical aspects of drug metabolism, drug disposition and drug action. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2359015/),[ml] / [min],222,96493,DB00661,Verapamil
above,8402633,tissue level/blood level ratio,"After i.v. administration to mice, GF120918 penetrates thoroughly various organs that have a tissue level/blood level ratio above 10.","In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8402633/),,10,98460,DB00661,Verapamil
,8402633,half-time,It is eliminated from organs and blood with a half-time of approximately 2.7 h.,"In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8402633/),h,2.7,98461,DB00661,Verapamil
,2967742,peak digoxin level,"Analyst-blind RIA serum digoxin determinations demonstrated that the nine subjects who received isradipine, 5 mg t.i.d., had a small increment in peak digoxin level from 2.3 +/- 0.6 to 2.9 +/- 0.7 ng/ml (p less than 0.05) but no significant change in steady-state level or AUC over 12 hours.",Comparative effects of verapamil and isradipine on steady-state digoxin kinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967742/),[ng] / [ml],2.3,98768,DB00661,Verapamil
,2967742,peak digoxin level,"Analyst-blind RIA serum digoxin determinations demonstrated that the nine subjects who received isradipine, 5 mg t.i.d., had a small increment in peak digoxin level from 2.3 +/- 0.6 to 2.9 +/- 0.7 ng/ml (p less than 0.05) but no significant change in steady-state level or AUC over 12 hours.",Comparative effects of verapamil and isradipine on steady-state digoxin kinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967742/),[ng] / [ml],2.9,98769,DB00661,Verapamil
,2967742,steady-state,"By contrast, the 10 subjects who received verapamil, 80 mg t.i.d., showed significant increases in steady-state (0.9 +/- 0.1 to 1.3 +/- 0.2 ng/ml; p less than 0.001) and peak serum digoxin concentrations (2.5 +/- 0.7 to 3.6 +/- 0.8 ng/ml; p less than 0.001) and in AUC (15.7 +/- 1.7 to 23.6 +/- 2.9 ng . hr/ml; p less than 0.001).",Comparative effects of verapamil and isradipine on steady-state digoxin kinetics. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967742/),[ng] / [ml],0.9,98770,DB00661,Verapamil
,2967742,steady-state,"By contrast, the 10 subjects who received verapamil, 80 mg t.i.d., showed significant increases in steady-state (0.9 +/- 0.1 to 1.3 +/- 0.2 ng/ml; p less than 0.001) and peak serum digoxin concentrations (2.5 +/- 0.7 to 3.6 +/- 0.8 ng/ml; p less than 0.001) and in AUC (15.7 +/- 1.7 to 23.6 +/- 2.9 ng . hr/ml; p less than 0.001).",Comparative effects of verapamil and isradipine on steady-state digoxin kinetics. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967742/),[ng] / [ml],1.3,98771,DB00661,Verapamil
,2967742,peak serum digoxin concentrations,"By contrast, the 10 subjects who received verapamil, 80 mg t.i.d., showed significant increases in steady-state (0.9 +/- 0.1 to 1.3 +/- 0.2 ng/ml; p less than 0.001) and peak serum digoxin concentrations (2.5 +/- 0.7 to 3.6 +/- 0.8 ng/ml; p less than 0.001) and in AUC (15.7 +/- 1.7 to 23.6 +/- 2.9 ng . hr/ml; p less than 0.001).",Comparative effects of verapamil and isradipine on steady-state digoxin kinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967742/),[ng] / [ml],2.5,98772,DB00661,Verapamil
,2967742,peak serum digoxin concentrations,"By contrast, the 10 subjects who received verapamil, 80 mg t.i.d., showed significant increases in steady-state (0.9 +/- 0.1 to 1.3 +/- 0.2 ng/ml; p less than 0.001) and peak serum digoxin concentrations (2.5 +/- 0.7 to 3.6 +/- 0.8 ng/ml; p less than 0.001) and in AUC (15.7 +/- 1.7 to 23.6 +/- 2.9 ng . hr/ml; p less than 0.001).",Comparative effects of verapamil and isradipine on steady-state digoxin kinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967742/),[ng] / [ml],3.6,98773,DB00661,Verapamil
,2967742,AUC,"By contrast, the 10 subjects who received verapamil, 80 mg t.i.d., showed significant increases in steady-state (0.9 +/- 0.1 to 1.3 +/- 0.2 ng/ml; p less than 0.001) and peak serum digoxin concentrations (2.5 +/- 0.7 to 3.6 +/- 0.8 ng/ml; p less than 0.001) and in AUC (15.7 +/- 1.7 to 23.6 +/- 2.9 ng . hr/ml; p less than 0.001).",Comparative effects of verapamil and isradipine on steady-state digoxin kinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967742/),[h·ng] / [ml],15.7,98774,DB00661,Verapamil
,2967742,AUC,"By contrast, the 10 subjects who received verapamil, 80 mg t.i.d., showed significant increases in steady-state (0.9 +/- 0.1 to 1.3 +/- 0.2 ng/ml; p less than 0.001) and peak serum digoxin concentrations (2.5 +/- 0.7 to 3.6 +/- 0.8 ng/ml; p less than 0.001) and in AUC (15.7 +/- 1.7 to 23.6 +/- 2.9 ng . hr/ml; p less than 0.001).",Comparative effects of verapamil and isradipine on steady-state digoxin kinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2967742/),[h·ng] / [ml],23.6,98775,DB00661,Verapamil
,24786847,Tmax,The results showed that piperine increased the plasma exposure (AUC) of linarin by 381% along with an increase in the Cmax by 346% and the Tmax from 0.05 h to 0.2 h.,Effects of piperine on the intestinal permeability and pharmacokinetics of linarin in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24786847/),h,0.05,99080,DB00661,Verapamil
,24786847,Tmax,The results showed that piperine increased the plasma exposure (AUC) of linarin by 381% along with an increase in the Cmax by 346% and the Tmax from 0.05 h to 0.2 h.,Effects of piperine on the intestinal permeability and pharmacokinetics of linarin in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24786847/),h,0.2,99081,DB00661,Verapamil
,1390328,plasma clearance,"The plasma clearance of verapamil was reduced from 1.3 l/min after acute dosing to 0.8 l/min during chronic treatment, but there was no significant independent age-related effect.",Low-dose verapamil in middle-aged and elderly patients with angina pectoris: no evidence of increased susceptibility to the cardiac effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1390328/),[l] / [min],1.3,99156,DB00661,Verapamil
,1390328,plasma clearance,"The plasma clearance of verapamil was reduced from 1.3 l/min after acute dosing to 0.8 l/min during chronic treatment, but there was no significant independent age-related effect.",Low-dose verapamil in middle-aged and elderly patients with angina pectoris: no evidence of increased susceptibility to the cardiac effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1390328/),[l] / [min],0.8,99157,DB00661,Verapamil
,10709150,Clearance,Clearance of i.v. and p.o. verapamil was 13.7 +/- 4.3 and 58.4 +/- 35 ml/min/kg (mean +/- SD) in women compared to 12.6 +/- 3.4 and 82.6 +/- 70 ml/min/kg in men (p = 0.076).,Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10709150/),[ml] / [kg·min],13.7,99185,DB00661,Verapamil
,10709150,Clearance,Clearance of i.v. and p.o. verapamil was 13.7 +/- 4.3 and 58.4 +/- 35 ml/min/kg (mean +/- SD) in women compared to 12.6 +/- 3.4 and 82.6 +/- 70 ml/min/kg in men (p = 0.076).,Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10709150/),[ml] / [kg·min],58.4,99186,DB00661,Verapamil
,10709150,Clearance,Clearance of i.v. and p.o. verapamil was 13.7 +/- 4.3 and 58.4 +/- 35 ml/min/kg (mean +/- SD) in women compared to 12.6 +/- 3.4 and 82.6 +/- 70 ml/min/kg in men (p = 0.076).,Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10709150/),[ml] / [kg·min],12.6,99187,DB00661,Verapamil
,10709150,Clearance,Clearance of i.v. and p.o. verapamil was 13.7 +/- 4.3 and 58.4 +/- 35 ml/min/kg (mean +/- SD) in women compared to 12.6 +/- 3.4 and 82.6 +/- 70 ml/min/kg in men (p = 0.076).,Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10709150/),[ml] / [kg·min],82.6,99188,DB00661,Verapamil
,10709150,Bioavailability,"Bioavailability was higher in women (0.25 +/- 0.09) compared to men (0.20 +/- 0.09, p = 0.019) with a significant Gender x Formulation interaction (p = 0.04).",Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10709150/),,0.25,99189,DB00661,Verapamil
,10709150,Bioavailability,"Bioavailability was higher in women (0.25 +/- 0.09) compared to men (0.20 +/- 0.09, p = 0.019) with a significant Gender x Formulation interaction (p = 0.04).",Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10709150/),,0.20,99190,DB00661,Verapamil
,14677272,Cmax,"The Cmax was found to be 51.4 +/- 15.5 and 48.6 +/- 17.9 (ng/ml) for Manidon and B, respectively and the corresponding tmax were 7.0 +/- 1.9 and 6.0 +/- 0, respectively.",Intra-gastric performance and bioavailability study of a new per-oral bioadhesive Verapamil HCl matrix tablet in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14677272/),[ng] / [ml],51.4,99631,DB00661,Verapamil
,14677272,Cmax,"The Cmax was found to be 51.4 +/- 15.5 and 48.6 +/- 17.9 (ng/ml) for Manidon and B, respectively and the corresponding tmax were 7.0 +/- 1.9 and 6.0 +/- 0, respectively.",Intra-gastric performance and bioavailability study of a new per-oral bioadhesive Verapamil HCl matrix tablet in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14677272/),[ng] / [ml],48.6,99632,DB00661,Verapamil
,14677272,tmax,"The Cmax was found to be 51.4 +/- 15.5 and 48.6 +/- 17.9 (ng/ml) for Manidon and B, respectively and the corresponding tmax were 7.0 +/- 1.9 and 6.0 +/- 0, respectively.",Intra-gastric performance and bioavailability study of a new per-oral bioadhesive Verapamil HCl matrix tablet in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14677272/),,7.0,99633,DB00661,Verapamil
,14677272,tmax,"The Cmax was found to be 51.4 +/- 15.5 and 48.6 +/- 17.9 (ng/ml) for Manidon and B, respectively and the corresponding tmax were 7.0 +/- 1.9 and 6.0 +/- 0, respectively.",Intra-gastric performance and bioavailability study of a new per-oral bioadhesive Verapamil HCl matrix tablet in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14677272/),,6.0,99634,DB00661,Verapamil
,14677272,AUCO-.,"The AUCO-. for Manidon and B were 949.84 +/- 245.11 and 722.92 +/- 144.42 ng.h/ml, respectively.",Intra-gastric performance and bioavailability study of a new per-oral bioadhesive Verapamil HCl matrix tablet in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14677272/),[h·ng] / [ml],949.84,99635,DB00661,Verapamil
,14677272,AUCO-.,"The AUCO-. for Manidon and B were 949.84 +/- 245.11 and 722.92 +/- 144.42 ng.h/ml, respectively.",Intra-gastric performance and bioavailability study of a new per-oral bioadhesive Verapamil HCl matrix tablet in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14677272/),[h·ng] / [ml],722.92,99636,DB00661,Verapamil
,6184565,half-life,"The half-life appears to be approximately 5 h, but may increase as dose size is increased.",Clinical pharmacokinetics of calcium channel antagonists. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6184565/),h,5,100878,DB00661,Verapamil
,4061274,t1/2,Puppies exhibited a shorter t1/2 than adults after intravenous administration (62.3 +/- 10.8 minutes compared to 87.3 +/- 7.8 minutes).,Age-related changes in the pharmacodynamics of verapamil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4061274/),min,62.3,101349,DB00661,Verapamil
,4061274,t1/2,Puppies exhibited a shorter t1/2 than adults after intravenous administration (62.3 +/- 10.8 minutes compared to 87.3 +/- 7.8 minutes).,Age-related changes in the pharmacodynamics of verapamil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4061274/),min,87.3,101350,DB00661,Verapamil
,16411525,CrCl,"Verapamil significantly increased peritoneal CrCl [51.3 (44.3 - 53.3) vs baseline 45.8 (41.4 - 50.5) L/week/ 1.73 m2, p < 0.05], weekly Kt/V urea [1.75 (1.60 - 1.78) vs baseline 1.59 (1.54 - 1.73), p < 0.05], and drained dialysate volume [8.80 (8.30 - 8.96) vs baseline 8.44 (8.20 - 8.50) L/day, p < 0.05].","Effect of oral administration of losartan, prazosin, and verapamil on peritoneal solute transport in continuous ambulatory peritoneal dialysis patients. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16411525/),[l] / [·1.73·m2·week],51.3,101575,DB00661,Verapamil
,16411525,CrCl,"Verapamil significantly increased peritoneal CrCl [51.3 (44.3 - 53.3) vs baseline 45.8 (41.4 - 50.5) L/week/ 1.73 m2, p < 0.05], weekly Kt/V urea [1.75 (1.60 - 1.78) vs baseline 1.59 (1.54 - 1.73), p < 0.05], and drained dialysate volume [8.80 (8.30 - 8.96) vs baseline 8.44 (8.20 - 8.50) L/day, p < 0.05].","Effect of oral administration of losartan, prazosin, and verapamil on peritoneal solute transport in continuous ambulatory peritoneal dialysis patients. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16411525/),[l] / [·1.73·m2·week],45.8,101576,DB00661,Verapamil
,16411525,Kt/V urea,"Verapamil significantly increased peritoneal CrCl [51.3 (44.3 - 53.3) vs baseline 45.8 (41.4 - 50.5) L/week/ 1.73 m2, p < 0.05], weekly Kt/V urea [1.75 (1.60 - 1.78) vs baseline 1.59 (1.54 - 1.73), p < 0.05], and drained dialysate volume [8.80 (8.30 - 8.96) vs baseline 8.44 (8.20 - 8.50) L/day, p < 0.05].","Effect of oral administration of losartan, prazosin, and verapamil on peritoneal solute transport in continuous ambulatory peritoneal dialysis patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16411525/),,1.75,101577,DB00661,Verapamil
,16411525,Kt/V urea,"Verapamil significantly increased peritoneal CrCl [51.3 (44.3 - 53.3) vs baseline 45.8 (41.4 - 50.5) L/week/ 1.73 m2, p < 0.05], weekly Kt/V urea [1.75 (1.60 - 1.78) vs baseline 1.59 (1.54 - 1.73), p < 0.05], and drained dialysate volume [8.80 (8.30 - 8.96) vs baseline 8.44 (8.20 - 8.50) L/day, p < 0.05].","Effect of oral administration of losartan, prazosin, and verapamil on peritoneal solute transport in continuous ambulatory peritoneal dialysis patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16411525/),,1.59,101578,DB00661,Verapamil
,16411525,drained dialysate volume,"Verapamil significantly increased peritoneal CrCl [51.3 (44.3 - 53.3) vs baseline 45.8 (41.4 - 50.5) L/week/ 1.73 m2, p < 0.05], weekly Kt/V urea [1.75 (1.60 - 1.78) vs baseline 1.59 (1.54 - 1.73), p < 0.05], and drained dialysate volume [8.80 (8.30 - 8.96) vs baseline 8.44 (8.20 - 8.50) L/day, p < 0.05].","Effect of oral administration of losartan, prazosin, and verapamil on peritoneal solute transport in continuous ambulatory peritoneal dialysis patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16411525/),[l] / [d],8.80,101579,DB00661,Verapamil
,16411525,drained dialysate volume,"Verapamil significantly increased peritoneal CrCl [51.3 (44.3 - 53.3) vs baseline 45.8 (41.4 - 50.5) L/week/ 1.73 m2, p < 0.05], weekly Kt/V urea [1.75 (1.60 - 1.78) vs baseline 1.59 (1.54 - 1.73), p < 0.05], and drained dialysate volume [8.80 (8.30 - 8.96) vs baseline 8.44 (8.20 - 8.50) L/day, p < 0.05].","Effect of oral administration of losartan, prazosin, and verapamil on peritoneal solute transport in continuous ambulatory peritoneal dialysis patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16411525/),[l] / [d],8.44,101580,DB00661,Verapamil
,8792420,AUC0-1,"After log transformation, the mean AUC0-1 +/- %cv (ng.h/mL) on Occasion 1 (878 +/- 38) was 23% greater (p = 0.031) than on Occasion 2 (713 +/- 41).",High variability in drug pharmacokinetics complicates determination of bioequivalence: experience with verapamil. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8792420/),[h·ng] / [ml],878,102263,DB00661,Verapamil
,8792420,AUC0-1,"After log transformation, the mean AUC0-1 +/- %cv (ng.h/mL) on Occasion 1 (878 +/- 38) was 23% greater (p = 0.031) than on Occasion 2 (713 +/- 41).",High variability in drug pharmacokinetics complicates determination of bioequivalence: experience with verapamil. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8792420/),[h·ng] / [ml],713,102264,DB00661,Verapamil
,8792420,Cmax,The Cmax varied > 9 fold (30-278 ng/mL) among subjects.,High variability in drug pharmacokinetics complicates determination of bioequivalence: experience with verapamil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8792420/),[ng] / [ml],30-278,102265,DB00661,Verapamil
,8554934,half-life,"The mean half-life values of R- and S-verapamil for elderly subjects were approximately 20 h compared with approximately 13 h for young subjects, respectively.",Age and gender related changes in stereoselective pharmacokinetics and pharmacodynamics of verapamil and norverapamil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8554934/),h,20,102974,DB00661,Verapamil
,8554934,half-life,"The mean half-life values of R- and S-verapamil for elderly subjects were approximately 20 h compared with approximately 13 h for young subjects, respectively.",Age and gender related changes in stereoselective pharmacokinetics and pharmacodynamics of verapamil and norverapamil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8554934/),h,13,102975,DB00661,Verapamil
,8554934,half-life,"The mean half-life values of R- and S-norverapamil for elderly subjects were approximately 31 h and 20 h, respectively, compared with approximately 19 h and 21 h for young subjects, respectively.",Age and gender related changes in stereoselective pharmacokinetics and pharmacodynamics of verapamil and norverapamil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8554934/),h,31,102976,DB00661,Verapamil
,8554934,half-life,"The mean half-life values of R- and S-norverapamil for elderly subjects were approximately 31 h and 20 h, respectively, compared with approximately 19 h and 21 h for young subjects, respectively.",Age and gender related changes in stereoselective pharmacokinetics and pharmacodynamics of verapamil and norverapamil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8554934/),h,20,102977,DB00661,Verapamil
,8554934,half-life,"The mean half-life values of R- and S-norverapamil for elderly subjects were approximately 31 h and 20 h, respectively, compared with approximately 19 h and 21 h for young subjects, respectively.",Age and gender related changes in stereoselective pharmacokinetics and pharmacodynamics of verapamil and norverapamil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8554934/),h,19,102978,DB00661,Verapamil
,8554934,half-life,"The mean half-life values of R- and S-norverapamil for elderly subjects were approximately 31 h and 20 h, respectively, compared with approximately 19 h and 21 h for young subjects, respectively.",Age and gender related changes in stereoselective pharmacokinetics and pharmacodynamics of verapamil and norverapamil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8554934/),h,21,102979,DB00661,Verapamil
,15966465,time to peak,"The mean +/- SD time to peak and maximal S-verapamil concentrations were 9.5 +/- 1.2 hours and 46.4 +/- 35.8 ng/ml, respectively.",A pharmacodynamic model of the effects of controlled-onset extended-release verapamil on 24-hour ambulatory blood pressure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966465/),h,9.5,103094,DB00661,Verapamil
,15966465,maximal S-verapamil concentrations,"The mean +/- SD time to peak and maximal S-verapamil concentrations were 9.5 +/- 1.2 hours and 46.4 +/- 35.8 ng/ml, respectively.",A pharmacodynamic model of the effects of controlled-onset extended-release verapamil on 24-hour ambulatory blood pressure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966465/),[ng] / [ml],46.4,103095,DB00661,Verapamil
,15966465,(Emax D) pressures,"(Emax D) pressures and C50 were 101 +/- 14 mmHg, 61 +/- 9.9 mmHg and 32.9 +/- 22.8 ng/ml, respectively.",A pharmacodynamic model of the effects of controlled-onset extended-release verapamil on 24-hour ambulatory blood pressure. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966465/),mmhg,101,103096,DB00661,Verapamil
,15966465,C50,"(Emax D) pressures and C50 were 101 +/- 14 mmHg, 61 +/- 9.9 mmHg and 32.9 +/- 22.8 ng/ml, respectively.",A pharmacodynamic model of the effects of controlled-onset extended-release verapamil on 24-hour ambulatory blood pressure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966465/),mmhg,61,103097,DB00661,Verapamil
,15966465,C50,"(Emax D) pressures and C50 were 101 +/- 14 mmHg, 61 +/- 9.9 mmHg and 32.9 +/- 22.8 ng/ml, respectively.",A pharmacodynamic model of the effects of controlled-onset extended-release verapamil on 24-hour ambulatory blood pressure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15966465/),[ng] / [ml],32.9,103098,DB00661,Verapamil
,28795912,oral bioavailability,The oral bioavailability increased significantly (p < 0.05) from 3.84% to 6.84% with the pretreatment of verapamil.,Effects of verapamil on the pharmacokinetics of dihydromyricetin in rats and its potential mechanism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28795912/),%,3.84,104492,DB00661,Verapamil
,28795912,oral bioavailability,The oral bioavailability increased significantly (p < 0.05) from 3.84% to 6.84% with the pretreatment of verapamil.,Effects of verapamil on the pharmacokinetics of dihydromyricetin in rats and its potential mechanism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28795912/),%,6.84,104493,DB00661,Verapamil
,28795912,intrinsic clearance rate,"Additionally, the intrinsic clearance rate of dihydromyricetin was decreased by the pretreatment with verapamil (27.0 versus 32.5 μL/min/mg protein).",Effects of verapamil on the pharmacokinetics of dihydromyricetin in rats and its potential mechanism. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28795912/),[μl] / [mg·min],27.0,104494,DB00661,Verapamil
,28795912,intrinsic clearance rate,"Additionally, the intrinsic clearance rate of dihydromyricetin was decreased by the pretreatment with verapamil (27.0 versus 32.5 μL/min/mg protein).",Effects of verapamil on the pharmacokinetics of dihydromyricetin in rats and its potential mechanism. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28795912/),[μl] / [mg·min],32.5,104495,DB00661,Verapamil
,10084158,nasal bioavailability,"The nasal bioavailability of nicardipine from plain buffered solution was 44%, and increased steadily to 56-79% in direct proportion to the amount of PEG 400 added.",Evaluation of the effect of polyethylene glycol 400 on the nasal absorption of nicardipine and verapamil in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10084158/),%,44,104913,DB00661,Verapamil
,10084158,nasal bioavailability,"The nasal bioavailability of nicardipine from plain buffered solution was 44%, and increased steadily to 56-79% in direct proportion to the amount of PEG 400 added.",Evaluation of the effect of polyethylene glycol 400 on the nasal absorption of nicardipine and verapamil in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10084158/),%,56-79,104914,DB00661,Verapamil
,10084158,bioavailability,"Verapamil, on the other hand, exhibited an intranasal bioavailability of 52% in the absence of PEG 400, and between 61-68% in the presence of increasing concentrations of PEG 400.",Evaluation of the effect of polyethylene glycol 400 on the nasal absorption of nicardipine and verapamil in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10084158/),%,52,104915,DB00661,Verapamil
,10084158,bioavailability,"Verapamil, on the other hand, exhibited an intranasal bioavailability of 52% in the absence of PEG 400, and between 61-68% in the presence of increasing concentrations of PEG 400.",Evaluation of the effect of polyethylene glycol 400 on the nasal absorption of nicardipine and verapamil in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10084158/),%,61-68,104916,DB00661,Verapamil
,24297779,transepithelial permeability ratios,"In vitro data showed that: 1) paraquat failed to stimulate ATPase activity; 2) resistance to paraquat-induced cytotoxicity was unchanged in P-gp-expressing cells in the absence or presence of P-gp inhibitors GF120918 [N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide] and verapamil-37.0 [95% confidence interval (CI): 33.2-41.4], 46.2 (42.5-50.2), and 34.1 µM (31.2-37.2)-respectively; 3) transepithelial permeability ratios of paraquat were the same in P-gp-expressing and nonexpressing cells (1.55 ± 0.39 and 1.39 ± 0.43, respectively); and 4) paraquat did not inhibit rhodamine-123 transport.",Absence of P-glycoprotein transport in the pharmacokinetics and toxicity of the herbicide paraquat. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24297779/),,1.55,106194,DB00661,Verapamil
,24297779,transepithelial permeability ratios,"In vitro data showed that: 1) paraquat failed to stimulate ATPase activity; 2) resistance to paraquat-induced cytotoxicity was unchanged in P-gp-expressing cells in the absence or presence of P-gp inhibitors GF120918 [N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide] and verapamil-37.0 [95% confidence interval (CI): 33.2-41.4], 46.2 (42.5-50.2), and 34.1 µM (31.2-37.2)-respectively; 3) transepithelial permeability ratios of paraquat were the same in P-gp-expressing and nonexpressing cells (1.55 ± 0.39 and 1.39 ± 0.43, respectively); and 4) paraquat did not inhibit rhodamine-123 transport.",Absence of P-glycoprotein transport in the pharmacokinetics and toxicity of the herbicide paraquat. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24297779/),,1.39,106195,DB00661,Verapamil
,24297779,clearances,"Population pharmacokinetic modeling revealed minor differences between FVB wild-type and mdr1a(-/-)/mdr1b(-/-) mice: clearances of 0.47 [95% confidence interval (CI): 0.42-0.52] and 0.78 l/h (0.58-0.98), respectively, and volume of distributions of 1.77 (95% CI: 1.50-2.04) and 3.36 liters (2.39-4.33), respectively; however, the change in clearance was in the opposite direction of what would be expected.",Absence of P-glycoprotein transport in the pharmacokinetics and toxicity of the herbicide paraquat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24297779/),[l] / [h],0.47,106196,DB00661,Verapamil
,24297779,clearances,"Population pharmacokinetic modeling revealed minor differences between FVB wild-type and mdr1a(-/-)/mdr1b(-/-) mice: clearances of 0.47 [95% confidence interval (CI): 0.42-0.52] and 0.78 l/h (0.58-0.98), respectively, and volume of distributions of 1.77 (95% CI: 1.50-2.04) and 3.36 liters (2.39-4.33), respectively; however, the change in clearance was in the opposite direction of what would be expected.",Absence of P-glycoprotein transport in the pharmacokinetics and toxicity of the herbicide paraquat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24297779/),[l] / [h],0.78,106197,DB00661,Verapamil
,24297779,volume of distributions,"Population pharmacokinetic modeling revealed minor differences between FVB wild-type and mdr1a(-/-)/mdr1b(-/-) mice: clearances of 0.47 [95% confidence interval (CI): 0.42-0.52] and 0.78 l/h (0.58-0.98), respectively, and volume of distributions of 1.77 (95% CI: 1.50-2.04) and 3.36 liters (2.39-4.33), respectively; however, the change in clearance was in the opposite direction of what would be expected.",Absence of P-glycoprotein transport in the pharmacokinetics and toxicity of the herbicide paraquat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24297779/),l,1.77,106198,DB00661,Verapamil
,24297779,volume of distributions,"Population pharmacokinetic modeling revealed minor differences between FVB wild-type and mdr1a(-/-)/mdr1b(-/-) mice: clearances of 0.47 [95% confidence interval (CI): 0.42-0.52] and 0.78 l/h (0.58-0.98), respectively, and volume of distributions of 1.77 (95% CI: 1.50-2.04) and 3.36 liters (2.39-4.33), respectively; however, the change in clearance was in the opposite direction of what would be expected.",Absence of P-glycoprotein transport in the pharmacokinetics and toxicity of the herbicide paraquat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24297779/),l,3.36,106199,DB00661,Verapamil
,27016067,absorptive transport,"The absorptive transport from mucosal-to-serosal (M → S) and secretory transport from serosal-to-mucosal (S → M) for VP-16 solution over 90 min were found to be (3.58 ± 0.32) × 10-6 and (14.63 ± 3.11) × 10-6 cm/s, respectively, with a net efflux of 4.08.",The Ameliorated Pharmacokinetics of VP-16 in Wistar Rats: A Possible Role of P-Glycoprotein Inhibition by Pharmaceutical Excipients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27016067/),[cm] / [s],3.58,107284,DB00661,Verapamil
,27016067,secretory transport,"The absorptive transport from mucosal-to-serosal (M → S) and secretory transport from serosal-to-mucosal (S → M) for VP-16 solution over 90 min were found to be (3.58 ± 0.32) × 10-6 and (14.63 ± 3.11) × 10-6 cm/s, respectively, with a net efflux of 4.08.",The Ameliorated Pharmacokinetics of VP-16 in Wistar Rats: A Possible Role of P-Glycoprotein Inhibition by Pharmaceutical Excipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27016067/),[cm] / [s],3.58,107285,DB00661,Verapamil
,27016067,secretory transport,"The absorptive transport from mucosal-to-serosal (M → S) and secretory transport from serosal-to-mucosal (S → M) for VP-16 solution over 90 min were found to be (3.58 ± 0.32) × 10-6 and (14.63 ± 3.11) × 10-6 cm/s, respectively, with a net efflux of 4.08.",The Ameliorated Pharmacokinetics of VP-16 in Wistar Rats: A Possible Role of P-Glycoprotein Inhibition by Pharmaceutical Excipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27016067/),[cm] / [s],14.63,107286,DB00661,Verapamil
,27016067,net efflux,"The absorptive transport from mucosal-to-serosal (M → S) and secretory transport from serosal-to-mucosal (S → M) for VP-16 solution over 90 min were found to be (3.58 ± 0.32) × 10-6 and (14.63 ± 3.11) × 10-6 cm/s, respectively, with a net efflux of 4.08.",The Ameliorated Pharmacokinetics of VP-16 in Wistar Rats: A Possible Role of P-Glycoprotein Inhibition by Pharmaceutical Excipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27016067/),,4.08,107287,DB00661,Verapamil
,27016067,Papp,"Addition of verapamil (200 µM), a P-glycoprotein inhibitor, elevated the transport from M → S [Papp from (3.58 ± 0.32) to (9.66 ± 1.55) × 10-6 cm/s, p < 0.05] and lowered the S → M [Papp from (14.63 ± 3.11) to (13.35 ± 2.01) × 10-6 cm/s, p < 0.01], with a net efflux of 1.38.",The Ameliorated Pharmacokinetics of VP-16 in Wistar Rats: A Possible Role of P-Glycoprotein Inhibition by Pharmaceutical Excipients. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27016067/),[cm] / [s],3.58,107288,DB00661,Verapamil
,27016067,Papp,"Addition of verapamil (200 µM), a P-glycoprotein inhibitor, elevated the transport from M → S [Papp from (3.58 ± 0.32) to (9.66 ± 1.55) × 10-6 cm/s, p < 0.05] and lowered the S → M [Papp from (14.63 ± 3.11) to (13.35 ± 2.01) × 10-6 cm/s, p < 0.01], with a net efflux of 1.38.",The Ameliorated Pharmacokinetics of VP-16 in Wistar Rats: A Possible Role of P-Glycoprotein Inhibition by Pharmaceutical Excipients. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27016067/),[cm] / [s],9.66,107289,DB00661,Verapamil
,27016067,Papp,"Addition of verapamil (200 µM), a P-glycoprotein inhibitor, elevated the transport from M → S [Papp from (3.58 ± 0.32) to (9.66 ± 1.55) × 10-6 cm/s, p < 0.05] and lowered the S → M [Papp from (14.63 ± 3.11) to (13.35 ± 2.01) × 10-6 cm/s, p < 0.01], with a net efflux of 1.38.",The Ameliorated Pharmacokinetics of VP-16 in Wistar Rats: A Possible Role of P-Glycoprotein Inhibition by Pharmaceutical Excipients. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27016067/),[cm] / [s],14.63,107290,DB00661,Verapamil
,27016067,Papp,"Addition of verapamil (200 µM), a P-glycoprotein inhibitor, elevated the transport from M → S [Papp from (3.58 ± 0.32) to (9.66 ± 1.55) × 10-6 cm/s, p < 0.05] and lowered the S → M [Papp from (14.63 ± 3.11) to (13.35 ± 2.01) × 10-6 cm/s, p < 0.01], with a net efflux of 1.38.",The Ameliorated Pharmacokinetics of VP-16 in Wistar Rats: A Possible Role of P-Glycoprotein Inhibition by Pharmaceutical Excipients. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27016067/),[cm] / [s],13.35,107291,DB00661,Verapamil
,27016067,net efflux,"Addition of verapamil (200 µM), a P-glycoprotein inhibitor, elevated the transport from M → S [Papp from (3.58 ± 0.32) to (9.66 ± 1.55) × 10-6 cm/s, p < 0.05] and lowered the S → M [Papp from (14.63 ± 3.11) to (13.35 ± 2.01) × 10-6 cm/s, p < 0.01], with a net efflux of 1.38.",The Ameliorated Pharmacokinetics of VP-16 in Wistar Rats: A Possible Role of P-Glycoprotein Inhibition by Pharmaceutical Excipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27016067/),,1.38,107292,DB00661,Verapamil
,29902922,contact angles,"Results revealed that superamphiphobic substrates were successfully prepared showing a rough micro-sized hierarchical structured surface upon observing with scanning electron microscope and were confirmed by high contact angles of 151.60 ± 2.42 and 142.80°±05.23° for water and olive oil, respectively.","Ultrahigh verapamil-loaded controlled release polymeric beads using superamphiphobic substrate: D-optimal statistical design, in vitro and in vivo performance. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29902922/),°,151.60,109147,DB00661,Verapamil
,29902922,contact angles,"Results revealed that superamphiphobic substrates were successfully prepared showing a rough micro-sized hierarchical structured surface upon observing with scanning electron microscope and were confirmed by high contact angles of 151.60 ± 2.42 and 142.80°±05.23° for water and olive oil, respectively.","Ultrahigh verapamil-loaded controlled release polymeric beads using superamphiphobic substrate: D-optimal statistical design, in vitro and in vivo performance. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29902922/),°,142.80,109148,DB00661,Verapamil
,29902922,Q12 h,All the prepared systems exhibited a controlled release behavior with Q12 h ranging between 5.46 and 95.90%w/w.,"Ultrahigh verapamil-loaded controlled release polymeric beads using superamphiphobic substrate: D-optimal statistical design, in vitro and in vivo performance. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29902922/),[%w] / [w],5.46 and 95.90,109149,DB00661,Verapamil
,12839868,Maximum binding,6. Maximum binding of (3)H-nitrendipine to cardiac cell membrane was significantly reduced from 63.2+/-2.5 fmol mg(-1) protein in controls to 46.4+/-2.0 in acute inflammation and from 66.8+/-2.2 fmol mg(-1) protein in controls to 42.2+/-2.0 in chronic inflammation.,"Despite increased plasma concentration, inflammation reduces potency of calcium channel antagonists due to lower binding to the rat heart. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12839868/),[fmol] / [mg],63.2,109408,DB00661,Verapamil
,12839868,Maximum binding,6. Maximum binding of (3)H-nitrendipine to cardiac cell membrane was significantly reduced from 63.2+/-2.5 fmol mg(-1) protein in controls to 46.4+/-2.0 in acute inflammation and from 66.8+/-2.2 fmol mg(-1) protein in controls to 42.2+/-2.0 in chronic inflammation.,"Despite increased plasma concentration, inflammation reduces potency of calcium channel antagonists due to lower binding to the rat heart. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12839868/),[fmol] / [mg],46.4,109409,DB00661,Verapamil
,12839868,Maximum binding,6. Maximum binding of (3)H-nitrendipine to cardiac cell membrane was significantly reduced from 63.2+/-2.5 fmol mg(-1) protein in controls to 46.4+/-2.0 in acute inflammation and from 66.8+/-2.2 fmol mg(-1) protein in controls to 42.2+/-2.0 in chronic inflammation.,"Despite increased plasma concentration, inflammation reduces potency of calcium channel antagonists due to lower binding to the rat heart. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12839868/),[fmol] / [mg],66.8,109410,DB00661,Verapamil
,12839868,Maximum binding,6. Maximum binding of (3)H-nitrendipine to cardiac cell membrane was significantly reduced from 63.2+/-2.5 fmol mg(-1) protein in controls to 46.4+/-2.0 in acute inflammation and from 66.8+/-2.2 fmol mg(-1) protein in controls to 42.2+/-2.0 in chronic inflammation.,"Despite increased plasma concentration, inflammation reduces potency of calcium channel antagonists due to lower binding to the rat heart. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12839868/),,42.2,109411,DB00661,Verapamil
,31990625,peak plasma concentration,"Results: Verapamil significantly increased the peak plasma concentration (from 91.97 ± 11.30 to 125.30 ± 13.50 ng/mL), and decrease the oral clearance (from 63.85 ± 10.79 to 32.95 ± 6.17 L/h/kg).",Effect of verapamil on the pharmacokinetics of hydroxycamptothecin and its potential mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31990625/),[ng] / [ml],91.97,111465,DB00661,Verapamil
,31990625,peak plasma concentration,"Results: Verapamil significantly increased the peak plasma concentration (from 91.97 ± 11.30 to 125.30 ± 13.50 ng/mL), and decrease the oral clearance (from 63.85 ± 10.79 to 32.95 ± 6.17 L/h/kg).",Effect of verapamil on the pharmacokinetics of hydroxycamptothecin and its potential mechanism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31990625/),[ng] / [ml],125.30,111466,DB00661,Verapamil
,31990625,oral clearance,"Results: Verapamil significantly increased the peak plasma concentration (from 91.97 ± 11.30 to 125.30 ± 13.50 ng/mL), and decrease the oral clearance (from 63.85 ± 10.79 to 32.95 ± 6.17 L/h/kg).",Effect of verapamil on the pharmacokinetics of hydroxycamptothecin and its potential mechanism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31990625/),[l] / [h·kg],63.85,111467,DB00661,Verapamil
,31990625,oral clearance,"Results: Verapamil significantly increased the peak plasma concentration (from 91.97 ± 11.30 to 125.30 ± 13.50 ng/mL), and decrease the oral clearance (from 63.85 ± 10.79 to 32.95 ± 6.17 L/h/kg).",Effect of verapamil on the pharmacokinetics of hydroxycamptothecin and its potential mechanism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31990625/),[l] / [h·kg],32.95,111468,DB00661,Verapamil
,31990625,intrinsic clearance rate,The intrinsic clearance rate was also significantly decreased (from 39.49 ± 0.42 to 28.64 ± 0.30 μL/min/mg protein) by the preincubation of verapamil.,Effect of verapamil on the pharmacokinetics of hydroxycamptothecin and its potential mechanism. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31990625/),[μl] / [mg·min],39.49,111469,DB00661,Verapamil
,31990625,intrinsic clearance rate,The intrinsic clearance rate was also significantly decreased (from 39.49 ± 0.42 to 28.64 ± 0.30 μL/min/mg protein) by the preincubation of verapamil.,Effect of verapamil on the pharmacokinetics of hydroxycamptothecin and its potential mechanism. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31990625/),[μl] / [mg·min],28.64,111470,DB00661,Verapamil
,31990625,efflux ratio,"The results of Caco-2 cell transwell experiments showed the efflux of HCPT was inhibited by verapamil, as the efflux ratio decreased from 1.82 to 1.21.",Effect of verapamil on the pharmacokinetics of hydroxycamptothecin and its potential mechanism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31990625/),,1.82,111471,DB00661,Verapamil
,31990625,efflux ratio,"The results of Caco-2 cell transwell experiments showed the efflux of HCPT was inhibited by verapamil, as the efflux ratio decreased from 1.82 to 1.21.",Effect of verapamil on the pharmacokinetics of hydroxycamptothecin and its potential mechanism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31990625/),,1.21,111472,DB00661,Verapamil
,9065315,relative bioavailability,A mean relative bioavailability of 101% was observed after the test substance both for verapamil and N-norverapamil.,"[Bioavailability of two verapamil formulations following repeated administration in steady-state conditions. An open, two-period, crossover study]. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9065315/),%,101,111569,DB00661,Verapamil
,9065315,maximum plasma concentrations,"The mean maximum plasma concentrations for verapamil and N-norverapamil were 50.0 and 49.7 ng/ml, respectively.","[Bioavailability of two verapamil formulations following repeated administration in steady-state conditions. An open, two-period, crossover study]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9065315/),[ng] / [ml],50.0,111570,DB00661,Verapamil
,9065315,maximum plasma concentrations,"The mean maximum plasma concentrations for verapamil and N-norverapamil were 50.0 and 49.7 ng/ml, respectively.","[Bioavailability of two verapamil formulations following repeated administration in steady-state conditions. An open, two-period, crossover study]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9065315/),[ng] / [ml],49.7,111571,DB00661,Verapamil
,9065315,PTF,"The mean PTF-values for verapamil and N-norverapamil were 178 and 76.6% after the test substance and 182 and 79.6% after the standard formulation, respectively.","[Bioavailability of two verapamil formulations following repeated administration in steady-state conditions. An open, two-period, crossover study]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9065315/),%,178,111572,DB00661,Verapamil
,9065315,PTF,"The mean PTF-values for verapamil and N-norverapamil were 178 and 76.6% after the test substance and 182 and 79.6% after the standard formulation, respectively.","[Bioavailability of two verapamil formulations following repeated administration in steady-state conditions. An open, two-period, crossover study]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9065315/),%,76.6,111573,DB00661,Verapamil
,9065315,PTF,"The mean PTF-values for verapamil and N-norverapamil were 178 and 76.6% after the test substance and 182 and 79.6% after the standard formulation, respectively.","[Bioavailability of two verapamil formulations following repeated administration in steady-state conditions. An open, two-period, crossover study]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9065315/),%,182,111574,DB00661,Verapamil
,9065315,PTF,"The mean PTF-values for verapamil and N-norverapamil were 178 and 76.6% after the test substance and 182 and 79.6% after the standard formulation, respectively.","[Bioavailability of two verapamil formulations following repeated administration in steady-state conditions. An open, two-period, crossover study]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9065315/),%,79.6,111575,DB00661,Verapamil
,11785692,absolute bioavailability (BA),The liver had a high intrinsic capacity for clearing VL because the absolute bioavailability (BA) of VL was 21.7% after PV administration.,Differentiation of gut and hepatic first-pass effect of drugs: 1. Studies of verapamil in ported dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11785692/),%,21.7,112787,DB00661,Verapamil
,11785692,BA,"The BA of VL after ID administration was 23.5%; therefore, intestinal absorption was complete and intestinal extraction was negligible (ER(GI) approximately 0).",Differentiation of gut and hepatic first-pass effect of drugs: 1. Studies of verapamil in ported dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11785692/),%,23.5,112788,DB00661,Verapamil
,21970310,clearance factor C(trough)-0.180,The full version of the final NONMEM® model was where CCB is 1 for concomitant administration of a CCB and is 0 otherwise; CHF is 1 for patients with CHF and is 0 otherwise; SEX is 0 for male and is 1 for female; and the elderly clearance factor C(trough)-0.180 is 1 for digoxin C(trough) <1.7 ng/mL.,Determination of digoxin clearance in Japanese elderly patients for optimization of drug therapy: a population pharmacokinetics analysis using nonlinear mixed-effects modelling. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21970310/),,1,113291,DB00661,Verapamil
<,21970310,C(trough),The full version of the final NONMEM® model was where CCB is 1 for concomitant administration of a CCB and is 0 otherwise; CHF is 1 for patients with CHF and is 0 otherwise; SEX is 0 for male and is 1 for female; and the elderly clearance factor C(trough)-0.180 is 1 for digoxin C(trough) <1.7 ng/mL.,Determination of digoxin clearance in Japanese elderly patients for optimization of drug therapy: a population pharmacokinetics analysis using nonlinear mixed-effects modelling. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21970310/),[ng] / [ml],1.7,113292,DB00661,Verapamil
,15626582,absolute bioavailability,"The absolute bioavailability of paclitaxel with verapamil (3.9-5.4%) was significantly (p<0.05 at 5 mg/kg and 0.5 h; p<0.01 at 15 mg/kg, 3 days and 6 days) higher than that of the control (2.2%).",The effect of verapamil on the pharmacokinetics of paclitaxel in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15626582/),%,3.9-5.4,113378,DB00661,Verapamil
,15626582,absolute bioavailability,"The absolute bioavailability of paclitaxel with verapamil (3.9-5.4%) was significantly (p<0.05 at 5 mg/kg and 0.5 h; p<0.01 at 15 mg/kg, 3 days and 6 days) higher than that of the control (2.2%).",The effect of verapamil on the pharmacokinetics of paclitaxel in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15626582/),%,2.2,113379,DB00661,Verapamil
,6611645,sustained,"In contrast, verapamil was given intravenously to 3 dogs by a bolus-infusion method to produce sustained steady state plasma concentrations (80, 140, 250 ng/ml) for 1, 2, and 3 h.",The pharmacology of verapamil. V. Tissue distribution of verapamil and norverapamil in rat and dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6611645/),[ng] / [ml],80,113576,DB00661,Verapamil
,6611645,sustained,"In contrast, verapamil was given intravenously to 3 dogs by a bolus-infusion method to produce sustained steady state plasma concentrations (80, 140, 250 ng/ml) for 1, 2, and 3 h.",The pharmacology of verapamil. V. Tissue distribution of verapamil and norverapamil in rat and dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6611645/),[ng] / [ml],140,113577,DB00661,Verapamil
,6611645,steady state plasma concentrations,"In contrast, verapamil was given intravenously to 3 dogs by a bolus-infusion method to produce sustained steady state plasma concentrations (80, 140, 250 ng/ml) for 1, 2, and 3 h.",The pharmacology of verapamil. V. Tissue distribution of verapamil and norverapamil in rat and dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6611645/),[ng] / [ml],80,113578,DB00661,Verapamil
,6611645,steady state plasma concentrations,"In contrast, verapamil was given intravenously to 3 dogs by a bolus-infusion method to produce sustained steady state plasma concentrations (80, 140, 250 ng/ml) for 1, 2, and 3 h.",The pharmacology of verapamil. V. Tissue distribution of verapamil and norverapamil in rat and dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6611645/),[ng] / [ml],140,113579,DB00661,Verapamil
,6611645,steady state plasma concentrations,"In contrast, verapamil was given intravenously to 3 dogs by a bolus-infusion method to produce sustained steady state plasma concentrations (80, 140, 250 ng/ml) for 1, 2, and 3 h.",The pharmacology of verapamil. V. Tissue distribution of verapamil and norverapamil in rat and dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6611645/),[ng] / [ml],250,113580,DB00661,Verapamil
,3740673,Total verapamil,Total verapamil clearance was decreased in elderly (10.5 +/- 3.5 mL/min X kg; p less than 0.05) and very elderly (8.0 +/- 4.1 mL/min X kg; p less than 0.01) when compared with that in young patients (15.5 +/- 4.5 mL/min X kg).,Verapamil pharmacodynamics and disposition in young and elderly hypertensive patients. Altered electrocardiographic and hypotensive responses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3740673/),[ml] / [kg·min],10.5,115869,DB00661,Verapamil
,3740673,Total verapamil,Total verapamil clearance was decreased in elderly (10.5 +/- 3.5 mL/min X kg; p less than 0.05) and very elderly (8.0 +/- 4.1 mL/min X kg; p less than 0.01) when compared with that in young patients (15.5 +/- 4.5 mL/min X kg).,Verapamil pharmacodynamics and disposition in young and elderly hypertensive patients. Altered electrocardiographic and hypotensive responses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3740673/),[ml] / [kg·min],8.0,115870,DB00661,Verapamil
,3740673,Total verapamil,Total verapamil clearance was decreased in elderly (10.5 +/- 3.5 mL/min X kg; p less than 0.05) and very elderly (8.0 +/- 4.1 mL/min X kg; p less than 0.01) when compared with that in young patients (15.5 +/- 4.5 mL/min X kg).,Verapamil pharmacodynamics and disposition in young and elderly hypertensive patients. Altered electrocardiographic and hypotensive responses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3740673/),[ml] / [kg·min],15.5,115871,DB00661,Verapamil
,3740673,clearance,Total verapamil clearance was decreased in elderly (10.5 +/- 3.5 mL/min X kg; p less than 0.05) and very elderly (8.0 +/- 4.1 mL/min X kg; p less than 0.01) when compared with that in young patients (15.5 +/- 4.5 mL/min X kg).,Verapamil pharmacodynamics and disposition in young and elderly hypertensive patients. Altered electrocardiographic and hypotensive responses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3740673/),[ml] / [kg·min],10.5,115872,DB00661,Verapamil
,3740673,clearance,Total verapamil clearance was decreased in elderly (10.5 +/- 3.5 mL/min X kg; p less than 0.05) and very elderly (8.0 +/- 4.1 mL/min X kg; p less than 0.01) when compared with that in young patients (15.5 +/- 4.5 mL/min X kg).,Verapamil pharmacodynamics and disposition in young and elderly hypertensive patients. Altered electrocardiographic and hypotensive responses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3740673/),[ml] / [kg·min],8.0,115873,DB00661,Verapamil
,3740673,clearance,Total verapamil clearance was decreased in elderly (10.5 +/- 3.5 mL/min X kg; p less than 0.05) and very elderly (8.0 +/- 4.1 mL/min X kg; p less than 0.01) when compared with that in young patients (15.5 +/- 4.5 mL/min X kg).,Verapamil pharmacodynamics and disposition in young and elderly hypertensive patients. Altered electrocardiographic and hypotensive responses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3740673/),[ml] / [kg·min],15.5,115874,DB00661,Verapamil
,3740673,Elimination half-life,Elimination half-life was prolonged in the elderly (7.4 +/- 3.3 h; p less than 0.01) and very elderly (8.0 +/- 1.2 h; p less than 0.01) compared with that in young patients (3.8 +/- 1.1 h).,Verapamil pharmacodynamics and disposition in young and elderly hypertensive patients. Altered electrocardiographic and hypotensive responses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3740673/),h,7.4,115875,DB00661,Verapamil
,3740673,Elimination half-life,Elimination half-life was prolonged in the elderly (7.4 +/- 3.3 h; p less than 0.01) and very elderly (8.0 +/- 1.2 h; p less than 0.01) compared with that in young patients (3.8 +/- 1.1 h).,Verapamil pharmacodynamics and disposition in young and elderly hypertensive patients. Altered electrocardiographic and hypotensive responses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3740673/),h,8.0,115876,DB00661,Verapamil
,3740673,Elimination half-life,Elimination half-life was prolonged in the elderly (7.4 +/- 3.3 h; p less than 0.01) and very elderly (8.0 +/- 1.2 h; p less than 0.01) compared with that in young patients (3.8 +/- 1.1 h).,Verapamil pharmacodynamics and disposition in young and elderly hypertensive patients. Altered electrocardiographic and hypotensive responses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3740673/),h,3.8,115877,DB00661,Verapamil
,11876441,AUC(0-infinity),"Values of 1,226.4 ng h/ml (Tramadol) and 1,397.01 ng x h/ml (Tramal) for the parameter AUC(0-infinity) demonstrate a nearly identical extent of drug absorption.",Bioavailability of tramadol hydrochloride from tramadol--capsules 50 mg. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11876441/),[h·ng] / [ml],"1,226.4",116259,DB00661,Verapamil
,11876441,AUC(0-infinity),"Values of 1,226.4 ng h/ml (Tramadol) and 1,397.01 ng x h/ml (Tramal) for the parameter AUC(0-infinity) demonstrate a nearly identical extent of drug absorption.",Bioavailability of tramadol hydrochloride from tramadol--capsules 50 mg. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11876441/),[h·ng] / [ml],"1,397.01",116260,DB00661,Verapamil
,11876441,Maximum concentrations--Cmax,Maximum concentrations--Cmax (217.81 ng/ml and 246.0 ng/ml) and time to reach maximum plasma concentration--Tmax (2.14 and 2.31 h) achieved for Tramadol and reference preparation did not differ significantly.,Bioavailability of tramadol hydrochloride from tramadol--capsules 50 mg. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11876441/),[ng] / [ml],217.81,116261,DB00661,Verapamil
,11876441,Maximum concentrations--Cmax,Maximum concentrations--Cmax (217.81 ng/ml and 246.0 ng/ml) and time to reach maximum plasma concentration--Tmax (2.14 and 2.31 h) achieved for Tramadol and reference preparation did not differ significantly.,Bioavailability of tramadol hydrochloride from tramadol--capsules 50 mg. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11876441/),[ng] / [ml],246.0,116262,DB00661,Verapamil
,11876441,time to reach maximum plasma concentration--Tmax,Maximum concentrations--Cmax (217.81 ng/ml and 246.0 ng/ml) and time to reach maximum plasma concentration--Tmax (2.14 and 2.31 h) achieved for Tramadol and reference preparation did not differ significantly.,Bioavailability of tramadol hydrochloride from tramadol--capsules 50 mg. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11876441/),h,2.14,116263,DB00661,Verapamil
,11876441,time to reach maximum plasma concentration--Tmax,Maximum concentrations--Cmax (217.81 ng/ml and 246.0 ng/ml) and time to reach maximum plasma concentration--Tmax (2.14 and 2.31 h) achieved for Tramadol and reference preparation did not differ significantly.,Bioavailability of tramadol hydrochloride from tramadol--capsules 50 mg. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11876441/),h,2.31,116264,DB00661,Verapamil
,2095796,AUC/D,Following peroral administration the mean +/- SD AUC/D was (5.4 +/- 1.9) x 10(-3) micrograms ml-1 h per microgram dose and after administration of chewing gum (6.6 +/- 2.3) x 10(-3) micrograms ml-1 h per microgram dose (NS).,Relative bioavailability of (+/-)-verapamil hydrochloride administered in tablets and chewing gum. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2095796/),[h·μg] / [ml·μg],5.4,117379,DB00661,Verapamil
,2095796,AUC/D,Following peroral administration the mean +/- SD AUC/D was (5.4 +/- 1.9) x 10(-3) micrograms ml-1 h per microgram dose and after administration of chewing gum (6.6 +/- 2.3) x 10(-3) micrograms ml-1 h per microgram dose (NS).,Relative bioavailability of (+/-)-verapamil hydrochloride administered in tablets and chewing gum. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2095796/),[-1·h·μg] / [ml],6.6,117380,DB00661,Verapamil
,2095796,AUC ratio,"The AUC ratio of verapamil to the metabolite norverapamil was 1.5 after oral and 0.8 after peroral administration, indicating that a part of the verapamil administered in chewing gum was absorbed through the oral mucosa.",Relative bioavailability of (+/-)-verapamil hydrochloride administered in tablets and chewing gum. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2095796/),,1.5,117381,DB00661,Verapamil
,2095796,AUC ratio,"The AUC ratio of verapamil to the metabolite norverapamil was 1.5 after oral and 0.8 after peroral administration, indicating that a part of the verapamil administered in chewing gum was absorbed through the oral mucosa.",Relative bioavailability of (+/-)-verapamil hydrochloride administered in tablets and chewing gum. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2095796/),,0.8,117382,DB00661,Verapamil
,24498193,Cmax,"Furthermore, the infection reduced absorption of orally administered enrofloxacin, significantly decreased Cmax (0.34 vs 0.98 µg mL(-1), P = 0.000) and AUC0-12h (4.37 vs 8.88 µg mL(-1) h, P = 0.042) of enrofloxacin, but increased Tmax (8.32 vs 3.28 h, P = 0.040), T1/2a(2.66 vs 1.64 h(-1), P = 0.050) and V/F (26.7 vs 5.2 L, P = 0.040).",E. coli infection modulates the pharmacokinetics of oral enrofloxacin by targeting P-glycoprotein in small intestine and CYP450 3A in liver and kidney of broilers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24498193/),[μg] / [ml],0.34,117605,DB00661,Verapamil
,24498193,Cmax,"Furthermore, the infection reduced absorption of orally administered enrofloxacin, significantly decreased Cmax (0.34 vs 0.98 µg mL(-1), P = 0.000) and AUC0-12h (4.37 vs 8.88 µg mL(-1) h, P = 0.042) of enrofloxacin, but increased Tmax (8.32 vs 3.28 h, P = 0.040), T1/2a(2.66 vs 1.64 h(-1), P = 0.050) and V/F (26.7 vs 5.2 L, P = 0.040).",E. coli infection modulates the pharmacokinetics of oral enrofloxacin by targeting P-glycoprotein in small intestine and CYP450 3A in liver and kidney of broilers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24498193/),[μg] / [ml],0.98,117606,DB00661,Verapamil
,24498193,AUC0-12h,"Furthermore, the infection reduced absorption of orally administered enrofloxacin, significantly decreased Cmax (0.34 vs 0.98 µg mL(-1), P = 0.000) and AUC0-12h (4.37 vs 8.88 µg mL(-1) h, P = 0.042) of enrofloxacin, but increased Tmax (8.32 vs 3.28 h, P = 0.040), T1/2a(2.66 vs 1.64 h(-1), P = 0.050) and V/F (26.7 vs 5.2 L, P = 0.040).",E. coli infection modulates the pharmacokinetics of oral enrofloxacin by targeting P-glycoprotein in small intestine and CYP450 3A in liver and kidney of broilers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24498193/),[h·μg] / [ml],4.37,117607,DB00661,Verapamil
,24498193,AUC0-12h,"Furthermore, the infection reduced absorption of orally administered enrofloxacin, significantly decreased Cmax (0.34 vs 0.98 µg mL(-1), P = 0.000) and AUC0-12h (4.37 vs 8.88 µg mL(-1) h, P = 0.042) of enrofloxacin, but increased Tmax (8.32 vs 3.28 h, P = 0.040), T1/2a(2.66 vs 1.64 h(-1), P = 0.050) and V/F (26.7 vs 5.2 L, P = 0.040).",E. coli infection modulates the pharmacokinetics of oral enrofloxacin by targeting P-glycoprotein in small intestine and CYP450 3A in liver and kidney of broilers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24498193/),[h·μg] / [ml],8.88,117608,DB00661,Verapamil
,24498193,Tmax,"Furthermore, the infection reduced absorption of orally administered enrofloxacin, significantly decreased Cmax (0.34 vs 0.98 µg mL(-1), P = 0.000) and AUC0-12h (4.37 vs 8.88 µg mL(-1) h, P = 0.042) of enrofloxacin, but increased Tmax (8.32 vs 3.28 h, P = 0.040), T1/2a(2.66 vs 1.64 h(-1), P = 0.050) and V/F (26.7 vs 5.2 L, P = 0.040).",E. coli infection modulates the pharmacokinetics of oral enrofloxacin by targeting P-glycoprotein in small intestine and CYP450 3A in liver and kidney of broilers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24498193/),h,8.32,117609,DB00661,Verapamil
,24498193,Tmax,"Furthermore, the infection reduced absorption of orally administered enrofloxacin, significantly decreased Cmax (0.34 vs 0.98 µg mL(-1), P = 0.000) and AUC0-12h (4.37 vs 8.88 µg mL(-1) h, P = 0.042) of enrofloxacin, but increased Tmax (8.32 vs 3.28 h, P = 0.040), T1/2a(2.66 vs 1.64 h(-1), P = 0.050) and V/F (26.7 vs 5.2 L, P = 0.040).",E. coli infection modulates the pharmacokinetics of oral enrofloxacin by targeting P-glycoprotein in small intestine and CYP450 3A in liver and kidney of broilers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24498193/),h,3.28,117610,DB00661,Verapamil
,24498193,T1/2a,"Furthermore, the infection reduced absorption of orally administered enrofloxacin, significantly decreased Cmax (0.34 vs 0.98 µg mL(-1), P = 0.000) and AUC0-12h (4.37 vs 8.88 µg mL(-1) h, P = 0.042) of enrofloxacin, but increased Tmax (8.32 vs 3.28 h, P = 0.040), T1/2a(2.66 vs 1.64 h(-1), P = 0.050) and V/F (26.7 vs 5.2 L, P = 0.040).",E. coli infection modulates the pharmacokinetics of oral enrofloxacin by targeting P-glycoprotein in small intestine and CYP450 3A in liver and kidney of broilers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24498193/),1/[h],2.66,117611,DB00661,Verapamil
,24498193,T1/2a,"Furthermore, the infection reduced absorption of orally administered enrofloxacin, significantly decreased Cmax (0.34 vs 0.98 µg mL(-1), P = 0.000) and AUC0-12h (4.37 vs 8.88 µg mL(-1) h, P = 0.042) of enrofloxacin, but increased Tmax (8.32 vs 3.28 h, P = 0.040), T1/2a(2.66 vs 1.64 h(-1), P = 0.050) and V/F (26.7 vs 5.2 L, P = 0.040).",E. coli infection modulates the pharmacokinetics of oral enrofloxacin by targeting P-glycoprotein in small intestine and CYP450 3A in liver and kidney of broilers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24498193/),1/[h],1.64,117612,DB00661,Verapamil
,24498193,V/F,"Furthermore, the infection reduced absorption of orally administered enrofloxacin, significantly decreased Cmax (0.34 vs 0.98 µg mL(-1), P = 0.000) and AUC0-12h (4.37 vs 8.88 µg mL(-1) h, P = 0.042) of enrofloxacin, but increased Tmax (8.32 vs 3.28 h, P = 0.040), T1/2a(2.66 vs 1.64 h(-1), P = 0.050) and V/F (26.7 vs 5.2 L, P = 0.040).",E. coli infection modulates the pharmacokinetics of oral enrofloxacin by targeting P-glycoprotein in small intestine and CYP450 3A in liver and kidney of broilers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24498193/),l,26.7,117613,DB00661,Verapamil
,24498193,V/F,"Furthermore, the infection reduced absorption of orally administered enrofloxacin, significantly decreased Cmax (0.34 vs 0.98 µg mL(-1), P = 0.000) and AUC0-12h (4.37 vs 8.88 µg mL(-1) h, P = 0.042) of enrofloxacin, but increased Tmax (8.32 vs 3.28 h, P = 0.040), T1/2a(2.66 vs 1.64 h(-1), P = 0.050) and V/F (26.7 vs 5.2 L, P = 0.040).",E. coli infection modulates the pharmacokinetics of oral enrofloxacin by targeting P-glycoprotein in small intestine and CYP450 3A in liver and kidney of broilers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24498193/),l,5.2,117614,DB00661,Verapamil
,9211992,distribution volumes,"During short experimental times (in situ brain perfusion technique), a comparable enhancement was found (4.26-fold): mean distribution volumes of colchicine were enhanced from 0.23 +/- 0.17 to 0.98 +/- 0.19 microl/g for the eight gray areas, and no effect was observed in the choroid plexus, which do not express P-gp.",Role of P-170 glycoprotein in colchicine brain uptake. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9211992/),[μl] / [g],0.23,118629,DB00661,Verapamil
,9211992,distribution volumes,"During short experimental times (in situ brain perfusion technique), a comparable enhancement was found (4.26-fold): mean distribution volumes of colchicine were enhanced from 0.23 +/- 0.17 to 0.98 +/- 0.19 microl/g for the eight gray areas, and no effect was observed in the choroid plexus, which do not express P-gp.",Role of P-170 glycoprotein in colchicine brain uptake. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9211992/),[μl] / [g],0.98,118630,DB00661,Verapamil
,2291745,peak plasma concentration,The mean peak plasma concentration (36.1 +/- 13.1 ng/ml) of the test preparation was reached after 3.75 +/- 0.8 h.,[Bioavailability of two slow-release formulations of verapamil]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291745/),[ng] / [ml],36.1,118969,DB00661,Verapamil
,2291745,peak values,The control preparation (R) produced peak values of 34.4 +/- 8.1 ng/ml after 5.6 +/- 3.1 h.,[Bioavailability of two slow-release formulations of verapamil]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291745/),[ng] / [ml],34.4,118970,DB00661,Verapamil
,2291745,MRT,MRT (P) was 17.6 +/- 8.2 h and for (R) was 21.1 +/- 7.5 h after (R).,[Bioavailability of two slow-release formulations of verapamil]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291745/),h,17.6,118971,DB00661,Verapamil
,2291745,MRT,MRT (P) was 17.6 +/- 8.2 h and for (R) was 21.1 +/- 7.5 h after (R).,[Bioavailability of two slow-release formulations of verapamil]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2291745/),h,21.1,118972,DB00661,Verapamil
,15333515,systemic clearance,The systemic clearance of propranolol (approximately 1.53 l/h/kg) suggested that the hepatic blood flow in CHPs is comparable to that in humans.,The chimpanzee (Pan troglodytes) as a pharmacokinetic model for selection of drug candidates: model characterization and application. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15333515/),[l] / [h·kg],1.53,119920,DB00661,Verapamil
,3741715,oral clearance,The oral clearance of antipyrine was decreased from 2.18 to 1.95 l h-1 (P less than 0.01) by verapamil (80 mg three times daily for 2 days prior to antipyrine administration and 2 days following) while half-life was increased from 13.2 to 15.6 h (P less than 0.01).,The effect of verapamil on antipyrine pharmacokinetics and metabolism in man. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3741715/),[l] / [h],2,120073,DB00661,Verapamil
,3741715,oral clearance,The oral clearance of antipyrine was decreased from 2.18 to 1.95 l h-1 (P less than 0.01) by verapamil (80 mg three times daily for 2 days prior to antipyrine administration and 2 days following) while half-life was increased from 13.2 to 15.6 h (P less than 0.01).,The effect of verapamil on antipyrine pharmacokinetics and metabolism in man. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3741715/),[l] / [h],1,120074,DB00661,Verapamil
,3741715,half-life,The oral clearance of antipyrine was decreased from 2.18 to 1.95 l h-1 (P less than 0.01) by verapamil (80 mg three times daily for 2 days prior to antipyrine administration and 2 days following) while half-life was increased from 13.2 to 15.6 h (P less than 0.01).,The effect of verapamil on antipyrine pharmacokinetics and metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3741715/),h,13,120075,DB00661,Verapamil
,33595422,AUC0-∞,"Co-administered verapamil at 25 and 50 mg/kg, the AUC0-∞ increased from 432 ± 64.2 to 539 ± 53.6 and 836 ± 116 ng × h/mL, respectively, and the oral clearance decreased from 23.6 ± 3.50 to 18.7 ± 1.85 and 12.2 ± 1.85 L/h/kg, respectively.",Influence of verapamil on the pharmacokinetics of rotundic acid in rats and its potential mechanism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33595422/),[h·ng] / [ml],432,120504,DB00661,Verapamil
,33595422,AUC0-∞,"Co-administered verapamil at 25 and 50 mg/kg, the AUC0-∞ increased from 432 ± 64.2 to 539 ± 53.6 and 836 ± 116 ng × h/mL, respectively, and the oral clearance decreased from 23.6 ± 3.50 to 18.7 ± 1.85 and 12.2 ± 1.85 L/h/kg, respectively.",Influence of verapamil on the pharmacokinetics of rotundic acid in rats and its potential mechanism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33595422/),[h·ng] / [ml],539,120505,DB00661,Verapamil
,33595422,AUC0-∞,"Co-administered verapamil at 25 and 50 mg/kg, the AUC0-∞ increased from 432 ± 64.2 to 539 ± 53.6 and 836 ± 116 ng × h/mL, respectively, and the oral clearance decreased from 23.6 ± 3.50 to 18.7 ± 1.85 and 12.2 ± 1.85 L/h/kg, respectively.",Influence of verapamil on the pharmacokinetics of rotundic acid in rats and its potential mechanism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33595422/),[h·ng] / [ml],836,120506,DB00661,Verapamil
,33595422,oral clearance,"Co-administered verapamil at 25 and 50 mg/kg, the AUC0-∞ increased from 432 ± 64.2 to 539 ± 53.6 and 836 ± 116 ng × h/mL, respectively, and the oral clearance decreased from 23.6 ± 3.50 to 18.7 ± 1.85 and 12.2 ± 1.85 L/h/kg, respectively.",Influence of verapamil on the pharmacokinetics of rotundic acid in rats and its potential mechanism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33595422/),[l] / [h·kg],23.6,120507,DB00661,Verapamil
,33595422,oral clearance,"Co-administered verapamil at 25 and 50 mg/kg, the AUC0-∞ increased from 432 ± 64.2 to 539 ± 53.6 and 836 ± 116 ng × h/mL, respectively, and the oral clearance decreased from 23.6 ± 3.50 to 18.7 ± 1.85 and 12.2 ± 1.85 L/h/kg, respectively.",Influence of verapamil on the pharmacokinetics of rotundic acid in rats and its potential mechanism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33595422/),[l] / [h·kg],18.7,120508,DB00661,Verapamil
,33595422,oral clearance,"Co-administered verapamil at 25 and 50 mg/kg, the AUC0-∞ increased from 432 ± 64.2 to 539 ± 53.6 and 836 ± 116 ng × h/mL, respectively, and the oral clearance decreased from 23.6 ± 3.50 to 18.7 ± 1.85 and 12.2 ± 1.85 L/h/kg, respectively.",Influence of verapamil on the pharmacokinetics of rotundic acid in rats and its potential mechanism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33595422/),[l] / [h·kg],12.2,120509,DB00661,Verapamil
,33595422,intrinsic clearance,"Additionally, verapamil could increase the absorption of RA by inhibiting the activity of P-gp, and slow down the intrinsic clearance of RA from 48.5 ± 3.18 to 12.0 ± 1.06 µL/min/mg protein.",Influence of verapamil on the pharmacokinetics of rotundic acid in rats and its potential mechanism. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33595422/),[μl] / [mg·min],48.5,120510,DB00661,Verapamil
,33595422,intrinsic clearance,"Additionally, verapamil could increase the absorption of RA by inhibiting the activity of P-gp, and slow down the intrinsic clearance of RA from 48.5 ± 3.18 to 12.0 ± 1.06 µL/min/mg protein.",Influence of verapamil on the pharmacokinetics of rotundic acid in rats and its potential mechanism. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33595422/),[μl] / [mg·min],12.0,120511,DB00661,Verapamil
,26663256,Total running time,Total running time was only 1.5 min.,A quantitative determination of fluorochloridone in rat plasma by UPLC-MS/MS method: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26663256/),min,1.5,122541,DB00661,Verapamil
,1549537,time to peak serum concentration,The time to peak serum concentration (mean +/- SD) was 77.6 +/- 38.1 minutes after SLV.,Comparison of the pharmacokinetics and electrocardiographic effects of sublingual and intravenous verapamil. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1549537/),min,77.6,123766,DB00661,Verapamil
,1549537,Bioavailability,Bioavailability of SLV was 58.2 +/- 36.9% compared to IVV.,Comparison of the pharmacokinetics and electrocardiographic effects of sublingual and intravenous verapamil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1549537/),%,58.2,123767,DB00661,Verapamil
,1549537,half-lives,"Verapamil half-lives after IVV and SLV were 2.83 +/- 0.93 and 2.28 +/- 0.45 hours (NS), respectively.",Comparison of the pharmacokinetics and electrocardiographic effects of sublingual and intravenous verapamil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1549537/),h,2.83,123768,DB00661,Verapamil
,1549537,half-lives,"Verapamil half-lives after IVV and SLV were 2.83 +/- 0.93 and 2.28 +/- 0.45 hours (NS), respectively.",Comparison of the pharmacokinetics and electrocardiographic effects of sublingual and intravenous verapamil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1549537/),h,2.28,123769,DB00661,Verapamil
,1549537,Times to peak increase,"Times to peak increase in PR interval were 28.3 +/- 15.7 and 57.0 +/- 17.5 minutes after IVV and SLV (p less than 0.05), respectively.",Comparison of the pharmacokinetics and electrocardiographic effects of sublingual and intravenous verapamil. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1549537/),min,28.3,123770,DB00661,Verapamil
,1549537,Times to peak increase,"Times to peak increase in PR interval were 28.3 +/- 15.7 and 57.0 +/- 17.5 minutes after IVV and SLV (p less than 0.05), respectively.",Comparison of the pharmacokinetics and electrocardiographic effects of sublingual and intravenous verapamil. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1549537/),min,57.0,123771,DB00661,Verapamil
,12353056,absolute bioavailability,Almotriptan is well absorbed orally; its absolute bioavailability in humans is 70%.,"Almotriptan, a new anti-migraine agent: a review. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12353056/),%,70,123996,DB00661,Verapamil
,12353056,elimination half-life,Its peak plasma levels are reached at 1 to 3 h after its administration; its elimination half-life is 3 to 4 h.,"Almotriptan, a new anti-migraine agent: a review. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12353056/),h,3 to 4,123997,DB00661,Verapamil
,32014539,QA interval,QA interval decreased with nifedipine (30 ± 1 versus 24 ± 0 ms) and diltiazem (34 ± 1 versus 27 ± 1 ms) but increased with verapamil (30 ± 0 versus 37 ± 1 ms) demonstrating pharmacological activity of each agent.,A pharmacological characterization of electrocardiogram PR and QRS intervals in conscious telemetered rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32014539/),ms,30,124537,DB00661,Verapamil
,32014539,QA interval,QA interval decreased with nifedipine (30 ± 1 versus 24 ± 0 ms) and diltiazem (34 ± 1 versus 27 ± 1 ms) but increased with verapamil (30 ± 0 versus 37 ± 1 ms) demonstrating pharmacological activity of each agent.,A pharmacological characterization of electrocardiogram PR and QRS intervals in conscious telemetered rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32014539/),ms,24,124538,DB00661,Verapamil
,32014539,QA interval,QA interval decreased with nifedipine (30 ± 1 versus 24 ± 0 ms) and diltiazem (34 ± 1 versus 27 ± 1 ms) but increased with verapamil (30 ± 0 versus 37 ± 1 ms) demonstrating pharmacological activity of each agent.,A pharmacological characterization of electrocardiogram PR and QRS intervals in conscious telemetered rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32014539/),ms,34,124539,DB00661,Verapamil
,32014539,QA interval,QA interval decreased with nifedipine (30 ± 1 versus 24 ± 0 ms) and diltiazem (34 ± 1 versus 27 ± 1 ms) but increased with verapamil (30 ± 0 versus 37 ± 1 ms) demonstrating pharmacological activity of each agent.,A pharmacological characterization of electrocardiogram PR and QRS intervals in conscious telemetered rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32014539/),ms,27,124540,DB00661,Verapamil
,32014539,QA interval,QA interval decreased with nifedipine (30 ± 1 versus 24 ± 0 ms) and diltiazem (34 ± 1 versus 27 ± 1 ms) but increased with verapamil (30 ± 0 versus 37 ± 1 ms) demonstrating pharmacological activity of each agent.,A pharmacological characterization of electrocardiogram PR and QRS intervals in conscious telemetered rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32014539/),ms,30,124541,DB00661,Verapamil
,32014539,QA interval,QA interval decreased with nifedipine (30 ± 1 versus 24 ± 0 ms) and diltiazem (34 ± 1 versus 27 ± 1 ms) but increased with verapamil (30 ± 0 versus 37 ± 1 ms) demonstrating pharmacological activity of each agent.,A pharmacological characterization of electrocardiogram PR and QRS intervals in conscious telemetered rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32014539/),ms,37,124542,DB00661,Verapamil
,9572542,elimination half-life,"The elimination half-life of verapamil after treatment with 0.5% verapamil was 0.76 hour for aqueous, 4.34 hours for vitreous, and 1.82 hours for serum.",Distribution of verapamil and norverapamil in the eye and systemic circulation after topical administration of verapamil in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9572542/),h,0.76,125287,DB00661,Verapamil
,9572542,elimination half-life,"The elimination half-life of verapamil after treatment with 0.5% verapamil was 0.76 hour for aqueous, 4.34 hours for vitreous, and 1.82 hours for serum.",Distribution of verapamil and norverapamil in the eye and systemic circulation after topical administration of verapamil in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9572542/),h,4.34,125288,DB00661,Verapamil
,9572542,elimination half-life,"The elimination half-life of verapamil after treatment with 0.5% verapamil was 0.76 hour for aqueous, 4.34 hours for vitreous, and 1.82 hours for serum.",Distribution of verapamil and norverapamil in the eye and systemic circulation after topical administration of verapamil in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9572542/),h,1.82,125289,DB00661,Verapamil
,9572542,peak concentrations,"The peak concentrations for aqueous, vitreous, and serum were 2.34 x 10(-6) M by 0.5 hour, 1.57 x 10(-7) M at 2 hours, and 3.39 x 10(-8) M by 0.5 hour following instillation of one drop of 0.5% verapamil; and 1.41 x 10(-6) M by 0.5 hour, 5.48 x 10(-8) M at 4 hours, and 1.20 x 10(-8) M by 0.5 hour following 0.25% verapamil, respectively.",Distribution of verapamil and norverapamil in the eye and systemic circulation after topical administration of verapamil in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9572542/),M,2.34 x 10(-6),125290,DB00661,Verapamil
,9572542,peak concentrations,"The peak concentrations for aqueous, vitreous, and serum were 2.34 x 10(-6) M by 0.5 hour, 1.57 x 10(-7) M at 2 hours, and 3.39 x 10(-8) M by 0.5 hour following instillation of one drop of 0.5% verapamil; and 1.41 x 10(-6) M by 0.5 hour, 5.48 x 10(-8) M at 4 hours, and 1.20 x 10(-8) M by 0.5 hour following 0.25% verapamil, respectively.",Distribution of verapamil and norverapamil in the eye and systemic circulation after topical administration of verapamil in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9572542/),M,1.57 x 10(-7),125291,DB00661,Verapamil
,9572542,peak concentrations,"The peak concentrations for aqueous, vitreous, and serum were 2.34 x 10(-6) M by 0.5 hour, 1.57 x 10(-7) M at 2 hours, and 3.39 x 10(-8) M by 0.5 hour following instillation of one drop of 0.5% verapamil; and 1.41 x 10(-6) M by 0.5 hour, 5.48 x 10(-8) M at 4 hours, and 1.20 x 10(-8) M by 0.5 hour following 0.25% verapamil, respectively.",Distribution of verapamil and norverapamil in the eye and systemic circulation after topical administration of verapamil in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9572542/),M,3.39 x 10(-8),125292,DB00661,Verapamil
,9572542,peak concentrations,"The peak concentrations for aqueous, vitreous, and serum were 2.34 x 10(-6) M by 0.5 hour, 1.57 x 10(-7) M at 2 hours, and 3.39 x 10(-8) M by 0.5 hour following instillation of one drop of 0.5% verapamil; and 1.41 x 10(-6) M by 0.5 hour, 5.48 x 10(-8) M at 4 hours, and 1.20 x 10(-8) M by 0.5 hour following 0.25% verapamil, respectively.",Distribution of verapamil and norverapamil in the eye and systemic circulation after topical administration of verapamil in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9572542/),M,1.41 x 10(-6),125293,DB00661,Verapamil
,9572542,peak concentrations,"The peak concentrations for aqueous, vitreous, and serum were 2.34 x 10(-6) M by 0.5 hour, 1.57 x 10(-7) M at 2 hours, and 3.39 x 10(-8) M by 0.5 hour following instillation of one drop of 0.5% verapamil; and 1.41 x 10(-6) M by 0.5 hour, 5.48 x 10(-8) M at 4 hours, and 1.20 x 10(-8) M by 0.5 hour following 0.25% verapamil, respectively.",Distribution of verapamil and norverapamil in the eye and systemic circulation after topical administration of verapamil in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9572542/),M,5.48 x 10(-8),125294,DB00661,Verapamil
,9572542,peak concentrations,"The peak concentrations for aqueous, vitreous, and serum were 2.34 x 10(-6) M by 0.5 hour, 1.57 x 10(-7) M at 2 hours, and 3.39 x 10(-8) M by 0.5 hour following instillation of one drop of 0.5% verapamil; and 1.41 x 10(-6) M by 0.5 hour, 5.48 x 10(-8) M at 4 hours, and 1.20 x 10(-8) M by 0.5 hour following 0.25% verapamil, respectively.",Distribution of verapamil and norverapamil in the eye and systemic circulation after topical administration of verapamil in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9572542/),M,1.20 x 10(-8),125295,DB00661,Verapamil
,9572542,peak concentrations,"The metabolite norverapamil was found at peak concentrations of 8.65 x 10-(8) M by 0.5 hour in aqueous, 1.65 x 10(-8) M at 2 hours in vitreous, and 1.30 x 10(-9) M by 0.5 hr in serum following administration of 0.5% verapamil.",Distribution of verapamil and norverapamil in the eye and systemic circulation after topical administration of verapamil in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9572542/),M,8.65 x 10-(8),125296,DB00661,Verapamil
,9572542,peak concentrations,"The metabolite norverapamil was found at peak concentrations of 8.65 x 10-(8) M by 0.5 hour in aqueous, 1.65 x 10(-8) M at 2 hours in vitreous, and 1.30 x 10(-9) M by 0.5 hr in serum following administration of 0.5% verapamil.",Distribution of verapamil and norverapamil in the eye and systemic circulation after topical administration of verapamil in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9572542/),M,1.65 x 10(-8,125297,DB00661,Verapamil
,9572542,peak concentrations,"The metabolite norverapamil was found at peak concentrations of 8.65 x 10-(8) M by 0.5 hour in aqueous, 1.65 x 10(-8) M at 2 hours in vitreous, and 1.30 x 10(-9) M by 0.5 hr in serum following administration of 0.5% verapamil.",Distribution of verapamil and norverapamil in the eye and systemic circulation after topical administration of verapamil in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9572542/),M,1.30 x 10(-9),125298,DB00661,Verapamil
,9572542,elimination half-life,"The elimination half-life of norverapamil for aqueous, vitreous, and serum following treatment with 0.5% verapamil was 0.91 hour, 1.43 hours, and 3.60 hours, respectively.",Distribution of verapamil and norverapamil in the eye and systemic circulation after topical administration of verapamil in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9572542/),h,0.91,125299,DB00661,Verapamil
,9572542,elimination half-life,"The elimination half-life of norverapamil for aqueous, vitreous, and serum following treatment with 0.5% verapamil was 0.91 hour, 1.43 hours, and 3.60 hours, respectively.",Distribution of verapamil and norverapamil in the eye and systemic circulation after topical administration of verapamil in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9572542/),h,1.43,125300,DB00661,Verapamil
,9572542,elimination half-life,"The elimination half-life of norverapamil for aqueous, vitreous, and serum following treatment with 0.5% verapamil was 0.91 hour, 1.43 hours, and 3.60 hours, respectively.",Distribution of verapamil and norverapamil in the eye and systemic circulation after topical administration of verapamil in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9572542/),h,3.60,125301,DB00661,Verapamil
,16187976,C(max),"During verapamil co-administration, everolimus C(max) increased 2.3-fold (90% CI, 1.9, 2.7) from 21 +/- 8 to 47 +/- 18 ng ml(-1) and AUC increased 3.5-fold (90% CI, 3.1, 3.9) from 115 +/- 45 to 392 +/- 142 ng ml(-1) h.",Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187976/),[ng] / [ml],21,126057,DB00661,Verapamil
,16187976,C(max),"During verapamil co-administration, everolimus C(max) increased 2.3-fold (90% CI, 1.9, 2.7) from 21 +/- 8 to 47 +/- 18 ng ml(-1) and AUC increased 3.5-fold (90% CI, 3.1, 3.9) from 115 +/- 45 to 392 +/- 142 ng ml(-1) h.",Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187976/),[ng] / [ml],47,126058,DB00661,Verapamil
,16187976,AUC,"During verapamil co-administration, everolimus C(max) increased 2.3-fold (90% CI, 1.9, 2.7) from 21 +/- 8 to 47 +/- 18 ng ml(-1) and AUC increased 3.5-fold (90% CI, 3.1, 3.9) from 115 +/- 45 to 392 +/- 142 ng ml(-1) h.",Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187976/),[h·ng] / [ml],115,126059,DB00661,Verapamil
,16187976,AUC,"During verapamil co-administration, everolimus C(max) increased 2.3-fold (90% CI, 1.9, 2.7) from 21 +/- 8 to 47 +/- 18 ng ml(-1) and AUC increased 3.5-fold (90% CI, 3.1, 3.9) from 115 +/- 45 to 392 +/- 142 ng ml(-1) h.",Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187976/),[h·ng] / [ml],392,126060,DB00661,Verapamil
,16187976,half-life,Everolimus half-life was only prolonged to a minor extent (32 +/- 6 vs. 37 +/- 6 h).,Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187976/),h,32,126061,DB00661,Verapamil
,16187976,half-life,Everolimus half-life was only prolonged to a minor extent (32 +/- 6 vs. 37 +/- 6 h).,Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187976/),h,37,126062,DB00661,Verapamil
,16187976,predose,Verapamil predose concentrations doubled from 32 +/- 16 to 74 +/- 42 ng ml(-1) after single dose administration of everolimus.,Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187976/),[ng] / [ml],32,126063,DB00661,Verapamil
,16187976,predose,Verapamil predose concentrations doubled from 32 +/- 16 to 74 +/- 42 ng ml(-1) after single dose administration of everolimus.,Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187976/),[ng] / [ml],74,126064,DB00661,Verapamil
,16187976,concentrations,Verapamil predose concentrations doubled from 32 +/- 16 to 74 +/- 42 ng ml(-1) after single dose administration of everolimus.,Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187976/),[ng] / [ml],32,126065,DB00661,Verapamil
,16187976,concentrations,Verapamil predose concentrations doubled from 32 +/- 16 to 74 +/- 42 ng ml(-1) after single dose administration of everolimus.,Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16187976/),[ng] / [ml],74,126066,DB00661,Verapamil
,6508982,Cmax,"(+)-verapamil exhibited approximately five times greater Cmax (+): 240 +/- 81.1 ng/ml, (-): 46.1 +/- 15.7 ng/ml, P less than 0.0001) and AUC than (-)-verapamil.",Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6508982/),[ng] / [ml],240,127402,DB00661,Verapamil
,6508982,Cmax,"(+)-verapamil exhibited approximately five times greater Cmax (+): 240 +/- 81.1 ng/ml, (-): 46.1 +/- 15.7 ng/ml, P less than 0.0001) and AUC than (-)-verapamil.",Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6508982/),[ng] / [ml],46.1,127403,DB00661,Verapamil
,6508982,apparent oral clearance (CLo),"The apparent oral clearance (CLo) for (+)-verapamil was significantly smaller than that for (-)-verapamil (+): 1.72 +/- 0.57 l/min, (-): 7.46 +/- 2.16 l/min, P less than 0.001).",Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6508982/),[l] / [min],1.72,127404,DB00661,Verapamil
,6508982,apparent oral clearance (CLo),"The apparent oral clearance (CLo) for (+)-verapamil was significantly smaller than that for (-)-verapamil (+): 1.72 +/- 0.57 l/min, (-): 7.46 +/- 2.16 l/min, P less than 0.001).",Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6508982/),[l] / [min],7.46,127405,DB00661,Verapamil
,6508982,bioavailability,"The bioavailability of (+)-verapamil (50%) was 2.5 times greater than that of (-)-verapamil (20%), P less than 0.005).",Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6508982/),%,50,127406,DB00661,Verapamil
,6508982,bioavailability,"The bioavailability of (+)-verapamil (50%) was 2.5 times greater than that of (-)-verapamil (20%), P less than 0.005).",Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6508982/),%,20,127407,DB00661,Verapamil
,6508982,"elimination of t1/2,z","The elimination of t1/2,z for each verapamil isomer obtained following oral administration (+): 4.03 h, (-): 5.38 h) were similar to those previously obtained following intravenous administration (+): 4.15 h, (-): 5.38 h, respectively.",Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6508982/),h,4.03,127408,DB00661,Verapamil
,6508982,"elimination of t1/2,z","The elimination of t1/2,z for each verapamil isomer obtained following oral administration (+): 4.03 h, (-): 5.38 h) were similar to those previously obtained following intravenous administration (+): 4.15 h, (-): 5.38 h, respectively.",Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6508982/),h,5.38,127409,DB00661,Verapamil
,6508982,"elimination of t1/2,z","The elimination of t1/2,z for each verapamil isomer obtained following oral administration (+): 4.03 h, (-): 5.38 h) were similar to those previously obtained following intravenous administration (+): 4.15 h, (-): 5.38 h, respectively.",Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6508982/),h,4.15,127410,DB00661,Verapamil
,6508982,plasma concentration ratio,"Whereas the (+)- to (-)-verapamil plasma concentration ratio following oral administration was 4.92 +/- 0.48, the ratio following i.v. administration was approximately 2.",Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6508982/),,4.92,127411,DB00661,Verapamil
,6508982,ratio,"Whereas the (+)- to (-)-verapamil plasma concentration ratio following oral administration was 4.92 +/- 0.48, the ratio following i.v. administration was approximately 2.",Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6508982/),,2,127412,DB00661,Verapamil
,3840089,relative bioavailability,The relative bioavailability of verapamil in 200 mg SR tablets was 93-96% as compared to the conventional tablets.,Pharmacokinetics of sustained-release verapamil after a single administration and at steady state. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3840089/),%,93-96,128065,DB00661,Verapamil
,3840089,peak serum levels,"After 200 mg X 2 and 80 mg X 3, the peak serum levels were about 300 and 190 ng/ml, respectively and the trough levels 123-153 and 52-56 ng/ml, respectively.",Pharmacokinetics of sustained-release verapamil after a single administration and at steady state. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3840089/),[ng] / [ml],300,128066,DB00661,Verapamil
,3840089,peak serum levels,"After 200 mg X 2 and 80 mg X 3, the peak serum levels were about 300 and 190 ng/ml, respectively and the trough levels 123-153 and 52-56 ng/ml, respectively.",Pharmacokinetics of sustained-release verapamil after a single administration and at steady state. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3840089/),[ng] / [ml],190,128067,DB00661,Verapamil
,3840089,trough levels,"After 200 mg X 2 and 80 mg X 3, the peak serum levels were about 300 and 190 ng/ml, respectively and the trough levels 123-153 and 52-56 ng/ml, respectively.",Pharmacokinetics of sustained-release verapamil after a single administration and at steady state. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3840089/),[ng] / [ml],123-153,128068,DB00661,Verapamil
,3840089,trough levels,"After 200 mg X 2 and 80 mg X 3, the peak serum levels were about 300 and 190 ng/ml, respectively and the trough levels 123-153 and 52-56 ng/ml, respectively.",Pharmacokinetics of sustained-release verapamil after a single administration and at steady state. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3840089/),[ng] / [ml],52-56,128069,DB00661,Verapamil
,3840089,ratio,The verapamil/norverapamil ratio varied from 0.69 to 0.84 after a single dose and from 0.8 to 0.93 at steady-state.,Pharmacokinetics of sustained-release verapamil after a single administration and at steady state. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3840089/),,0.69 to 0.84,128070,DB00661,Verapamil
,3840089,ratio,The verapamil/norverapamil ratio varied from 0.69 to 0.84 after a single dose and from 0.8 to 0.93 at steady-state.,Pharmacokinetics of sustained-release verapamil after a single administration and at steady state. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3840089/),,0.8 to 0.93,128071,DB00661,Verapamil
,3840089,accumulation ratios,"By the 4th days of treatment, the accumulation ratios ranged between 1.75-2.07 and 1.30-1.75 for verapamil and norverapamil, respectively.",Pharmacokinetics of sustained-release verapamil after a single administration and at steady state. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3840089/),,1.75-2.07,128072,DB00661,Verapamil
,3840089,accumulation ratios,"By the 4th days of treatment, the accumulation ratios ranged between 1.75-2.07 and 1.30-1.75 for verapamil and norverapamil, respectively.",Pharmacokinetics of sustained-release verapamil after a single administration and at steady state. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3840089/),,1.30-1.75,128073,DB00661,Verapamil
,29475007,net efflux ratio,The net efflux ratio of afatinib was 2.3 across vector-/MDR1-MDCKII cell monolayers and was decreased by P-gp inhibitor.,P-gp is involved in the intestinal absorption and biliary excretion of afatinib in vitro and in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29475007/),,2.3,129722,DB00661,Verapamil
,29475007,Km,"The activity of P-gp ATPase was induced by afatinib and the Km and Vmax were 1.05μM and 59.88nmol ATP/mg hP-gp/min, respectively.",P-gp is involved in the intestinal absorption and biliary excretion of afatinib in vitro and in rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29475007/),μM,1.05,129723,DB00661,Verapamil
,29475007,Vmax,"The activity of P-gp ATPase was induced by afatinib and the Km and Vmax were 1.05μM and 59.88nmol ATP/mg hP-gp/min, respectively.",P-gp is involved in the intestinal absorption and biliary excretion of afatinib in vitro and in rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29475007/),[atp·nM] / [h·mg],59.88,129724,DB00661,Verapamil
,8458675,bioavailability,Two subjects achieved measurable verapamil concentrations after intranasal administration with a mean bioavailability of 16.1%.,Comparison of intranasal versus intravenous verapamil bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8458675/),%,16.1,129977,DB00661,Verapamil
,6721991,fu,The fu of (-)- (0.11) was almost twice as much as that of (+)-verapamil (0.064).,"Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6721991/),,0.,130835,DB00661,Verapamil
,20595378,apparent elimination rate constant (λ(z)),"The vitreal pharmacokinetic parameters of quinidine in the presence of verapamil [apparent elimination rate constant (λ(z)), 0.0027 ± 0.0002 min(-1); clearance (CL_F), 131 ± 21 ml/min; area under the curve (AUC(0-∞)), 39 ± 7.0 μg · min/ml; and mean residence time, 435 ± 20 min] were significantly different from those of the control (0.0058 ± 0.0006 min(-1), 296 ± 46 ml/min, 17 ± 3 μg · min/ml, and 232 ± 20 min, respectively).",Interaction between topically and systemically coadministered P-glycoprotein substrates/inhibitors: effect on vitreal kinetics. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20595378/),1/[min],0.0027,131299,DB00661,Verapamil
,20595378,clearance (CL_F),"The vitreal pharmacokinetic parameters of quinidine in the presence of verapamil [apparent elimination rate constant (λ(z)), 0.0027 ± 0.0002 min(-1); clearance (CL_F), 131 ± 21 ml/min; area under the curve (AUC(0-∞)), 39 ± 7.0 μg · min/ml; and mean residence time, 435 ± 20 min] were significantly different from those of the control (0.0058 ± 0.0006 min(-1), 296 ± 46 ml/min, 17 ± 3 μg · min/ml, and 232 ± 20 min, respectively).",Interaction between topically and systemically coadministered P-glycoprotein substrates/inhibitors: effect on vitreal kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20595378/),[ml] / [min],131,131300,DB00661,Verapamil
,20595378,area under the curve (AUC(0-∞)),"The vitreal pharmacokinetic parameters of quinidine in the presence of verapamil [apparent elimination rate constant (λ(z)), 0.0027 ± 0.0002 min(-1); clearance (CL_F), 131 ± 21 ml/min; area under the curve (AUC(0-∞)), 39 ± 7.0 μg · min/ml; and mean residence time, 435 ± 20 min] were significantly different from those of the control (0.0058 ± 0.0006 min(-1), 296 ± 46 ml/min, 17 ± 3 μg · min/ml, and 232 ± 20 min, respectively).",Interaction between topically and systemically coadministered P-glycoprotein substrates/inhibitors: effect on vitreal kinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20595378/),[min·μg] / [ml],39,131301,DB00661,Verapamil
,20595378,area under the curve (AUC(0-∞)),"The vitreal pharmacokinetic parameters of quinidine in the presence of verapamil [apparent elimination rate constant (λ(z)), 0.0027 ± 0.0002 min(-1); clearance (CL_F), 131 ± 21 ml/min; area under the curve (AUC(0-∞)), 39 ± 7.0 μg · min/ml; and mean residence time, 435 ± 20 min] were significantly different from those of the control (0.0058 ± 0.0006 min(-1), 296 ± 46 ml/min, 17 ± 3 μg · min/ml, and 232 ± 20 min, respectively).",Interaction between topically and systemically coadministered P-glycoprotein substrates/inhibitors: effect on vitreal kinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20595378/),1/[min],0.0058,131302,DB00661,Verapamil
,20595378,mean residence time,"The vitreal pharmacokinetic parameters of quinidine in the presence of verapamil [apparent elimination rate constant (λ(z)), 0.0027 ± 0.0002 min(-1); clearance (CL_F), 131 ± 21 ml/min; area under the curve (AUC(0-∞)), 39 ± 7.0 μg · min/ml; and mean residence time, 435 ± 20 min] were significantly different from those of the control (0.0058 ± 0.0006 min(-1), 296 ± 46 ml/min, 17 ± 3 μg · min/ml, and 232 ± 20 min, respectively).",Interaction between topically and systemically coadministered P-glycoprotein substrates/inhibitors: effect on vitreal kinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20595378/),min,435,131303,DB00661,Verapamil
,20595378,mean residence time,"The vitreal pharmacokinetic parameters of quinidine in the presence of verapamil [apparent elimination rate constant (λ(z)), 0.0027 ± 0.0002 min(-1); clearance (CL_F), 131 ± 21 ml/min; area under the curve (AUC(0-∞)), 39 ± 7.0 μg · min/ml; and mean residence time, 435 ± 20 min] were significantly different from those of the control (0.0058 ± 0.0006 min(-1), 296 ± 46 ml/min, 17 ± 3 μg · min/ml, and 232 ± 20 min, respectively).",Interaction between topically and systemically coadministered P-glycoprotein substrates/inhibitors: effect on vitreal kinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20595378/),1/[min],0.0058,131304,DB00661,Verapamil
,20595378,mean residence time,"The vitreal pharmacokinetic parameters of quinidine in the presence of verapamil [apparent elimination rate constant (λ(z)), 0.0027 ± 0.0002 min(-1); clearance (CL_F), 131 ± 21 ml/min; area under the curve (AUC(0-∞)), 39 ± 7.0 μg · min/ml; and mean residence time, 435 ± 20 min] were significantly different from those of the control (0.0058 ± 0.0006 min(-1), 296 ± 46 ml/min, 17 ± 3 μg · min/ml, and 232 ± 20 min, respectively).",Interaction between topically and systemically coadministered P-glycoprotein substrates/inhibitors: effect on vitreal kinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20595378/),[ml] / [min],296,131305,DB00661,Verapamil
,20595378,mean residence time,"The vitreal pharmacokinetic parameters of quinidine in the presence of verapamil [apparent elimination rate constant (λ(z)), 0.0027 ± 0.0002 min(-1); clearance (CL_F), 131 ± 21 ml/min; area under the curve (AUC(0-∞)), 39 ± 7.0 μg · min/ml; and mean residence time, 435 ± 20 min] were significantly different from those of the control (0.0058 ± 0.0006 min(-1), 296 ± 46 ml/min, 17 ± 3 μg · min/ml, and 232 ± 20 min, respectively).",Interaction between topically and systemically coadministered P-glycoprotein substrates/inhibitors: effect on vitreal kinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20595378/),min,232,131306,DB00661,Verapamil
,8646796,50% inhibitory concentrations (IC50,"Both agents were very potent inhibitors of cell growth, with dolastatin 10 being an average of 9.1-fold more potent than dolastatin 15 [mean 50% inhibitory concentrations (IC50 values) 2.3 x 10(-10) and 2.1 x 10(-9) M, respectively; P < 0.05] and more potent than paclitaxel or vinblastine.",Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646796/),M,2.3 x 10(-10),133271,DB00661,Verapamil
,8646796,50% inhibitory concentrations (IC50,"Both agents were very potent inhibitors of cell growth, with dolastatin 10 being an average of 9.1-fold more potent than dolastatin 15 [mean 50% inhibitory concentrations (IC50 values) 2.3 x 10(-10) and 2.1 x 10(-9) M, respectively; P < 0.05] and more potent than paclitaxel or vinblastine.",Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646796/),M,2.1 x 10(-9),133272,DB00661,Verapamil
,8646796,limit of detection,A radioimmunoassay for dolastatin 10 (limit of detection in mouse plasma 5 ng/ml) was developed.,Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646796/),[ng] / [ml],5,133273,DB00661,Verapamil
,8646796,areas under the plasma concentration-time curve (AUC values),"In addition, areas under the plasma concentration-time curve (AUC values) were 1.6-fold higher for dolastatin 10 (333 versus 208 ng ml-1 h).",Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646796/),[h·ng] / [ml],333,133274,DB00661,Verapamil
,8646796,areas under the plasma concentration-time curve (AUC values),"In addition, areas under the plasma concentration-time curve (AUC values) were 1.6-fold higher for dolastatin 10 (333 versus 208 ng ml-1 h).",Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646796/),[h·ng] / [ml],208,133275,DB00661,Verapamil
exceeded,8646796,Plasma binding,Plasma binding of dolastatin 10 exceeded 90%.,Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8646796/),%,90,133276,DB00661,Verapamil
,3756058,bioavailability,"In practice the important pharmacokinetic properties of verapamil are low bioavailability (20%), predominant elimination by metabolism (greater than 95%) and a relatively short half-life (t1/2, beta is 3-5 h).",Pharmacokinetics of conventional and slow-release verapamil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756058/),%,20,134260,DB00661,Verapamil
,3756058,"half-life (t1/2, beta","In practice the important pharmacokinetic properties of verapamil are low bioavailability (20%), predominant elimination by metabolism (greater than 95%) and a relatively short half-life (t1/2, beta is 3-5 h).",Pharmacokinetics of conventional and slow-release verapamil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756058/),h,3-5,134261,DB00661,Verapamil
,3756058,relative bioavailability (AUCSR/AUCC),A comparison of conventional (C) and SR tablets in a 1-week treatment of eight cardiac patients showed a relative bioavailability (AUCSR/AUCC) of 90 +/- 30%.,Pharmacokinetics of conventional and slow-release verapamil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3756058/),%,90,134262,DB00661,Verapamil
greater,3042243,plasma protein binding,Three of the 8 dihydropyridines have been reported to have plasma protein binding greater than 90%.,Pharmacokinetics of calcium antagonists under development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3042243/),%,90,134432,DB00661,Verapamil
,9023574,half-life,"The decline in plasma verapamil and norverapamil concentrations followed first-order kinetics, and the half-life of verapamil was 7.8 h and 15.1 h, respectively.",Pharmacokinetics of verapamil in overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9023574/),h,7.8,134495,DB00661,Verapamil
,9023574,half-life,"The decline in plasma verapamil and norverapamil concentrations followed first-order kinetics, and the half-life of verapamil was 7.8 h and 15.1 h, respectively.",Pharmacokinetics of verapamil in overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9023574/),h,15.1,134496,DB00661,Verapamil
,25034865,efflux ratios,"The efflux ratios of transporting digoxin, the prototypical substrate of P-gp in 21- and 7-day systems were 16.04 and 24.92, respectively.","Development, validation, and application of a novel 7-day Caco-2 cell culture system. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25034865/),,16.04,135873,DB00661,Verapamil
,25034865,efflux ratios,"The efflux ratios of transporting digoxin, the prototypical substrate of P-gp in 21- and 7-day systems were 16.04 and 24.92, respectively.","Development, validation, and application of a novel 7-day Caco-2 cell culture system. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25034865/),,24.92,135874,DB00661,Verapamil
,25034865,efflux ratios,"When the P-gp inhibitor verapamil was present, the efflux ratios of 21- and 7-day systems were 1.37 and 0.86, respectively, suggesting the comparability of the P-gp functional activity in both systems.","Development, validation, and application of a novel 7-day Caco-2 cell culture system. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25034865/),,1.37,135875,DB00661,Verapamil
,25034865,efflux ratios,"When the P-gp inhibitor verapamil was present, the efflux ratios of 21- and 7-day systems were 1.37 and 0.86, respectively, suggesting the comparability of the P-gp functional activity in both systems.","Development, validation, and application of a novel 7-day Caco-2 cell culture system. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25034865/),,0.86,135876,DB00661,Verapamil
,2452316,Elimination half-life,"Elimination half-life was prolonged in obese patients (10.1 +/- 1.8 vs. 3.6 +/- 0.4 h; p less than 0.005) due to a marked increase in volume of distribution at steady-state (713 +/- 99 vs. 301 +/- 33 L; p less than 0.005) with no change in total verapamil clearance [1,339 +/- 180 obese vs. 1,250 +/- 147 ml/min; not significant (NS)].",Verapamil pharmacodynamics and disposition in obese hypertensive patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2452316/),h,10.1,135947,DB00661,Verapamil
,2452316,Elimination half-life,"Elimination half-life was prolonged in obese patients (10.1 +/- 1.8 vs. 3.6 +/- 0.4 h; p less than 0.005) due to a marked increase in volume of distribution at steady-state (713 +/- 99 vs. 301 +/- 33 L; p less than 0.005) with no change in total verapamil clearance [1,339 +/- 180 obese vs. 1,250 +/- 147 ml/min; not significant (NS)].",Verapamil pharmacodynamics and disposition in obese hypertensive patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2452316/),h,3.6,135948,DB00661,Verapamil
,2452316,volume of distribution at steady-state,"Elimination half-life was prolonged in obese patients (10.1 +/- 1.8 vs. 3.6 +/- 0.4 h; p less than 0.005) due to a marked increase in volume of distribution at steady-state (713 +/- 99 vs. 301 +/- 33 L; p less than 0.005) with no change in total verapamil clearance [1,339 +/- 180 obese vs. 1,250 +/- 147 ml/min; not significant (NS)].",Verapamil pharmacodynamics and disposition in obese hypertensive patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2452316/),l,713,135949,DB00661,Verapamil
,2452316,volume of distribution at steady-state,"Elimination half-life was prolonged in obese patients (10.1 +/- 1.8 vs. 3.6 +/- 0.4 h; p less than 0.005) due to a marked increase in volume of distribution at steady-state (713 +/- 99 vs. 301 +/- 33 L; p less than 0.005) with no change in total verapamil clearance [1,339 +/- 180 obese vs. 1,250 +/- 147 ml/min; not significant (NS)].",Verapamil pharmacodynamics and disposition in obese hypertensive patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2452316/),l,301,135950,DB00661,Verapamil
,2452316,total verapamil clearance,"Elimination half-life was prolonged in obese patients (10.1 +/- 1.8 vs. 3.6 +/- 0.4 h; p less than 0.005) due to a marked increase in volume of distribution at steady-state (713 +/- 99 vs. 301 +/- 33 L; p less than 0.005) with no change in total verapamil clearance [1,339 +/- 180 obese vs. 1,250 +/- 147 ml/min; not significant (NS)].",Verapamil pharmacodynamics and disposition in obese hypertensive patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2452316/),[ml] / [min],"1,339",135951,DB00661,Verapamil
,2452316,total verapamil clearance,"Elimination half-life was prolonged in obese patients (10.1 +/- 1.8 vs. 3.6 +/- 0.4 h; p less than 0.005) due to a marked increase in volume of distribution at steady-state (713 +/- 99 vs. 301 +/- 33 L; p less than 0.005) with no change in total verapamil clearance [1,339 +/- 180 obese vs. 1,250 +/- 147 ml/min; not significant (NS)].",Verapamil pharmacodynamics and disposition in obese hypertensive patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2452316/),[ml] / [min],"1,250",135952,DB00661,Verapamil
,2452316,percent unbound,"Verapamil plasma protein binding was similar between groups (percent unbound, 4.8 +/- 0.5 obese vs. 5.1 +/- 0.5%; NS).",Verapamil pharmacodynamics and disposition in obese hypertensive patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2452316/),%,4.8,135953,DB00661,Verapamil
,2452316,percent unbound,"Verapamil plasma protein binding was similar between groups (percent unbound, 4.8 +/- 0.5 obese vs. 5.1 +/- 0.5%; NS).",Verapamil pharmacodynamics and disposition in obese hypertensive patients. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2452316/),%,5.1,135954,DB00661,Verapamil
,2452316,Emax,"Using a sigmoid Emax pharmacodynamic model, Emax (maximal prolongation in P-R interval) was unchanged in obesity (53.7 +/- 12.5 obese vs. 45.9 +/- 12.0 ms; NS).",Verapamil pharmacodynamics and disposition in obese hypertensive patients. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2452316/),ms,53.7,135955,DB00661,Verapamil
,2452316,Emax,"Using a sigmoid Emax pharmacodynamic model, Emax (maximal prolongation in P-R interval) was unchanged in obesity (53.7 +/- 12.5 obese vs. 45.9 +/- 12.0 ms; NS).",Verapamil pharmacodynamics and disposition in obese hypertensive patients. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2452316/),ms,45.9,135956,DB00661,Verapamil
,2452316,EC50,"However, EC50 (verapamil concentration required to achieve 50% of Emax prolongation in P-R interval) was greater in obese patients (45.9 +/- 6.7 vs. 22.6 +/- 2.0 ng/ml; p less than 0.005).",Verapamil pharmacodynamics and disposition in obese hypertensive patients. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2452316/),[ng] / [ml],45.9,135957,DB00661,Verapamil
,2452316,EC50,"However, EC50 (verapamil concentration required to achieve 50% of Emax prolongation in P-R interval) was greater in obese patients (45.9 +/- 6.7 vs. 22.6 +/- 2.0 ng/ml; p less than 0.005).",Verapamil pharmacodynamics and disposition in obese hypertensive patients. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2452316/),[ng] / [ml],22.6,135958,DB00661,Verapamil
,20166433,absolute bioavailability (A.B.),"Consequently, the absolute bioavailability (A.B.) of verapamil with simvastatin (7.3% at 0.3 mg/kg, 9.3% at 1.0 mg/kg) were significantly higher than those in the control group (P < 0.05, 5.2%).","Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166433/),%,7.3,136145,DB00661,Verapamil
,20166433,absolute bioavailability (A.B.),"Consequently, the absolute bioavailability (A.B.) of verapamil with simvastatin (7.3% at 0.3 mg/kg, 9.3% at 1.0 mg/kg) were significantly higher than those in the control group (P < 0.05, 5.2%).","Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166433/),%,9.3,136146,DB00661,Verapamil
,20166433,absolute bioavailability (A.B.),"Consequently, the absolute bioavailability (A.B.) of verapamil with simvastatin (7.3% at 0.3 mg/kg, 9.3% at 1.0 mg/kg) were significantly higher than those in the control group (P < 0.05, 5.2%).","Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20166433/),%,5.2,136147,DB00661,Verapamil
,27328778,peak plasma concentration,The results showed that verapamil could significantly increase the peak plasma concentration (from 60.17 ng/mL to 93.66 ng/mL) and AUC0-t (from 289.57 to 764.02 ng·h/mL) of curculigoside.,The effects of verapamil on the pharmacokinetics of curculigoside in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27328778/),[ng] / [ml],60.17,136359,DB00661,Verapamil
,27328778,peak plasma concentration,The results showed that verapamil could significantly increase the peak plasma concentration (from 60.17 ng/mL to 93.66 ng/mL) and AUC0-t (from 289.57 to 764.02 ng·h/mL) of curculigoside.,The effects of verapamil on the pharmacokinetics of curculigoside in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27328778/),[ng] / [ml],93.66,136360,DB00661,Verapamil
,27328778,AUC0-t,The results showed that verapamil could significantly increase the peak plasma concentration (from 60.17 ng/mL to 93.66 ng/mL) and AUC0-t (from 289.57 to 764.02 ng·h/mL) of curculigoside.,The effects of verapamil on the pharmacokinetics of curculigoside in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27328778/),[h·ng] / [ml],289.57,136361,DB00661,Verapamil
,27328778,AUC0-t,The results showed that verapamil could significantly increase the peak plasma concentration (from 60.17 ng/mL to 93.66 ng/mL) and AUC0-t (from 289.57 to 764.02 ng·h/mL) of curculigoside.,The effects of verapamil on the pharmacokinetics of curculigoside in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27328778/),[h·ng] / [ml],764.02,136362,DB00661,Verapamil
,27328778,efflux ratio,"The Caco-2 cell experiments indicated that the efflux ratio of curculigoside was 3.92 (PappAB 6.43 ± 0.57 × 10 -7 cm/s; PappBA 2.52 ± 0.37 × 10 -36 cm/s), P-gp might be involved in the transport of curculigoside, and verapamil could inhibit the efflux of curculigoside and increase the absorption of curculigoside significantly in the Caco-2 cell monolayer.",The effects of verapamil on the pharmacokinetics of curculigoside in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27328778/),,3.92,136363,DB00661,Verapamil
,27328778,PappAB,"The Caco-2 cell experiments indicated that the efflux ratio of curculigoside was 3.92 (PappAB 6.43 ± 0.57 × 10 -7 cm/s; PappBA 2.52 ± 0.37 × 10 -36 cm/s), P-gp might be involved in the transport of curculigoside, and verapamil could inhibit the efflux of curculigoside and increase the absorption of curculigoside significantly in the Caco-2 cell monolayer.",The effects of verapamil on the pharmacokinetics of curculigoside in rats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27328778/),[cm] / [s],6.43,136364,DB00661,Verapamil
,27328778,PappBA,"The Caco-2 cell experiments indicated that the efflux ratio of curculigoside was 3.92 (PappAB 6.43 ± 0.57 × 10 -7 cm/s; PappBA 2.52 ± 0.37 × 10 -36 cm/s), P-gp might be involved in the transport of curculigoside, and verapamil could inhibit the efflux of curculigoside and increase the absorption of curculigoside significantly in the Caco-2 cell monolayer.",The effects of verapamil on the pharmacokinetics of curculigoside in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27328778/),[cm] / [s],2.52,136365,DB00661,Verapamil
,27328778,intrinsic clearance rate,"Additionally, the rat liver microsome incubation experiments indicated that verapamil could significantly decrease the intrinsic clearance rate of curculigoside (from 38.8 to 23.6 μL/min/mg protein).",The effects of verapamil on the pharmacokinetics of curculigoside in rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27328778/),[μl] / [mg·min],38.8,136366,DB00661,Verapamil
,27328778,intrinsic clearance rate,"Additionally, the rat liver microsome incubation experiments indicated that verapamil could significantly decrease the intrinsic clearance rate of curculigoside (from 38.8 to 23.6 μL/min/mg protein).",The effects of verapamil on the pharmacokinetics of curculigoside in rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27328778/),[μl] / [mg·min],23.6,136367,DB00661,Verapamil
,8010021,Kr),The results showed that the dissolution behaviors were of zero-order kinetic and release constant in vitro (Kr) of C was 9.9450.,[Study on dissolution test in vitro and bioavailability of oral osmotic pump of verapamil hydrochloride]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010021/),,9.9450,136621,DB00661,Verapamil
,8010021,bioavailability,"The bioavailability of tablet C relative to B and A was 101.7%, 96.16% respectively.",[Study on dissolution test in vitro and bioavailability of oral osmotic pump of verapamil hydrochloride]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010021/),%,101.7,136622,DB00661,Verapamil
,8010021,bioavailability,"The bioavailability of tablet C relative to B and A was 101.7%, 96.16% respectively.",[Study on dissolution test in vitro and bioavailability of oral osmotic pump of verapamil hydrochloride]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010021/),%,96.16,136623,DB00661,Verapamil
less,8950073,half-life times,"In the elgodipine plasma concentration profile (HPLC), three phases of elimination with half-life times of less than 1 hour, between 3 and 7 hours, and between 10 and 24 hours may be distinguished, indicating a ""shallow"" and a ""deep"" compartment.","Hemodynamic effects of intravenous elgodipine in coronary artery disease during rest and exercise, and basic pharmacokinetic parameters. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8950073/),h,1,138293,DB00661,Verapamil
,8950073,half-life times,"In the elgodipine plasma concentration profile (HPLC), three phases of elimination with half-life times of less than 1 hour, between 3 and 7 hours, and between 10 and 24 hours may be distinguished, indicating a ""shallow"" and a ""deep"" compartment.","Hemodynamic effects of intravenous elgodipine in coronary artery disease during rest and exercise, and basic pharmacokinetic parameters. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8950073/),h,3 and 7,138294,DB00661,Verapamil
,8950073,half-life times,"In the elgodipine plasma concentration profile (HPLC), three phases of elimination with half-life times of less than 1 hour, between 3 and 7 hours, and between 10 and 24 hours may be distinguished, indicating a ""shallow"" and a ""deep"" compartment.","Hemodynamic effects of intravenous elgodipine in coronary artery disease during rest and exercise, and basic pharmacokinetic parameters. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8950073/),h,10 and 24,138295,DB00661,Verapamil
,18432283,AUC,"The pharmacokinetics of verapamil was enantioselective in the control group, with a higher plasma proportion of the S-verapamil (AUC 250.8 versus 120.4 ng x h x mL(-1); p < or = 0.05, Wilcoxon test) and S-norverapamil (AUC 72.3 versus 52.3 ng x h x mL(-1); p < or = 0.05, Wilcoxon test).",Reduction of enantioselectivity in the kinetic disposition and metabolism of verapamil in rats exposed to toluene. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18432283/),[h·ng] / [ml],250.8,140111,DB00661,Verapamil
,18432283,AUC,"The pharmacokinetics of verapamil was enantioselective in the control group, with a higher plasma proportion of the S-verapamil (AUC 250.8 versus 120.4 ng x h x mL(-1); p < or = 0.05, Wilcoxon test) and S-norverapamil (AUC 72.3 versus 52.3 ng x h x mL(-1); p < or = 0.05, Wilcoxon test).",Reduction of enantioselectivity in the kinetic disposition and metabolism of verapamil in rats exposed to toluene. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18432283/),[h·ng] / [ml],120.4,140112,DB00661,Verapamil
,18432283,AUC,"The pharmacokinetics of verapamil was enantioselective in the control group, with a higher plasma proportion of the S-verapamil (AUC 250.8 versus 120.4 ng x h x mL(-1); p < or = 0.05, Wilcoxon test) and S-norverapamil (AUC 72.3 versus 52.3 ng x h x mL(-1); p < or = 0.05, Wilcoxon test).",Reduction of enantioselectivity in the kinetic disposition and metabolism of verapamil in rats exposed to toluene. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18432283/),[h·ng] / [ml],72.3,140113,DB00661,Verapamil
,18432283,AUC,"The pharmacokinetics of verapamil was enantioselective in the control group, with a higher plasma proportion of the S-verapamil (AUC 250.8 versus 120.4 ng x h x mL(-1); p < or = 0.05, Wilcoxon test) and S-norverapamil (AUC 72.3 versus 52.3 ng x h x mL(-1); p < or = 0.05, Wilcoxon test).",Reduction of enantioselectivity in the kinetic disposition and metabolism of verapamil in rats exposed to toluene. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18432283/),[h·ng] / [ml],52.3,140114,DB00661,Verapamil
,2530866,absolute bioavailability,A single intravenous dose of 10 mg resulted in an absolute bioavailability of 64% and a calculated elimination half-life of 34 hours.,The pharmacokinetic profile of amlodipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),%,64,140280,DB00661,Verapamil
,2530866,elimination half-life,A single intravenous dose of 10 mg resulted in an absolute bioavailability of 64% and a calculated elimination half-life of 34 hours.,The pharmacokinetic profile of amlodipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),h,34,140281,DB00661,Verapamil
,2530866,elimination half-life,These results were significantly different from those seen with most other dihydropyridines (elimination half-life of 3 to 10 hours and absolute bioavailability of 10% to 30%) and nondihydropyridine calcium antagonists (elimination half-life 3 to 6 hours and low absolute bioavailability).,The pharmacokinetic profile of amlodipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),h,3 to 10,140282,DB00661,Verapamil
,2530866,absolute bioavailability,These results were significantly different from those seen with most other dihydropyridines (elimination half-life of 3 to 10 hours and absolute bioavailability of 10% to 30%) and nondihydropyridine calcium antagonists (elimination half-life 3 to 6 hours and low absolute bioavailability).,The pharmacokinetic profile of amlodipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),%,10,140283,DB00661,Verapamil
,2530866,absolute bioavailability,These results were significantly different from those seen with most other dihydropyridines (elimination half-life of 3 to 10 hours and absolute bioavailability of 10% to 30%) and nondihydropyridine calcium antagonists (elimination half-life 3 to 6 hours and low absolute bioavailability).,The pharmacokinetic profile of amlodipine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),%,30,140284,DB00661,Verapamil
,2530866,elimination half-life,These results were significantly different from those seen with most other dihydropyridines (elimination half-life of 3 to 10 hours and absolute bioavailability of 10% to 30%) and nondihydropyridine calcium antagonists (elimination half-life 3 to 6 hours and low absolute bioavailability).,The pharmacokinetic profile of amlodipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),h,3 to 6,140285,DB00661,Verapamil
,2530866,elimination half-life,"In the elderly population, elimination half-life of 5 mg oral doses is significantly prolonged (48 vs 35 hours; p less than 0.025) suggesting decreased oral clearance or increased bioavailability.",The pharmacokinetic profile of amlodipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),h,48,140286,DB00661,Verapamil
,2530866,elimination half-life,"In the elderly population, elimination half-life of 5 mg oral doses is significantly prolonged (48 vs 35 hours; p less than 0.025) suggesting decreased oral clearance or increased bioavailability.",The pharmacokinetic profile of amlodipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),h,35,140287,DB00661,Verapamil
,2530866,elimination half-life,"In patients with cirrhosis, elimination half-life is significantly prolonged (60 vs 34 hours; p less than 0.01) suggesting that there is a greater accumulation of amlodipine in patients with severe liver disease than in individuals with normal hepatic function.",The pharmacokinetic profile of amlodipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),h,60,140288,DB00661,Verapamil
,2530866,elimination half-life,"In patients with cirrhosis, elimination half-life is significantly prolonged (60 vs 34 hours; p less than 0.01) suggesting that there is a greater accumulation of amlodipine in patients with severe liver disease than in individuals with normal hepatic function.",The pharmacokinetic profile of amlodipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2530866/),h,34,140289,DB00661,Verapamil
,10859149,Area under the plasma concentration time curve (AUC),Area under the plasma concentration time curve (AUC) was greater for verapamil (mean +/- S. D.) (2815 +/- 733 older versus 1639 +/- 466 ng/ml.h(-1) young; P <. 0007) and norverapamil (2927 +/- 655 versus 2143 +/- 471 ng/ml.,Verapamil metabolite exposure in older and younger men during steady-state oral verapamil administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10859149/),[ml·ng] / [h],2815,140457,DB00661,Verapamil
,10859149,Area under the plasma concentration time curve (AUC),Area under the plasma concentration time curve (AUC) was greater for verapamil (mean +/- S. D.) (2815 +/- 733 older versus 1639 +/- 466 ng/ml.h(-1) young; P <. 0007) and norverapamil (2927 +/- 655 versus 2143 +/- 471 ng/ml.,Verapamil metabolite exposure in older and younger men during steady-state oral verapamil administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10859149/),[ml·ng] / [h],1639,140458,DB00661,Verapamil
,10859149,Area under the plasma concentration time curve (AUC),Area under the plasma concentration time curve (AUC) was greater for verapamil (mean +/- S. D.) (2815 +/- 733 older versus 1639 +/- 466 ng/ml.h(-1) young; P <. 0007) and norverapamil (2927 +/- 655 versus 2143 +/- 471 ng/ml.,Verapamil metabolite exposure in older and younger men during steady-state oral verapamil administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10859149/),[ng] / [ml],2927,140459,DB00661,Verapamil
,10859149,Area under the plasma concentration time curve (AUC),Area under the plasma concentration time curve (AUC) was greater for verapamil (mean +/- S. D.) (2815 +/- 733 older versus 1639 +/- 466 ng/ml.h(-1) young; P <. 0007) and norverapamil (2927 +/- 655 versus 2143 +/- 471 ng/ml.,Verapamil metabolite exposure in older and younger men during steady-state oral verapamil administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10859149/),[ng] / [ml],2143,140460,DB00661,Verapamil
,10631627,K(m),"In this model system, atorvastatin exhibited efflux or secretion kinetics with a K(m) of 110 microM.",Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10631627/),μM,110,141142,DB00661,Verapamil
,25993421,absolute oral bioavailability,The absolute oral bioavailability of triptolide is 63.9% at a dose of 1 mg·kg-1.,Absorption and Metabolism Characteristics of Triptolide as Determined by a Sensitive and Reliable LC-MS/MS Method. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25993421/),%,63.9,141621,DB00661,Verapamil
,25993421,t1/2,"In HLMs, incubations with an initial triptolide concentration of 1 μM resulted in an 82.4% loss of substrate over 60 min, and the t1/2 was 38 min, which indicated that triptolide was easily metabolized in human liver microsomes.",Absorption and Metabolism Characteristics of Triptolide as Determined by a Sensitive and Reliable LC-MS/MS Method. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25993421/),min,38,141622,DB00661,Verapamil
,16497784,systemic bioavailabilities,"The systemic bioavailabilities of CTS after oral and intraperitoneal administration at 100 mg/kg were 2.05 and 10.60%, respectively.","A mechanistic study of the intestinal absorption of cryptotanshinone, the major active constituent of Salvia miltiorrhiza. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16497784/),%,2.05,142503,DB00661,Verapamil
,16497784,systemic bioavailabilities,"The systemic bioavailabilities of CTS after oral and intraperitoneal administration at 100 mg/kg were 2.05 and 10.60%, respectively.","A mechanistic study of the intestinal absorption of cryptotanshinone, the major active constituent of Salvia miltiorrhiza. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16497784/),%,10.60,142504,DB00661,Verapamil
,8790221,ratio of accumulation,"In in vitro experiments with cells, the ratio of accumulation of 11C-daunorubicin in drug sensitive/resistant cell lines was 16.",Carbon-11-labeled daunorubicin and verapamil for probing P-glycoprotein in tumors with PET. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8790221/),,16,143692,DB00661,Verapamil
,8790221,ratios,The ratios of 11C-verapamil accumulation in drug-sensitive versus the MDR counterpart were 4-5.,Carbon-11-labeled daunorubicin and verapamil for probing P-glycoprotein in tumors with PET. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8790221/),,4-5,143693,DB00661,Verapamil
,29779093,absolute bioavailability,Finerenone absolute bioavailability was 43.5% due to first-pass metabolism in the gut wall and liver.,"Pharmacokinetics of the Novel, Selective, Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in Healthy Volunteers: Results from an Absolute Bioavailability Study and Drug-Drug Interaction Studies In Vitro and In Vivo. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29779093/),%,43.5,144528,DB00661,Verapamil
,29779093,AUC0-∞ ratios,"The geometric mean AUC0-∞ ratios of finerenone (drug + inhibitor/drug alone) were 3.48, 2.70 and 1.10 with erythromycin, verapamil and gemfibrozil, respectively.","Pharmacokinetics of the Novel, Selective, Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in Healthy Volunteers: Results from an Absolute Bioavailability Study and Drug-Drug Interaction Studies In Vitro and In Vivo. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29779093/),,3.48,144529,DB00661,Verapamil
,29779093,AUC0-∞ ratios,"The geometric mean AUC0-∞ ratios of finerenone (drug + inhibitor/drug alone) were 3.48, 2.70 and 1.10 with erythromycin, verapamil and gemfibrozil, respectively.","Pharmacokinetics of the Novel, Selective, Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in Healthy Volunteers: Results from an Absolute Bioavailability Study and Drug-Drug Interaction Studies In Vitro and In Vivo. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29779093/),,2.70,144530,DB00661,Verapamil
,29779093,AUC0-∞ ratios,"The geometric mean AUC0-∞ ratios of finerenone (drug + inhibitor/drug alone) were 3.48, 2.70 and 1.10 with erythromycin, verapamil and gemfibrozil, respectively.","Pharmacokinetics of the Novel, Selective, Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in Healthy Volunteers: Results from an Absolute Bioavailability Study and Drug-Drug Interaction Studies In Vitro and In Vivo. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29779093/),,1.10,144531,DB00661,Verapamil
,7545750,systemic clearance,The kinetics of FD-4 after intravenous doses of 1 or 10 mg could be described by a two-compartment model with a systemic clearance of approximately 2 mL min-1 and a terminal plasma half-life of approximately 36 min.,Absorption enhancement of a hydrophilic model compound by verapamil after rectal administration to rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7545750/),[ml] / [min],2,146016,DB00661,Verapamil
,7545750,terminal plasma half-life,The kinetics of FD-4 after intravenous doses of 1 or 10 mg could be described by a two-compartment model with a systemic clearance of approximately 2 mL min-1 and a terminal plasma half-life of approximately 36 min.,Absorption enhancement of a hydrophilic model compound by verapamil after rectal administration to rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7545750/),min,36,146017,DB00661,Verapamil
,14744949,kinact,"The values of the inactivation kinetic parameters kinact and KI obtained with the cDNA-expressed CYP3A4 (+b5) were 0.39 min(-1) and 6.46 microM for R-verapamil, 0.64 min(-1) and 2.97 microM for S-verapamil, 1.12 min(-1) and 5.89 microM for (+/-)-norverapamil, and 0.07 min(-1) and 7.93 microM for D617.",Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),1/[min],0.39,146728,DB00661,Verapamil
,14744949,kinact,"The values of the inactivation kinetic parameters kinact and KI obtained with the cDNA-expressed CYP3A4 (+b5) were 0.39 min(-1) and 6.46 microM for R-verapamil, 0.64 min(-1) and 2.97 microM for S-verapamil, 1.12 min(-1) and 5.89 microM for (+/-)-norverapamil, and 0.07 min(-1) and 7.93 microM for D617.",Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),μM,6.46,146729,DB00661,Verapamil
,14744949,kinact,"The values of the inactivation kinetic parameters kinact and KI obtained with the cDNA-expressed CYP3A4 (+b5) were 0.39 min(-1) and 6.46 microM for R-verapamil, 0.64 min(-1) and 2.97 microM for S-verapamil, 1.12 min(-1) and 5.89 microM for (+/-)-norverapamil, and 0.07 min(-1) and 7.93 microM for D617.",Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),1/[min],0.64,146730,DB00661,Verapamil
,14744949,kinact,"The values of the inactivation kinetic parameters kinact and KI obtained with the cDNA-expressed CYP3A4 (+b5) were 0.39 min(-1) and 6.46 microM for R-verapamil, 0.64 min(-1) and 2.97 microM for S-verapamil, 1.12 min(-1) and 5.89 microM for (+/-)-norverapamil, and 0.07 min(-1) and 7.93 microM for D617.",Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),1/[min],1.12,146731,DB00661,Verapamil
,14744949,kinact,"The values of the inactivation kinetic parameters kinact and KI obtained with the cDNA-expressed CYP3A4 (+b5) were 0.39 min(-1) and 6.46 microM for R-verapamil, 0.64 min(-1) and 2.97 microM for S-verapamil, 1.12 min(-1) and 5.89 microM for (+/-)-norverapamil, and 0.07 min(-1) and 7.93 microM for D617.",Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),1/[min],0.07,146732,DB00661,Verapamil
,14744949,KI,"The values of the inactivation kinetic parameters kinact and KI obtained with the cDNA-expressed CYP3A4 (+b5) were 0.39 min(-1) and 6.46 microM for R-verapamil, 0.64 min(-1) and 2.97 microM for S-verapamil, 1.12 min(-1) and 5.89 microM for (+/-)-norverapamil, and 0.07 min(-1) and 7.93 microM for D617.",Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),μM,6.46,146733,DB00661,Verapamil
,14744949,KI,"The values of the inactivation kinetic parameters kinact and KI obtained with the cDNA-expressed CYP3A4 (+b5) were 0.39 min(-1) and 6.46 microM for R-verapamil, 0.64 min(-1) and 2.97 microM for S-verapamil, 1.12 min(-1) and 5.89 microM for (+/-)-norverapamil, and 0.07 min(-1) and 7.93 microM for D617.",Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),1/[min],1.12,146734,DB00661,Verapamil
,14744949,KI,"The values of the inactivation kinetic parameters kinact and KI obtained with the cDNA-expressed CYP3A4 (+b5) were 0.39 min(-1) and 6.46 microM for R-verapamil, 0.64 min(-1) and 2.97 microM for S-verapamil, 1.12 min(-1) and 5.89 microM for (+/-)-norverapamil, and 0.07 min(-1) and 7.93 microM for D617.",Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),μM,5.89,146735,DB00661,Verapamil
,14744949,KI,"The values of the inactivation kinetic parameters kinact and KI obtained with the cDNA-expressed CYP3A4 (+b5) were 0.39 min(-1) and 6.46 microM for R-verapamil, 0.64 min(-1) and 2.97 microM for S-verapamil, 1.12 min(-1) and 5.89 microM for (+/-)-norverapamil, and 0.07 min(-1) and 7.93 microM for D617.",Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),1/[min],0.07,146736,DB00661,Verapamil
,14744949,KI,"The values of the inactivation kinetic parameters kinact and KI obtained with the cDNA-expressed CYP3A4 (+b5) were 0.39 min(-1) and 6.46 microM for R-verapamil, 0.64 min(-1) and 2.97 microM for S-verapamil, 1.12 min(-1) and 5.89 microM for (+/-)-norverapamil, and 0.07 min(-1) and 7.93 microM for D617.",Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),μM,7.93,146737,DB00661,Verapamil
,14744949,unbound fraction,"The in vitro unbound fraction was 0.84 for S-verapamil, 0.68 for R-verapamil, and 0.84 for (+/-)-norverapamil.",Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),,0.84,146738,DB00661,Verapamil
,14744949,unbound fraction,"The in vitro unbound fraction was 0.84 for S-verapamil, 0.68 for R-verapamil, and 0.84 for (+/-)-norverapamil.",Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),,0.68,146739,DB00661,Verapamil
,14744949,fm,A mechanism-based pharmacokinetic model predicted that the oral area under the curve (AUC) of a CYP3A substrate that is eliminated completely (fm=1) by the hepatic CYP3A increased 1.6- to 2.2-fold after repeated oral administration of verapamil.,Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),,1,146740,DB00661,Verapamil
,14744949,fm,"For midazolam (fm=0.9), a drug that undergoes extensive intestinal wall metabolism, the predicted increase in oral AUC was 3.2- to 4.5-fold.",Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14744949/),,0.9,146741,DB00661,Verapamil
,3252045,clearance,"Both verapamil and diltiazem treatment decreased antipyrine clearance (verapamil, 42.5 to 30.1 ml/min, P less than .01; diltiazem, 41.7 to 29.9 ml/min, P less than .01), resulting in prolonged antipyrine half-life with no change in distribution volume.",Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252045/),[ml] / [min],42.5 to 30.1,149488,DB00661,Verapamil
,3252045,clearance,"Both verapamil and diltiazem treatment decreased antipyrine clearance (verapamil, 42.5 to 30.1 ml/min, P less than .01; diltiazem, 41.7 to 29.9 ml/min, P less than .01), resulting in prolonged antipyrine half-life with no change in distribution volume.",Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252045/),[ml] / [min],41.7 to 29.9,149489,DB00661,Verapamil
,3252045,clearance,"Effect on theophylline clearance differed between verapamil treatment (57.7 to 44.7 ml/min; P less than .01) and diltiazem treatment (50.2 to 49.4 ml/min; N.S.), with prolonged theophylline half-life during verapamil treatment, no change in half-life during diltiazem treatment and distribution volume unchanged by either treatment.",Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252045/),[ml] / [min],57.7 to 44.7,149490,DB00661,Verapamil
,3252045,clearance,"Effect on theophylline clearance differed between verapamil treatment (57.7 to 44.7 ml/min; P less than .01) and diltiazem treatment (50.2 to 49.4 ml/min; N.S.), with prolonged theophylline half-life during verapamil treatment, no change in half-life during diltiazem treatment and distribution volume unchanged by either treatment.",Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252045/),[ml] / [min],50.2 to 49.4,149491,DB00661,Verapamil
,24120885,in,"An in situ intestinal perfusion study in rats showed that verapamil co-perfusion caused a significant increase in the intestinal permeability of AC, from 0.22×10(-5) to 2.85×10(-5) cm/s.","P-glycoprotein is responsible for the poor intestinal absorption and low toxicity of oral aconitine: in vitro, in situ, in vivo and in silico studies. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24120885/),[cm] / [s],0.22×10(-5),149527,DB00661,Verapamil
,24120885,permeability,"An in situ intestinal perfusion study in rats showed that verapamil co-perfusion caused a significant increase in the intestinal permeability of AC, from 0.22×10(-5) to 2.85×10(-5) cm/s.","P-glycoprotein is responsible for the poor intestinal absorption and low toxicity of oral aconitine: in vitro, in situ, in vivo and in silico studies. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24120885/),[cm] / [s],0.22×10(-5),149528,DB00661,Verapamil
,24120885,permeability,"An in situ intestinal perfusion study in rats showed that verapamil co-perfusion caused a significant increase in the intestinal permeability of AC, from 0.22×10(-5) to 2.85×10(-5) cm/s.","P-glycoprotein is responsible for the poor intestinal absorption and low toxicity of oral aconitine: in vitro, in situ, in vivo and in silico studies. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24120885/),[cm] / [s],2.85×10(-5),149529,DB00661,Verapamil
,24120885,maximum plasma concentration (Cmax),"With pre-treatment of verapamil, the maximum plasma concentration (Cmax) of AC increased sharply, from 39.43 to 1490.7 ng/ml.","P-glycoprotein is responsible for the poor intestinal absorption and low toxicity of oral aconitine: in vitro, in situ, in vivo and in silico studies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24120885/),[ng] / [ml],39.43,149530,DB00661,Verapamil
,24120885,maximum plasma concentration (Cmax),"With pre-treatment of verapamil, the maximum plasma concentration (Cmax) of AC increased sharply, from 39.43 to 1490.7 ng/ml.","P-glycoprotein is responsible for the poor intestinal absorption and low toxicity of oral aconitine: in vitro, in situ, in vivo and in silico studies. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24120885/),[ng] / [ml],1490.7,149531,DB00661,Verapamil
,6209501,fraction unbound,The mean +/- SD fraction unbound in the patients was 0.16 +/- 0.05 compared with 0.099 +/- 0.015 in the control group (p less than 0.01).,Decreased binding of verapamil to plasma proteins in patients with liver disease. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6209501/),,0.16,152432,DB00661,Verapamil
,6209501,fraction unbound,The mean +/- SD fraction unbound in the patients was 0.16 +/- 0.05 compared with 0.099 +/- 0.015 in the control group (p less than 0.01).,Decreased binding of verapamil to plasma proteins in patients with liver disease. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6209501/),,0.099,152433,DB00661,Verapamil
>,22563974,bioavailability,"Pharmacokinetic results show that FLAP has high bioavailability (> 75%), long T1/2 (> 260 min), and short peak time (<20 min).",Disposition of orally administered a promising chemotherapeutic agent flavopiridol in the intestine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22563974/),%,75,155259,DB00661,Verapamil
>,22563974,T1/2,"Pharmacokinetic results show that FLAP has high bioavailability (> 75%), long T1/2 (> 260 min), and short peak time (<20 min).",Disposition of orally administered a promising chemotherapeutic agent flavopiridol in the intestine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22563974/),min,260,155260,DB00661,Verapamil
<,22563974,peak time,"Pharmacokinetic results show that FLAP has high bioavailability (> 75%), long T1/2 (> 260 min), and short peak time (<20 min).",Disposition of orally administered a promising chemotherapeutic agent flavopiridol in the intestine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22563974/),min,20,155261,DB00661,Verapamil
,22563974,permeability,"In the Caco-2 cell culture model, the bidirectional permeability of FLAP was 0.47 × 10(-5) cm/s to 1.53 × 10(-5) cm/s and the efflux ratios were 3.27 and 2.17 at 10 and 30 μM, respectively.",Disposition of orally administered a promising chemotherapeutic agent flavopiridol in the intestine. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22563974/),[cm] / [s],0.47 × 10(-5),155262,DB00661,Verapamil
,22563974,permeability,"In the Caco-2 cell culture model, the bidirectional permeability of FLAP was 0.47 × 10(-5) cm/s to 1.53 × 10(-5) cm/s and the efflux ratios were 3.27 and 2.17 at 10 and 30 μM, respectively.",Disposition of orally administered a promising chemotherapeutic agent flavopiridol in the intestine. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22563974/),[cm] / [s],1.53 × 10(-5),155263,DB00661,Verapamil
,22563974,efflux ratios,"In the Caco-2 cell culture model, the bidirectional permeability of FLAP was 0.47 × 10(-5) cm/s to 1.53 × 10(-5) cm/s and the efflux ratios were 3.27 and 2.17 at 10 and 30 μM, respectively.",Disposition of orally administered a promising chemotherapeutic agent flavopiridol in the intestine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22563974/),,3.27,155264,DB00661,Verapamil
,22563974,efflux ratios,"In the Caco-2 cell culture model, the bidirectional permeability of FLAP was 0.47 × 10(-5) cm/s to 1.53 × 10(-5) cm/s and the efflux ratios were 3.27 and 2.17 at 10 and 30 μM, respectively.",Disposition of orally administered a promising chemotherapeutic agent flavopiridol in the intestine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22563974/),,2.17,155265,DB00661,Verapamil
,22563974,biliary excretions,"In the four-site model, 10 and 40 μM FLAP perfusions were well absorbed at various regions of the intestine, and the biliary excretions of FLAP glucuronides were 1.60-2.84 nmol and 12.47-17.33 nmol, respectively.",Disposition of orally administered a promising chemotherapeutic agent flavopiridol in the intestine. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22563974/),nM,1.60-2.84,155266,DB00661,Verapamil
,22563974,biliary excretions,"In the four-site model, 10 and 40 μM FLAP perfusions were well absorbed at various regions of the intestine, and the biliary excretions of FLAP glucuronides were 1.60-2.84 nmol and 12.47-17.33 nmol, respectively.",Disposition of orally administered a promising chemotherapeutic agent flavopiridol in the intestine. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22563974/),nM,12.47-17.33,155267,DB00661,Verapamil
,26291333,EC50,"FD18 is a potent (EC50 = 148 nM for paclitaxel), safe (selective index = 574), and selective P-glycoprotein (P-gp) modulator.","A New Class of Safe, Potent, and Specific P-gp Modulator: Flavonoid Dimer FD18 Reverses P-gp-Mediated Multidrug Resistance in Human Breast Xenograft in Vivo. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26291333/),nM,148,155958,DB00661,Verapamil
,26291333,EC50,Pharmacokinetics studies indicated that intraperitoneal administration of 45 mg/kg FD18 was enough to maintain a plasma level above EC50 (148 nM) for more than 600 min.,"A New Class of Safe, Potent, and Specific P-gp Modulator: Flavonoid Dimer FD18 Reverses P-gp-Mediated Multidrug Resistance in Human Breast Xenograft in Vivo. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26291333/),nM,148,155959,DB00661,Verapamil
,8903664,maximal PQ,"The mean +/- SD maximal PQ prolongation (difference from placebo) was 15.6 +/- 16.1 ms, compared with 44.0 +/- 22.6 ms for verapamil and 56.0 +/- 48.9 ms for diltiazem (P<0.05 mibefradil versus verapamil; P<0.01 mibefradil versus diltiazem).","Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40-5967), a novel calcium antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8903664/),ms,15.6,156484,DB00661,Verapamil
,8903664,maximal PQ,"The mean +/- SD maximal PQ prolongation (difference from placebo) was 15.6 +/- 16.1 ms, compared with 44.0 +/- 22.6 ms for verapamil and 56.0 +/- 48.9 ms for diltiazem (P<0.05 mibefradil versus verapamil; P<0.01 mibefradil versus diltiazem).","Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40-5967), a novel calcium antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8903664/),ms,44.0,156485,DB00661,Verapamil
,8903664,maximal PQ,"The mean +/- SD maximal PQ prolongation (difference from placebo) was 15.6 +/- 16.1 ms, compared with 44.0 +/- 22.6 ms for verapamil and 56.0 +/- 48.9 ms for diltiazem (P<0.05 mibefradil versus verapamil; P<0.01 mibefradil versus diltiazem).","Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40-5967), a novel calcium antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8903664/),ms,56.0,156486,DB00661,Verapamil
,8903664,elimination half-life (t1/2),"The mean +/- SD elimination half-life (t1/2) of mibefradil under steady-state conditions was 26.8 +/- 5.5 h (versus an apparent t1/2 of 16.9 +/- 11.1 h for verapamil SR, P<0.05).","Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40-5967), a novel calcium antagonist. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8903664/),h,26.8,156487,DB00661,Verapamil
,8903664,apparent t1/2,"The mean +/- SD elimination half-life (t1/2) of mibefradil under steady-state conditions was 26.8 +/- 5.5 h (versus an apparent t1/2 of 16.9 +/- 11.1 h for verapamil SR, P<0.05).","Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40-5967), a novel calcium antagonist. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8903664/),h,16.9,156488,DB00661,Verapamil
,21696352,peak drug concentration,Animal studies were carried out using Dawley rats and the data obtained from the plasma drug analysis showed that peak drug concentration of about 244.94 ± 1.25 ng/mL was achieved in 6 h after the application of the patch and plasma drug concentration was maintained till 24 h.,In vitro and in vivo characterization of novel biomaterial for transdermal application. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21696352/),[ng] / [ml],244.94,159824,DB00661,Verapamil
,2186259,AUC (0-24),"The mean AUC (0-24) after application of Veramex 80, calculated with 217.2 micrograms X h/l +/- 65.6, was approximately 10% less than the mean AUC (0-24) after application of the reference substance, which reached 240.4 micrograms X h/l +/- 87.0.",[Bioequivalence of non-retard verapamil. Realization of a draft monograph exemplified by Veramex 80]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186259/),[h·μg] / [l],217.2,160736,DB00661,Verapamil
,2186259,AUC (0-24),"The mean AUC (0-24) after application of Veramex 80, calculated with 217.2 micrograms X h/l +/- 65.6, was approximately 10% less than the mean AUC (0-24) after application of the reference substance, which reached 240.4 micrograms X h/l +/- 87.0.",[Bioequivalence of non-retard verapamil. Realization of a draft monograph exemplified by Veramex 80]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186259/),[h·μg] / [l],240.4,160737,DB00661,Verapamil
,2186259,maximal concentration (cmax),"After application of the reference drug the mean maximal concentration (cmax) of Verapamil was 58.1 micrograms/l and thus approximately 10% higher than the appropriate value detected after application of Veramex 80, which was 51.8 micrograms/l.",[Bioequivalence of non-retard verapamil. Realization of a draft monograph exemplified by Veramex 80]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186259/),[μg] / [l],58.1,160738,DB00661,Verapamil
,2186259,maximal concentration (cmax),"After application of the reference drug the mean maximal concentration (cmax) of Verapamil was 58.1 micrograms/l and thus approximately 10% higher than the appropriate value detected after application of Veramex 80, which was 51.8 micrograms/l.",[Bioequivalence of non-retard verapamil. Realization of a draft monograph exemplified by Veramex 80]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186259/),[μg] / [l],51.8,160739,DB00661,Verapamil
,2612558,half-life,During the night (24.00 h-06.00 h) the half-life of verapamil was significantly longer than during the day (16.00 h-22.00 h).,Circadian variation in the pharmacokinetics of verapamil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612558/),h,16.00,161047,DB00661,Verapamil
,2612558,half-life,During the night (24.00 h-06.00 h) the half-life of verapamil was significantly longer than during the day (16.00 h-22.00 h).,Circadian variation in the pharmacokinetics of verapamil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612558/),h,22.00,161048,DB00661,Verapamil
,7636546,clearance,Concomitant administration of R-verapamil resulted in a decrease in mean (+/- SD) paclitaxel clearance from 179 +/- 67 mL/min/m2 to 90 +/- 34 mL/min/m2 (P < .03) and in a twofold increase in paclitaxel exposure (area under the curve [AUC]).,Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7636546/),[ml] / [m2·min],179,161477,DB00661,Verapamil
,7636546,clearance,Concomitant administration of R-verapamil resulted in a decrease in mean (+/- SD) paclitaxel clearance from 179 +/- 67 mL/min/m2 to 90 +/- 34 mL/min/m2 (P < .03) and in a twofold increase in paclitaxel exposure (area under the curve [AUC]).,Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7636546/),[ml] / [m2·min],90,161478,DB00661,Verapamil
,28755970,total bioavailability,Pharmacokinetic data showed that the total bioavailability of RIN was 5.9 folds higher than that of IRN (23.4% vs. 4.0%).,Differences of first-pass effect in the liver and intestine contribute to the stereoselective pharmacokinetics of rhynchophylline and isorhynchophylline epimers in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28755970/),%,23.4,161501,DB00661,Verapamil
,28755970,total bioavailability,Pharmacokinetic data showed that the total bioavailability of RIN was 5.9 folds higher than that of IRN (23.4% vs. 4.0%).,Differences of first-pass effect in the liver and intestine contribute to the stereoselective pharmacokinetics of rhynchophylline and isorhynchophylline epimers in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28755970/),%,4.0,161502,DB00661,Verapamil
,28755970,hepatic availability,"The hepatic availability of RIN was 4.6 folds higher than that of IRN (46.9% vs. 10.3%), whereas the intestinal availability of RIN (48.1%) was comparable to that of IRN (42.7%).",Differences of first-pass effect in the liver and intestine contribute to the stereoselective pharmacokinetics of rhynchophylline and isorhynchophylline epimers in rats. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28755970/),%,46.9,161503,DB00661,Verapamil
,28755970,hepatic availability,"The hepatic availability of RIN was 4.6 folds higher than that of IRN (46.9% vs. 10.3%), whereas the intestinal availability of RIN (48.1%) was comparable to that of IRN (42.7%).",Differences of first-pass effect in the liver and intestine contribute to the stereoselective pharmacokinetics of rhynchophylline and isorhynchophylline epimers in rats. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28755970/),%,10.3,161504,DB00661,Verapamil
,28755970,intestinal availability,"The hepatic availability of RIN was 4.6 folds higher than that of IRN (46.9% vs. 10.3%), whereas the intestinal availability of RIN (48.1%) was comparable to that of IRN (42.7%).",Differences of first-pass effect in the liver and intestine contribute to the stereoselective pharmacokinetics of rhynchophylline and isorhynchophylline epimers in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28755970/),%,48.1,161505,DB00661,Verapamil
,28755970,intestinal availability,"The hepatic availability of RIN was 4.6 folds higher than that of IRN (46.9% vs. 10.3%), whereas the intestinal availability of RIN (48.1%) was comparable to that of IRN (42.7%).",Differences of first-pass effect in the liver and intestine contribute to the stereoselective pharmacokinetics of rhynchophylline and isorhynchophylline epimers in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28755970/),%,42.7,161506,DB00661,Verapamil
,22369125,Extraction recoveries,Extraction recoveries of mefloquine in plasma or saliva were 76-86% or 83-93% respectively.,A high performance liquid chromatographic assay of mefloquine in saliva after a single oral dose in healthy adult Africans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22369125/),%,76-86,161593,DB00661,Verapamil
,22369125,Extraction recoveries,Extraction recoveries of mefloquine in plasma or saliva were 76-86% or 83-93% respectively.,A high performance liquid chromatographic assay of mefloquine in saliva after a single oral dose in healthy adult Africans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22369125/),%,83-93,161594,DB00661,Verapamil
,22369125,Limit of quantification,Limit of quantification of mefloquine was 20 ng/ml.,A high performance liquid chromatographic assay of mefloquine in saliva after a single oral dose in healthy adult Africans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22369125/),[ng] / [ml],20,161595,DB00661,Verapamil
,22369125,Saliva:plasma concentrations ratio,Saliva:plasma concentrations ratio was 0.42.,A high performance liquid chromatographic assay of mefloquine in saliva after a single oral dose in healthy adult Africans. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22369125/),,0.42,161596,DB00661,Verapamil
,32078103,fraction absorbed,The in vivo contribution of P-gp is minimal for high permeable compounds owing to their fraction absorbed of nearly 1.0.,"Evaluation of the Role of P-glycoprotein (P-gp)-Mediated Efflux in the Intestinal Absorption of Common Substrates with Elacridar, a P-gp Inhibitor, in Rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32078103/),,1.0,161619,DB00661,Verapamil
,29319234,run time,The chromatographic separation was achieved on a Gemini C18 reversed phase column using a gradient elution mode with a run time of 10 minutes.,"Comparative pharmacokinetics of trandolapril, its active metabolite, and verapamil in human plasma of Egyptian population using HPLC-MS/MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29319234/),min,10,162441,DB00661,Verapamil
,6339196,bioavailability,"However, the bioavailability of verapamil has been studied extensively; about 22% of an orally administered dose of verapamil is systemically available.",Calcium antagonists. Pharmacokinetic properties. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6339196/),%,22,163725,DB00661,Verapamil
,6339196,elimination half-lives,"The elimination half-lives of verapamil and diltiazem are about 8 and 5 hours, respectively.",Calcium antagonists. Pharmacokinetic properties. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6339196/),h,8,163726,DB00661,Verapamil
,6339196,elimination half-lives,"The elimination half-lives of verapamil and diltiazem are about 8 and 5 hours, respectively.",Calcium antagonists. Pharmacokinetic properties. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6339196/),h,5,163727,DB00661,Verapamil
,21937184,flow-rate,"Chromatographic separation was carried out on an ACQUITY UPLC™ HSS T(3) column with mobile phase consisting of methanol-water containing 0.1% formic acid (80:20, v/v) at a flow-rate of 0.20mL/min.",Determination of palonosetron in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21937184/),[ml] / [min],0.20,163769,DB00661,Verapamil
,21937184,m/z,"The ion transitions of PALO and I.S. were m/z 297.3→109.8 and m/z 455.1→164.9, respectively.",Determination of palonosetron in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21937184/),,297.3,163770,DB00661,Verapamil
,21937184,m/z,"The ion transitions of PALO and I.S. were m/z 297.3→109.8 and m/z 455.1→164.9, respectively.",Determination of palonosetron in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21937184/),,109.8,163771,DB00661,Verapamil
,21937184,m/z,"The ion transitions of PALO and I.S. were m/z 297.3→109.8 and m/z 455.1→164.9, respectively.",Determination of palonosetron in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21937184/),,455.1,163772,DB00661,Verapamil
,21937184,m/z,"The ion transitions of PALO and I.S. were m/z 297.3→109.8 and m/z 455.1→164.9, respectively.",Determination of palonosetron in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21937184/),,164.9,163773,DB00661,Verapamil
,16026004,clearance,"Increasing the i.v. dose from 2 to 20 micromol/kg decreased the clearance (26 +/- 3 to 12 +/- 1 mL/min/kg), the hepatic extraction (66 +/- 8 to 30 +/- 2%), and the volume of distribution (7.3 +/- 0.3 to 2.1 +/- 0.7 L/kg) for fluvastatin (p < 0.05).",Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16026004/),[ml] / [kg·min],26,164283,DB00661,Verapamil
,16026004,clearance,"Increasing the i.v. dose from 2 to 20 micromol/kg decreased the clearance (26 +/- 3 to 12 +/- 1 mL/min/kg), the hepatic extraction (66 +/- 8 to 30 +/- 2%), and the volume of distribution (7.3 +/- 0.3 to 2.1 +/- 0.7 L/kg) for fluvastatin (p < 0.05).",Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16026004/),[ml] / [kg·min],12,164284,DB00661,Verapamil
,16026004,hepatic extraction,"Increasing the i.v. dose from 2 to 20 micromol/kg decreased the clearance (26 +/- 3 to 12 +/- 1 mL/min/kg), the hepatic extraction (66 +/- 8 to 30 +/- 2%), and the volume of distribution (7.3 +/- 0.3 to 2.1 +/- 0.7 L/kg) for fluvastatin (p < 0.05).",Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16026004/),,30,164285,DB00661,Verapamil
,16026004,volume of distribution,"Increasing the i.v. dose from 2 to 20 micromol/kg decreased the clearance (26 +/- 3 to 12 +/- 1 mL/min/kg), the hepatic extraction (66 +/- 8 to 30 +/- 2%), and the volume of distribution (7.3 +/- 0.3 to 2.1 +/- 0.7 L/kg) for fluvastatin (p < 0.05).",Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16026004/),[l] / [kg],7.3,164286,DB00661,Verapamil
,16026004,volume of distribution,"Increasing the i.v. dose from 2 to 20 micromol/kg decreased the clearance (26 +/- 3 to 12 +/- 1 mL/min/kg), the hepatic extraction (66 +/- 8 to 30 +/- 2%), and the volume of distribution (7.3 +/- 0.3 to 2.1 +/- 0.7 L/kg) for fluvastatin (p < 0.05).",Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16026004/),[l] / [kg],2.1,164287,DB00661,Verapamil
>,16026004,permeability,The in vitro permeability for fluvastatin was high (>10 x 10(-6) cm/s).,Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16026004/),[cm] / [s],10 x 10(-6),164288,DB00661,Verapamil
,8355215,clearance,"After single i.v. doses S-verapamil clearance (young, 102 +/- 6 vs. older, 77 +/- 6 l/hr; P < .01) and R-verapamil clearance (young, 61 +/- 3 vs. older, 45 +/- 3 l/hr; P < .01) were similarly decreased.",Stereoselective verapamil disposition and dynamics in aging during racemic verapamil administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8355215/),[l] / [h],102,164525,DB00661,Verapamil
,8355215,clearance,"After single i.v. doses S-verapamil clearance (young, 102 +/- 6 vs. older, 77 +/- 6 l/hr; P < .01) and R-verapamil clearance (young, 61 +/- 3 vs. older, 45 +/- 3 l/hr; P < .01) were similarly decreased.",Stereoselective verapamil disposition and dynamics in aging during racemic verapamil administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8355215/),[l] / [h],77,164526,DB00661,Verapamil
,8355215,clearance,"After single i.v. doses S-verapamil clearance (young, 102 +/- 6 vs. older, 77 +/- 6 l/hr; P < .01) and R-verapamil clearance (young, 61 +/- 3 vs. older, 45 +/- 3 l/hr; P < .01) were similarly decreased.",Stereoselective verapamil disposition and dynamics in aging during racemic verapamil administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8355215/),[l] / [h],61,164527,DB00661,Verapamil
,8355215,clearance,"After single i.v. doses S-verapamil clearance (young, 102 +/- 6 vs. older, 77 +/- 6 l/hr; P < .01) and R-verapamil clearance (young, 61 +/- 3 vs. older, 45 +/- 3 l/hr; P < .01) were similarly decreased.",Stereoselective verapamil disposition and dynamics in aging during racemic verapamil administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8355215/),[l] / [h],45,164528,DB00661,Verapamil
,8355215,Emax,"Electrocardiographic P-R prolongation using S-verapamil concentrations and an Emax model (young Emax, 69 +/- 8 vs. older, 42 +/- 6 msec; P < .05: young EC50, 15 +/- 1 vs. older, 23 +/- 3 ng/ml; P < .05) was greater in the young.",Stereoselective verapamil disposition and dynamics in aging during racemic verapamil administration. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8355215/),ms,69,164529,DB00661,Verapamil
,8355215,Emax,"Electrocardiographic P-R prolongation using S-verapamil concentrations and an Emax model (young Emax, 69 +/- 8 vs. older, 42 +/- 6 msec; P < .05: young EC50, 15 +/- 1 vs. older, 23 +/- 3 ng/ml; P < .05) was greater in the young.",Stereoselective verapamil disposition and dynamics in aging during racemic verapamil administration. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8355215/),ms,42,164530,DB00661,Verapamil
,8355215,EC50,"Electrocardiographic P-R prolongation using S-verapamil concentrations and an Emax model (young Emax, 69 +/- 8 vs. older, 42 +/- 6 msec; P < .05: young EC50, 15 +/- 1 vs. older, 23 +/- 3 ng/ml; P < .05) was greater in the young.",Stereoselective verapamil disposition and dynamics in aging during racemic verapamil administration. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8355215/),[ng] / [ml],15,164531,DB00661,Verapamil
,8355215,EC50,"Electrocardiographic P-R prolongation using S-verapamil concentrations and an Emax model (young Emax, 69 +/- 8 vs. older, 42 +/- 6 msec; P < .05: young EC50, 15 +/- 1 vs. older, 23 +/- 3 ng/ml; P < .05) was greater in the young.",Stereoselective verapamil disposition and dynamics in aging during racemic verapamil administration. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8355215/),[ng] / [ml],23,164532,DB00661,Verapamil
,8355215,clearance,"Simulated steady-state i.v. S-verapamil clearance (young, 76 +/- 3 vs. older, 49 +/- 2 l/hr; P < .01) and R-verapamil clearance (young, 47 +/- 2 vs. older, 28 +/- 1 l/hr; P < .01) were similarly less in older subjects and this was unrelated to infusion rate.",Stereoselective verapamil disposition and dynamics in aging during racemic verapamil administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8355215/),[l] / [h],76,164533,DB00661,Verapamil
,8355215,clearance,"Simulated steady-state i.v. S-verapamil clearance (young, 76 +/- 3 vs. older, 49 +/- 2 l/hr; P < .01) and R-verapamil clearance (young, 47 +/- 2 vs. older, 28 +/- 1 l/hr; P < .01) were similarly less in older subjects and this was unrelated to infusion rate.",Stereoselective verapamil disposition and dynamics in aging during racemic verapamil administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8355215/),[l] / [h],49,164534,DB00661,Verapamil
,8355215,clearance,"Simulated steady-state i.v. S-verapamil clearance (young, 76 +/- 3 vs. older, 49 +/- 2 l/hr; P < .01) and R-verapamil clearance (young, 47 +/- 2 vs. older, 28 +/- 1 l/hr; P < .01) were similarly less in older subjects and this was unrelated to infusion rate.",Stereoselective verapamil disposition and dynamics in aging during racemic verapamil administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8355215/),[l] / [h],47,164535,DB00661,Verapamil
,8355215,clearance,"Simulated steady-state i.v. S-verapamil clearance (young, 76 +/- 3 vs. older, 49 +/- 2 l/hr; P < .01) and R-verapamil clearance (young, 47 +/- 2 vs. older, 28 +/- 1 l/hr; P < .01) were similarly less in older subjects and this was unrelated to infusion rate.",Stereoselective verapamil disposition and dynamics in aging during racemic verapamil administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8355215/),[l] / [h],28,164536,DB00661,Verapamil
,8355215,Plasma protein binding,"Plasma protein binding of S-verapamil was less in both groups (young, 8.5 +/- 0.4 and older, 8.0 +/- 0.5% unbound) than that of R-verapamil (young, 5.4 +/- 0.2 and older, 5.1 +/- 0.3% unbound) and not different between groups.",Stereoselective verapamil disposition and dynamics in aging during racemic verapamil administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8355215/),%,8.5,164537,DB00661,Verapamil
,8355215,Plasma protein binding,"Plasma protein binding of S-verapamil was less in both groups (young, 8.5 +/- 0.4 and older, 8.0 +/- 0.5% unbound) than that of R-verapamil (young, 5.4 +/- 0.2 and older, 5.1 +/- 0.3% unbound) and not different between groups.",Stereoselective verapamil disposition and dynamics in aging during racemic verapamil administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8355215/),%,8.0,164538,DB00661,Verapamil
,8355215,Plasma protein binding,"Plasma protein binding of S-verapamil was less in both groups (young, 8.5 +/- 0.4 and older, 8.0 +/- 0.5% unbound) than that of R-verapamil (young, 5.4 +/- 0.2 and older, 5.1 +/- 0.3% unbound) and not different between groups.",Stereoselective verapamil disposition and dynamics in aging during racemic verapamil administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8355215/),%,5.4,164539,DB00661,Verapamil
,8355215,Plasma protein binding,"Plasma protein binding of S-verapamil was less in both groups (young, 8.5 +/- 0.4 and older, 8.0 +/- 0.5% unbound) than that of R-verapamil (young, 5.4 +/- 0.2 and older, 5.1 +/- 0.3% unbound) and not different between groups.",Stereoselective verapamil disposition and dynamics in aging during racemic verapamil administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8355215/),%,5.1,164540,DB00661,Verapamil
,25963583,Km,"The 'unbound' Km determined with RLM (2.8 µM) was divided by the 'unbound' Km determined with fresh and cryopreserved SRH (3.9 µM and 2.1 µM, respectively) to calculate the ratio of intracellular to extracellular unbound concentration (Kpu,u).",Verapamil hepatic clearance in four preclinical rat models: towards activity-based scaling. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25963583/),μM,2.8,164977,DB00661,Verapamil
,25963583,Km,"The 'unbound' Km determined with RLM (2.8 µM) was divided by the 'unbound' Km determined with fresh and cryopreserved SRH (3.9 µM and 2.1 µM, respectively) to calculate the ratio of intracellular to extracellular unbound concentration (Kpu,u).",Verapamil hepatic clearance in four preclinical rat models: towards activity-based scaling. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25963583/),μM,3.9,164978,DB00661,Verapamil
,25963583,Km,"The 'unbound' Km determined with RLM (2.8 µM) was divided by the 'unbound' Km determined with fresh and cryopreserved SRH (3.9 µM and 2.1 µM, respectively) to calculate the ratio of intracellular to extracellular unbound concentration (Kpu,u).",Verapamil hepatic clearance in four preclinical rat models: towards activity-based scaling. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25963583/),μM,2.1,164979,DB00661,Verapamil
,25963583,"Kpu,u","Kpu,u was significantly different between freshly isolated (0.71) and cryopreserved (1.31) SRH, but intracellular capacity for verapamil metabolism was maintained after cryopreservation (200 vs. 191 µl/min/million cells).",Verapamil hepatic clearance in four preclinical rat models: towards activity-based scaling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25963583/),[μl] / [cells·million·min],0.71,164980,DB00661,Verapamil
,25963583,"Kpu,u","Kpu,u was significantly different between freshly isolated (0.71) and cryopreserved (1.31) SRH, but intracellular capacity for verapamil metabolism was maintained after cryopreservation (200 vs. 191 µl/min/million cells).",Verapamil hepatic clearance in four preclinical rat models: towards activity-based scaling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25963583/),[μl] / [cells·million·min],1.31,164981,DB00661,Verapamil
,25963583,"Kpu,u","Kpu,u was significantly different between freshly isolated (0.71) and cryopreserved (1.31) SRH, but intracellular capacity for verapamil metabolism was maintained after cryopreservation (200 vs. 191 µl/min/million cells).",Verapamil hepatic clearance in four preclinical rat models: towards activity-based scaling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25963583/),[μl] / [cells·million·min],200,164982,DB00661,Verapamil
,25963583,"Kpu,u","Kpu,u was significantly different between freshly isolated (0.71) and cryopreserved (1.31) SRH, but intracellular capacity for verapamil metabolism was maintained after cryopreservation (200 vs. 191 µl/min/million cells).",Verapamil hepatic clearance in four preclinical rat models: towards activity-based scaling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25963583/),[μl] / [cells·million·min],191,164983,DB00661,Verapamil
,25963583,hepatic blood flow,"Likewise, the hepatic blood flow (61 ml/min/kg b.wt) was calculated using IPRL Clint and the in vivo Cl.",Verapamil hepatic clearance in four preclinical rat models: towards activity-based scaling. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25963583/),[ml] / [b·kg·min·wt],61,164984,DB00661,Verapamil
,8820952,peak concentrations,"Pharmacokinetic analysis revealed median peak concentrations of dexverapamil and its metabolite, nor-dexverapamil, of 1.66 mumol/l and 1.58 mumol/l, respectively.",Clinical reversal of multidrug resistance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820952/),[μM] / [l],1.66,165049,DB00661,Verapamil
,8820952,peak concentrations,"Pharmacokinetic analysis revealed median peak concentrations of dexverapamil and its metabolite, nor-dexverapamil, of 1.66 mumol/l and 1.58 mumol/l, respectively.",Clinical reversal of multidrug resistance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820952/),[μM] / [l],1.58,165050,DB00661,Verapamil
,8820952,peak total reversing concentration,"Since both are comparable antagonists, a median peak total reversing concentration of 3.24 mumol/l was achieved.",Clinical reversal of multidrug resistance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8820952/),[μM] / [l],3.24,165051,DB00661,Verapamil
,1910493,elimination half-life,The elimination half-life of intravenous indocyanine green was only 1 hour after oral nifedipine (20 mg) significantly decreased.,[The effects of verapamil and nifedipine on the biotransformation of model substances and on the indocyanine green elimination]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1910493/),h,1,165139,DB00661,Verapamil
,3360112,oral clearance,"At the end of the course a decrease of oral clearance of VP as compared with its beginning (from 3.02 to 1.57 l/min, p less than 0.01) and an increase of the drug half-life (from 6.48 to 9.49 hrs, p less than 0.01) were found.",[Pharmacokinetics of verapamil and its N-dealkylated metabolites in patients with chronic ischemic heart disease undergoing long-term monotherapy]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360112/),[l] / [min],3.02,166668,DB00661,Verapamil
,3360112,oral clearance,"At the end of the course a decrease of oral clearance of VP as compared with its beginning (from 3.02 to 1.57 l/min, p less than 0.01) and an increase of the drug half-life (from 6.48 to 9.49 hrs, p less than 0.01) were found.",[Pharmacokinetics of verapamil and its N-dealkylated metabolites in patients with chronic ischemic heart disease undergoing long-term monotherapy]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360112/),[l] / [min],1,166669,DB00661,Verapamil
,3360112,half-life,"At the end of the course a decrease of oral clearance of VP as compared with its beginning (from 3.02 to 1.57 l/min, p less than 0.01) and an increase of the drug half-life (from 6.48 to 9.49 hrs, p less than 0.01) were found.",[Pharmacokinetics of verapamil and its N-dealkylated metabolites in patients with chronic ischemic heart disease undergoing long-term monotherapy]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360112/),h,6,166670,DB00661,Verapamil
,3360112,half-life,"At the end of the course a decrease of oral clearance of VP as compared with its beginning (from 3.02 to 1.57 l/min, p less than 0.01) and an increase of the drug half-life (from 6.48 to 9.49 hrs, p less than 0.01) were found.",[Pharmacokinetics of verapamil and its N-dealkylated metabolites in patients with chronic ischemic heart disease undergoing long-term monotherapy]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360112/),h,9,166671,DB00661,Verapamil
,3360112,Half-lives,"Half-lives of nor-VP and D-617 at the end of VP course (12.1 and 19.7 hrs, respectively) were also higher than at its beginning (8.7 and 14.2 hrs, respectively), half-life of D-620 underwent no significant changes (29.5 hrs at the beginning and 31.6 hrs at the end of VP course).",[Pharmacokinetics of verapamil and its N-dealkylated metabolites in patients with chronic ischemic heart disease undergoing long-term monotherapy]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360112/),h,12.1,166672,DB00661,Verapamil
,3360112,Half-lives,"Half-lives of nor-VP and D-617 at the end of VP course (12.1 and 19.7 hrs, respectively) were also higher than at its beginning (8.7 and 14.2 hrs, respectively), half-life of D-620 underwent no significant changes (29.5 hrs at the beginning and 31.6 hrs at the end of VP course).",[Pharmacokinetics of verapamil and its N-dealkylated metabolites in patients with chronic ischemic heart disease undergoing long-term monotherapy]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360112/),h,19.7,166673,DB00661,Verapamil
,3360112,Half-lives,"Half-lives of nor-VP and D-617 at the end of VP course (12.1 and 19.7 hrs, respectively) were also higher than at its beginning (8.7 and 14.2 hrs, respectively), half-life of D-620 underwent no significant changes (29.5 hrs at the beginning and 31.6 hrs at the end of VP course).",[Pharmacokinetics of verapamil and its N-dealkylated metabolites in patients with chronic ischemic heart disease undergoing long-term monotherapy]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360112/),h,8.7,166674,DB00661,Verapamil
,3360112,Half-lives,"Half-lives of nor-VP and D-617 at the end of VP course (12.1 and 19.7 hrs, respectively) were also higher than at its beginning (8.7 and 14.2 hrs, respectively), half-life of D-620 underwent no significant changes (29.5 hrs at the beginning and 31.6 hrs at the end of VP course).",[Pharmacokinetics of verapamil and its N-dealkylated metabolites in patients with chronic ischemic heart disease undergoing long-term monotherapy]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360112/),h,14.2,166675,DB00661,Verapamil
,3360112,half-life,"Half-lives of nor-VP and D-617 at the end of VP course (12.1 and 19.7 hrs, respectively) were also higher than at its beginning (8.7 and 14.2 hrs, respectively), half-life of D-620 underwent no significant changes (29.5 hrs at the beginning and 31.6 hrs at the end of VP course).",[Pharmacokinetics of verapamil and its N-dealkylated metabolites in patients with chronic ischemic heart disease undergoing long-term monotherapy]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360112/),h,29.5,166676,DB00661,Verapamil
,3360112,half-life,"Half-lives of nor-VP and D-617 at the end of VP course (12.1 and 19.7 hrs, respectively) were also higher than at its beginning (8.7 and 14.2 hrs, respectively), half-life of D-620 underwent no significant changes (29.5 hrs at the beginning and 31.6 hrs at the end of VP course).",[Pharmacokinetics of verapamil and its N-dealkylated metabolites in patients with chronic ischemic heart disease undergoing long-term monotherapy]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360112/),h,31.6,166677,DB00661,Verapamil
,3360112,clearance,"At the end of VP course the patients exhibited a decrease of antipyrine clearance (to 28.7 versus 43.2 ml/min at the beginning of VP course, p less than 0.01) that indicates a reduced activity of oxidative microsomal enzymes of the liver due to long-term VP therapy.",[Pharmacokinetics of verapamil and its N-dealkylated metabolites in patients with chronic ischemic heart disease undergoing long-term monotherapy]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360112/),[ml] / [min],28.7,166678,DB00661,Verapamil
,3360112,clearance,"At the end of VP course the patients exhibited a decrease of antipyrine clearance (to 28.7 versus 43.2 ml/min at the beginning of VP course, p less than 0.01) that indicates a reduced activity of oxidative microsomal enzymes of the liver due to long-term VP therapy.",[Pharmacokinetics of verapamil and its N-dealkylated metabolites in patients with chronic ischemic heart disease undergoing long-term monotherapy]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360112/),[ml] / [min],43.2,166679,DB00661,Verapamil
,9863159,Ver,"Dox cytotoxicity was enhanced 2.0-fold in Swiss-3T3 cells by Ver (3 mumol.L-1) and 3.6-fold in MCF-7Adr cells by Ver (6 mumol.L-1), but not in MCF-7WT cells (Ver 6 mumol.L-1).",Doxorubicin cellular pharmacokinetics plays no role in chemosensitizing effect of verapamil on Swiss-3T3 cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9863159/),[μM] / [l],6,167494,DB00661,Verapamil
,2720134,Cmax,"The mean Cmax after dosing with whole tablets, 143 (95 per cent confidence limits 91.6-223) ng ml-1 was lower than after dosing with half tablets, 160 (107-241) ng ml-1, but this was not significant (p = 0.49).",Multiple dose comparison of a whole 240 mg verapamil sustained-release tablet with two half tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720134/),[ng] / [ml],143,171388,DB00661,Verapamil
,2720134,Cmax,"The mean Cmax after dosing with whole tablets, 143 (95 per cent confidence limits 91.6-223) ng ml-1 was lower than after dosing with half tablets, 160 (107-241) ng ml-1, but this was not significant (p = 0.49).",Multiple dose comparison of a whole 240 mg verapamil sustained-release tablet with two half tablets. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720134/),[ng] / [ml],160,171389,DB00661,Verapamil
,2720134,steady-state Cmin,"The mean steady-state Cmin values after whole and half tablets were also similar: 22.2 (12.6-39.4) ng ml-1 and 22.0 (16.2-29.9) ng ml-1, respectively (p = 0.96).",Multiple dose comparison of a whole 240 mg verapamil sustained-release tablet with two half tablets. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720134/),[ng] / [ml],22.2,171390,DB00661,Verapamil
,2720134,steady-state Cmin,"The mean steady-state Cmin values after whole and half tablets were also similar: 22.2 (12.6-39.4) ng ml-1 and 22.0 (16.2-29.9) ng ml-1, respectively (p = 0.96).",Multiple dose comparison of a whole 240 mg verapamil sustained-release tablet with two half tablets. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720134/),[ng] / [ml],22.0,171391,DB00661,Verapamil
,2720134,tmax,"The mean (+/- S.D.) tmax, AUC0-24 and t 1/2 were not significantly different: whole tablet 3.5 +/- 1.2 h, 1733 +/- 1125 ng.h ml-1 and 10.5 +/- 3.4 h, respectively, and half tablets 3.6 +/- 1.0 h, 1780 +/- 1057 ng.h ml-1 and 9.6 +/- 2.3 h, respectively.",Multiple dose comparison of a whole 240 mg verapamil sustained-release tablet with two half tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720134/),h,3.5,171392,DB00661,Verapamil
,2720134,AUC0-24,"The mean (+/- S.D.) tmax, AUC0-24 and t 1/2 were not significantly different: whole tablet 3.5 +/- 1.2 h, 1733 +/- 1125 ng.h ml-1 and 10.5 +/- 3.4 h, respectively, and half tablets 3.6 +/- 1.0 h, 1780 +/- 1057 ng.h ml-1 and 9.6 +/- 2.3 h, respectively.",Multiple dose comparison of a whole 240 mg verapamil sustained-release tablet with two half tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720134/),[h·ng] / [ml],1733,171393,DB00661,Verapamil
,2720134,AUC0-24,"The mean (+/- S.D.) tmax, AUC0-24 and t 1/2 were not significantly different: whole tablet 3.5 +/- 1.2 h, 1733 +/- 1125 ng.h ml-1 and 10.5 +/- 3.4 h, respectively, and half tablets 3.6 +/- 1.0 h, 1780 +/- 1057 ng.h ml-1 and 9.6 +/- 2.3 h, respectively.",Multiple dose comparison of a whole 240 mg verapamil sustained-release tablet with two half tablets. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720134/),h,3.6,171394,DB00661,Verapamil
,2720134,t 1/2,"The mean (+/- S.D.) tmax, AUC0-24 and t 1/2 were not significantly different: whole tablet 3.5 +/- 1.2 h, 1733 +/- 1125 ng.h ml-1 and 10.5 +/- 3.4 h, respectively, and half tablets 3.6 +/- 1.0 h, 1780 +/- 1057 ng.h ml-1 and 9.6 +/- 2.3 h, respectively.",Multiple dose comparison of a whole 240 mg verapamil sustained-release tablet with two half tablets. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720134/),h,10.5,171395,DB00661,Verapamil
,2720134,t 1/2,"The mean (+/- S.D.) tmax, AUC0-24 and t 1/2 were not significantly different: whole tablet 3.5 +/- 1.2 h, 1733 +/- 1125 ng.h ml-1 and 10.5 +/- 3.4 h, respectively, and half tablets 3.6 +/- 1.0 h, 1780 +/- 1057 ng.h ml-1 and 9.6 +/- 2.3 h, respectively.",Multiple dose comparison of a whole 240 mg verapamil sustained-release tablet with two half tablets. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2720134/),h,3.6,171396,DB00661,Verapamil
exceeding,31159447,EE,Results revealed that the prepared superhydrophobic substrates were able to fabricate VP-loaded beads with extremely high EE exceeding 90% w/w compared to only 27.80% when using conventional ionotropic gelation technique.,Superhydrophobic Substrates for Ultrahigh Encapsulation of Hydrophilic Drug into Controlled-Release Polyelectrolyte Complex Beads: Statistical Optimization and In Vivo Evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31159447/),%,90,172030,DB00661,Verapamil
,31159447,EE,Results revealed that the prepared superhydrophobic substrates were able to fabricate VP-loaded beads with extremely high EE exceeding 90% w/w compared to only 27.80% when using conventional ionotropic gelation technique.,Superhydrophobic Substrates for Ultrahigh Encapsulation of Hydrophilic Drug into Controlled-Release Polyelectrolyte Complex Beads: Statistical Optimization and In Vivo Evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31159447/),%,27.80,172031,DB00661,Verapamil
,7460471,bioavailability,"Verapamil bioavailability is low, and the intensive-care patients and healthy subjects examined it ranged from 13% to 21%.","Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7460471/),%,13,172079,DB00661,Verapamil
,7460471,bioavailability,"Verapamil bioavailability is low, and the intensive-care patients and healthy subjects examined it ranged from 13% to 21%.","Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7460471/),%,21,172080,DB00661,Verapamil
,7460471,bioavailability,"There was considerable variation in liver disease subjects, in whom verapamil bioavailability ranged from 3.8% to 64%.","Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7460471/),%,3.8,172081,DB00661,Verapamil
,7460471,bioavailability,"There was considerable variation in liver disease subjects, in whom verapamil bioavailability ranged from 3.8% to 64%.","Verapamil disposition in liver disease and intensive-care patients: kinetics, clearance, and apparent blood flow relationships. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7460471/),%,64,172082,DB00661,Verapamil
,16615674,heart rate,"Her heart rate was 75 beats per minute, (bpm) and her blood pressure dropped from 70/50 to 50/00 mmHg.",Monitoring of verapamil enantiomers concentration in overdose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16615674/),[beats] / [min],75,172338,DB00661,Verapamil
,16615674,serum concentrations,"On admission, R-(+)- and S-(-)-verapamil serum concentrations were 2252 ng/ml and 810 ng/ ml, respectively.",Monitoring of verapamil enantiomers concentration in overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16615674/),[ng] / [ml],2252,172339,DB00661,Verapamil
,16615674,serum concentrations,"On admission, R-(+)- and S-(-)-verapamil serum concentrations were 2252 ng/ml and 810 ng/ ml, respectively.",Monitoring of verapamil enantiomers concentration in overdose. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16615674/),[ng] / [ml],810,172340,DB00661,Verapamil
,16615674,Terminal elimination half-lives,"Terminal elimination half-lives were 18.7 (21.3) and 17.0 (18.5) hours, respectively, for R-(+)- and S-(-)-verapamil.",Monitoring of verapamil enantiomers concentration in overdose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16615674/),h,18.7,172341,DB00661,Verapamil
,16615674,Terminal elimination half-lives,"Terminal elimination half-lives were 18.7 (21.3) and 17.0 (18.5) hours, respectively, for R-(+)- and S-(-)-verapamil.",Monitoring of verapamil enantiomers concentration in overdose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16615674/),h,17.0,172342,DB00661,Verapamil
,28314475,Maximum concentration (Cmax),"As pharmacokinetic data indicated, Maximum concentration (Cmax) of curcumin increased significantly to 394.06; the time reach maximum concentration (Tmax) and elimination half-life (T1/2) were 0.5 and 0.67h, respectively; CONCLUSION: The results provide a good strategy for the investigation of TCM formula especially the couplets, as well as a fast, selective and sensitive UPLC-MS-MS method determining active components in-vivo.","Pharmacokinetic based study on ""lagged stimulation"" of Curcumae Longae Rhizoma - Piper nigrum couplet in their main active components' metabolism using UPLC-MS-MS. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28314475/),,394.06,173783,DB00661,Verapamil
,28314475,time reach maximum concentration (Tmax),"As pharmacokinetic data indicated, Maximum concentration (Cmax) of curcumin increased significantly to 394.06; the time reach maximum concentration (Tmax) and elimination half-life (T1/2) were 0.5 and 0.67h, respectively; CONCLUSION: The results provide a good strategy for the investigation of TCM formula especially the couplets, as well as a fast, selective and sensitive UPLC-MS-MS method determining active components in-vivo.","Pharmacokinetic based study on ""lagged stimulation"" of Curcumae Longae Rhizoma - Piper nigrum couplet in their main active components' metabolism using UPLC-MS-MS. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28314475/),h,0.5,173784,DB00661,Verapamil
,28314475,elimination half-life (T1/2),"As pharmacokinetic data indicated, Maximum concentration (Cmax) of curcumin increased significantly to 394.06; the time reach maximum concentration (Tmax) and elimination half-life (T1/2) were 0.5 and 0.67h, respectively; CONCLUSION: The results provide a good strategy for the investigation of TCM formula especially the couplets, as well as a fast, selective and sensitive UPLC-MS-MS method determining active components in-vivo.","Pharmacokinetic based study on ""lagged stimulation"" of Curcumae Longae Rhizoma - Piper nigrum couplet in their main active components' metabolism using UPLC-MS-MS. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28314475/),h,0.67,173785,DB00661,Verapamil
,8054253,ventricular rate at peak plasma verapamil concentration,"The ventricular rate at peak plasma verapamil concentration (+/- s.d.) was significantly slower than on admission (101.6 +/- 11.3 and 159 +/- 5.3 beats min-1 respectively, P < 0.01).",Preliminary investigation of the efficacy of sublingual verapamil in the management of acute atrial fibrillation and flutter. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8054253/),[beats] / [min],101.6,174111,DB00661,Verapamil
,8054253,ventricular rate at peak plasma verapamil concentration,"The ventricular rate at peak plasma verapamil concentration (+/- s.d.) was significantly slower than on admission (101.6 +/- 11.3 and 159 +/- 5.3 beats min-1 respectively, P < 0.01).",Preliminary investigation of the efficacy of sublingual verapamil in the management of acute atrial fibrillation and flutter. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8054253/),[beats] / [min],159,174112,DB00661,Verapamil
,8054253,maximum peak plasma concentration,Sublingual verapamil was rapidly absorbed with the maximum peak plasma concentration (153.3 +/- 15.5 ng ml-1) being achieved after 1.21 +/- 0.18 h.,Preliminary investigation of the efficacy of sublingual verapamil in the management of acute atrial fibrillation and flutter. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8054253/),[ng] / [ml],153.3,174113,DB00661,Verapamil
,1414906,time to peak concentration,"The time to peak concentration was longer (7.5 +/- 3.0 vs 4.4 +/- 2.3 hours), resulting in a lower peak verapamil serum concentration (118 +/- 43 vs 175 +/- 50 ng/ml) when SR verapamil was administered with food (p < 0.05).",Impact of food on the pharmacokinetics and electrocardiographic effects of sustained release verapamil in normal subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1414906/),h,7.5,174192,DB00661,Verapamil
,1414906,time to peak concentration,"The time to peak concentration was longer (7.5 +/- 3.0 vs 4.4 +/- 2.3 hours), resulting in a lower peak verapamil serum concentration (118 +/- 43 vs 175 +/- 50 ng/ml) when SR verapamil was administered with food (p < 0.05).",Impact of food on the pharmacokinetics and electrocardiographic effects of sustained release verapamil in normal subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1414906/),h,4.4,174193,DB00661,Verapamil
,1414906,peak verapamil serum concentration,"The time to peak concentration was longer (7.5 +/- 3.0 vs 4.4 +/- 2.3 hours), resulting in a lower peak verapamil serum concentration (118 +/- 43 vs 175 +/- 50 ng/ml) when SR verapamil was administered with food (p < 0.05).",Impact of food on the pharmacokinetics and electrocardiographic effects of sustained release verapamil in normal subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1414906/),[ng] / [ml],118,174194,DB00661,Verapamil
,1414906,peak verapamil serum concentration,"The time to peak concentration was longer (7.5 +/- 3.0 vs 4.4 +/- 2.3 hours), resulting in a lower peak verapamil serum concentration (118 +/- 43 vs 175 +/- 50 ng/ml) when SR verapamil was administered with food (p < 0.05).",Impact of food on the pharmacokinetics and electrocardiographic effects of sustained release verapamil in normal subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1414906/),[ng] / [ml],175,174195,DB00661,Verapamil
,1414906,bioavailability,"Food tended to decrease the bioavailability of SR verapamil (34 +/- 12 vs 49 +/- 14%), although this difference did not reach statistical significance (p = 0.065).",Impact of food on the pharmacokinetics and electrocardiographic effects of sustained release verapamil in normal subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1414906/),%,34,174196,DB00661,Verapamil
,1414906,bioavailability,"Food tended to decrease the bioavailability of SR verapamil (34 +/- 12 vs 49 +/- 14%), although this difference did not reach statistical significance (p = 0.065).",Impact of food on the pharmacokinetics and electrocardiographic effects of sustained release verapamil in normal subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1414906/),%,49,174197,DB00661,Verapamil
,26347996,peak concentration,"The results indicated that, when the rats were pretreated with verapamil, the peak concentration of pristimerin increased from 189.13 to 277.53 ng/mL (46.7%), and the AUC0-t increased by approximately 82.0%.",Influence of verapamil on pharmacokinetics of pristimerin in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26347996/),[ng] / [ml],189.13,174289,DB00661,Verapamil
,26347996,peak concentration,"The results indicated that, when the rats were pretreated with verapamil, the peak concentration of pristimerin increased from 189.13 to 277.53 ng/mL (46.7%), and the AUC0-t increased by approximately 82.0%.",Influence of verapamil on pharmacokinetics of pristimerin in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26347996/),[ng] / [ml],277.53,174290,DB00661,Verapamil
,1623692,peak blood ethanol concentration,"Compared with placebo, verapamil increased the peak blood ethanol concentration (106.45 +/- 21.40 to 124.24 +/- 24.74 mg/dl, p less than 0.05) and area under the ethanol concentration versus time curve (365.67 +/- 93.52 to 475.07 +/- 97.24 mg.hr/dl, p less than 0.005).",Verapamil inhibits ethanol elimination and prolongs the perception of intoxication. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1623692/),[mg] / [dl],106.45,174685,DB00661,Verapamil
,1623692,peak blood ethanol concentration,"Compared with placebo, verapamil increased the peak blood ethanol concentration (106.45 +/- 21.40 to 124.24 +/- 24.74 mg/dl, p less than 0.05) and area under the ethanol concentration versus time curve (365.67 +/- 93.52 to 475.07 +/- 97.24 mg.hr/dl, p less than 0.005).",Verapamil inhibits ethanol elimination and prolongs the perception of intoxication. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1623692/),[mg] / [dl],124.24,174686,DB00661,Verapamil
,1623692,area under the ethanol concentration versus time curve,"Compared with placebo, verapamil increased the peak blood ethanol concentration (106.45 +/- 21.40 to 124.24 +/- 24.74 mg/dl, p less than 0.05) and area under the ethanol concentration versus time curve (365.67 +/- 93.52 to 475.07 +/- 97.24 mg.hr/dl, p less than 0.005).",Verapamil inhibits ethanol elimination and prolongs the perception of intoxication. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1623692/),[h·mg] / [dl],365.67,174687,DB00661,Verapamil
,1623692,area under the ethanol concentration versus time curve,"Compared with placebo, verapamil increased the peak blood ethanol concentration (106.45 +/- 21.40 to 124.24 +/- 24.74 mg/dl, p less than 0.05) and area under the ethanol concentration versus time curve (365.67 +/- 93.52 to 475.07 +/- 97.24 mg.hr/dl, p less than 0.005).",Verapamil inhibits ethanol elimination and prolongs the perception of intoxication. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1623692/),[h·mg] / [dl],475.07,174688,DB00661,Verapamil
,1623692,area under the effect versus time curve,"Compared with placebo, verapamil significantly increased area under the effect versus time curve (10.19 +/- 7.6 to 13.83 +/- 7.81 cm.hr, p less than 0.002) but did not change the peak effect or time to peak effect.",Verapamil inhibits ethanol elimination and prolongs the perception of intoxication. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1623692/),cm·h,10.19,174689,DB00661,Verapamil
,1623692,area under the effect versus time curve,"Compared with placebo, verapamil significantly increased area under the effect versus time curve (10.19 +/- 7.6 to 13.83 +/- 7.81 cm.hr, p less than 0.002) but did not change the peak effect or time to peak effect.",Verapamil inhibits ethanol elimination and prolongs the perception of intoxication. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1623692/),cm·h,13.83,174690,DB00661,Verapamil
,11249778,oral bioavailability,A new formulation of the drug has recently been developed with better oral bioavailability (60%) and less interindividual variability.,"Technology evaluation: Valspodar, Novartis AG. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11249778/),%,60,176839,DB00661,Verapamil
,3593905,Elimination half-life,Elimination half-life of verapamil was similar among plasma and tissues evaluated (1.5 to 2.2 h).,Physiological pharmacokinetics and pharmacodynamics of (+/-)-verapamil in female rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3593905/),h,1.5 to 2.2,177082,DB00661,Verapamil
,3593905,not bound,The per cent verapamil not bound to plasma proteins was concentration-independent and similar between rats receiving i.p. (mean +/- S.D.) (2.28 +/- 0.72 per cent) and i.v. (2.08 +/- 0.03 per cent) verapamil.,Physiological pharmacokinetics and pharmacodynamics of (+/-)-verapamil in female rats. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3593905/),%,2.28,177083,DB00661,Verapamil
,3593905,not bound,The per cent verapamil not bound to plasma proteins was concentration-independent and similar between rats receiving i.p. (mean +/- S.D.) (2.28 +/- 0.72 per cent) and i.v. (2.08 +/- 0.03 per cent) verapamil.,Physiological pharmacokinetics and pharmacodynamics of (+/-)-verapamil in female rats. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3593905/),%,2.08,177084,DB00661,Verapamil
,8361862,bioavailability,Assessments of bioequivalency (based on confidence intervals) demonstrated that this generic drug's bioavailability was from 4-118% and peak serum concentration from 10-139% greater than the brand-name drug.,Differences in serum concentrations of and responses to generic verapamil in the elderly. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8361862/),%,4-118,177181,DB00661,Verapamil
,20679500,24-hour urine volume,"After a single dose of tolvaptan (day 1, day 12), 24-hour urine volume was about 7.5 L.",In vitro P-glycoprotein interactions and steady-state pharmacokinetic interactions between tolvaptan and digoxin in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20679500/),l,7.5,179444,DB00661,Verapamil
,20679500,IC50,Tolvaptan (50 µM) inhibited basolateral to apical digoxin secretion to the same extent as 30 µM verapamil; the IC50 of tolvaptan was determined to be 15.9 µM.,In vitro P-glycoprotein interactions and steady-state pharmacokinetic interactions between tolvaptan and digoxin in healthy subjects. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20679500/),μM,15.9,179445,DB00661,Verapamil
,2778093,clearance,"Theophylline clearance decreased by 11.5%, from a mean (+/-SD) of 1.39 +/- 0.38 mL/min/kg in the control phase to 1.23 +/- 0.21 mL/min/kg with the co-administration of verapamil (P = 0.104).",The effect of verapamil on the pharmacokinetic disposition of theophylline in cigarette smokers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778093/),[ml] / [kg·min],1.39,180088,DB00661,Verapamil
,2778093,clearance,"Theophylline clearance decreased by 11.5%, from a mean (+/-SD) of 1.39 +/- 0.38 mL/min/kg in the control phase to 1.23 +/- 0.21 mL/min/kg with the co-administration of verapamil (P = 0.104).",The effect of verapamil on the pharmacokinetic disposition of theophylline in cigarette smokers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778093/),[ml] / [kg·min],1.23,180089,DB00661,Verapamil
,2778093,elimination rate constant,Theophylline elimination rate constant decreased by approximately 9.4% from 0.171 +/- 0.032 to 0.155 + 0.023 hr-1 during the treatment phase (P = 0.085).,The effect of verapamil on the pharmacokinetic disposition of theophylline in cigarette smokers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778093/),1/[h],0.171,180090,DB00661,Verapamil
,2778093,elimination rate constant,Theophylline elimination rate constant decreased by approximately 9.4% from 0.171 +/- 0.032 to 0.155 + 0.023 hr-1 during the treatment phase (P = 0.085).,The effect of verapamil on the pharmacokinetic disposition of theophylline in cigarette smokers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778093/),1/[h],0.155,180091,DB00661,Verapamil
,24014108,extraction recovery rates,The extraction recovery rates ranged from 85.34 to 111.62 %.,"The study of absorption kinetics of berberine based on portal vein in rat, and the influence of verapamil and borneol to its absorption ability by UHPLC method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24014108/),%,85,180092,DB00661,Verapamil
,24014108,extraction recovery rates,The extraction recovery rates ranged from 85.34 to 111.62 %.,"The study of absorption kinetics of berberine based on portal vein in rat, and the influence of verapamil and borneol to its absorption ability by UHPLC method. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24014108/),%,111,180093,DB00661,Verapamil
,11014410,area under the concentration versus time curve (AUC),"The area under the concentration versus time curve (AUC) after administration of sustained-release verapamil was 48,951 +/- 18,079 ng/mL x min(-1) in women compared with 25,595 +/- 10,245 in men and lower than after administration of regular-release verapamil (63,055 +/- 24,411 for women and 34,686 +/- 25,279 in men; P = .05 for sex-related effect and P < .02 for formulation effect).",Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11014410/),[ml·ng] / [min],"48,951",180207,DB00661,Verapamil
,11014410,area under the concentration versus time curve (AUC),"The area under the concentration versus time curve (AUC) after administration of sustained-release verapamil was 48,951 +/- 18,079 ng/mL x min(-1) in women compared with 25,595 +/- 10,245 in men and lower than after administration of regular-release verapamil (63,055 +/- 24,411 for women and 34,686 +/- 25,279 in men; P = .05 for sex-related effect and P < .02 for formulation effect).",Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11014410/),[ml·ng] / [min],"25,595",180208,DB00661,Verapamil
,11014410,area under the concentration versus time curve (AUC),"The area under the concentration versus time curve (AUC) after administration of sustained-release verapamil was 48,951 +/- 18,079 ng/mL x min(-1) in women compared with 25,595 +/- 10,245 in men and lower than after administration of regular-release verapamil (63,055 +/- 24,411 for women and 34,686 +/- 25,279 in men; P = .05 for sex-related effect and P < .02 for formulation effect).",Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11014410/),[ml·ng] / [min],"63,055",180209,DB00661,Verapamil
,11014410,area under the concentration versus time curve (AUC),"The area under the concentration versus time curve (AUC) after administration of sustained-release verapamil was 48,951 +/- 18,079 ng/mL x min(-1) in women compared with 25,595 +/- 10,245 in men and lower than after administration of regular-release verapamil (63,055 +/- 24,411 for women and 34,686 +/- 25,279 in men; P = .05 for sex-related effect and P < .02 for formulation effect).",Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11014410/),[ml·ng] / [min],"34,686",180210,DB00661,Verapamil
,11014410,AUC ratios,AUC ratios of norverapamil (N-demethylated metabolite) to verapamil after administration of sustained-release verapamil were 1.43 +/- 0.26 in women compared with 1.74 +/- 0.41 in men and 1.43 +/- 0.26 in women compared with 1.78 +/- 0.37 in men after administration of regular-release verapamil (P = .1 for sex-related effect and P = .9 for formulation effect).,Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11014410/),,1.43,180211,DB00661,Verapamil
,11014410,AUC ratios,AUC ratios of norverapamil (N-demethylated metabolite) to verapamil after administration of sustained-release verapamil were 1.43 +/- 0.26 in women compared with 1.74 +/- 0.41 in men and 1.43 +/- 0.26 in women compared with 1.78 +/- 0.37 in men after administration of regular-release verapamil (P = .1 for sex-related effect and P = .9 for formulation effect).,Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11014410/),,1.74,180212,DB00661,Verapamil
,11014410,AUC ratios,AUC ratios of norverapamil (N-demethylated metabolite) to verapamil after administration of sustained-release verapamil were 1.43 +/- 0.26 in women compared with 1.74 +/- 0.41 in men and 1.43 +/- 0.26 in women compared with 1.78 +/- 0.37 in men after administration of regular-release verapamil (P = .1 for sex-related effect and P = .9 for formulation effect).,Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11014410/),,1.78,180213,DB00661,Verapamil
,11014410,Apparent oral clearance,Apparent oral clearance was 43 +/- 15 mL/min/kg in women compared with 75 +/- 29 in men after administration of sustained-release verapamil and 35 +/- 16 mL/min/kg in women compared with 65 +/- 31 in men after administration of regular-release verapamil (P < .05 for sex-related effect and P < .02 for formulation effect).,Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11014410/),[ml] / [kg·min],43,180214,DB00661,Verapamil
,11014410,Apparent oral clearance,Apparent oral clearance was 43 +/- 15 mL/min/kg in women compared with 75 +/- 29 in men after administration of sustained-release verapamil and 35 +/- 16 mL/min/kg in women compared with 65 +/- 31 in men after administration of regular-release verapamil (P < .05 for sex-related effect and P < .02 for formulation effect).,Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11014410/),[ml] / [kg·min],75,180215,DB00661,Verapamil
,11014410,Apparent oral clearance,Apparent oral clearance was 43 +/- 15 mL/min/kg in women compared with 75 +/- 29 in men after administration of sustained-release verapamil and 35 +/- 16 mL/min/kg in women compared with 65 +/- 31 in men after administration of regular-release verapamil (P < .05 for sex-related effect and P < .02 for formulation effect).,Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11014410/),[ml] / [kg·min],35,180216,DB00661,Verapamil
,11014410,Apparent oral clearance,Apparent oral clearance was 43 +/- 15 mL/min/kg in women compared with 75 +/- 29 in men after administration of sustained-release verapamil and 35 +/- 16 mL/min/kg in women compared with 65 +/- 31 in men after administration of regular-release verapamil (P < .05 for sex-related effect and P < .02 for formulation effect).,Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11014410/),,65,180217,DB00661,Verapamil
<,28173641,bioavailability,"However, its oral administration is impeded by very low bioavailability (<5%) due to the P-glycopprotein (P-gp) efflux pump effect.",Effects of Adamantyl Derivatives on Pharmacokinetic Behavior of Paclitaxel in Rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28173641/),%,5,180431,DB00661,Verapamil
,15175422,Rate of elimination (k(10)),"Rate of elimination (k(10)) for erythromycin and those with inhibitors was found to be similar (141 +/- 23 min), suggesting that elimination pathways were not altered.",Pharmacokinetics of erythromycin in rabbit corneas after single-dose infusion: role of P-glycoprotein as a barrier to in vivo ocular drug absorption. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15175422/),min,141,181611,DB00661,Verapamil
,8251610,Vdss,Verapamil was distributed to the extravascular tissues very rapidly as indicated by the large Vdss (2.99 +/- 0.57 l kg-1) and Vd beta (5.08 +/- 0.54 l kg-1).,Intravenous verapamil kinetics in rats: marked arteriovenous concentration difference and comparison with humans. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8251610/),[l] / [kg],2.99,182463,DB00661,Verapamil
,8251610,Vd beta,Verapamil was distributed to the extravascular tissues very rapidly as indicated by the large Vdss (2.99 +/- 0.57 l kg-1) and Vd beta (5.08 +/- 0.54 l kg-1).,Intravenous verapamil kinetics in rats: marked arteriovenous concentration difference and comparison with humans. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8251610/),[l] / [kg],5.08,182464,DB00661,Verapamil
,8251610,apparent terminal plasma T1/2,"The apparent terminal plasma T1/2, MRTiv, and CLp were 1.59 +/- 0.46, 1.26 +/- 0.12 h, and 40.4 +/- 9.73 ml min-1 kg-1, respectively.",Intravenous verapamil kinetics in rats: marked arteriovenous concentration difference and comparison with humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8251610/),h,1.59,182465,DB00661,Verapamil
,8251610,MRTiv,"The apparent terminal plasma T1/2, MRTiv, and CLp were 1.59 +/- 0.46, 1.26 +/- 0.12 h, and 40.4 +/- 9.73 ml min-1 kg-1, respectively.",Intravenous verapamil kinetics in rats: marked arteriovenous concentration difference and comparison with humans. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8251610/),h,1.26,182466,DB00661,Verapamil
,8251610,CLp,"The apparent terminal plasma T1/2, MRTiv, and CLp were 1.59 +/- 0.46, 1.26 +/- 0.12 h, and 40.4 +/- 9.73 ml min-1 kg-1, respectively.",Intravenous verapamil kinetics in rats: marked arteriovenous concentration difference and comparison with humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8251610/),[ml] / [kg·min],40.4,182467,DB00661,Verapamil
,8251610,blood to plasma,"The average blood to plasma and plasma to blood cell concentration ratios were 0.85 and 1.47, respectively.",Intravenous verapamil kinetics in rats: marked arteriovenous concentration difference and comparison with humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8251610/),,0.85,182468,DB00661,Verapamil
,8251610,plasma to blood cell concentration ratios,"The average blood to plasma and plasma to blood cell concentration ratios were 0.85 and 1.47, respectively.",Intravenous verapamil kinetics in rats: marked arteriovenous concentration difference and comparison with humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8251610/),,1.47,182469,DB00661,Verapamil
,8251610,hepatic extraction ratio,"In contrast to propranolol, blood data rather than plasma data should be used to predict the hepatic extraction ratio of verapamil (0.87).",Intravenous verapamil kinetics in rats: marked arteriovenous concentration difference and comparison with humans. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8251610/),,0.87,182470,DB00661,Verapamil
,8251610,plasma protein binding,The plasma protein binding of verapamil in humans (90%) and rats (95%) were quite similar and constant over the wide concentration range studied.,Intravenous verapamil kinetics in rats: marked arteriovenous concentration difference and comparison with humans. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8251610/),%,90,182471,DB00661,Verapamil
,8251610,plasma protein binding,The plasma protein binding of verapamil in humans (90%) and rats (95%) were quite similar and constant over the wide concentration range studied.,Intravenous verapamil kinetics in rats: marked arteriovenous concentration difference and comparison with humans. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8251610/),%,95,182472,DB00661,Verapamil
,19552748,AUC(0-infinity),"During the control phase, the mean AUC(0-infinity) of S(-)- and R(+)-fexofenadine was 700 ng h(-1) ml(-1)[95% confidence interval (CI) 577, 823] and 1202 ng h(-1) ml(-1) (95% CI 1007, 1396), respectively, with a significant difference (P < 0.001).",Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19552748/),[ng] / [h·ml],700,182565,DB00661,Verapamil
,19552748,AUC(0-infinity),"During the control phase, the mean AUC(0-infinity) of S(-)- and R(+)-fexofenadine was 700 ng h(-1) ml(-1)[95% confidence interval (CI) 577, 823] and 1202 ng h(-1) ml(-1) (95% CI 1007, 1396), respectively, with a significant difference (P < 0.001).",Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19552748/),[ng] / [h·ml],1202,182566,DB00661,Verapamil
,19552748,R/S ratio,The R/S ratio for the AUC(0-infinity) was reduced from 1.76 to 1.32 (P < 0.001) by verapamil treatments.,Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19552748/),,1.76,182567,DB00661,Verapamil
,19552748,R/S ratio,The R/S ratio for the AUC(0-infinity) was reduced from 1.76 to 1.32 (P < 0.001) by verapamil treatments.,Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19552748/),,1.32,182568,DB00661,Verapamil
,1598834,flow rate,To increase life of the YWG-C18 column a mixture of methanol and 5 mmol.L-1 phosphate buffer (70:30 vol/vol) was selected as mobile phase with a flow rate of 0.8 ml.min-1.,[Determination of m-nifedipine and its pharmacokinetic study in rabbits by high-pressure liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1598834/),[ml] / [min],0.8,183331,DB00661,Verapamil
,1598834,recoveries,"The within-day and day-to-day precisions (CV) of this method were 4.5% and 7.0%, respectively, with recoveries of 95-102% (10-1000 ng.ml-1).",[Determination of m-nifedipine and its pharmacokinetic study in rabbits by high-pressure liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1598834/),%,95-102,183332,DB00661,Verapamil
,1598834,recoveries,"The within-day and day-to-day precisions (CV) of this method were 4.5% and 7.0%, respectively, with recoveries of 95-102% (10-1000 ng.ml-1).",[Determination of m-nifedipine and its pharmacokinetic study in rabbits by high-pressure liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1598834/),[ng] / [ml],10-1000,183333,DB00661,Verapamil
,1598834,Vc,"The parameters obtained were as follow: Vc 6.3 L.kg-1, Cl 0.021 L.kg-1.min-1, T1/2 alpha 30 min, T1/2 beta 230 min, AUC 102 micrograms.min.ml-1.",[Determination of m-nifedipine and its pharmacokinetic study in rabbits by high-pressure liquid chromatography]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1598834/),[l] / [kg],6.3,183334,DB00661,Verapamil
,1598834,Cl,"The parameters obtained were as follow: Vc 6.3 L.kg-1, Cl 0.021 L.kg-1.min-1, T1/2 alpha 30 min, T1/2 beta 230 min, AUC 102 micrograms.min.ml-1.",[Determination of m-nifedipine and its pharmacokinetic study in rabbits by high-pressure liquid chromatography]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1598834/),[l] / [kg·min],0.021,183335,DB00661,Verapamil
,1598834,T1/2 alpha,"The parameters obtained were as follow: Vc 6.3 L.kg-1, Cl 0.021 L.kg-1.min-1, T1/2 alpha 30 min, T1/2 beta 230 min, AUC 102 micrograms.min.ml-1.",[Determination of m-nifedipine and its pharmacokinetic study in rabbits by high-pressure liquid chromatography]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1598834/),min,30,183336,DB00661,Verapamil
,1598834,T1/2 beta,"The parameters obtained were as follow: Vc 6.3 L.kg-1, Cl 0.021 L.kg-1.min-1, T1/2 alpha 30 min, T1/2 beta 230 min, AUC 102 micrograms.min.ml-1.",[Determination of m-nifedipine and its pharmacokinetic study in rabbits by high-pressure liquid chromatography]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1598834/),min,230,183337,DB00661,Verapamil
,1598834,AUC,"The parameters obtained were as follow: Vc 6.3 L.kg-1, Cl 0.021 L.kg-1.min-1, T1/2 alpha 30 min, T1/2 beta 230 min, AUC 102 micrograms.min.ml-1.",[Determination of m-nifedipine and its pharmacokinetic study in rabbits by high-pressure liquid chromatography]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1598834/),[min·μg] / [ml],102,183338,DB00661,Verapamil
,10320950,peak plasma concentration (Cmax),"The mean peak plasma concentration (Cmax) is approximately 2.5 micrograms/L, and the time to reach the peak is under 1 hour.","Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),[μg] / [l],2.5,183615,DB00661,Verapamil
under,10320950,time to reach the peak,"The mean peak plasma concentration (Cmax) is approximately 2.5 micrograms/L, and the time to reach the peak is under 1 hour.","Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),h,1,183616,DB00661,Verapamil
,10320950,absolute bioavailability,The absolute bioavailability of buspirone is approximately 4%.,"Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),%,4,183617,DB00661,Verapamil
,10320950,volume of distribution,"Buspirone has a volume of distribution of 5.3 L/kg, a systemic clearance of about 1.7 L/h/kg, an elimination half-life of about 2.5 hours and the pharmacokinetics are linear over the dose range 10 to 40 mg.","Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),[l] / [kg],5.3,183618,DB00661,Verapamil
,10320950,systemic clearance,"Buspirone has a volume of distribution of 5.3 L/kg, a systemic clearance of about 1.7 L/h/kg, an elimination half-life of about 2.5 hours and the pharmacokinetics are linear over the dose range 10 to 40 mg.","Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),[l] / [h·kg],1.7,183619,DB00661,Verapamil
,10320950,elimination half-life,"Buspirone has a volume of distribution of 5.3 L/kg, a systemic clearance of about 1.7 L/h/kg, an elimination half-life of about 2.5 hours and the pharmacokinetics are linear over the dose range 10 to 40 mg.","Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320950/),h,2.5,183620,DB00661,Verapamil
,12593761,biliary clearance,"The biliary clearance in AA rats was significantly lower than that in normal rats (1.186 versus 5.621 ml min(-1) kg(-1)), and lower intrinsic biliary clearance was also observed in AA rats (40.33 versus 69.83 ml min(-1) kg(-1)).",Differences in pharmacokinetics and hepatobiliary transport of a novel anti-inflammatory agent between normal and adjuvant arthritis rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593761/),[ml] / [kg·min],1.186,183706,DB00661,Verapamil
,12593761,biliary clearance,"The biliary clearance in AA rats was significantly lower than that in normal rats (1.186 versus 5.621 ml min(-1) kg(-1)), and lower intrinsic biliary clearance was also observed in AA rats (40.33 versus 69.83 ml min(-1) kg(-1)).",Differences in pharmacokinetics and hepatobiliary transport of a novel anti-inflammatory agent between normal and adjuvant arthritis rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593761/),[ml] / [kg·min],5.621,183707,DB00661,Verapamil
,12593761,intrinsic biliary clearance,"The biliary clearance in AA rats was significantly lower than that in normal rats (1.186 versus 5.621 ml min(-1) kg(-1)), and lower intrinsic biliary clearance was also observed in AA rats (40.33 versus 69.83 ml min(-1) kg(-1)).",Differences in pharmacokinetics and hepatobiliary transport of a novel anti-inflammatory agent between normal and adjuvant arthritis rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593761/),[ml] / [kg·min],40.33,183708,DB00661,Verapamil
,12593761,intrinsic biliary clearance,"The biliary clearance in AA rats was significantly lower than that in normal rats (1.186 versus 5.621 ml min(-1) kg(-1)), and lower intrinsic biliary clearance was also observed in AA rats (40.33 versus 69.83 ml min(-1) kg(-1)).",Differences in pharmacokinetics and hepatobiliary transport of a novel anti-inflammatory agent between normal and adjuvant arthritis rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12593761/),[ml] / [kg·min],69.83,183709,DB00661,Verapamil
,22677487,resolution factors,"Separation was achieved on a Chiralcel OD-RH (150 × 4.6 mm, 5 µm) analytical column with resolution factors of 1.4 and 1.9 for (R)- and (S)-enantiomers of verapamil and norverapamil, respectively.","Enantiomeric separation of verapamil and its active metabolite, norverapamil, and simultaneous quantification in human plasma by LC-ESI-MS-MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22677487/),,1.4,183928,DB00661,Verapamil
,22677487,resolution factors,"Separation was achieved on a Chiralcel OD-RH (150 × 4.6 mm, 5 µm) analytical column with resolution factors of 1.4 and 1.9 for (R)- and (S)-enantiomers of verapamil and norverapamil, respectively.","Enantiomeric separation of verapamil and its active metabolite, norverapamil, and simultaneous quantification in human plasma by LC-ESI-MS-MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22677487/),,1.9,183929,DB00661,Verapamil
,22677487,capacity factors,"A mobile phase consisting of 0.05% trifluoroacetic acid in water-acetonitrile (70:30, v/v) afforded capacity factors of 2.45, 3.05, 2.27 and 3.13 for (R)- and (S)-enantiomers of verapamil and norverapamil, respectively.","Enantiomeric separation of verapamil and its active metabolite, norverapamil, and simultaneous quantification in human plasma by LC-ESI-MS-MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22677487/),,2.45,183930,DB00661,Verapamil
,22677487,capacity factors,"A mobile phase consisting of 0.05% trifluoroacetic acid in water-acetonitrile (70:30, v/v) afforded capacity factors of 2.45, 3.05, 2.27 and 3.13 for (R)- and (S)-enantiomers of verapamil and norverapamil, respectively.","Enantiomeric separation of verapamil and its active metabolite, norverapamil, and simultaneous quantification in human plasma by LC-ESI-MS-MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22677487/),,3.05,183931,DB00661,Verapamil
,22677487,capacity factors,"A mobile phase consisting of 0.05% trifluoroacetic acid in water-acetonitrile (70:30, v/v) afforded capacity factors of 2.45, 3.05, 2.27 and 3.13 for (R)- and (S)-enantiomers of verapamil and norverapamil, respectively.","Enantiomeric separation of verapamil and its active metabolite, norverapamil, and simultaneous quantification in human plasma by LC-ESI-MS-MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22677487/),,2.27,183932,DB00661,Verapamil
,22677487,capacity factors,"A mobile phase consisting of 0.05% trifluoroacetic acid in water-acetonitrile (70:30, v/v) afforded capacity factors of 2.45, 3.05, 2.27 and 3.13 for (R)- and (S)-enantiomers of verapamil and norverapamil, respectively.","Enantiomeric separation of verapamil and its active metabolite, norverapamil, and simultaneous quantification in human plasma by LC-ESI-MS-MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22677487/),,3.13,183933,DB00661,Verapamil
,22677487,Absolute recovery,Absolute recovery for the analytes ranged from 91.1 to 108.1%.,"Enantiomeric separation of verapamil and its active metabolite, norverapamil, and simultaneous quantification in human plasma by LC-ESI-MS-MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22677487/),%,91.1 to 108.1,183934,DB00661,Verapamil
,24028617,bioavailability,"The bioavailability of VOG after intraportal, intestinal as well as gastric administration was 45.1%, 8.1% and 9.8%, respectively.",Hepatic and gastrointestinal first-pass effects of vitexin-4″-O-glucoside in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24028617/),%,45.1,184617,DB00661,Verapamil
,24028617,bioavailability,"The bioavailability of VOG after intraportal, intestinal as well as gastric administration was 45.1%, 8.1% and 9.8%, respectively.",Hepatic and gastrointestinal first-pass effects of vitexin-4″-O-glucoside in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24028617/),%,8.1,184618,DB00661,Verapamil
,24028617,bioavailability,"The bioavailability of VOG after intraportal, intestinal as well as gastric administration was 45.1%, 8.1% and 9.8%, respectively.",Hepatic and gastrointestinal first-pass effects of vitexin-4″-O-glucoside in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24028617/),%,9.8,184619,DB00661,Verapamil
,16415090,pseudo steady-state C,"Under isoflurane anesthesia, male Sprague-Dawley rats were administered i.v. CsA to achieve pseudo steady-state CsA blood concentrations ranging from 0 to approximately 12 microM.","Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415090/),μM,0 to,185380,DB00661,Verapamil
,16415090,blood concentrations,"Under isoflurane anesthesia, male Sprague-Dawley rats were administered i.v. CsA to achieve pseudo steady-state CsA blood concentrations ranging from 0 to approximately 12 microM.","Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415090/),μM,0 to,185381,DB00661,Verapamil
,16415090,E(max),"The percentage increase in the brain/blood (3)H radioactivity (relative to 0 microM CsA) was described by the Hill equation with E(max), 1290%; EC(50), 7.2 microM; and gamma, 3.8.","Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415090/),%,1290,185382,DB00661,Verapamil
,16415090,EC(50),"The percentage increase in the brain/blood (3)H radioactivity (relative to 0 microM CsA) was described by the Hill equation with E(max), 1290%; EC(50), 7.2 microM; and gamma, 3.8.","Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415090/),μM,7.2,185383,DB00661,Verapamil
,16415090,gamma,"The percentage increase in the brain/blood (3)H radioactivity (relative to 0 microM CsA) was described by the Hill equation with E(max), 1290%; EC(50), 7.2 microM; and gamma, 3.8.","Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415090/),,3.8,185384,DB00661,Verapamil
,17443134,oral clearance,There was a significantly higher oral clearance of R-verapamil (165.1+/-86.4 versus 91.2+/-36.5 l/h; P=0.009) and S-verapamil (919.4+/-517.4 versus 460.2+/-239.7 l/h; P=0.01) in CYP3A5 expressers compared to nonexpressers.,Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17443134/),[l] / [h],165.1,185656,DB00661,Verapamil
,17443134,oral clearance,There was a significantly higher oral clearance of R-verapamil (165.1+/-86.4 versus 91.2+/-36.5 l/h; P=0.009) and S-verapamil (919.4+/-517.4 versus 460.2+/-239.7 l/h; P=0.01) in CYP3A5 expressers compared to nonexpressers.,Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17443134/),[l] / [h],91.2,185657,DB00661,Verapamil
,17443134,oral clearance,There was a significantly higher oral clearance of R-verapamil (165.1+/-86.4 versus 91.2+/-36.5 l/h; P=0.009) and S-verapamil (919.4+/-517.4 versus 460.2+/-239.7 l/h; P=0.01) in CYP3A5 expressers compared to nonexpressers.,Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17443134/),[l] / [h],919.4,185658,DB00661,Verapamil
,17443134,oral clearance,There was a significantly higher oral clearance of R-verapamil (165.1+/-86.4 versus 91.2+/-36.5 l/h; P=0.009) and S-verapamil (919.4+/-517.4 versus 460.2+/-239.7 l/h; P=0.01) in CYP3A5 expressers compared to nonexpressers.,Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17443134/),[l] / [h],460.2,185659,DB00661,Verapamil
,8009573,Oral clearances,"Oral clearances for L-propranolol for Phases A, B, and C were 198 +/- 70, 156 +/- 76, and 143 +/- 85 L/h, respectively.",Evaluation of dosage-release formulations on inhibition of drug clearance: effect of sustained- and immediate-release verapamil on propranolol pharmacokinetic parameters. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8009573/),[l] / [h],198,185922,DB00661,Verapamil
,8009573,Oral clearances,"Oral clearances for L-propranolol for Phases A, B, and C were 198 +/- 70, 156 +/- 76, and 143 +/- 85 L/h, respectively.",Evaluation of dosage-release formulations on inhibition of drug clearance: effect of sustained- and immediate-release verapamil on propranolol pharmacokinetic parameters. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8009573/),[l] / [h],156,185923,DB00661,Verapamil
,8009573,Oral clearances,"Oral clearances for L-propranolol for Phases A, B, and C were 198 +/- 70, 156 +/- 76, and 143 +/- 85 L/h, respectively.",Evaluation of dosage-release formulations on inhibition of drug clearance: effect of sustained- and immediate-release verapamil on propranolol pharmacokinetic parameters. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8009573/),[l] / [h],143,185924,DB00661,Verapamil
,8009573,Oral clearances,"Oral clearances for D-propranolol for Phases A, B, and C were 203 +/- 96, 172 +/- 96, and 152 +/- 102 L/h, respectively.",Evaluation of dosage-release formulations on inhibition of drug clearance: effect of sustained- and immediate-release verapamil on propranolol pharmacokinetic parameters. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8009573/),[l] / [h],203,185925,DB00661,Verapamil
,8009573,Oral clearances,"Oral clearances for D-propranolol for Phases A, B, and C were 203 +/- 96, 172 +/- 96, and 152 +/- 102 L/h, respectively.",Evaluation of dosage-release formulations on inhibition of drug clearance: effect of sustained- and immediate-release verapamil on propranolol pharmacokinetic parameters. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8009573/),[l] / [h],172,185926,DB00661,Verapamil
,8009573,Oral clearances,"Oral clearances for D-propranolol for Phases A, B, and C were 203 +/- 96, 172 +/- 96, and 152 +/- 102 L/h, respectively.",Evaluation of dosage-release formulations on inhibition of drug clearance: effect of sustained- and immediate-release verapamil on propranolol pharmacokinetic parameters. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8009573/),[l] / [h],152,185927,DB00661,Verapamil
,23262165,absolute bioavailability,Thiolated formulations provided an absolute bioavailability of 0.89%.,Development and in vivo evaluation of an oral vitamin B12 delivery system. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23262165/),%,0.89,187920,DB00661,Verapamil
,6500748,plasma half-life,"The results of plasma half-life of the drug, calculated in a dose interval, were 3.14 hr and 2.10 hr, respectively.","Use of oral verapamil in long-term treatment of neonatal, paroxysmal supraventricular tachycardia. A pharmacokinetic study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6500748/),h,3.14,188873,DB00661,Verapamil
,6500748,plasma half-life,"The results of plasma half-life of the drug, calculated in a dose interval, were 3.14 hr and 2.10 hr, respectively.","Use of oral verapamil in long-term treatment of neonatal, paroxysmal supraventricular tachycardia. A pharmacokinetic study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6500748/),h,2.10,188874,DB00661,Verapamil
,3542336,bioavailabilities,"Therefore, their bioavailabilities (diltiazem 40 to 50%; nifedipine 40 to 50%; verapamil 10 to 30%) are low despite almost complete absorption following oral administration.","Clinical pharmacokinetics of verapamil, nifedipine and diltiazem. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3542336/),%,40 to 50,190352,DB00661,Verapamil
,3542336,bioavailabilities,"Therefore, their bioavailabilities (diltiazem 40 to 50%; nifedipine 40 to 50%; verapamil 10 to 30%) are low despite almost complete absorption following oral administration.","Clinical pharmacokinetics of verapamil, nifedipine and diltiazem. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3542336/),%,10 to 30,190353,DB00661,Verapamil
,1990794,time to maximal prolongation,"Calcium had no significant affect on verapamil-induced PR prolongation (maximum percent change in PR interval: phase I = 19 +/- 11%, phase III = 18 +/- 7%; time to maximal prolongation: phase I = 0.38 +/- 0.21 hours, phase III = 0.37 +/- 0.26 hours; and area under the percent change in PR vs time curve: phase I = 15.5 +/- 10, phase III = 21 +/- 9).",Evaluation of the pharmacokinetics and electrocardiographic effects of intravenous verapamil with intravenous calcium chloride pretreatment in normal subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1990794/),h,0.38,190538,DB00661,Verapamil
,1990794,time to maximal prolongation,"Calcium had no significant affect on verapamil-induced PR prolongation (maximum percent change in PR interval: phase I = 19 +/- 11%, phase III = 18 +/- 7%; time to maximal prolongation: phase I = 0.38 +/- 0.21 hours, phase III = 0.37 +/- 0.26 hours; and area under the percent change in PR vs time curve: phase I = 15.5 +/- 10, phase III = 21 +/- 9).",Evaluation of the pharmacokinetics and electrocardiographic effects of intravenous verapamil with intravenous calcium chloride pretreatment in normal subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1990794/),h,0.37,190539,DB00661,Verapamil
,1990794,area under the percent change in PR vs time curve,"Calcium had no significant affect on verapamil-induced PR prolongation (maximum percent change in PR interval: phase I = 19 +/- 11%, phase III = 18 +/- 7%; time to maximal prolongation: phase I = 0.38 +/- 0.21 hours, phase III = 0.37 +/- 0.26 hours; and area under the percent change in PR vs time curve: phase I = 15.5 +/- 10, phase III = 21 +/- 9).",Evaluation of the pharmacokinetics and electrocardiographic effects of intravenous verapamil with intravenous calcium chloride pretreatment in normal subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1990794/),,15.5,190540,DB00661,Verapamil
,1990794,area under the percent change in PR vs time curve,"Calcium had no significant affect on verapamil-induced PR prolongation (maximum percent change in PR interval: phase I = 19 +/- 11%, phase III = 18 +/- 7%; time to maximal prolongation: phase I = 0.38 +/- 0.21 hours, phase III = 0.37 +/- 0.26 hours; and area under the percent change in PR vs time curve: phase I = 15.5 +/- 10, phase III = 21 +/- 9).",Evaluation of the pharmacokinetics and electrocardiographic effects of intravenous verapamil with intravenous calcium chloride pretreatment in normal subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1990794/),,21,190541,DB00661,Verapamil
,16783561,AUC(0-infinity),"In the control phase, the AUC(0-infinity) values for rabeprazole and rabeprazole thioether were 1,005+/-366 and 412+/-149 ng.h/ml in homozygous EMs, 1,108+/-340 and 491+/-245 ng.h/ml in heterozygous EMs, and 2,697+/-364 and 2,116+/-373 ng.h/ml in PMs, respectively.",Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16783561/),[h·ng] / [ml],"1,005",192578,DB00661,Verapamil
,16783561,AUC(0-infinity),"In the control phase, the AUC(0-infinity) values for rabeprazole and rabeprazole thioether were 1,005+/-366 and 412+/-149 ng.h/ml in homozygous EMs, 1,108+/-340 and 491+/-245 ng.h/ml in heterozygous EMs, and 2,697+/-364 and 2,116+/-373 ng.h/ml in PMs, respectively.",Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16783561/),[h·ng] / [ml],412,192579,DB00661,Verapamil
,16783561,AUC(0-infinity),"In the control phase, the AUC(0-infinity) values for rabeprazole and rabeprazole thioether were 1,005+/-366 and 412+/-149 ng.h/ml in homozygous EMs, 1,108+/-340 and 491+/-245 ng.h/ml in heterozygous EMs, and 2,697+/-364 and 2,116+/-373 ng.h/ml in PMs, respectively.",Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16783561/),[h·ng] / [ml],"1,108",192580,DB00661,Verapamil
,16783561,AUC(0-infinity),"In the control phase, the AUC(0-infinity) values for rabeprazole and rabeprazole thioether were 1,005+/-366 and 412+/-149 ng.h/ml in homozygous EMs, 1,108+/-340 and 491+/-245 ng.h/ml in heterozygous EMs, and 2,697+/-364 and 2,116+/-373 ng.h/ml in PMs, respectively.",Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16783561/),[h·ng] / [ml],491,192581,DB00661,Verapamil
,16783561,AUC(0-infinity),"In the control phase, the AUC(0-infinity) values for rabeprazole and rabeprazole thioether were 1,005+/-366 and 412+/-149 ng.h/ml in homozygous EMs, 1,108+/-340 and 491+/-245 ng.h/ml in heterozygous EMs, and 2,697+/-364 and 2,116+/-373 ng.h/ml in PMs, respectively.",Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16783561/),[h·ng] / [ml],"2,697",192582,DB00661,Verapamil
,16783561,AUC(0-infinity),"In the control phase, the AUC(0-infinity) values for rabeprazole and rabeprazole thioether were 1,005+/-366 and 412+/-149 ng.h/ml in homozygous EMs, 1,108+/-340 and 491+/-245 ng.h/ml in heterozygous EMs, and 2,697+/-364 and 2,116+/-373 ng.h/ml in PMs, respectively.",Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16783561/),[h·ng] / [ml],"2,116",192583,DB00661,Verapamil
,19564365,cellular-to-extracellular-concentration ratios,"CEM-101 reached cellular-to-extracellular-concentration ratios of about 350 within 24 h (versus approximately 20, 30, and 160 for telithromycin, clarithromycin, and azithromycin, respectively).","Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19564365/),,350,194896,DB00661,Verapamil
,19564365,cellular-to-extracellular-concentration ratios,"CEM-101 reached cellular-to-extracellular-concentration ratios of about 350 within 24 h (versus approximately 20, 30, and 160 for telithromycin, clarithromycin, and azithromycin, respectively).","Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19564365/),,20,194897,DB00661,Verapamil
,19564365,cellular-to-extracellular-concentration ratios,"CEM-101 reached cellular-to-extracellular-concentration ratios of about 350 within 24 h (versus approximately 20, 30, and 160 for telithromycin, clarithromycin, and azithromycin, respectively).","Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19564365/),,30,194898,DB00661,Verapamil
,19564365,cellular-to-extracellular-concentration ratios,"CEM-101 reached cellular-to-extracellular-concentration ratios of about 350 within 24 h (versus approximately 20, 30, and 160 for telithromycin, clarithromycin, and azithromycin, respectively).","Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19564365/),,160,194899,DB00661,Verapamil
,9296319,infusion rate (ko),"After a loading dose (0.15 mg kg-1 followed by 12 h continuous i.v. infusion at 0.20 mg kg-1 h-1), the infusion rate (ko) of verapamil was increased every 24 h (0.25, 0.30, 0.35, and 0.40 mg kg-1 h-1).",Non-linear pharmacokinetics of high-dose intravenous verapamil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9296319/),[mg] / [h·kg],0.,195826,DB00661,Verapamil
,9296319,infusion rate (ko),"After a loading dose (0.15 mg kg-1 followed by 12 h continuous i.v. infusion at 0.20 mg kg-1 h-1), the infusion rate (ko) of verapamil was increased every 24 h (0.25, 0.30, 0.35, and 0.40 mg kg-1 h-1).",Non-linear pharmacokinetics of high-dose intravenous verapamil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9296319/),[mg] / [h·kg],0,195827,DB00661,Verapamil
,9296319,CL,"CL was dose-dependent and in all nine patients a significant reduction in CL was observed over the dose range (mean CL +/- s.d. were 0.51 +/- 0.31, 0.38 +/- 0.16, 0.32 +/- 0.18, and 0.27 +/- 0.11 l h-1 kg-1, respectively, at 0.25, 0.30, 0.35, and 0.40 mg kg-1 h-1; P = 0.0001).",Non-linear pharmacokinetics of high-dose intravenous verapamil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9296319/),[l] / [h],0.51,195828,DB00661,Verapamil
,9296319,CL,"CL was dose-dependent and in all nine patients a significant reduction in CL was observed over the dose range (mean CL +/- s.d. were 0.51 +/- 0.31, 0.38 +/- 0.16, 0.32 +/- 0.18, and 0.27 +/- 0.11 l h-1 kg-1, respectively, at 0.25, 0.30, 0.35, and 0.40 mg kg-1 h-1; P = 0.0001).",Non-linear pharmacokinetics of high-dose intravenous verapamil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9296319/),[l] / [h],0.38,195829,DB00661,Verapamil
,9296319,CL,"CL was dose-dependent and in all nine patients a significant reduction in CL was observed over the dose range (mean CL +/- s.d. were 0.51 +/- 0.31, 0.38 +/- 0.16, 0.32 +/- 0.18, and 0.27 +/- 0.11 l h-1 kg-1, respectively, at 0.25, 0.30, 0.35, and 0.40 mg kg-1 h-1; P = 0.0001).",Non-linear pharmacokinetics of high-dose intravenous verapamil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9296319/),[l] / [h],0.32,195830,DB00661,Verapamil
,9296319,CL,"CL was dose-dependent and in all nine patients a significant reduction in CL was observed over the dose range (mean CL +/- s.d. were 0.51 +/- 0.31, 0.38 +/- 0.16, 0.32 +/- 0.18, and 0.27 +/- 0.11 l h-1 kg-1, respectively, at 0.25, 0.30, 0.35, and 0.40 mg kg-1 h-1; P = 0.0001).",Non-linear pharmacokinetics of high-dose intravenous verapamil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9296319/),[l] / [h],0.27,195831,DB00661,Verapamil
,9296319,K(m),"Css increased more than proportionally to the dose rate and the Css vs rate relationship was best defined by a Michaelis-Menten equation (K(m) = 730 micrograms l-1; V.Vm = 0.55 mg kg-1 h-1), (r = 0.994; P = 0.006).",Non-linear pharmacokinetics of high-dose intravenous verapamil. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9296319/),[μg] / [l],730,195832,DB00661,Verapamil
,9296319,V.Vm,"Css increased more than proportionally to the dose rate and the Css vs rate relationship was best defined by a Michaelis-Menten equation (K(m) = 730 micrograms l-1; V.Vm = 0.55 mg kg-1 h-1), (r = 0.994; P = 0.006).",Non-linear pharmacokinetics of high-dose intravenous verapamil. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9296319/),[mg] / [h·kg],0.55,195833,DB00661,Verapamil
,6587753,biologic availability,"The mean biologic availability (22.8%) was in the same range as reported for normal persons, but individual variations would seem to be greater.",Pharmacokinetics of calcium blockers in patients with renal insufficiency and in geriatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6587753/),%,22.8,196157,DB00661,Verapamil
,6587753,biologic availability,The biologic availability in the elderly was higher than in younger persons with a mean value of 37.69% and a wide range from 9.16 to 82.76%.,Pharmacokinetics of calcium blockers in patients with renal insufficiency and in geriatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6587753/),%,37.69,196158,DB00661,Verapamil
,21336515,absorptive P (app),"The absorptive P (app) were 7.15, 6.39 and 10.03 × 10(-6) cm s(-1), respectively, for different concentrations (2.2, 4.8 and 8.4 μg ml(-1)) in Caco-2 cells.",Assessment and modulation of phillyrin absorption by P-gp using Caco-2 cells and MDR1-MDCKII cells. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21336515/),[cm] / [s],7.15,196667,DB00661,Verapamil
,21336515,absorptive P (app),"The absorptive P (app) were 7.15, 6.39 and 10.03 × 10(-6) cm s(-1), respectively, for different concentrations (2.2, 4.8 and 8.4 μg ml(-1)) in Caco-2 cells.",Assessment and modulation of phillyrin absorption by P-gp using Caco-2 cells and MDR1-MDCKII cells. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21336515/),[cm] / [s],6.39,196668,DB00661,Verapamil
,21336515,absorptive P (app),"The absorptive P (app) were 7.15, 6.39 and 10.03 × 10(-6) cm s(-1), respectively, for different concentrations (2.2, 4.8 and 8.4 μg ml(-1)) in Caco-2 cells.",Assessment and modulation of phillyrin absorption by P-gp using Caco-2 cells and MDR1-MDCKII cells. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21336515/),[cm] / [s],10.03 × 10(-6),196669,DB00661,Verapamil
lower,31505985,bioavailability,Lovastatin shows low bioavailability (lower than 5%) after oral administration because of the poor aqueous solubility and widely metabolized by CYP3A4.,The characteristics and mechanism of co-administration of lovastatin solid dispersion with kaempferol to increase oral bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31505985/),%,5,197251,DB00661,Verapamil
up to,31505985,absolute bioavailability,"The oral bioavailability of lovastatin and lovastatin acid after oral administration of lovastatin solid dispersion with 10 mg/kg kaempferol (CYP3A4 inhibitor) were increased about 3.79-fold and 2.51-fold than that of lovastatin suspension, and the absolute bioavailability of lovastatin was up to 33.0%.",The characteristics and mechanism of co-administration of lovastatin solid dispersion with kaempferol to increase oral bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31505985/),%,33.0,197252,DB00661,Verapamil
,31230510,peak plasma concentration,"The results showed that puerarin could significantly increase the peak plasma concentration (from 187.25 ± 15.36 to 219.67 ± 21.52 ng/mL), and decrease its oral clearance (from 4.92 ± 0.35 to 62.46 ± 3.75 ± 0.19 L/h/kg).",Effects of puerarin on the pharmacokinetics of triptolide in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31230510/),[ng] / [ml],187.25,197605,DB00661,Verapamil
,31230510,peak plasma concentration,"The results showed that puerarin could significantly increase the peak plasma concentration (from 187.25 ± 15.36 to 219.67 ± 21.52 ng/mL), and decrease its oral clearance (from 4.92 ± 0.35 to 62.46 ± 3.75 ± 0.19 L/h/kg).",Effects of puerarin on the pharmacokinetics of triptolide in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31230510/),[ng] / [ml],219.67,197606,DB00661,Verapamil
,31230510,oral clearance,"The results showed that puerarin could significantly increase the peak plasma concentration (from 187.25 ± 15.36 to 219.67 ± 21.52 ng/mL), and decrease its oral clearance (from 4.92 ± 0.35 to 62.46 ± 3.75 ± 0.19 L/h/kg).",Effects of puerarin on the pharmacokinetics of triptolide in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31230510/),[l] / [h·kg],4.92,197607,DB00661,Verapamil
,31230510,oral clearance,"The results showed that puerarin could significantly increase the peak plasma concentration (from 187.25 ± 15.36 to 219.67 ± 21.52 ng/mL), and decrease its oral clearance (from 4.92 ± 0.35 to 62.46 ± 3.75 ± 0.19 L/h/kg).",Effects of puerarin on the pharmacokinetics of triptolide in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31230510/),[l] / [h·kg],62.46,197608,DB00661,Verapamil
,31230510,efflux ratio,"The Caco-2 cell transwell experiments indicated that puerarin could decrease the efflux ratio of triptolide from 2.70 to 1.33, and the intrinsic clearance rate of triptolide was decreased by the pretreatment with puerarin (38.8 ± 4.7 vs. 32.9 ± 6.5 μL/min/mg protein).",Effects of puerarin on the pharmacokinetics of triptolide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31230510/),,2.70,197609,DB00661,Verapamil
,31230510,efflux ratio,"The Caco-2 cell transwell experiments indicated that puerarin could decrease the efflux ratio of triptolide from 2.70 to 1.33, and the intrinsic clearance rate of triptolide was decreased by the pretreatment with puerarin (38.8 ± 4.7 vs. 32.9 ± 6.5 μL/min/mg protein).",Effects of puerarin on the pharmacokinetics of triptolide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31230510/),,1.33,197610,DB00661,Verapamil
,31230510,intrinsic clearance rate,"The Caco-2 cell transwell experiments indicated that puerarin could decrease the efflux ratio of triptolide from 2.70 to 1.33, and the intrinsic clearance rate of triptolide was decreased by the pretreatment with puerarin (38.8 ± 4.7 vs. 32.9 ± 6.5 μL/min/mg protein).",Effects of puerarin on the pharmacokinetics of triptolide in rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31230510/),[μl] / [mg·min],38.8,197611,DB00661,Verapamil
,31230510,intrinsic clearance rate,"The Caco-2 cell transwell experiments indicated that puerarin could decrease the efflux ratio of triptolide from 2.70 to 1.33, and the intrinsic clearance rate of triptolide was decreased by the pretreatment with puerarin (38.8 ± 4.7 vs. 32.9 ± 6.5 μL/min/mg protein).",Effects of puerarin on the pharmacokinetics of triptolide in rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31230510/),[μl] / [mg·min],32.9,197612,DB00661,Verapamil
,33049584,bioavailability,The bioavailability was 8.676 %.,Studies on pharmacokinetic properties and absorption mechanism of phloretin: In vivo and in vitro. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33049584/),%,8.676,198449,DB00661,Verapamil
,2730689,flow rate,"The analytes were extracted from serum using diethylether under alkaline conditions, followed by back extraction into dilute hydrochlorid acid for chromatographic analysis on a reversed-phase column with a mobile phase consisting of acetonitrile, water and perchloric acid at a flow rate of 1 l/min.",Quantitative determination of verapamil and metabolites in human serum by high-performance liquid chromatography and its application to biopharmaceutic investigations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2730689/),[l] / [min],1,198641,DB00661,Verapamil
,24927684,critical micelle concentration,"CQ conjugate had low critical micelle concentration (55.14 μg/mL), and could self assemble in aqueous condition to form polymeric micelles (PMs).",Amphiphilic carboxymethyl chitosan-quercetin conjugate with P-gp inhibitory properties for oral delivery of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24927684/),[μg] / [ml],55.14,198715,DB00661,Verapamil
,24927684,polydispersity index (PDI),PTX-loaded CQ PMs displayed a particle size of 185.8 ± 4.6 nm and polydispersity index (PDI) of 0.134 ± 0.056.,Amphiphilic carboxymethyl chitosan-quercetin conjugate with P-gp inhibitory properties for oral delivery of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24927684/),,0.134,198716,DB00661,Verapamil
,24927684,drug-loading content (DL),"The drug-loading content (DL) and entrapment efficiency (EE) were 33.62 ± 1.34% and 85.63 ± 1.26%, respectively.",Amphiphilic carboxymethyl chitosan-quercetin conjugate with P-gp inhibitory properties for oral delivery of paclitaxel. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24927684/),%,33.62,198717,DB00661,Verapamil
,24927684,entrapment efficiency (EE),"The drug-loading content (DL) and entrapment efficiency (EE) were 33.62 ± 1.34% and 85.63 ± 1.26%, respectively.",Amphiphilic carboxymethyl chitosan-quercetin conjugate with P-gp inhibitory properties for oral delivery of paclitaxel. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24927684/),%,85.63,198718,DB00661,Verapamil
,2054511,KS,"KS were 15 microM and 2150 microM, respectively.",[The effect of finoptin on the metabolism and pharmacological action of cyclophosphane in vivo and in vitro]. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2054511/),μM,15,200278,DB00661,Verapamil
,2054511,KS,"KS were 15 microM and 2150 microM, respectively.",[The effect of finoptin on the metabolism and pharmacological action of cyclophosphane in vivo and in vitro]. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2054511/),μM,2150,200279,DB00661,Verapamil
,2054511,LD50,LD50 was 388.0 +/- 13.9 mg/kg for CP and LD50 was 342.8 +/- 16.9 mg/kg for CP in combination with Ph.,[The effect of finoptin on the metabolism and pharmacological action of cyclophosphane in vivo and in vitro]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2054511/),[mg] / [kg],388.0,200280,DB00661,Verapamil
,2054511,LD50,LD50 was 388.0 +/- 13.9 mg/kg for CP and LD50 was 342.8 +/- 16.9 mg/kg for CP in combination with Ph.,[The effect of finoptin on the metabolism and pharmacological action of cyclophosphane in vivo and in vitro]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2054511/),[mg] / [kg],342.8,200281,DB00661,Verapamil
,15964599,area under curve,"On the other hand, verapamil treatments increased the area under curve of DM in the brain (from 1221 to 2393 ng h/g) and spinal cord (from 1753 to 3221 ng h/g) by approximately 2-fold.",Enhancing the uptake of dextromethorphan in the CNS of rats by concomitant administration of the P-gp inhibitor verapamil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15964599/),[h·ng] / [g],1221 to 2393,200289,DB00661,Verapamil
,15964599,area under curve,"On the other hand, verapamil treatments increased the area under curve of DM in the brain (from 1221 to 2393 ng h/g) and spinal cord (from 1753 to 3221 ng h/g) by approximately 2-fold.",Enhancing the uptake of dextromethorphan in the CNS of rats by concomitant administration of the P-gp inhibitor verapamil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15964599/),[h·ng] / [g],1753 to 3221,200290,DB00661,Verapamil
,16621934,E(H),"Fexofenadine had a low liver extraction (E(H); mean +/- S.E.M.), and the given doses of verapamil did not affect the E(H) (0.13 +/- 0.04, 0.16 +/- 0.03, and 0.12 +/- 0.02 for G1, G2, and G3, respectively) or biliary clearance.",First-pass effects of verapamil on the intestinal absorption and liver disposition of fexofenadine in the porcine model. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16621934/),,0.13,200647,DB00661,Verapamil
,16621934,E(H),"Fexofenadine had a low liver extraction (E(H); mean +/- S.E.M.), and the given doses of verapamil did not affect the E(H) (0.13 +/- 0.04, 0.16 +/- 0.03, and 0.12 +/- 0.02 for G1, G2, and G3, respectively) or biliary clearance.",First-pass effects of verapamil on the intestinal absorption and liver disposition of fexofenadine in the porcine model. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16621934/),,0.16,200648,DB00661,Verapamil
,16621934,E(H),"Fexofenadine had a low liver extraction (E(H); mean +/- S.E.M.), and the given doses of verapamil did not affect the E(H) (0.13 +/- 0.04, 0.16 +/- 0.03, and 0.12 +/- 0.02 for G1, G2, and G3, respectively) or biliary clearance.",First-pass effects of verapamil on the intestinal absorption and liver disposition of fexofenadine in the porcine model. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16621934/),,0.12,200649,DB00661,Verapamil
,7074765,Renal digoxin clearance,"Renal digoxin clearance decreased significantly (26.1 +/- 0.7 vs 55.1 +/- 12.3 ml/min, p less than 0.005) in six patients in whom serum digoxin concentration increased.",The influence of verapamil on serum digoxin concentration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7074765/),[ml] / [min],26.1,200987,DB00661,Verapamil
,7074765,Renal digoxin clearance,"Renal digoxin clearance decreased significantly (26.1 +/- 0.7 vs 55.1 +/- 12.3 ml/min, p less than 0.005) in six patients in whom serum digoxin concentration increased.",The influence of verapamil on serum digoxin concentration. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7074765/),[ml] / [min],55.1,200988,DB00661,Verapamil
,10671907,apparent oral clearances,The apparent oral clearances (R: 4.8 l min-1 (95% CI: 2.9-6.8); S: 5.5 l min-1 (95% CI: 2.5-8.5)) and half-lives (R: 6.2 h; S: 7.2 h) of R- and S-gallopamil were similar (P >0.05).,Pharmacokinetics and pharmacodynamics of R- and S-gallopamil during multiple dosing. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10671907/),[l] / [min],4.8,201010,DB00661,Verapamil
,10671907,apparent oral clearances,The apparent oral clearances (R: 4.8 l min-1 (95% CI: 2.9-6.8); S: 5.5 l min-1 (95% CI: 2.5-8.5)) and half-lives (R: 6.2 h; S: 7.2 h) of R- and S-gallopamil were similar (P >0.05).,Pharmacokinetics and pharmacodynamics of R- and S-gallopamil during multiple dosing. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10671907/),[l] / [min],5.5,201011,DB00661,Verapamil
,10671907,half-lives,The apparent oral clearances (R: 4.8 l min-1 (95% CI: 2.9-6.8); S: 5.5 l min-1 (95% CI: 2.5-8.5)) and half-lives (R: 6.2 h; S: 7.2 h) of R- and S-gallopamil were similar (P >0.05).,Pharmacokinetics and pharmacodynamics of R- and S-gallopamil during multiple dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10671907/),h,6.2,201012,DB00661,Verapamil
,10671907,half-lives,The apparent oral clearances (R: 4.8 l min-1 (95% CI: 2.9-6.8); S: 5.5 l min-1 (95% CI: 2.5-8.5)) and half-lives (R: 6.2 h; S: 7.2 h) of R- and S-gallopamil were similar (P >0.05).,Pharmacokinetics and pharmacodynamics of R- and S-gallopamil during multiple dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10671907/),h,7.2,201013,DB00661,Verapamil
,9550306,peak levels,"Following the instillation of 0.125% verapamil eye drops in a total dose of 125 microg RS-verapamil, mean (+/- SEM) aqueous humor peak levels of 1607 +/- 272 ng/ml were achieved after 20 min.",Ocular pharmacokinetics of verapamil in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9550306/),[ng] / [ml],1607,203891,DB00661,Verapamil
,9550306,half-life,Mean half-life for the elimination from the aqueous humor was 33 min.,Ocular pharmacokinetics of verapamil in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9550306/),min,33,203892,DB00661,Verapamil
,9550306,serum peak concentrations,Topical application of verapamil produced very low serum peak concentrations (10.5 +/- 1.3 ng/ml).,Ocular pharmacokinetics of verapamil in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9550306/),[ng] / [ml],10.5,203893,DB00661,Verapamil
,2338632,tmax,"Concomitant food administration significantly prolonged the tmax of SR-verapamil from 7.3 +/- 3.4 to 11.7 +/- 6.3 h, but had little effect on Cmax, t1/2, or AUC.",Influence of food on the bioavailability of a sustained-release verapamil preparation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338632/),h,7.3,204963,DB00661,Verapamil
,2338632,tmax,"Concomitant food administration significantly prolonged the tmax of SR-verapamil from 7.3 +/- 3.4 to 11.7 +/- 6.3 h, but had little effect on Cmax, t1/2, or AUC.",Influence of food on the bioavailability of a sustained-release verapamil preparation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2338632/),h,11.7,204964,DB00661,Verapamil
,22670860,peak concentration,Quercetin significantly increases the plasma concentration of valsartan and peak concentration (70.45 µg/mL) was achieved at 3.5 h.,Pharmacokinetic interaction study between quercetin and valsartan in rats and in vitro models. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22670860/),[μg] / [ml],70.45,205371,DB00661,Verapamil
,22670860,transport,The transport of valsartan from serosal side to mucosal side decreased from 53.12 ± 1.27 to 40.15 ± 0.45 µg/mL in the presence of quercetin and from 53.12 ± 1.27 to 28.68 ± 0.31 µg/mL in the presence of verapamil (standard P-glycoprotein (P-gp) inhibitor) at 120 min.,Pharmacokinetic interaction study between quercetin and valsartan in rats and in vitro models. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22670860/),[μg] / [ml],53.12,205372,DB00661,Verapamil
,22670860,transport,The transport of valsartan from serosal side to mucosal side decreased from 53.12 ± 1.27 to 40.15 ± 0.45 µg/mL in the presence of quercetin and from 53.12 ± 1.27 to 28.68 ± 0.31 µg/mL in the presence of verapamil (standard P-glycoprotein (P-gp) inhibitor) at 120 min.,Pharmacokinetic interaction study between quercetin and valsartan in rats and in vitro models. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22670860/),[μg] / [ml],40.15,205373,DB00661,Verapamil
,22670860,transport,The transport of valsartan from serosal side to mucosal side decreased from 53.12 ± 1.27 to 40.15 ± 0.45 µg/mL in the presence of quercetin and from 53.12 ± 1.27 to 28.68 ± 0.31 µg/mL in the presence of verapamil (standard P-glycoprotein (P-gp) inhibitor) at 120 min.,Pharmacokinetic interaction study between quercetin and valsartan in rats and in vitro models. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22670860/),[μg] / [ml],28.68,205374,DB00661,Verapamil
,2410676,clearances,"The mean (+/- SD) clearances of d- and dl-verapamil were 0.13 +/- 0.03 and 0.12 +/- 0.05 L/min/kg, respectively.",The pharmacokinetics and pharmacodynamics of d- and dl-verapamil in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2410676/),[l] / [kg·min],0.13,205900,DB00661,Verapamil
,2410676,clearances,"The mean (+/- SD) clearances of d- and dl-verapamil were 0.13 +/- 0.03 and 0.12 +/- 0.05 L/min/kg, respectively.",The pharmacokinetics and pharmacodynamics of d- and dl-verapamil in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2410676/),[l] / [kg·min],0.12,205901,DB00661,Verapamil
,2410676,steady-state volume of distribution,The mean (+/- SD) steady-state volume of distribution was 9.7 +/- 5.2 L/kg for d-verapamil and 8.1 +/- 4.1 L/kg for dl-verapamil.,The pharmacokinetics and pharmacodynamics of d- and dl-verapamil in rabbits. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2410676/),[l] / [kg],9.7,205902,DB00661,Verapamil
,2410676,steady-state volume of distribution,The mean (+/- SD) steady-state volume of distribution was 9.7 +/- 5.2 L/kg for d-verapamil and 8.1 +/- 4.1 L/kg for dl-verapamil.,The pharmacokinetics and pharmacodynamics of d- and dl-verapamil in rabbits. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2410676/),[l] / [kg],8.1,205903,DB00661,Verapamil
,2410676,half-life,The mean (+/- SD) half-life in plasma was 98.7 +/- 63.8 min for d-verapamil and 96.3 +/- 38.0 min for dl-verapamil.,The pharmacokinetics and pharmacodynamics of d- and dl-verapamil in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2410676/),min,98.7,205904,DB00661,Verapamil
,2410676,half-life,The mean (+/- SD) half-life in plasma was 98.7 +/- 63.8 min for d-verapamil and 96.3 +/- 38.0 min for dl-verapamil.,The pharmacokinetics and pharmacodynamics of d- and dl-verapamil in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2410676/),min,96.3,205905,DB00661,Verapamil
,23873286,IC50,"Prior to in vivo studies, ketoconazole and ritonavir were shown to inhibit midazolam hydroxylation with IC50 values of 350 ± 60 nm and 11 ± 3 nm, respectively, in rat liver microsomes (RLM).",Assessment of CYP3A-mediated drug-drug interaction potential for victim drugs using an in vivo rat model. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23873286/),nm,350,206834,DB00661,Verapamil
,23873286,IC50,"Prior to in vivo studies, ketoconazole and ritonavir were shown to inhibit midazolam hydroxylation with IC50 values of 350 ± 60 nm and 11 ± 3 nm, respectively, in rat liver microsomes (RLM).",Assessment of CYP3A-mediated drug-drug interaction potential for victim drugs using an in vivo rat model. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23873286/),nm,11,206835,DB00661,Verapamil
,12954187,intestinal clearance,"The intestinal clearance of ABZSO was 0.106+/-0.010 ml/min, exhibiting a stereoselective intestinal elimination to (-)ABZSO form.",Intestinal elimination of albendazole sulfoxide: pharmacokinetic effects of inhibitors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12954187/),[ml] / [min],0.106,208940,DB00661,Verapamil
,12954187,intestinal elimination,"Oxfendazole, ampicillin and cyclosporine significantly reduced the intestinal elimination of ABZSO to 0.079+/-0.008, 0.069+/-0.009 and 0.065+/-0.012 ml/min, respectively.",Intestinal elimination of albendazole sulfoxide: pharmacokinetic effects of inhibitors. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12954187/),[ml] / [min],0.079,208941,DB00661,Verapamil
,12954187,intestinal elimination,"Oxfendazole, ampicillin and cyclosporine significantly reduced the intestinal elimination of ABZSO to 0.079+/-0.008, 0.069+/-0.009 and 0.065+/-0.012 ml/min, respectively.",Intestinal elimination of albendazole sulfoxide: pharmacokinetic effects of inhibitors. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12954187/),[ml] / [min],0.069,208942,DB00661,Verapamil
,12954187,intestinal elimination,"Oxfendazole, ampicillin and cyclosporine significantly reduced the intestinal elimination of ABZSO to 0.079+/-0.008, 0.069+/-0.009 and 0.065+/-0.012 ml/min, respectively.",Intestinal elimination of albendazole sulfoxide: pharmacokinetic effects of inhibitors. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12954187/),[ml] / [min],0.065,208943,DB00661,Verapamil
,1709224,absolute bioavailability,The absolute bioavailability was 23% in both investigations for the 80 mg preparation and 32% in both investigations for the 240 mg dosage form.,Pharmacodynamic profile of verapamil in relation to absolute bioavailability: investigations with a conventional and a controlled-release formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1709224/),%,23,209925,DB00661,Verapamil
,1709224,absolute bioavailability,The absolute bioavailability was 23% in both investigations for the 80 mg preparation and 32% in both investigations for the 240 mg dosage form.,Pharmacodynamic profile of verapamil in relation to absolute bioavailability: investigations with a conventional and a controlled-release formulation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1709224/),%,32,209926,DB00661,Verapamil
,1709224,drug input rate,Estimation of the drug input rate showed significantly (p less than 0.05) smaller values when the controlled-release tablet was given (80 mg tablet: 95.1 and 107.7 mg/h; 240 mg tablet; 55.8 and 46.3 mg/h).,Pharmacodynamic profile of verapamil in relation to absolute bioavailability: investigations with a conventional and a controlled-release formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1709224/),[mg] / [h],95.1,209927,DB00661,Verapamil
,1709224,drug input rate,Estimation of the drug input rate showed significantly (p less than 0.05) smaller values when the controlled-release tablet was given (80 mg tablet: 95.1 and 107.7 mg/h; 240 mg tablet; 55.8 and 46.3 mg/h).,Pharmacodynamic profile of verapamil in relation to absolute bioavailability: investigations with a conventional and a controlled-release formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1709224/),[mg] / [h],107.7,209928,DB00661,Verapamil
,1709224,drug input rate,Estimation of the drug input rate showed significantly (p less than 0.05) smaller values when the controlled-release tablet was given (80 mg tablet: 95.1 and 107.7 mg/h; 240 mg tablet; 55.8 and 46.3 mg/h).,Pharmacodynamic profile of verapamil in relation to absolute bioavailability: investigations with a conventional and a controlled-release formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1709224/),[mg] / [h],55.8,209929,DB00661,Verapamil
,1709224,drug input rate,Estimation of the drug input rate showed significantly (p less than 0.05) smaller values when the controlled-release tablet was given (80 mg tablet: 95.1 and 107.7 mg/h; 240 mg tablet; 55.8 and 46.3 mg/h).,Pharmacodynamic profile of verapamil in relation to absolute bioavailability: investigations with a conventional and a controlled-release formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1709224/),[mg] / [h],46.3,209930,DB00661,Verapamil
,14586383,effective jejunal permeability,"The mean (+/-SD) effective jejunal permeability values were 0.06 +/- 0.07. 10(-4) cm/s and 0.04 +/- 0.07. 10(-4) cm/s in the control and treatment periods, respectively.",Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586383/),[cm] / [s],0.06,215145,DB00661,Verapamil
,14586383,effective jejunal permeability,"The mean (+/-SD) effective jejunal permeability values were 0.06 +/- 0.07. 10(-4) cm/s and 0.04 +/- 0.07. 10(-4) cm/s in the control and treatment periods, respectively.",Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586383/),[cm] / [s],0.04,215146,DB00661,Verapamil
,14586383,apparent absorption rate constant into the systemic circulation,"However, verapamil increased the apparent absorption rate constant into the systemic circulation and the area under the plasma concentration-time curve for fexofenadine from 0.0030 +/- 0.0012 min(-1) to 0.0255 +/- 0.0103 min(-1) (P <.001) and from 161 +/- 181 ng/mL x min to 664 +/- 537 ng/mL x min (P <.01), respectively.",Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586383/),1/[min],0.0030,215147,DB00661,Verapamil
,14586383,area under the plasma concentration-time curve,"However, verapamil increased the apparent absorption rate constant into the systemic circulation and the area under the plasma concentration-time curve for fexofenadine from 0.0030 +/- 0.0012 min(-1) to 0.0255 +/- 0.0103 min(-1) (P <.001) and from 161 +/- 181 ng/mL x min to 664 +/- 537 ng/mL x min (P <.01), respectively.",Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586383/),[ng] / [min·ml],161,215148,DB00661,Verapamil
,14586383,area under the plasma concentration-time curve,"However, verapamil increased the apparent absorption rate constant into the systemic circulation and the area under the plasma concentration-time curve for fexofenadine from 0.0030 +/- 0.0012 min(-1) to 0.0255 +/- 0.0103 min(-1) (P <.001) and from 161 +/- 181 ng/mL x min to 664 +/- 537 ng/mL x min (P <.01), respectively.",Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14586383/),[ng] / [min·ml],664,215149,DB00661,Verapamil
,7654488,apparent half-life,After an overdose of verapamil (2.4 g) in a 59-year-old man the apparent half-life of verapamil was prolonged (15 h).,Prolonged half-life of verapamil in a case of overdose: implications for therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654488/),h,15,215442,DB00661,Verapamil
,2888422,plasma concentrations,"In a first group of seven dogs, studied awake and during halothane (1.2%), enflurane (2.5%), and isoflurane anesthesia (1.6%), verapamil was infused for 30 min in doses calculated to obtain similar plasma concentrations (83 +/- 10, 82 +/- 6, 81 +/- 10, and 77 +/- 9 ng.ml-1, respectively).",Cardiovascular effects of and interaction between calcium blocking drugs and anesthetics in chronically instrumented dogs. V. Role of pharmacokinetics and the autonomic nervous system in the interactions between verapamil and inhalational anesthetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888422/),,83,215807,DB00661,Verapamil
,2888422,plasma concentrations,"In a first group of seven dogs, studied awake and during halothane (1.2%), enflurane (2.5%), and isoflurane anesthesia (1.6%), verapamil was infused for 30 min in doses calculated to obtain similar plasma concentrations (83 +/- 10, 82 +/- 6, 81 +/- 10, and 77 +/- 9 ng.ml-1, respectively).",Cardiovascular effects of and interaction between calcium blocking drugs and anesthetics in chronically instrumented dogs. V. Role of pharmacokinetics and the autonomic nervous system in the interactions between verapamil and inhalational anesthetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888422/),,82,215808,DB00661,Verapamil
,2888422,plasma concentrations,"In a first group of seven dogs, studied awake and during halothane (1.2%), enflurane (2.5%), and isoflurane anesthesia (1.6%), verapamil was infused for 30 min in doses calculated to obtain similar plasma concentrations (83 +/- 10, 82 +/- 6, 81 +/- 10, and 77 +/- 9 ng.ml-1, respectively).",Cardiovascular effects of and interaction between calcium blocking drugs and anesthetics in chronically instrumented dogs. V. Role of pharmacokinetics and the autonomic nervous system in the interactions between verapamil and inhalational anesthetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888422/),,81,215809,DB00661,Verapamil
,2888422,plasma concentrations,"In a first group of seven dogs, studied awake and during halothane (1.2%), enflurane (2.5%), and isoflurane anesthesia (1.6%), verapamil was infused for 30 min in doses calculated to obtain similar plasma concentrations (83 +/- 10, 82 +/- 6, 81 +/- 10, and 77 +/- 9 ng.ml-1, respectively).",Cardiovascular effects of and interaction between calcium blocking drugs and anesthetics in chronically instrumented dogs. V. Role of pharmacokinetics and the autonomic nervous system in the interactions between verapamil and inhalational anesthetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888422/),,77,215810,DB00661,Verapamil
,2888422,heart rate,"In awake dogs, verapamil induced an increase in heart rate (24 +/- 5 bpm) and PR interval (35 +/- 9 msec) and a decrease in mean arterial pressure (-5 +/- 2 mmHg) and dP/dt (-494 +/- 116 mmHg/s).",Cardiovascular effects of and interaction between calcium blocking drugs and anesthetics in chronically instrumented dogs. V. Role of pharmacokinetics and the autonomic nervous system in the interactions between verapamil and inhalational anesthetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888422/),bpm,24,215811,DB00661,Verapamil
,15918524,absolute bioavailability (F(A.B)),"The absolute bioavailability (F(A.B)) and the relative bioavailability (F(R.B)) of verapamil in the rabbits with hepatic failure were significantly higher (13.6-22.2% and 150-244%, respectively) than the control (9.1% and 100%, respectively).","Pharmacokinetics of verapamil and its major metabolite, norverapamil from oral administration of verapamil in rabbits with hepatic failure induced by carbon tetrachloride. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15918524/),%,13.6-22.2,217356,DB00661,Verapamil
,15918524,absolute bioavailability (F(A.B)),"The absolute bioavailability (F(A.B)) and the relative bioavailability (F(R.B)) of verapamil in the rabbits with hepatic failure were significantly higher (13.6-22.2% and 150-244%, respectively) than the control (9.1% and 100%, respectively).","Pharmacokinetics of verapamil and its major metabolite, norverapamil from oral administration of verapamil in rabbits with hepatic failure induced by carbon tetrachloride. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15918524/),%,9.1,217357,DB00661,Verapamil
,15918524,relative bioavailability (F(R.B)),"The absolute bioavailability (F(A.B)) and the relative bioavailability (F(R.B)) of verapamil in the rabbits with hepatic failure were significantly higher (13.6-22.2% and 150-244%, respectively) than the control (9.1% and 100%, respectively).","Pharmacokinetics of verapamil and its major metabolite, norverapamil from oral administration of verapamil in rabbits with hepatic failure induced by carbon tetrachloride. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15918524/),%,150-244,217358,DB00661,Verapamil
,15918524,relative bioavailability (F(R.B)),"The absolute bioavailability (F(A.B)) and the relative bioavailability (F(R.B)) of verapamil in the rabbits with hepatic failure were significantly higher (13.6-22.2% and 150-244%, respectively) than the control (9.1% and 100%, respectively).","Pharmacokinetics of verapamil and its major metabolite, norverapamil from oral administration of verapamil in rabbits with hepatic failure induced by carbon tetrachloride. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15918524/),%,9.1,217359,DB00661,Verapamil
,15918524,relative bioavailability (F(R.B)),"The absolute bioavailability (F(A.B)) and the relative bioavailability (F(R.B)) of verapamil in the rabbits with hepatic failure were significantly higher (13.6-22.2% and 150-244%, respectively) than the control (9.1% and 100%, respectively).","Pharmacokinetics of verapamil and its major metabolite, norverapamil from oral administration of verapamil in rabbits with hepatic failure induced by carbon tetrachloride. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15918524/),%,100,217360,DB00661,Verapamil
,3392664,total apparent oral clearance,"Mean total apparent oral clearance after a single dose of verapamil was increased after phenobarbital treatment (75.1 +/- 49.2 vs. 376.2 +/- 221.8 ml/min/kg, P less than .05).",Effects of chronic phenobarbital on verapamil disposition in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392664/),[ml] / [kg·min],75.1,217679,DB00661,Verapamil
,3392664,total apparent oral clearance,"Mean total apparent oral clearance after a single dose of verapamil was increased after phenobarbital treatment (75.1 +/- 49.2 vs. 376.2 +/- 221.8 ml/min/kg, P less than .05).",Effects of chronic phenobarbital on verapamil disposition in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392664/),[ml] / [kg·min],376.2,217680,DB00661,Verapamil
,3392664,systemic clearance,"Mean total verapamil systemic clearance was increased (9.95 +/- 1.3 vs. 18.9 +/- 8.7 ml/min/kg, P less than .05); however free drug clearance was not altered.",Effects of chronic phenobarbital on verapamil disposition in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392664/),[ml] / [kg·min],9.95,217681,DB00661,Verapamil
,3392664,systemic clearance,"Mean total verapamil systemic clearance was increased (9.95 +/- 1.3 vs. 18.9 +/- 8.7 ml/min/kg, P less than .05); however free drug clearance was not altered.",Effects of chronic phenobarbital on verapamil disposition in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392664/),[ml] / [kg·min],18.9,217682,DB00661,Verapamil
,3392664,apparent oral clearance,"After multiple oral administration, total verapamil apparent oral clearance was increased after phenobarbital pretreatment (21.2 +/- 9.8 vs. 91.2 +/- 28.5 ml/min/kg, P less than .05).",Effects of chronic phenobarbital on verapamil disposition in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392664/),[ml] / [kg·min],21.2,217683,DB00661,Verapamil
,3392664,apparent oral clearance,"After multiple oral administration, total verapamil apparent oral clearance was increased after phenobarbital pretreatment (21.2 +/- 9.8 vs. 91.2 +/- 28.5 ml/min/kg, P less than .05).",Effects of chronic phenobarbital on verapamil disposition in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392664/),[ml] / [kg·min],91.2,217684,DB00661,Verapamil
,6628501,total-body clearance,Verapamil decreased total-body clearance of digoxin from 4.68 +/- 0.41 to 3.29 +/- 0.26 ml/min/kg (p less than 0.001) and increased the plasma half-life of the drug from 33.50 +/- 2.38 to 41.31 +/- 2.27 h (p less than 0.01).,Influence of verapamil on the inotropism and pharmacokinetics of digoxin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628501/),[ml] / [kg·min],4.68,218037,DB00661,Verapamil
,6628501,total-body clearance,Verapamil decreased total-body clearance of digoxin from 4.68 +/- 0.41 to 3.29 +/- 0.26 ml/min/kg (p less than 0.001) and increased the plasma half-life of the drug from 33.50 +/- 2.38 to 41.31 +/- 2.27 h (p less than 0.01).,Influence of verapamil on the inotropism and pharmacokinetics of digoxin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628501/),[ml] / [kg·min],3.29,218038,DB00661,Verapamil
,6628501,plasma half-life,Verapamil decreased total-body clearance of digoxin from 4.68 +/- 0.41 to 3.29 +/- 0.26 ml/min/kg (p less than 0.001) and increased the plasma half-life of the drug from 33.50 +/- 2.38 to 41.31 +/- 2.27 h (p less than 0.01).,Influence of verapamil on the inotropism and pharmacokinetics of digoxin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628501/),h,33.50,218039,DB00661,Verapamil
,6628501,plasma half-life,Verapamil decreased total-body clearance of digoxin from 4.68 +/- 0.41 to 3.29 +/- 0.26 ml/min/kg (p less than 0.001) and increased the plasma half-life of the drug from 33.50 +/- 2.38 to 41.31 +/- 2.27 h (p less than 0.01).,Influence of verapamil on the inotropism and pharmacokinetics of digoxin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6628501/),h,41.31,218040,DB00661,Verapamil
,11214778,steady-state peak,"During the grapefruit juice period, the steady-state peak and trough concentrations of S-verapamil were moderately increased (peak 41+/-25 ng ml(-1) versus 26+/-13 ng ml(-1), trough 14+/-7 ng ml(-1) versus 12+/-6 ng ml(-1), P=0.08).",Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214778/),[ng] / [ml],41,218749,DB00661,Verapamil
,11214778,peak,"During the grapefruit juice period, the steady-state peak and trough concentrations of S-verapamil were moderately increased (peak 41+/-25 ng ml(-1) versus 26+/-13 ng ml(-1), trough 14+/-7 ng ml(-1) versus 12+/-6 ng ml(-1), P=0.08).",Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214778/),[ng] / [ml],41,218750,DB00661,Verapamil
,11214778,trough,"During the grapefruit juice period, the steady-state peak and trough concentrations of S-verapamil were moderately increased (peak 41+/-25 ng ml(-1) versus 26+/-13 ng ml(-1), trough 14+/-7 ng ml(-1) versus 12+/-6 ng ml(-1), P=0.08).",Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214778/),[ng] / [ml],14,218751,DB00661,Verapamil
,11214778,trough,"During the grapefruit juice period, the steady-state peak and trough concentrations of S-verapamil were moderately increased (peak 41+/-25 ng ml(-1) versus 26+/-13 ng ml(-1), trough 14+/-7 ng ml(-1) versus 12+/-6 ng ml(-1), P=0.08).",Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214778/),[ng] / [ml],12,218752,DB00661,Verapamil
,11214778,area under the plasma concentration-time curve during the 12-h dose interval (AUC0-12 h),"Grapefruit juice significantly increased the area under the plasma concentration-time curve during the 12-h dose interval (AUC0-12 h) of S-verapamil by 36% (292+/-146 ng h ml(-1) versus 215+/-102 ng h ml(-1), P=0.04).",Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214778/),[h·ng] / [ml],292,218753,DB00661,Verapamil
,11214778,area under the plasma concentration-time curve during the 12-h dose interval (AUC0-12 h),"Grapefruit juice significantly increased the area under the plasma concentration-time curve during the 12-h dose interval (AUC0-12 h) of S-verapamil by 36% (292+/-146 ng h ml(-1) versus 215+/-102 ng h ml(-1), P=0.04).",Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214778/),[h·ng] / [ml],215,218754,DB00661,Verapamil
,11214778,AUC0-12 h,"The AUC0-12 h of R-verapamil was increased by 28% (1022+/-412 ng h ml(-1) versus 800+/-316 ng h ml(-1), P=0.04).",Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214778/),[h·ng] / [ml],1022,218755,DB00661,Verapamil
,11214778,AUC0-12 h,"The AUC0-12 h of R-verapamil was increased by 28% (1022+/-412 ng h ml(-1) versus 800+/-316 ng h ml(-1), P=0.04).",Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214778/),[h·ng] / [ml],800,218756,DB00661,Verapamil
,23835420,transport,Morphine showed low transporter-independent membrane permeability (0.5 × 10⁻⁶ cm/s).,Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23835420/),[cm] / [s],0.5 × 10⁻⁶,218864,DB00661,Verapamil
,23835420,membrane permeability,Morphine showed low transporter-independent membrane permeability (0.5 × 10⁻⁶ cm/s).,Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23835420/),[cm] / [s],0.5 × 10⁻⁶,218865,DB00661,Verapamil
,23835420,KM,"The increase was concentration-dependent and followed Michaelis-Menten kinetics (KM = 3.4 μM, VMAX = 27 pmol/min/mg protein).",Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23835420/),μM,3.4,218866,DB00661,Verapamil
,23835420,VMAX,"The increase was concentration-dependent and followed Michaelis-Menten kinetics (KM = 3.4 μM, VMAX = 27 pmol/min/mg protein).",Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23835420/),[pM] / [mg·min],27,218867,DB00661,Verapamil
,23835420,transporter-independent,Codeine itself had high transporter-independent membrane permeability (8.2 × 10⁻⁶ cm/s).,Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23835420/),[cm] / [s],8.2 × 10⁻⁶,218868,DB00661,Verapamil
,23835420,membrane permeability,Codeine itself had high transporter-independent membrane permeability (8.2 × 10⁻⁶ cm/s).,Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23835420/),[cm] / [s],8.2 × 10⁻⁶,218869,DB00661,Verapamil
,6867470,apparent oral clearance,The mean apparent oral clearance of verapamil was highly variable with a mean of 21.9 +/- 9.1 ml/min/kg and a range of 7.7 to 32.0 ml/min/kg.,Pharmacokinetics of verapamil and norverapamil during long-term oral therapy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6867470/),[ml] / [kg·min],21.9,219952,DB00661,Verapamil
,6867470,ratio,"However, one patient with verapamil concentrations ranging from 300 to 900 ng/ml had a ratio of 1.37 suggesting saturation of the enzymes that convert verapamil to norverapamil.",Pharmacokinetics of verapamil and norverapamil during long-term oral therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6867470/),,1,219953,DB00661,Verapamil
,11304641,lag time,CODAS verapamil PM 200 mg dosed at night for 5 days results in a plasma profile with a lag time of approximately 4 hours suitable for nighttime dosing.,A steady-state evaluation of the bioavailability of chronotherapeutic oral drug absorption system verapamil PM after nighttime dosing versus immediate-acting verapamil dosed every eight hours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11304641/),h,4,220269,DB00661,Verapamil
,3330987,trough plasma concentrations,"Mean trough plasma concentrations of verapamil were 70 and 59 ng/ml at 2 and 4 weeks, respectively, after treatment with IR verapamil; the corresponding values were 70 and 94 ng/ml for the SR verapamil group.",Antihypertensive efficacy of sustained-release verapamil. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3330987/),[ng] / [ml],70,220909,DB00661,Verapamil
,3330987,trough plasma concentrations,"Mean trough plasma concentrations of verapamil were 70 and 59 ng/ml at 2 and 4 weeks, respectively, after treatment with IR verapamil; the corresponding values were 70 and 94 ng/ml for the SR verapamil group.",Antihypertensive efficacy of sustained-release verapamil. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3330987/),[ng] / [ml],59,220910,DB00661,Verapamil
,3330987,trough plasma concentrations,"Mean trough plasma concentrations of verapamil were 70 and 59 ng/ml at 2 and 4 weeks, respectively, after treatment with IR verapamil; the corresponding values were 70 and 94 ng/ml for the SR verapamil group.",Antihypertensive efficacy of sustained-release verapamil. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3330987/),[ng] / [ml],94,220911,DB00661,Verapamil
,3752571,terminal volume of distribution at steady-state,"Verapamil terminal volume of distribution at steady-state was reduced by halothane, enflurane, and isoflurane exposure as compared with awake: 65 +/- 10, 80 +/- 9, and 93 +/- 191, respectively, versus 132 +/- 121 (mean +/- SEM; P less than 0.05).",Effects of inhalational anesthetics on verapamil pharmacokinetics in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752571/),,65,221707,DB00661,Verapamil
,3752571,terminal volume of distribution at steady-state,"Verapamil terminal volume of distribution at steady-state was reduced by halothane, enflurane, and isoflurane exposure as compared with awake: 65 +/- 10, 80 +/- 9, and 93 +/- 191, respectively, versus 132 +/- 121 (mean +/- SEM; P less than 0.05).",Effects of inhalational anesthetics on verapamil pharmacokinetics in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752571/),,80,221708,DB00661,Verapamil
,3752571,terminal volume of distribution at steady-state,"Verapamil terminal volume of distribution at steady-state was reduced by halothane, enflurane, and isoflurane exposure as compared with awake: 65 +/- 10, 80 +/- 9, and 93 +/- 191, respectively, versus 132 +/- 121 (mean +/- SEM; P less than 0.05).",Effects of inhalational anesthetics on verapamil pharmacokinetics in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752571/),,93,221709,DB00661,Verapamil
,3752571,terminal volume of distribution at steady-state,"Verapamil terminal volume of distribution at steady-state was reduced by halothane, enflurane, and isoflurane exposure as compared with awake: 65 +/- 10, 80 +/- 9, and 93 +/- 191, respectively, versus 132 +/- 121 (mean +/- SEM; P less than 0.05).",Effects of inhalational anesthetics on verapamil pharmacokinetics in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752571/),,132,221710,DB00661,Verapamil
,3752571,total clearance,"Verapamil total clearance was also reduced by halothane, enflurane, and isoflurane as compared with awake: 37 +/- 4, 39 +/- 2 and 41 +/- 31 X h-1, respectively, versus 64 +/- 71 X h-1 (P less than 0.05).",Effects of inhalational anesthetics on verapamil pharmacokinetics in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752571/),1/[h],37,221711,DB00661,Verapamil
,3752571,total clearance,"Verapamil total clearance was also reduced by halothane, enflurane, and isoflurane as compared with awake: 37 +/- 4, 39 +/- 2 and 41 +/- 31 X h-1, respectively, versus 64 +/- 71 X h-1 (P less than 0.05).",Effects of inhalational anesthetics on verapamil pharmacokinetics in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752571/),1/[h],39,221712,DB00661,Verapamil
,3752571,total clearance,"Verapamil total clearance was also reduced by halothane, enflurane, and isoflurane as compared with awake: 37 +/- 4, 39 +/- 2 and 41 +/- 31 X h-1, respectively, versus 64 +/- 71 X h-1 (P less than 0.05).",Effects of inhalational anesthetics on verapamil pharmacokinetics in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752571/),1/[h],41,221713,DB00661,Verapamil
,3752571,total clearance,"Verapamil total clearance was also reduced by halothane, enflurane, and isoflurane as compared with awake: 37 +/- 4, 39 +/- 2 and 41 +/- 31 X h-1, respectively, versus 64 +/- 71 X h-1 (P less than 0.05).",Effects of inhalational anesthetics on verapamil pharmacokinetics in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752571/),1/[h],64,221714,DB00661,Verapamil
,3752571,cardiac output,Verapamil administered to awake animals resulted in a decrease from baseline in mean arterial pressure; 95 +/- 8 mmHg versus 108 +/- 4 mmHg (P less than 0.05): and an increase in cardiac output; 2.60 +/- 0.33 1 X min-1 versus 1.93 +/- 0.22 1 X min-1 (P less than 0.05).,Effects of inhalational anesthetics on verapamil pharmacokinetics in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752571/),[1] / [min],2.60,221715,DB00661,Verapamil
,3752571,cardiac output,Verapamil administered to awake animals resulted in a decrease from baseline in mean arterial pressure; 95 +/- 8 mmHg versus 108 +/- 4 mmHg (P less than 0.05): and an increase in cardiac output; 2.60 +/- 0.33 1 X min-1 versus 1.93 +/- 0.22 1 X min-1 (P less than 0.05).,Effects of inhalational anesthetics on verapamil pharmacokinetics in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3752571/),[1] / [min],1.93,221716,DB00661,Verapamil
,1505606,AUC,"Mean theophylline AUC for phase I-IV was 93.6, 105.6, 110.8, 120.1 mg.",The effect of three different oral doses of verapamil on the disposition of theophylline. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505606/),mg,93.6,222883,DB00661,Verapamil
,1505606,AUC,"Mean theophylline AUC for phase I-IV was 93.6, 105.6, 110.8, 120.1 mg.",The effect of three different oral doses of verapamil on the disposition of theophylline. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505606/),mg,105.6,222884,DB00661,Verapamil
,1505606,AUC,"Mean theophylline AUC for phase I-IV was 93.6, 105.6, 110.8, 120.1 mg.",The effect of three different oral doses of verapamil on the disposition of theophylline. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505606/),mg,110.8,222885,DB00661,Verapamil
,1505606,AUC,"Mean theophylline AUC for phase I-IV was 93.6, 105.6, 110.8, 120.1 mg.",The effect of three different oral doses of verapamil on the disposition of theophylline. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505606/),mg,120.1,222886,DB00661,Verapamil
,1505606,clearance,"Mean theophylline clearance for phase I-IV was 3.89, 3.59, 3.35, and 3.20 l.h-1, respectively.",The effect of three different oral doses of verapamil on the disposition of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505606/),[l] / [h],3.89,222887,DB00661,Verapamil
,1505606,clearance,"Mean theophylline clearance for phase I-IV was 3.89, 3.59, 3.35, and 3.20 l.h-1, respectively.",The effect of three different oral doses of verapamil on the disposition of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505606/),[l] / [h],3.59,222888,DB00661,Verapamil
,1505606,clearance,"Mean theophylline clearance for phase I-IV was 3.89, 3.59, 3.35, and 3.20 l.h-1, respectively.",The effect of three different oral doses of verapamil on the disposition of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505606/),[l] / [h],3.35,222889,DB00661,Verapamil
,1505606,clearance,"Mean theophylline clearance for phase I-IV was 3.89, 3.59, 3.35, and 3.20 l.h-1, respectively.",The effect of three different oral doses of verapamil on the disposition of theophylline. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505606/),[l] / [h],3.20,222890,DB00661,Verapamil
,3070032,plasma half-life,The mean plasma half-life of verapamil was 6.9 +/- 1.1 hours.,The antihypertensive efficacy of verapamil in the elderly evaluated by ambulatory blood pressure measurement. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3070032/),h,6.9,224195,DB00661,Verapamil
,21721007,Absolute bioavailability,Absolute bioavailability of AP was 2.67%.,Poor oral bioavailability of a promising anticancer agent andrographolide is due to extensive metabolism and efflux by P-glycoprotein. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21721007/),%,2.67,224424,DB00661,Verapamil
,21721007,apparent permeability (P(app) ),The apparent permeability (P(app) ) of AP from basolateral (B) to apical (A) (4.94 × 10 cm/s) in the Caco-2 model was four times higher than the P(app) from A to B (1.14 × 10(-5) cm/s).,Poor oral bioavailability of a promising anticancer agent andrographolide is due to extensive metabolism and efflux by P-glycoprotein. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21721007/),[cm] / [s],4.94 × 10,224425,DB00661,Verapamil
,21721007,P(app),The apparent permeability (P(app) ) of AP from basolateral (B) to apical (A) (4.94 × 10 cm/s) in the Caco-2 model was four times higher than the P(app) from A to B (1.14 × 10(-5) cm/s).,Poor oral bioavailability of a promising anticancer agent andrographolide is due to extensive metabolism and efflux by P-glycoprotein. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21721007/),[cm] / [s],1.14 × 10(-5),224426,DB00661,Verapamil
,15762767,half-life,The compound has a half-life of approximately 3 hours.,"Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15762767/),h,3,226151,DB00661,Verapamil
,15762767,absolute bioavailability,Almotriptan is well absorbed after oral administration and the mean absolute bioavailability is 69.1%.,"Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15762767/),%,69.1,226152,DB00661,Verapamil
,1687016,R/S ratio,The hepatic clearance of metoprolol was slightly (S)-enantioselective (R/S ratio = 0.89 +/- 0.04) in control dogs.,Pharmacokinetic interaction between verapamil and metoprolol in the dog. Stereochemical aspects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1687016/),,0.89,226297,DB00661,Verapamil
,1687016,R/S ratio,"Inhibition of hepatic clearance of metoprolol by verapamil was selective towards (S)-metoprolol, such that the enantioselectivity in hepatic clearance toward (S)-metoprolol disappeared following verapamil co-administration (R/S ratio = 1.01 +/- 0.05).",Pharmacokinetic interaction between verapamil and metoprolol in the dog. Stereochemical aspects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1687016/),,1.01,226298,DB00661,Verapamil
,7849332,initial whole blood concentrations,Patients received cyclosporine 3-4 mg/kg by continuous infusion for 5 days followed by cyclosporine 10 mg/kg/d po to maintain initial whole blood concentrations of 300-400 ng/mL.,Effect of calcium-channel blockers on cyclosporine clearance and use in renal transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7849332/),[ng] / [ml],300-400,226740,DB00661,Verapamil
,7849332,clearance,"The mean clearance of intravenously administered cyclosporine +/- SD in patients receiving no CCB was 5.1 +/- 1.5 mL/min/kg, diltiazem was 3.7 +/- 0.8 mL/min/kg, nifedipine was 6.4 +/- 1.9 mL/min/kg, and verapamil was 5.2 +/- 2.2 mL/min/kg.",Effect of calcium-channel blockers on cyclosporine clearance and use in renal transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7849332/),[ml] / [kg·min],5.1,226741,DB00661,Verapamil
,7849332,clearance,"The mean clearance of intravenously administered cyclosporine +/- SD in patients receiving no CCB was 5.1 +/- 1.5 mL/min/kg, diltiazem was 3.7 +/- 0.8 mL/min/kg, nifedipine was 6.4 +/- 1.9 mL/min/kg, and verapamil was 5.2 +/- 2.2 mL/min/kg.",Effect of calcium-channel blockers on cyclosporine clearance and use in renal transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7849332/),[ml] / [kg·min],3.7,226742,DB00661,Verapamil
,7849332,clearance,"The mean clearance of intravenously administered cyclosporine +/- SD in patients receiving no CCB was 5.1 +/- 1.5 mL/min/kg, diltiazem was 3.7 +/- 0.8 mL/min/kg, nifedipine was 6.4 +/- 1.9 mL/min/kg, and verapamil was 5.2 +/- 2.2 mL/min/kg.",Effect of calcium-channel blockers on cyclosporine clearance and use in renal transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7849332/),[ml] / [kg·min],6.4,226743,DB00661,Verapamil
,7849332,clearance,"The mean clearance of intravenously administered cyclosporine +/- SD in patients receiving no CCB was 5.1 +/- 1.5 mL/min/kg, diltiazem was 3.7 +/- 0.8 mL/min/kg, nifedipine was 6.4 +/- 1.9 mL/min/kg, and verapamil was 5.2 +/- 2.2 mL/min/kg.",Effect of calcium-channel blockers on cyclosporine clearance and use in renal transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7849332/),[ml] / [kg·min],5.2,226744,DB00661,Verapamil
,21640186,area under the plasma concentration-time curve (AUC),"After per oral phenytoin dosing, the mean area under the plasma concentration-time curve (AUC) was found to be 35.03±1.83hμg/ml which was increased significantly, i.e. 62.33±2.49hμg/ml (P<0.001) when verapamil was co-administered.",Study on in situ and in vivo absorption kinetics of phenytoin by modulating P-glycoprotein with verapamil in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21640186/),[hμg] / [ml],35.03,227035,DB00661,Verapamil
,21640186,area under the plasma concentration-time curve (AUC),"After per oral phenytoin dosing, the mean area under the plasma concentration-time curve (AUC) was found to be 35.03±1.83hμg/ml which was increased significantly, i.e. 62.33±2.49hμg/ml (P<0.001) when verapamil was co-administered.",Study on in situ and in vivo absorption kinetics of phenytoin by modulating P-glycoprotein with verapamil in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21640186/),[hμg] / [ml],62.33,227036,DB00661,Verapamil
,21640186,maximum plasma concentration,Similarly the mean maximum plasma concentration of phenytoin increased from 3.2±0.148μg/ml without verapamil to 6.983±0.272μg/ml (P<0.001) with verapamil.,Study on in situ and in vivo absorption kinetics of phenytoin by modulating P-glycoprotein with verapamil in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21640186/),[μg] / [ml],3.2,227037,DB00661,Verapamil
,21640186,maximum plasma concentration,Similarly the mean maximum plasma concentration of phenytoin increased from 3.2±0.148μg/ml without verapamil to 6.983±0.272μg/ml (P<0.001) with verapamil.,Study on in situ and in vivo absorption kinetics of phenytoin by modulating P-glycoprotein with verapamil in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21640186/),[μg] / [ml],6.983,227038,DB00661,Verapamil
,20414861,apparent maximal concentration (K (M)),The apparent maximal concentration (K (M)) of the active efflux component was 93.4 µM.,"Transport of a hydrophilic paclitaxel derivative, 7-xylosyl-10-deacetylpaclitaxel, by human intestinal epithelial Caco-2 cells. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20414861/),μM,93.4,227071,DB00661,Verapamil
,20414861,apparent permeability coefficient ( P(app)),The relatively high apparent permeability coefficient ( P(app)) for the apical to basolateral 7-xylosyl-10-deacetylpaclitaxel transport (16.3 ± 6.3 × 10 (-6) cm/s; n = 3) suggests that the drug may still be effectively absorbed in the intestinal tract.,"Transport of a hydrophilic paclitaxel derivative, 7-xylosyl-10-deacetylpaclitaxel, by human intestinal epithelial Caco-2 cells. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20414861/),[cm] / [s],16.3,227072,DB00661,Verapamil
,8304970,ID50 concentration,Since the ID50 concentration for Ro11-2933 is 17.7 microM (5-12-fold less than the other modifiers) we have used isobologram analysis to demonstrate that the interaction with doxorubicin is supra-additive and cannot be explained by additive toxicity.,"Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro, toxicity in vivo and growth delay in a solid human tumour xenograft. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8304970/),μM,17.7,228549,DB00661,Verapamil
,8648372,MTD,The MTD of the combination was 225 mg/m2 of r-verapamil every 4 hours with paclitaxel 200 mg/m2 by 3-hour infusion.,Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8648372/),[mg] / [m2],225,229625,DB00661,Verapamil
,8648372,peak,"The median peak and trough serum verapamil concentrations at the MTD were 5.1 micromol/L (range, 1.9 to 6.3), respectively, which are within the range necessary for in vitro modulation of Pgp-mediated multidrug resistance (MDR).",Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8648372/),[μM] / [l],5.1,229626,DB00661,Verapamil
,11372000,clearance,"Compared with day 1, clearance of oral R -verapamil and S -verapamil was significantly reduced on day 21 (1007 +/- 380 versus 651 +/- 253 mL/min [-35%] and 5481 +/- 2731 versus 2855 +/- 1097 mL/min [-48%], respectively; P <.05), whereas only a moderate decrease was observed for intravenous R -verapamil and S -verapamil (-23% and -14%, respectively, not significant).",Disposition and pharmacologic effects of R/S-verapamil in patients with chronic atrial fibrillation: an investigation comparing single and multiple dosing. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11372000/),[ml] / [min],1007,229754,DB00661,Verapamil
,11372000,clearance,"Compared with day 1, clearance of oral R -verapamil and S -verapamil was significantly reduced on day 21 (1007 +/- 380 versus 651 +/- 253 mL/min [-35%] and 5481 +/- 2731 versus 2855 +/- 1097 mL/min [-48%], respectively; P <.05), whereas only a moderate decrease was observed for intravenous R -verapamil and S -verapamil (-23% and -14%, respectively, not significant).",Disposition and pharmacologic effects of R/S-verapamil in patients with chronic atrial fibrillation: an investigation comparing single and multiple dosing. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11372000/),[ml] / [min],651,229755,DB00661,Verapamil
,11372000,clearance,"Compared with day 1, clearance of oral R -verapamil and S -verapamil was significantly reduced on day 21 (1007 +/- 380 versus 651 +/- 253 mL/min [-35%] and 5481 +/- 2731 versus 2855 +/- 1097 mL/min [-48%], respectively; P <.05), whereas only a moderate decrease was observed for intravenous R -verapamil and S -verapamil (-23% and -14%, respectively, not significant).",Disposition and pharmacologic effects of R/S-verapamil in patients with chronic atrial fibrillation: an investigation comparing single and multiple dosing. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11372000/),[ml] / [min],5481,229756,DB00661,Verapamil
,11372000,clearance,"Compared with day 1, clearance of oral R -verapamil and S -verapamil was significantly reduced on day 21 (1007 +/- 380 versus 651 +/- 253 mL/min [-35%] and 5481 +/- 2731 versus 2855 +/- 1097 mL/min [-48%], respectively; P <.05), whereas only a moderate decrease was observed for intravenous R -verapamil and S -verapamil (-23% and -14%, respectively, not significant).",Disposition and pharmacologic effects of R/S-verapamil in patients with chronic atrial fibrillation: an investigation comparing single and multiple dosing. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11372000/),[ml] / [min],2855,229757,DB00661,Verapamil
,11372000,HR,"Mean HR (89 +/- 11 bpm before verapamil) was effectively reduced, with the same effects on day 1 (68 +/- 8 bpm) and day 21 (68 +/- 8 bpm).",Disposition and pharmacologic effects of R/S-verapamil in patients with chronic atrial fibrillation: an investigation comparing single and multiple dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11372000/),bpm,89,229758,DB00661,Verapamil
,11372000,HR,"Mean HR (89 +/- 11 bpm before verapamil) was effectively reduced, with the same effects on day 1 (68 +/- 8 bpm) and day 21 (68 +/- 8 bpm).",Disposition and pharmacologic effects of R/S-verapamil in patients with chronic atrial fibrillation: an investigation comparing single and multiple dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11372000/),bpm,68,229759,DB00661,Verapamil
,2315261,clearance,Theophylline clearance was reduced from 45.2 to 36.1 ml/hr/kg (20.1%; P less than 0.005).,Verapamil-induced inhibition of theophylline elimination in healthy humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2315261/),[ml] / [h·kg],45.2,229862,DB00661,Verapamil
,2315261,clearance,Theophylline clearance was reduced from 45.2 to 36.1 ml/hr/kg (20.1%; P less than 0.005).,Verapamil-induced inhibition of theophylline elimination in healthy humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2315261/),[ml] / [h·kg],36,229863,DB00661,Verapamil
,2315261,terminal half-life,The terminal half-life of theophylline was increased from 6.80 to 8.23 hr (21.0%; P less than 0.001).,Verapamil-induced inhibition of theophylline elimination in healthy humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2315261/),h,6.80,229864,DB00661,Verapamil
,2315261,terminal half-life,The terminal half-life of theophylline was increased from 6.80 to 8.23 hr (21.0%; P less than 0.001).,Verapamil-induced inhibition of theophylline elimination in healthy humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2315261/),h,8,229865,DB00661,Verapamil
,22877221,turnaround time,"The approach allows for the investigation of a set of six compounds simultaneously, with a turnaround time of 1 week or less.",A semi-automated method for the integrated evaluation of half-life and metabolic soft spots of discovery compounds. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22877221/),week,1,231407,DB00661,Verapamil
,12753725,Km,"Both Km and Vm values suggested that saturation of P-GP by telithromycin may occur at a lower dose level in humans than with roxithromycin (Km= 9.8 microM, Vm= 0.3 microM and Km= 45 microM, Vm= 1.1 microM, respectively).","Experimental estimation of the role of P-Glycoprotein in the pharmacokinetic behaviour of telithromycin, a novel ketolide, in comparison with roxithromycin and other macrolides using the Caco-2 cell model. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12753725/),μM,9.8,231668,DB00661,Verapamil
,12753725,Vm,"Both Km and Vm values suggested that saturation of P-GP by telithromycin may occur at a lower dose level in humans than with roxithromycin (Km= 9.8 microM, Vm= 0.3 microM and Km= 45 microM, Vm= 1.1 microM, respectively).","Experimental estimation of the role of P-Glycoprotein in the pharmacokinetic behaviour of telithromycin, a novel ketolide, in comparison with roxithromycin and other macrolides using the Caco-2 cell model. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12753725/),μM,0.3,231669,DB00661,Verapamil
,12753725,Km,"Both Km and Vm values suggested that saturation of P-GP by telithromycin may occur at a lower dose level in humans than with roxithromycin (Km= 9.8 microM, Vm= 0.3 microM and Km= 45 microM, Vm= 1.1 microM, respectively).","Experimental estimation of the role of P-Glycoprotein in the pharmacokinetic behaviour of telithromycin, a novel ketolide, in comparison with roxithromycin and other macrolides using the Caco-2 cell model. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12753725/),μM,45,231670,DB00661,Verapamil
,12753725,Vm,"Both Km and Vm values suggested that saturation of P-GP by telithromycin may occur at a lower dose level in humans than with roxithromycin (Km= 9.8 microM, Vm= 0.3 microM and Km= 45 microM, Vm= 1.1 microM, respectively).","Experimental estimation of the role of P-Glycoprotein in the pharmacokinetic behaviour of telithromycin, a novel ketolide, in comparison with roxithromycin and other macrolides using the Caco-2 cell model. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12753725/),μM,1.1,231671,DB00661,Verapamil
,33333557,limits of detection (S/N,The respective limits of detection (S/N = 3) were 0.006 and 0.024 μg/mL.,Determination of Verapamil Hydrochloride and Norverapamil Hydrochloride in Rat Plasma by Capillary Electrophoresis With End-Column Electrochemiluminescence Detection and Their Pharmacokinetics Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33333557/),[μg] / [ml],3,231953,DB00661,Verapamil
,33333557,limits of detection (S/N,The respective limits of detection (S/N = 3) were 0.006 and 0.024 μg/mL.,Determination of Verapamil Hydrochloride and Norverapamil Hydrochloride in Rat Plasma by Capillary Electrophoresis With End-Column Electrochemiluminescence Detection and Their Pharmacokinetics Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33333557/),[μg] / [ml],0.006,231954,DB00661,Verapamil
,33333557,limits of detection (S/N,The respective limits of detection (S/N = 3) were 0.006 and 0.024 μg/mL.,Determination of Verapamil Hydrochloride and Norverapamil Hydrochloride in Rat Plasma by Capillary Electrophoresis With End-Column Electrochemiluminescence Detection and Their Pharmacokinetics Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33333557/),[μg] / [ml],0.024,231955,DB00661,Verapamil
,33333557,maximum concentration (Cmax),"The maximum concentration (Cmax), half-life time (T1/2) and time to peak (Tmax) were 683.21 ± 74.81 ng/mL, 0.52 ± 0.21 h and 2.49 ± 0.32 h for VerHCl and 698.42 ± 71.45 ng/mL, 1.14 ± 0.26 h and 2.83 ± 0.23 h for NorHCl, respectively, following oral administration of 10 mg/kg VerHCl.",Determination of Verapamil Hydrochloride and Norverapamil Hydrochloride in Rat Plasma by Capillary Electrophoresis With End-Column Electrochemiluminescence Detection and Their Pharmacokinetics Study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33333557/),[ng] / [ml],683.21,231956,DB00661,Verapamil
,33333557,half-life time (T1/2),"The maximum concentration (Cmax), half-life time (T1/2) and time to peak (Tmax) were 683.21 ± 74.81 ng/mL, 0.52 ± 0.21 h and 2.49 ± 0.32 h for VerHCl and 698.42 ± 71.45 ng/mL, 1.14 ± 0.26 h and 2.83 ± 0.23 h for NorHCl, respectively, following oral administration of 10 mg/kg VerHCl.",Determination of Verapamil Hydrochloride and Norverapamil Hydrochloride in Rat Plasma by Capillary Electrophoresis With End-Column Electrochemiluminescence Detection and Their Pharmacokinetics Study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33333557/),h,0.52,231957,DB00661,Verapamil
,33333557,half-life time (T1/2),"The maximum concentration (Cmax), half-life time (T1/2) and time to peak (Tmax) were 683.21 ± 74.81 ng/mL, 0.52 ± 0.21 h and 2.49 ± 0.32 h for VerHCl and 698.42 ± 71.45 ng/mL, 1.14 ± 0.26 h and 2.83 ± 0.23 h for NorHCl, respectively, following oral administration of 10 mg/kg VerHCl.",Determination of Verapamil Hydrochloride and Norverapamil Hydrochloride in Rat Plasma by Capillary Electrophoresis With End-Column Electrochemiluminescence Detection and Their Pharmacokinetics Study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33333557/),[ng] / [ml],698.42,231958,DB00661,Verapamil
,33333557,half-life time (T1/2),"The maximum concentration (Cmax), half-life time (T1/2) and time to peak (Tmax) were 683.21 ± 74.81 ng/mL, 0.52 ± 0.21 h and 2.49 ± 0.32 h for VerHCl and 698.42 ± 71.45 ng/mL, 1.14 ± 0.26 h and 2.83 ± 0.23 h for NorHCl, respectively, following oral administration of 10 mg/kg VerHCl.",Determination of Verapamil Hydrochloride and Norverapamil Hydrochloride in Rat Plasma by Capillary Electrophoresis With End-Column Electrochemiluminescence Detection and Their Pharmacokinetics Study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33333557/),h,1.14,231959,DB00661,Verapamil
,33333557,time to peak (Tmax),"The maximum concentration (Cmax), half-life time (T1/2) and time to peak (Tmax) were 683.21 ± 74.81 ng/mL, 0.52 ± 0.21 h and 2.49 ± 0.32 h for VerHCl and 698.42 ± 71.45 ng/mL, 1.14 ± 0.26 h and 2.83 ± 0.23 h for NorHCl, respectively, following oral administration of 10 mg/kg VerHCl.",Determination of Verapamil Hydrochloride and Norverapamil Hydrochloride in Rat Plasma by Capillary Electrophoresis With End-Column Electrochemiluminescence Detection and Their Pharmacokinetics Study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33333557/),h,2.49,231960,DB00661,Verapamil
,33333557,time to peak (Tmax),"The maximum concentration (Cmax), half-life time (T1/2) and time to peak (Tmax) were 683.21 ± 74.81 ng/mL, 0.52 ± 0.21 h and 2.49 ± 0.32 h for VerHCl and 698.42 ± 71.45 ng/mL, 1.14 ± 0.26 h and 2.83 ± 0.23 h for NorHCl, respectively, following oral administration of 10 mg/kg VerHCl.",Determination of Verapamil Hydrochloride and Norverapamil Hydrochloride in Rat Plasma by Capillary Electrophoresis With End-Column Electrochemiluminescence Detection and Their Pharmacokinetics Study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33333557/),h,2.83,231961,DB00661,Verapamil
,24631811,detection limit,"The assay was linear from 50 to 2800ngmL(-1), with a detection limit of 12ngmL(-1).",High-performance liquid chromatography assay with programmed flow elution for cisatracurium in human plasma: application to pharmacokinetics in infants and children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24631811/),1/[ngml],12,232389,DB00661,Verapamil
,24631811,recoveries,The mean recoveries were in the range of 92.1-100.4%.,High-performance liquid chromatography assay with programmed flow elution for cisatracurium in human plasma: application to pharmacokinetics in infants and children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24631811/),%,92.1-100.4,232390,DB00661,Verapamil
less,24631811,total HPLC run time,The total HPLC run time was less than 10min.,High-performance liquid chromatography assay with programmed flow elution for cisatracurium in human plasma: application to pharmacokinetics in infants and children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24631811/),min,10,232391,DB00661,Verapamil
,10803762,area under the blood CsA concentration-time curve,"In ARF rats, the area under the blood CsA concentration-time curve after oral administration was significantly decreased in comparison with that of control rats; 5.81 +/- 0.55 vs 11.30 +/- 1.59 mg h mL(-1)(mean+/-s.e.m.), respectively, and the relative bioavailabilities in ARF and control rats after oral administration were 15.2% and 43.4%, respectively.",Factors that affect absorption behavior of cyclosporin a in gentamicin-induced acute renal failure in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10803762/),[h·mg] / [ml],5.81,232760,DB00661,Verapamil
,10803762,area under the blood CsA concentration-time curve,"In ARF rats, the area under the blood CsA concentration-time curve after oral administration was significantly decreased in comparison with that of control rats; 5.81 +/- 0.55 vs 11.30 +/- 1.59 mg h mL(-1)(mean+/-s.e.m.), respectively, and the relative bioavailabilities in ARF and control rats after oral administration were 15.2% and 43.4%, respectively.",Factors that affect absorption behavior of cyclosporin a in gentamicin-induced acute renal failure in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10803762/),[h·mg] / [ml],11.30,232761,DB00661,Verapamil
,10803762,relative bioavailabilities,"In ARF rats, the area under the blood CsA concentration-time curve after oral administration was significantly decreased in comparison with that of control rats; 5.81 +/- 0.55 vs 11.30 +/- 1.59 mg h mL(-1)(mean+/-s.e.m.), respectively, and the relative bioavailabilities in ARF and control rats after oral administration were 15.2% and 43.4%, respectively.",Factors that affect absorption behavior of cyclosporin a in gentamicin-induced acute renal failure in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10803762/),%,15.2,232762,DB00661,Verapamil
,10803762,relative bioavailabilities,"In ARF rats, the area under the blood CsA concentration-time curve after oral administration was significantly decreased in comparison with that of control rats; 5.81 +/- 0.55 vs 11.30 +/- 1.59 mg h mL(-1)(mean+/-s.e.m.), respectively, and the relative bioavailabilities in ARF and control rats after oral administration were 15.2% and 43.4%, respectively.",Factors that affect absorption behavior of cyclosporin a in gentamicin-induced acute renal failure in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10803762/),%,43.4,232763,DB00661,Verapamil
,16715372,drug payload,The drug payload of paclitaxel was 1.91 +/- 0.01 mg/g of aqueous dispersion.,Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715372/),[mg] / [g],1.91,234199,DB00661,Verapamil
,16715372,encapsulation efficiency,"The encapsulation efficiency was 99.9 +/- 1.0%, and 1.7 +/- 0.1% of paclitaxel was crystallized after 24 h.",Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715372/),%,99.9,234200,DB00661,Verapamil
,16715372,encapsulation efficiency,"The encapsulation efficiency was 99.9 +/- 1.0%, and 1.7 +/- 0.1% of paclitaxel was crystallized after 24 h.",Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715372/),%,1.7,234201,DB00661,Verapamil
,16715372,oral bioavailability,The oral bioavailability of Taxol alone was 6.5%.,Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715372/),%,6.5,234202,DB00661,Verapamil
,7202473,Total plasma clearance,"Total plasma clearance (1.26 1/min) approached liver blood flow (1.51/min), so it can be concluded that its clearance is liver blood flow-dependent.","Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isotope-labelled verapamil. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7202473/),[1] / [min],1.26,234882,DB00661,Verapamil
,7202473,Total plasma clearance,"Total plasma clearance (1.26 1/min) approached liver blood flow (1.51/min), so it can be concluded that its clearance is liver blood flow-dependent.","Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isotope-labelled verapamil. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7202473/),1/[min],1.51,234883,DB00661,Verapamil
,7202473,absolute bioavailability,"Although absorption was almost complete after oral administration, absolute bioavailability (20%) was low, due to extensive hepatic first-pass metabolism.","Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isotope-labelled verapamil. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7202473/),%,20,234884,DB00661,Verapamil
,6160352,distribution phase half-life,"The distribution phase half-life was 3.51 min and that of the elimination phase, 110.5 min; the volume of distribution was 178 +/- 26 liters, and the plasma clearance ws 1.06 +/- 0.27 liters/min.",The pharmacology of verapamil. Pharmacokinetics in normal subjects after intravenous drug administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6160352/),min,3.51,234971,DB00661,Verapamil
,6160352,distribution phase half-life,"The distribution phase half-life was 3.51 min and that of the elimination phase, 110.5 min; the volume of distribution was 178 +/- 26 liters, and the plasma clearance ws 1.06 +/- 0.27 liters/min.",The pharmacology of verapamil. Pharmacokinetics in normal subjects after intravenous drug administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6160352/),min,110.5,234972,DB00661,Verapamil
,6160352,volume of distribution,"The distribution phase half-life was 3.51 min and that of the elimination phase, 110.5 min; the volume of distribution was 178 +/- 26 liters, and the plasma clearance ws 1.06 +/- 0.27 liters/min.",The pharmacology of verapamil. Pharmacokinetics in normal subjects after intravenous drug administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6160352/),l,178,234973,DB00661,Verapamil
,6160352,plasma clearance ws,"The distribution phase half-life was 3.51 min and that of the elimination phase, 110.5 min; the volume of distribution was 178 +/- 26 liters, and the plasma clearance ws 1.06 +/- 0.27 liters/min.",The pharmacology of verapamil. Pharmacokinetics in normal subjects after intravenous drug administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6160352/),[l] / [min],1.06,234974,DB00661,Verapamil
,20561828,flow rate,"The mobile phase was methanol:perchloric acid (12 nM, aq) (56:44, v:v), with a flow rate of 1.0 mL/min.",Determination of TJ0711 hydrochloride in rat plasma by high performance liquid chromatography with fluorescence detection and its application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20561828/),[ml] / [min],1.0,235239,DB00661,Verapamil
,20561828,analytical recoveries,"The mean analytical recoveries of TJ0711 hydrochloride at different concentrations (50, 1000 and 8000 ng/mL) ranged from 88.3% to 92.9%.",Determination of TJ0711 hydrochloride in rat plasma by high performance liquid chromatography with fluorescence detection and its application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20561828/),%,88.3,235240,DB00661,Verapamil
,20561828,analytical recoveries,"The mean analytical recoveries of TJ0711 hydrochloride at different concentrations (50, 1000 and 8000 ng/mL) ranged from 88.3% to 92.9%.",Determination of TJ0711 hydrochloride in rat plasma by high performance liquid chromatography with fluorescence detection and its application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20561828/),%,92.9,235241,DB00661,Verapamil
,24086173,flow rate,Column elution at a flow rate of 1 mL/minute with UV detection at 225 nm at room temperature was used.,"Extraction and RP-HPLC determination of taxol in rat plasma, cell culture and quality control samples. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24086173/),[ml] / [min],1,235432,DB00661,Verapamil
,24086173,extraction efficiency,"To the best of our knowledge, this study also reported for the first time the optimization of different solvents for effective extraction of paclitaxel wherein tert.-butyl methyl ether (TBME): diethyl ether (DEE) in 50: 50 v/v composition was found most efficient with extraction efficiency ranging between 77.99% and 91.74% and between 76.14 and 93.66% in the plasma and cell culture, respectively.","Extraction and RP-HPLC determination of taxol in rat plasma, cell culture and quality control samples. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24086173/),%,77.99,235433,DB00661,Verapamil
,24086173,extraction efficiency,"To the best of our knowledge, this study also reported for the first time the optimization of different solvents for effective extraction of paclitaxel wherein tert.-butyl methyl ether (TBME): diethyl ether (DEE) in 50: 50 v/v composition was found most efficient with extraction efficiency ranging between 77.99% and 91.74% and between 76.14 and 93.66% in the plasma and cell culture, respectively.","Extraction and RP-HPLC determination of taxol in rat plasma, cell culture and quality control samples. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24086173/),%,91.74,235434,DB00661,Verapamil
,24086173,extraction efficiency,"To the best of our knowledge, this study also reported for the first time the optimization of different solvents for effective extraction of paclitaxel wherein tert.-butyl methyl ether (TBME): diethyl ether (DEE) in 50: 50 v/v composition was found most efficient with extraction efficiency ranging between 77.99% and 91.74% and between 76.14 and 93.66% in the plasma and cell culture, respectively.","Extraction and RP-HPLC determination of taxol in rat plasma, cell culture and quality control samples. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24086173/),%,76.14 and 93.66,235435,DB00661,Verapamil
,10096260,area under the concentration-time curve,The area under the concentration-time curve for talinolol from 0 to 24 hours was significantly decreased after R-verapamil versus placebo (721+/-231 ng x h x mL(-1) versus 945+/-188 ng x h x mL(-1); P < .01).,Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10096260/),[h·ng] / [ml],721,236020,DB00661,Verapamil
,10096260,area under the concentration-time curve,The area under the concentration-time curve for talinolol from 0 to 24 hours was significantly decreased after R-verapamil versus placebo (721+/-231 ng x h x mL(-1) versus 945+/-188 ng x h x mL(-1); P < .01).,Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10096260/),[h·ng] / [ml],945,236021,DB00661,Verapamil
,26588877,absolute bioavailability,"All three quercetin-3-O-glycosides showed poor oral absorption in mice, and the absolute bioavailability of hyperin after oral administration of 100 mg/kg was 1.2%.","Simultaneous quantification of hyperin, reynoutrin and guaijaverin in mice plasma by LC-MS/MS: application to a pharmacokinetic study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26588877/),%,1.2,237480,DB00661,Verapamil
,3872057,oral bioavailability,"The drug is completely absorbed from the gastrointestinal tract, but first-pass extraction reduces oral bioavailability to approximately 60%.",Pharmacokinetics and metabolism of bepridil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3872057/),%,60,237582,DB00661,Verapamil
,3872057,elimination half-life,"After single-dose administration, the elimination half-life of bepridil averages 33 +/- 15 hours.",Pharmacokinetics and metabolism of bepridil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3872057/),h,33,237583,DB00661,Verapamil
,3872057,half-life,"However, upon multiple dosing, a half-life of 42 +/- 12 hours is found.",Pharmacokinetics and metabolism of bepridil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3872057/),h,42,237584,DB00661,Verapamil
,3872057,free fraction,"The free fraction of bepridil in plasma is low, averaging only 0.23%.",Pharmacokinetics and metabolism of bepridil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3872057/),%,0.23,237585,DB00661,Verapamil
,9851956,area under the time-concentration curve [0 to 12 hours],"Plasma concentrations of both unlabeled enantiomers (ie, from oral therapy) were significantly (P<0.05) lower during the high-salt phase (eg, mean area under the time-concentration curve [0 to 12 hours] for S-verapamil: 7765+/-2591 ng. min. mL-1 [high salt] versus 12 514+/-3527 ng. min. mL-1 [low salt], P<0.05).",Modulation by dietary salt of verapamil disposition in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9851956/),[min·ng] / [ml],7765,237843,DB00661,Verapamil
,9851956,area under the time-concentration curve [0 to 12 hours],"Plasma concentrations of both unlabeled enantiomers (ie, from oral therapy) were significantly (P<0.05) lower during the high-salt phase (eg, mean area under the time-concentration curve [0 to 12 hours] for S-verapamil: 7765+/-2591 ng. min. mL-1 [high salt] versus 12 514+/-3527 ng. min. mL-1 [low salt], P<0.05).",Modulation by dietary salt of verapamil disposition in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9851956/),[min·ng] / [ml],12 514,237844,DB00661,Verapamil
,26111697,absolute bioavailability (AB%),"In the blank group, the average absolute bioavailability (AB%) of orally administered paclitaxel was only 2.81%, compared to that of 7.63% in radix euphorbiae pekinensis group.",[Effect of Radix euphorbiae pekinensis extract on bioavailability of paclitaxel after their oral co-administration]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26111697/),%,2.81,237998,DB00661,Verapamil
,26111697,absolute bioavailability (AB%),"In the blank group, the average absolute bioavailability (AB%) of orally administered paclitaxel was only 2.81%, compared to that of 7.63% in radix euphorbiae pekinensis group.",[Effect of Radix euphorbiae pekinensis extract on bioavailability of paclitaxel after their oral co-administration]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26111697/),%,7.63,237999,DB00661,Verapamil
,12536488,recovery rate,"ml-1, and the correlation coefficient was 0.9992, the recovery rate of HPLC was (100.23 +/- 3.00)%, within day RSD and between day RSD were no more than 5.56% and 3.30% respectively.",[Pharmacokinetics of high-dosage naftopidil capsules in dogs]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12536488/),%,100.23,238182,DB00661,Verapamil
no,12536488,recovery rate,"ml-1, and the correlation coefficient was 0.9992, the recovery rate of HPLC was (100.23 +/- 3.00)%, within day RSD and between day RSD were no more than 5.56% and 3.30% respectively.",[Pharmacokinetics of high-dosage naftopidil capsules in dogs]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12536488/),%,5.56,238183,DB00661,Verapamil
,12536488,recovery rate,"ml-1, and the correlation coefficient was 0.9992, the recovery rate of HPLC was (100.23 +/- 3.00)%, within day RSD and between day RSD were no more than 5.56% and 3.30% respectively.",[Pharmacokinetics of high-dosage naftopidil capsules in dogs]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12536488/),%,3.30,238184,DB00661,Verapamil
,12536488,T1/2Ke,"T1/2Ke value was (1.91-4.99) h, Tmax was (1.87-3.21) h, Cmax was (338.79-414.04) ng.ml-1.",[Pharmacokinetics of high-dosage naftopidil capsules in dogs]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12536488/),h,1.91-4.99,238185,DB00661,Verapamil
,12536488,Tmax,"T1/2Ke value was (1.91-4.99) h, Tmax was (1.87-3.21) h, Cmax was (338.79-414.04) ng.ml-1.",[Pharmacokinetics of high-dosage naftopidil capsules in dogs]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12536488/),h,1.87-3.21,238186,DB00661,Verapamil
,12536488,Cmax,"T1/2Ke value was (1.91-4.99) h, Tmax was (1.87-3.21) h, Cmax was (338.79-414.04) ng.ml-1.",[Pharmacokinetics of high-dosage naftopidil capsules in dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12536488/),[ng] / [ml],338.79-414.04,238187,DB00661,Verapamil
,3668853,initial volume of distribution,"Although verapamil did not affect lidocaine pharmacokinetics, in the presence of the steady-state lidocaine we recorded an increase in verapamil initial volume of distribution of 44% from 40 +/- 4 liters, and intercompartmental clearance increased by 88% from 101 +/- 20 liters/hr, combined with an increase in verapamil total clearance of 47% from 54 +/- 6 liters/hr (n = 6).",Pharmacodynamic and pharmacokinetic interactions between lidocaine and verapamil. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3668853/),l,40,238620,DB00661,Verapamil
,3668853,intercompartmental clearance,"Although verapamil did not affect lidocaine pharmacokinetics, in the presence of the steady-state lidocaine we recorded an increase in verapamil initial volume of distribution of 44% from 40 +/- 4 liters, and intercompartmental clearance increased by 88% from 101 +/- 20 liters/hr, combined with an increase in verapamil total clearance of 47% from 54 +/- 6 liters/hr (n = 6).",Pharmacodynamic and pharmacokinetic interactions between lidocaine and verapamil. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3668853/),[l] / [h],101,238621,DB00661,Verapamil
,3668853,total clearance,"Although verapamil did not affect lidocaine pharmacokinetics, in the presence of the steady-state lidocaine we recorded an increase in verapamil initial volume of distribution of 44% from 40 +/- 4 liters, and intercompartmental clearance increased by 88% from 101 +/- 20 liters/hr, combined with an increase in verapamil total clearance of 47% from 54 +/- 6 liters/hr (n = 6).",Pharmacodynamic and pharmacokinetic interactions between lidocaine and verapamil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3668853/),[l] / [h],54,238622,DB00661,Verapamil
,2605029,relative bioavailability,The relative bioavailability of Product A and B to Product C was respectively 96.3% (ESM = 12.4%) and 103.1% (ESM = 10.2%).,Bioequivalency of three tableted gallopamil products. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2605029/),%,96.3,239170,DB00661,Verapamil
,2605029,relative bioavailability,The relative bioavailability of Product A and B to Product C was respectively 96.3% (ESM = 12.4%) and 103.1% (ESM = 10.2%).,Bioequivalency of three tableted gallopamil products. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2605029/),%,103.1,239171,DB00661,Verapamil
,2605029,Tmax,Statistically significant (p less than 0.05) differences were found in Tmax between Product C (1.0 hr) and both Product A (2.1 hr) and Product B (2.4 hr).,Bioequivalency of three tableted gallopamil products. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2605029/),h,1.0,239172,DB00661,Verapamil
,2605029,Tmax,Statistically significant (p less than 0.05) differences were found in Tmax between Product C (1.0 hr) and both Product A (2.1 hr) and Product B (2.4 hr).,Bioequivalency of three tableted gallopamil products. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2605029/),h,2.1,239173,DB00661,Verapamil
,2605029,Tmax,Statistically significant (p less than 0.05) differences were found in Tmax between Product C (1.0 hr) and both Product A (2.1 hr) and Product B (2.4 hr).,Bioequivalency of three tableted gallopamil products. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2605029/),h,2.4,239174,DB00661,Verapamil
,11777750,maximum plasma concentration (C(max)),Mean value of maximum plasma concentration (C(max)) of V for floating pellets was 28.27 ng ml(-1) and t(max) 3.75 h.,Pharmacokinetics of verapamil and norverapamil from controlled release floating pellets in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11777750/),[ng] / [ml],28.27,239455,DB00661,Verapamil
,11777750,t(max),Mean value of maximum plasma concentration (C(max)) of V for floating pellets was 28.27 ng ml(-1) and t(max) 3.75 h.,Pharmacokinetics of verapamil and norverapamil from controlled release floating pellets in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11777750/),h,3.75,239456,DB00661,Verapamil
,11777750,"area under the concentrations versus time, AUC(0-infinity)","The value of the area under the concentrations versus time, AUC(0-infinity) was calculated as 364.65 ng ml(-1) h, biological half-lives of the absorption and elimination (t(0.5el)) phase were 0.5 h and 10.68 h, respectively.",Pharmacokinetics of verapamil and norverapamil from controlled release floating pellets in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11777750/),[h·ng] / [ml],364.65,239457,DB00661,Verapamil
,11777750,biological half-lives of the absorption,"The value of the area under the concentrations versus time, AUC(0-infinity) was calculated as 364.65 ng ml(-1) h, biological half-lives of the absorption and elimination (t(0.5el)) phase were 0.5 h and 10.68 h, respectively.",Pharmacokinetics of verapamil and norverapamil from controlled release floating pellets in humans. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11777750/),h,0.5,239458,DB00661,Verapamil
,11777750,elimination (t(0.5el)) phase,"The value of the area under the concentrations versus time, AUC(0-infinity) was calculated as 364.65 ng ml(-1) h, biological half-lives of the absorption and elimination (t(0.5el)) phase were 0.5 h and 10.68 h, respectively.",Pharmacokinetics of verapamil and norverapamil from controlled release floating pellets in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11777750/),h,0.5,239459,DB00661,Verapamil
,11777750,elimination (t(0.5el)) phase,"The value of the area under the concentrations versus time, AUC(0-infinity) was calculated as 364.65 ng ml(-1) h, biological half-lives of the absorption and elimination (t(0.5el)) phase were 0.5 h and 10.68 h, respectively.",Pharmacokinetics of verapamil and norverapamil from controlled release floating pellets in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11777750/),h,10.68,239460,DB00661,Verapamil
,17589660,flow rate,"Peaks eluted at 8.4 (Propranolol) and 17.5 min (verapamil, internal standard) from a C18 column, with a mobile phase 0.1 M acetate buffer, pH 5.0, and acetonitrile (60:40, v/v) at flow rate 0.7 mL/min, detected at 290 nm (excitation) and 358 nm (emission).",Propranolol plasma monitoring in children submitted to surgery of tetralogy of Fallot by a micromethod using high performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17589660/),[ml] / [min],0.7,239474,DB00661,Verapamil
,17589660,sensitivity,"Confidence limits of the method showed high selectivity and recovery, sensitivity of 0.02ng/mL, good linearity (0.05-1000 ng/mL), precision of 8.6% and accuracy of 3.1%.",Propranolol plasma monitoring in children submitted to surgery of tetralogy of Fallot by a micromethod using high performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17589660/),,0.02,239475,DB00661,Verapamil
,17589660,drug plasma concentration,"On the other hand a decrease on drug plasma concentration was obtained between periods, the beginning of surgery to the postoperative day 2 (7.09 ng/mL and 0.05 ng/mL, p<0.05 respectively) and from the end of CPB to the postoperative day 2 (2.79 ng/mL e 0.05 ng/mL, p<0.05).",Propranolol plasma monitoring in children submitted to surgery of tetralogy of Fallot by a micromethod using high performance liquid chromatography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17589660/),[ng] / [ml],7.09,239476,DB00661,Verapamil
,17589660,drug plasma concentration,"On the other hand a decrease on drug plasma concentration was obtained between periods, the beginning of surgery to the postoperative day 2 (7.09 ng/mL and 0.05 ng/mL, p<0.05 respectively) and from the end of CPB to the postoperative day 2 (2.79 ng/mL e 0.05 ng/mL, p<0.05).",Propranolol plasma monitoring in children submitted to surgery of tetralogy of Fallot by a micromethod using high performance liquid chromatography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17589660/),[ng] / [ml],0.05,239477,DB00661,Verapamil
,17589660,drug plasma concentration,"On the other hand a decrease on drug plasma concentration was obtained between periods, the beginning of surgery to the postoperative day 2 (7.09 ng/mL and 0.05 ng/mL, p<0.05 respectively) and from the end of CPB to the postoperative day 2 (2.79 ng/mL e 0.05 ng/mL, p<0.05).",Propranolol plasma monitoring in children submitted to surgery of tetralogy of Fallot by a micromethod using high performance liquid chromatography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17589660/),[ng] / [ml],2.79,239478,DB00661,Verapamil
,4041329,terminal elimination half-life,"Continued administration resulted in a significant decrease in verapamil clearance, compared to that following acute dosing, as assessed by increases in both terminal elimination half-life (from a mean +/- s.d. of 5.2 +/- 2.3 h to 6.7 +/- 2.0 h) and AUC (from a mean +/- s.d. of 800 +/- 353 ng ml-1 h to 1455 +/- 244 ng ml-1 h).",Verapamil pharmacokinetics and apparent hepatic and renal blood flow. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041329/),h,5.2,239818,DB00661,Verapamil
,4041329,terminal elimination half-life,"Continued administration resulted in a significant decrease in verapamil clearance, compared to that following acute dosing, as assessed by increases in both terminal elimination half-life (from a mean +/- s.d. of 5.2 +/- 2.3 h to 6.7 +/- 2.0 h) and AUC (from a mean +/- s.d. of 800 +/- 353 ng ml-1 h to 1455 +/- 244 ng ml-1 h).",Verapamil pharmacokinetics and apparent hepatic and renal blood flow. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041329/),h,6.7,239819,DB00661,Verapamil
,4041329,AUC,"Continued administration resulted in a significant decrease in verapamil clearance, compared to that following acute dosing, as assessed by increases in both terminal elimination half-life (from a mean +/- s.d. of 5.2 +/- 2.3 h to 6.7 +/- 2.0 h) and AUC (from a mean +/- s.d. of 800 +/- 353 ng ml-1 h to 1455 +/- 244 ng ml-1 h).",Verapamil pharmacokinetics and apparent hepatic and renal blood flow. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041329/),[h·ng] / [ml],800,239820,DB00661,Verapamil
,4041329,AUC,"Continued administration resulted in a significant decrease in verapamil clearance, compared to that following acute dosing, as assessed by increases in both terminal elimination half-life (from a mean +/- s.d. of 5.2 +/- 2.3 h to 6.7 +/- 2.0 h) and AUC (from a mean +/- s.d. of 800 +/- 353 ng ml-1 h to 1455 +/- 244 ng ml-1 h).",Verapamil pharmacokinetics and apparent hepatic and renal blood flow. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4041329/),[h·ng] / [ml],1455,239821,DB00661,Verapamil
,26582036,Cmax,"3. The results indicated that when the rats were pretreated with verapamil, the Cmax of sorafenib increased from 55.73 ng/ml to 87.72 ng/ml (57.40%), and the AUC(0-t) increased by approximately 58.2% when sorafenib was co-administered with verapamil.",The drug-drug interaction of sorafenib mediated by P-glycoprotein and CYP3A4. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26582036/),[ng] / [ml],55.73,240174,DB00661,Verapamil
,26582036,Cmax,"3. The results indicated that when the rats were pretreated with verapamil, the Cmax of sorafenib increased from 55.73 ng/ml to 87.72 ng/ml (57.40%), and the AUC(0-t) increased by approximately 58.2% when sorafenib was co-administered with verapamil.",The drug-drug interaction of sorafenib mediated by P-glycoprotein and CYP3A4. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26582036/),[ng] / [ml],87.72,240175,DB00661,Verapamil
,17003230,permeability,"The permeability of the chloro analogs ranged from 8.26 to 32.23 and from 1.37 to 21.65 x 10(-6) cm/s, whereas the efflux ratios ranged from 2.1 to 6.9 and from 3.3 to 28.4 across Madin-Darby canine kidney-multidrug resistance 1 (MDCK-MDR1) and Caco-2 monolayers, respectively.","Transport, metabolism, and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17003230/),[cm] / [s],8.26 to 32.23,241624,DB00661,Verapamil
,17003230,permeability,"The permeability of the chloro analogs ranged from 8.26 to 32.23 and from 1.37 to 21.65 x 10(-6) cm/s, whereas the efflux ratios ranged from 2.1 to 6.9 and from 3.3 to 28.4 across Madin-Darby canine kidney-multidrug resistance 1 (MDCK-MDR1) and Caco-2 monolayers, respectively.","Transport, metabolism, and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17003230/),[cm] / [s],1.37 to 21.65,241625,DB00661,Verapamil
,17003230,efflux ratios,"The permeability of the chloro analogs ranged from 8.26 to 32.23 and from 1.37 to 21.65 x 10(-6) cm/s, whereas the efflux ratios ranged from 2.1 to 6.9 and from 3.3 to 28.4 across Madin-Darby canine kidney-multidrug resistance 1 (MDCK-MDR1) and Caco-2 monolayers, respectively.","Transport, metabolism, and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17003230/),,2.1 to 6.9,241626,DB00661,Verapamil
,17003230,efflux ratios,"The permeability of the chloro analogs ranged from 8.26 to 32.23 and from 1.37 to 21.65 x 10(-6) cm/s, whereas the efflux ratios ranged from 2.1 to 6.9 and from 3.3 to 28.4 across Madin-Darby canine kidney-multidrug resistance 1 (MDCK-MDR1) and Caco-2 monolayers, respectively.","Transport, metabolism, and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17003230/),,3,241627,DB00661,Verapamil
,17003230,brain-to-plasma partition coefficient,"The brain uptake for 4'-Cl and 4',4''-diCl BZT was comparable and higher than previously reported for cocaine (brain-to-plasma partition coefficient = 4.6-4.7 versus 2.1 for cocaine).","Transport, metabolism, and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17003230/),,4.6-4.7,241628,DB00661,Verapamil
,17003230,brain-to-plasma partition coefficient,"The brain uptake for 4'-Cl and 4',4''-diCl BZT was comparable and higher than previously reported for cocaine (brain-to-plasma partition coefficient = 4.6-4.7 versus 2.1 for cocaine).","Transport, metabolism, and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17003230/),,2.1,241629,DB00661,Verapamil
,3391002,half-life,Increases in mean theophylline half-life were observed after verapamil (10.8 +/- 3.2 hours) and diltiazem (9.9 +/- 2.4 hours) (p less than 0.05) but not after nifedipine (8.6 +/- 2.4 hours) when compared with control (8.6 +/- 1.9 hours).,Effect of calcium channel blockers on theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3391002/),h,10.8,242191,DB00661,Verapamil
,3391002,half-life,Increases in mean theophylline half-life were observed after verapamil (10.8 +/- 3.2 hours) and diltiazem (9.9 +/- 2.4 hours) (p less than 0.05) but not after nifedipine (8.6 +/- 2.4 hours) when compared with control (8.6 +/- 1.9 hours).,Effect of calcium channel blockers on theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3391002/),h,9.9,242192,DB00661,Verapamil
,3391002,half-life,Increases in mean theophylline half-life were observed after verapamil (10.8 +/- 3.2 hours) and diltiazem (9.9 +/- 2.4 hours) (p less than 0.05) but not after nifedipine (8.6 +/- 2.4 hours) when compared with control (8.6 +/- 1.9 hours).,Effect of calcium channel blockers on theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3391002/),h,8.6,242193,DB00661,Verapamil
,3391002,half-life,Increases in mean theophylline half-life were observed after verapamil (10.8 +/- 3.2 hours) and diltiazem (9.9 +/- 2.4 hours) (p less than 0.05) but not after nifedipine (8.6 +/- 2.4 hours) when compared with control (8.6 +/- 1.9 hours).,Effect of calcium channel blockers on theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3391002/),h,8.6,242194,DB00661,Verapamil
,22817837,peak concentration (Cmax),"Quercetin increased the peak concentration (Cmax) of ranolazine from 254 ± 8.45 to 324 ± 10.21 and 331 ± 9.65 ng/mL in SDS and MDS, respectively.",Influence of quercetin on the pharmacokinetics of ranolazine in rats and in vitro models. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22817837/),[ng] / [ml],254,242516,DB00661,Verapamil
,22817837,peak concentration (Cmax),"Quercetin increased the peak concentration (Cmax) of ranolazine from 254 ± 8.45 to 324 ± 10.21 and 331 ± 9.65 ng/mL in SDS and MDS, respectively.",Influence of quercetin on the pharmacokinetics of ranolazine in rats and in vitro models. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22817837/),[ng] / [ml],324,242517,DB00661,Verapamil
,22817837,peak concentration (Cmax),"Quercetin increased the peak concentration (Cmax) of ranolazine from 254 ± 8.45 to 324 ± 10.21 and 331 ± 9.65 ng/mL in SDS and MDS, respectively.",Influence of quercetin on the pharmacokinetics of ranolazine in rats and in vitro models. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22817837/),[ng] / [ml],331,242518,DB00661,Verapamil
,22817837,area under the curve (AUC),"Quercetin also increased area under the curve (AUC) of ranolazine from 1565.12 ± 52.24 to 2016.98 ± 142.65 and 2070.85 ± 271.60 ng/mL/h in SDS and MDS, respectively.",Influence of quercetin on the pharmacokinetics of ranolazine in rats and in vitro models. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22817837/),[ng] / [h·ml],1565.12,242519,DB00661,Verapamil
,22817837,area under the curve (AUC),"Quercetin also increased area under the curve (AUC) of ranolazine from 1565.12 ± 52.24 to 2016.98 ± 142.65 and 2070.85 ± 271.60 ng/mL/h in SDS and MDS, respectively.",Influence of quercetin on the pharmacokinetics of ranolazine in rats and in vitro models. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22817837/),[ng] / [h·ml],2016.98,242520,DB00661,Verapamil
,22817837,area under the curve (AUC),"Quercetin also increased area under the curve (AUC) of ranolazine from 1565.12 ± 52.24 to 2016.98 ± 142.65 and 2070.85 ± 271.60 ng/mL/h in SDS and MDS, respectively.",Influence of quercetin on the pharmacokinetics of ranolazine in rats and in vitro models. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22817837/),[ng] / [h·ml],2070.85,242521,DB00661,Verapamil
,20012601,relative bioavailability,"Consequently, the relative bioavailability of verapamil was also significantly increased (by 76.5%).",Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20012601/),%,76.5,243714,DB00661,Verapamil
,6891597,peak serum concentration,After p.o. administration the mean peak serum concentration of 125.6 ng/ml was attained on average 80 min later.,[Pharmacokinetics and pharmacodynamics of verapamil in healthy volunteers after single oral and sublingual administration]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891597/),[ng] / [ml],125.6,243840,DB00661,Verapamil
,6891597,half-life for the distribution phase (t1/2a),The half-life for the distribution phase (t1/2a) was 0.95 h and for the elimination phase (t1/2 beta) 6.08 h.,[Pharmacokinetics and pharmacodynamics of verapamil in healthy volunteers after single oral and sublingual administration]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891597/),h,0.95,243841,DB00661,Verapamil
,6891597,elimination phase (t1/2 beta),The half-life for the distribution phase (t1/2a) was 0.95 h and for the elimination phase (t1/2 beta) 6.08 h.,[Pharmacokinetics and pharmacodynamics of verapamil in healthy volunteers after single oral and sublingual administration]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891597/),h,6.08,243842,DB00661,Verapamil
,6891597,peak serum concentration,After sublingual administration the mean peak serum concentration of verapamil was 26 ng/ml attained on average after 71.7 min.,[Pharmacokinetics and pharmacodynamics of verapamil in healthy volunteers after single oral and sublingual administration]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891597/),[ng] / [ml],26,243843,DB00661,Verapamil
,6891597,t1/2a,The mean t1/2a was 0.73 h and the mean T1/2 beta 4.39 h.,[Pharmacokinetics and pharmacodynamics of verapamil in healthy volunteers after single oral and sublingual administration]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891597/),h,0.73,243844,DB00661,Verapamil
,6891597,T1/2 beta,The mean t1/2a was 0.73 h and the mean T1/2 beta 4.39 h.,[Pharmacokinetics and pharmacodynamics of verapamil in healthy volunteers after single oral and sublingual administration]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891597/),h,4.39,243845,DB00661,Verapamil
,6891597,relative bioavailability,The relative bioavailability of verapamil sublingually was 2.7 (p.o. = 1.0).,[Pharmacokinetics and pharmacodynamics of verapamil in healthy volunteers after single oral and sublingual administration]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6891597/),,2.7,243846,DB00661,Verapamil
,2183884,half-life,Antipyrine half-life of 10.04 +/- 1.43 h (mean +/- SD) after a week intake of nifedipine (20 mg twice daily) was not significantly different from the control value of 10.64 +/- 2.15 h; nor was that of 10.02 +/- 1.49 h after 2 weeks pretreatment with the calcium channel blocker in eight healthy volunteers.,Effect of nifedipine on antipyrine and theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),h,10.04,244288,DB00661,Verapamil
,2183884,half-life,Antipyrine half-life of 10.04 +/- 1.43 h (mean +/- SD) after a week intake of nifedipine (20 mg twice daily) was not significantly different from the control value of 10.64 +/- 2.15 h; nor was that of 10.02 +/- 1.49 h after 2 weeks pretreatment with the calcium channel blocker in eight healthy volunteers.,Effect of nifedipine on antipyrine and theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),h,10.64,244289,DB00661,Verapamil
,2183884,half-life,Antipyrine half-life of 10.04 +/- 1.43 h (mean +/- SD) after a week intake of nifedipine (20 mg twice daily) was not significantly different from the control value of 10.64 +/- 2.15 h; nor was that of 10.02 +/- 1.49 h after 2 weeks pretreatment with the calcium channel blocker in eight healthy volunteers.,Effect of nifedipine on antipyrine and theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),h,10.02,244290,DB00661,Verapamil
,2183884,clearance,"Control antipyrine clearance (ml min-1) of 44.40 +/- 10.58 was not significantly different from that of 45.66 +/- 9.34 and 46.87 +/- 9.63 after nifedipine pretreatment of 1 and 2 weeks, respectively.",Effect of nifedipine on antipyrine and theophylline disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[ml] / [min],44.40,244291,DB00661,Verapamil
,2183884,clearance,"Control antipyrine clearance (ml min-1) of 44.40 +/- 10.58 was not significantly different from that of 45.66 +/- 9.34 and 46.87 +/- 9.63 after nifedipine pretreatment of 1 and 2 weeks, respectively.",Effect of nifedipine on antipyrine and theophylline disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[ml] / [min],45.66,244292,DB00661,Verapamil
,2183884,clearance,"Control antipyrine clearance (ml min-1) of 44.40 +/- 10.58 was not significantly different from that of 45.66 +/- 9.34 and 46.87 +/- 9.63 after nifedipine pretreatment of 1 and 2 weeks, respectively.",Effect of nifedipine on antipyrine and theophylline disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[ml] / [min],46.87,244293,DB00661,Verapamil
,2183884,volume of distribution,"Similarly volume of distribution was unaltered: 0.601 +/- 0.074, 0.591 +/- 0.078 and 0.602 +/- 0.051 l kg-1, respectively.",Effect of nifedipine on antipyrine and theophylline disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[l] / [kg],0.601,244294,DB00661,Verapamil
,2183884,volume of distribution,"Similarly volume of distribution was unaltered: 0.601 +/- 0.074, 0.591 +/- 0.078 and 0.602 +/- 0.051 l kg-1, respectively.",Effect of nifedipine on antipyrine and theophylline disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[l] / [kg],0.591,244295,DB00661,Verapamil
,2183884,volume of distribution,"Similarly volume of distribution was unaltered: 0.601 +/- 0.074, 0.591 +/- 0.078 and 0.602 +/- 0.051 l kg-1, respectively.",Effect of nifedipine on antipyrine and theophylline disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[l] / [kg],0.602,244296,DB00661,Verapamil
,2183884,half-life,A week pretreatment with nifedipine did not significantly alter either of theophylline half-life (7.32 +/- 0.81 h (control) to 7.50 +/- 0.80 h) or clearance (42.10 +/- 5.84 ml min-1 (control) to 43.77 +/- 4.00 ml min-1) in six volunteers.,Effect of nifedipine on antipyrine and theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),h,7.32,244297,DB00661,Verapamil
,2183884,half-life,A week pretreatment with nifedipine did not significantly alter either of theophylline half-life (7.32 +/- 0.81 h (control) to 7.50 +/- 0.80 h) or clearance (42.10 +/- 5.84 ml min-1 (control) to 43.77 +/- 4.00 ml min-1) in six volunteers.,Effect of nifedipine on antipyrine and theophylline disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),h,7.50,244298,DB00661,Verapamil
,2183884,clearance,A week pretreatment with nifedipine did not significantly alter either of theophylline half-life (7.32 +/- 0.81 h (control) to 7.50 +/- 0.80 h) or clearance (42.10 +/- 5.84 ml min-1 (control) to 43.77 +/- 4.00 ml min-1) in six volunteers.,Effect of nifedipine on antipyrine and theophylline disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[ml] / [min],42.10,244299,DB00661,Verapamil
,2183884,clearance,A week pretreatment with nifedipine did not significantly alter either of theophylline half-life (7.32 +/- 0.81 h (control) to 7.50 +/- 0.80 h) or clearance (42.10 +/- 5.84 ml min-1 (control) to 43.77 +/- 4.00 ml min-1) in six volunteers.,Effect of nifedipine on antipyrine and theophylline disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[ml] / [min],43.77,244300,DB00661,Verapamil
,2183884,volume of distribution,However the change in volume of distribution: 0.451 +/- 0.053 l kg-1 (control) to 0.483 +/- 0.062 l kg-1 was significant (p less than 0.025).,Effect of nifedipine on antipyrine and theophylline disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[l] / [kg],0.451,244301,DB00661,Verapamil
,2183884,volume of distribution,However the change in volume of distribution: 0.451 +/- 0.053 l kg-1 (control) to 0.483 +/- 0.062 l kg-1 was significant (p less than 0.025).,Effect of nifedipine on antipyrine and theophylline disposition. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183884/),[l] / [kg],0.483,244302,DB00661,Verapamil
,16898076,peak plasma verapamil concentrations,"New retard tablets produced peak plasma verapamil concentrations of 81.34+/-5.69microg/l, time to peak plasma concentrations of 4.91+/-0.89h and an AUC (0-24h) of 1291+/-103.4h x microg/l, with a terminal phase half-life of 55.1+/-14.9h.",Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. II: study in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16898076/),[μg] / [l],81.34,244468,DB00661,Verapamil
,16898076,time to peak plasma concentrations,"New retard tablets produced peak plasma verapamil concentrations of 81.34+/-5.69microg/l, time to peak plasma concentrations of 4.91+/-0.89h and an AUC (0-24h) of 1291+/-103.4h x microg/l, with a terminal phase half-life of 55.1+/-14.9h.",Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. II: study in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16898076/),h,4.91,244469,DB00661,Verapamil
,16898076,AUC (0-24h),"New retard tablets produced peak plasma verapamil concentrations of 81.34+/-5.69microg/l, time to peak plasma concentrations of 4.91+/-0.89h and an AUC (0-24h) of 1291+/-103.4h x microg/l, with a terminal phase half-life of 55.1+/-14.9h.",Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. II: study in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16898076/),[h·μg] / [l],1291,244470,DB00661,Verapamil
,16898076,terminal phase half-life,"New retard tablets produced peak plasma verapamil concentrations of 81.34+/-5.69microg/l, time to peak plasma concentrations of 4.91+/-0.89h and an AUC (0-24h) of 1291+/-103.4h x microg/l, with a terminal phase half-life of 55.1+/-14.9h.",Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. II: study in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16898076/),h,55.1,244471,DB00661,Verapamil
,16898076,terminal plasma half-life,After intravenous administration verapamil exhibited biphasic elimination kinetics with a terminal plasma half-life of 2.36+/-0.42h and systemic clearance of 34.32+/-5.81 l/h.,Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. II: study in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16898076/),h,2.36,244472,DB00661,Verapamil
,16898076,systemic clearance,After intravenous administration verapamil exhibited biphasic elimination kinetics with a terminal plasma half-life of 2.36+/-0.42h and systemic clearance of 34.32+/-5.81 l/h.,Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. II: study in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16898076/),[l] / [h],34.32,244473,DB00661,Verapamil
,16898076,Bioavailability,Bioavailability of the new peroral retard formulation ranged from 19.49+/-4.41% to 67.69+/-11.70%.,Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. II: study in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16898076/),%,19.49,244474,DB00661,Verapamil
,16898076,Bioavailability,Bioavailability of the new peroral retard formulation ranged from 19.49+/-4.41% to 67.69+/-11.70%.,Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. II: study in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16898076/),%,67.69,244475,DB00661,Verapamil
,16898076,Input rates,Input rates for the new verapamil retard formulation ranged from 0.77+/-0.20mg/h to 5.57+/-1.58mg/h.,Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. II: study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16898076/),[mg] / [h],0.77,244476,DB00661,Verapamil
,16898076,Input rates,Input rates for the new verapamil retard formulation ranged from 0.77+/-0.20mg/h to 5.57+/-1.58mg/h.,Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. II: study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16898076/),[mg] / [h],5.57,244477,DB00661,Verapamil
,22139693,t(1/2),"In vivo, the oral administration of rifampicin with or without Pluronic F68, Labrasol or verapamil resulted in statistically significant effect on t(1/2) (4.83 to 7.75, 6.42 and 7.46 h) and total body clearance (0.46 to 0.26, 0.28, 0.24 L/h/kg).",Effects of Pluronic F68 and Labrasol on the intestinal absorption and pharmacokinetics of rifampicin in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22139693/),h,4.83 to 7.75,245672,DB00661,Verapamil
,22139693,t(1/2),"In vivo, the oral administration of rifampicin with or without Pluronic F68, Labrasol or verapamil resulted in statistically significant effect on t(1/2) (4.83 to 7.75, 6.42 and 7.46 h) and total body clearance (0.46 to 0.26, 0.28, 0.24 L/h/kg).",Effects of Pluronic F68 and Labrasol on the intestinal absorption and pharmacokinetics of rifampicin in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22139693/),h,6.42,245673,DB00661,Verapamil
,22139693,t(1/2),"In vivo, the oral administration of rifampicin with or without Pluronic F68, Labrasol or verapamil resulted in statistically significant effect on t(1/2) (4.83 to 7.75, 6.42 and 7.46 h) and total body clearance (0.46 to 0.26, 0.28, 0.24 L/h/kg).",Effects of Pluronic F68 and Labrasol on the intestinal absorption and pharmacokinetics of rifampicin in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22139693/),h,7.46,245674,DB00661,Verapamil
,22139693,total body clearance,"In vivo, the oral administration of rifampicin with or without Pluronic F68, Labrasol or verapamil resulted in statistically significant effect on t(1/2) (4.83 to 7.75, 6.42 and 7.46 h) and total body clearance (0.46 to 0.26, 0.28, 0.24 L/h/kg).",Effects of Pluronic F68 and Labrasol on the intestinal absorption and pharmacokinetics of rifampicin in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22139693/),[l] / [h·kg],0.46 to 0.26,245675,DB00661,Verapamil
,22139693,total body clearance,"In vivo, the oral administration of rifampicin with or without Pluronic F68, Labrasol or verapamil resulted in statistically significant effect on t(1/2) (4.83 to 7.75, 6.42 and 7.46 h) and total body clearance (0.46 to 0.26, 0.28, 0.24 L/h/kg).",Effects of Pluronic F68 and Labrasol on the intestinal absorption and pharmacokinetics of rifampicin in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22139693/),[l] / [h·kg],0.28,245676,DB00661,Verapamil
,22139693,total body clearance,"In vivo, the oral administration of rifampicin with or without Pluronic F68, Labrasol or verapamil resulted in statistically significant effect on t(1/2) (4.83 to 7.75, 6.42 and 7.46 h) and total body clearance (0.46 to 0.26, 0.28, 0.24 L/h/kg).",Effects of Pluronic F68 and Labrasol on the intestinal absorption and pharmacokinetics of rifampicin in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22139693/),[l] / [h·kg],0.24,245677,DB00661,Verapamil
,8375122,area under the plasma concentration-time curves (AUC),"The area under the plasma concentration-time curves (AUC) of (S)- and (R)-verapamil were greater in the elderly group than in the young group [(S)-/(R)-verapamil (mean +/- SD), 214.4 +/- 123.0/1582.2 +/- 763.0 and 50.4 +/- 36.5/584.9 +/- 252.4 ng.hr/ml for the elderly and young groups, respectively (p < 0.001/p < 0.001)].",The effects of age and gender on the stereoselective pharmacokinetics of verapamil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8375122/),[h·ng] / [ml],214.4,245712,DB00661,Verapamil
,8375122,area under the plasma concentration-time curves (AUC),"The area under the plasma concentration-time curves (AUC) of (S)- and (R)-verapamil were greater in the elderly group than in the young group [(S)-/(R)-verapamil (mean +/- SD), 214.4 +/- 123.0/1582.2 +/- 763.0 and 50.4 +/- 36.5/584.9 +/- 252.4 ng.hr/ml for the elderly and young groups, respectively (p < 0.001/p < 0.001)].",The effects of age and gender on the stereoselective pharmacokinetics of verapamil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8375122/),[h·ng] / [ml],1582.2,245713,DB00661,Verapamil
,8375122,area under the plasma concentration-time curves (AUC),"The area under the plasma concentration-time curves (AUC) of (S)- and (R)-verapamil were greater in the elderly group than in the young group [(S)-/(R)-verapamil (mean +/- SD), 214.4 +/- 123.0/1582.2 +/- 763.0 and 50.4 +/- 36.5/584.9 +/- 252.4 ng.hr/ml for the elderly and young groups, respectively (p < 0.001/p < 0.001)].",The effects of age and gender on the stereoselective pharmacokinetics of verapamil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8375122/),[h·ng] / [ml],50.4,245714,DB00661,Verapamil
,8375122,area under the plasma concentration-time curves (AUC),"The area under the plasma concentration-time curves (AUC) of (S)- and (R)-verapamil were greater in the elderly group than in the young group [(S)-/(R)-verapamil (mean +/- SD), 214.4 +/- 123.0/1582.2 +/- 763.0 and 50.4 +/- 36.5/584.9 +/- 252.4 ng.hr/ml for the elderly and young groups, respectively (p < 0.001/p < 0.001)].",The effects of age and gender on the stereoselective pharmacokinetics of verapamil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8375122/),[h·ng] / [ml],584.9,245715,DB00661,Verapamil
,8375122,apparent oral clearance,"Conversely, the apparent oral clearance values of (S)- and (R)-verapamil were significantly smaller in the elderly group than in the young group [(S)-/(R)-verapamil (mean +/- SD), 4.8 +/- 3.0/0.53 +/- 0.21 and 22.5 +/- 21.3/1.30 +/- 0.67 L/hr/kg for the elderly and young groups, respectively (p < 0.01/p < 0.001)].",The effects of age and gender on the stereoselective pharmacokinetics of verapamil. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8375122/),[l] / [h·kg],4.8,245716,DB00661,Verapamil
,8375122,apparent oral clearance,"Conversely, the apparent oral clearance values of (S)- and (R)-verapamil were significantly smaller in the elderly group than in the young group [(S)-/(R)-verapamil (mean +/- SD), 4.8 +/- 3.0/0.53 +/- 0.21 and 22.5 +/- 21.3/1.30 +/- 0.67 L/hr/kg for the elderly and young groups, respectively (p < 0.01/p < 0.001)].",The effects of age and gender on the stereoselective pharmacokinetics of verapamil. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8375122/),[l] / [h·kg],0.53,245717,DB00661,Verapamil
,8375122,apparent oral clearance,"Conversely, the apparent oral clearance values of (S)- and (R)-verapamil were significantly smaller in the elderly group than in the young group [(S)-/(R)-verapamil (mean +/- SD), 4.8 +/- 3.0/0.53 +/- 0.21 and 22.5 +/- 21.3/1.30 +/- 0.67 L/hr/kg for the elderly and young groups, respectively (p < 0.01/p < 0.001)].",The effects of age and gender on the stereoselective pharmacokinetics of verapamil. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8375122/),[l] / [h·kg],22.5,245718,DB00661,Verapamil
,8375122,apparent oral clearance,"Conversely, the apparent oral clearance values of (S)- and (R)-verapamil were significantly smaller in the elderly group than in the young group [(S)-/(R)-verapamil (mean +/- SD), 4.8 +/- 3.0/0.53 +/- 0.21 and 22.5 +/- 21.3/1.30 +/- 0.67 L/hr/kg for the elderly and young groups, respectively (p < 0.01/p < 0.001)].",The effects of age and gender on the stereoselective pharmacokinetics of verapamil. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8375122/),[l] / [h·kg],1.30,245719,DB00661,Verapamil
,14704918,Area under the curve (AUC),"Vitreal pharmacokinetic parameters of quinidine in the presence of verapamil, i.e., Area under the curve (AUC) (39.27 +/- 6.47 min.","Effect of P-glycoprotein on the ocular disposition of a model substrate, quinidine. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14704918/),min,39.27,246287,DB00661,Verapamil
,14704918,maximum concentration achieved (Cmax),"microg/ml), maximum concentration achieved (Cmax) (0.095 +/- 0.011 microg/ml), vitreal elimination half-life (231.96 +/- 10.77 min), vitreal permeation half-life (16.57 +/- 6.96 min) were significantly different from the control values (19.21 +/- 3.73 min.","Effect of P-glycoprotein on the ocular disposition of a model substrate, quinidine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14704918/),[μg] / [ml],0.095,246288,DB00661,Verapamil
,14704918,elimination half-life,"microg/ml), maximum concentration achieved (Cmax) (0.095 +/- 0.011 microg/ml), vitreal elimination half-life (231.96 +/- 10.77 min), vitreal permeation half-life (16.57 +/- 6.96 min) were significantly different from the control values (19.21 +/- 3.73 min.","Effect of P-glycoprotein on the ocular disposition of a model substrate, quinidine. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14704918/),min,231.96,246289,DB00661,Verapamil
,14704918,permeation half-life,"microg/ml), maximum concentration achieved (Cmax) (0.095 +/- 0.011 microg/ml), vitreal elimination half-life (231.96 +/- 10.77 min), vitreal permeation half-life (16.57 +/- 6.96 min) were significantly different from the control values (19.21 +/- 3.73 min.","Effect of P-glycoprotein on the ocular disposition of a model substrate, quinidine. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14704918/),min,16.57,246290,DB00661,Verapamil
,14704918,permeation half-life,"microg/ml), maximum concentration achieved (Cmax) (0.095 +/- 0.011 microg/ml), vitreal elimination half-life (231.96 +/- 10.77 min), vitreal permeation half-life (16.57 +/- 6.96 min) were significantly different from the control values (19.21 +/- 3.73 min.","Effect of P-glycoprotein on the ocular disposition of a model substrate, quinidine. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14704918/),min,19.21,246291,DB00661,Verapamil
,3957489,Cumulative,"Cumulative urinary excretion of verapamil, norverapamil, D-617 and D-620 up to 48 h postdose was averaged to 1%, 2.2%, 11.4%, and 6.7% of the dose administered, respectively.",Disposition kinetics and urinary excretion of verapamil and some of its primary metabolites after oral administration in patients with angina pectoris. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957489/),%,1,246414,DB00661,Verapamil
,3957489,Cumulative,"Cumulative urinary excretion of verapamil, norverapamil, D-617 and D-620 up to 48 h postdose was averaged to 1%, 2.2%, 11.4%, and 6.7% of the dose administered, respectively.",Disposition kinetics and urinary excretion of verapamil and some of its primary metabolites after oral administration in patients with angina pectoris. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957489/),%,2.2,246415,DB00661,Verapamil
,3957489,Cumulative,"Cumulative urinary excretion of verapamil, norverapamil, D-617 and D-620 up to 48 h postdose was averaged to 1%, 2.2%, 11.4%, and 6.7% of the dose administered, respectively.",Disposition kinetics and urinary excretion of verapamil and some of its primary metabolites after oral administration in patients with angina pectoris. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957489/),%,6.7,246416,DB00661,Verapamil
,3957489,urinary excretion,"Cumulative urinary excretion of verapamil, norverapamil, D-617 and D-620 up to 48 h postdose was averaged to 1%, 2.2%, 11.4%, and 6.7% of the dose administered, respectively.",Disposition kinetics and urinary excretion of verapamil and some of its primary metabolites after oral administration in patients with angina pectoris. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957489/),%,1,246417,DB00661,Verapamil
,3957489,urinary excretion,"Cumulative urinary excretion of verapamil, norverapamil, D-617 and D-620 up to 48 h postdose was averaged to 1%, 2.2%, 11.4%, and 6.7% of the dose administered, respectively.",Disposition kinetics and urinary excretion of verapamil and some of its primary metabolites after oral administration in patients with angina pectoris. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957489/),%,2.2,246418,DB00661,Verapamil
,3957489,urinary excretion,"Cumulative urinary excretion of verapamil, norverapamil, D-617 and D-620 up to 48 h postdose was averaged to 1%, 2.2%, 11.4%, and 6.7% of the dose administered, respectively.",Disposition kinetics and urinary excretion of verapamil and some of its primary metabolites after oral administration in patients with angina pectoris. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957489/),%,11.4,246419,DB00661,Verapamil
,3957489,urinary excretion,"Cumulative urinary excretion of verapamil, norverapamil, D-617 and D-620 up to 48 h postdose was averaged to 1%, 2.2%, 11.4%, and 6.7% of the dose administered, respectively.",Disposition kinetics and urinary excretion of verapamil and some of its primary metabolites after oral administration in patients with angina pectoris. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957489/),%,6.7,246420,DB00661,Verapamil
,3957489,bioavailability,The extent of verapamil bioavailability was directly measured in one patient receiving an intravenous dose as well as an oral one and was found to be 42.3%.,Disposition kinetics and urinary excretion of verapamil and some of its primary metabolites after oral administration in patients with angina pectoris. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957489/),%,42.3,246421,DB00661,Verapamil
,3957489,bioavailability,"In other patients, bioavailability was assessed by means of a regression equation relating the reciprocal of bioavailability and oral clearance of the drug, and was averaged at 35.1%.",Disposition kinetics and urinary excretion of verapamil and some of its primary metabolites after oral administration in patients with angina pectoris. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3957489/),%,35.1,246422,DB00661,Verapamil
,8198928,area under the midazolam concentration-time curve,3. The area under the midazolam concentration-time curve was increased from 12 +/- 1 microgram ml-1 min to 45 +/- 5 micrograms ml-1 min by diltiazem (P < 0.001) and to 35 +/- 5 micrograms ml-1 min by verapamil (P < 0.001).,Dose of midazolam should be reduced during diltiazem and verapamil treatments. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198928/),[min·μg] / [ml],12,247239,DB00661,Verapamil
,8198928,area under the midazolam concentration-time curve,3. The area under the midazolam concentration-time curve was increased from 12 +/- 1 microgram ml-1 min to 45 +/- 5 micrograms ml-1 min by diltiazem (P < 0.001) and to 35 +/- 5 micrograms ml-1 min by verapamil (P < 0.001).,Dose of midazolam should be reduced during diltiazem and verapamil treatments. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198928/),[min·μg] / [ml],45,247240,DB00661,Verapamil
,8198928,area under the midazolam concentration-time curve,3. The area under the midazolam concentration-time curve was increased from 12 +/- 1 microgram ml-1 min to 45 +/- 5 micrograms ml-1 min by diltiazem (P < 0.001) and to 35 +/- 5 micrograms ml-1 min by verapamil (P < 0.001).,Dose of midazolam should be reduced during diltiazem and verapamil treatments. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198928/),[min·μg] / [ml],35,247241,DB00661,Verapamil
,2007320,steady-state plasma concentrations,"Verapamil induced a 44% increase in steady-state plasma concentrations of digoxin, from 0.80 +/- 0.24 to 1.15 +/- 0.40 nmol/L (p less than 0.01).",Digoxin-verapamil interaction: reduction of biliary but not renal digoxin clearance in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2007320/),[nM] / [l],0.80,248134,DB00661,Verapamil
,2007320,steady-state plasma concentrations,"Verapamil induced a 44% increase in steady-state plasma concentrations of digoxin, from 0.80 +/- 0.24 to 1.15 +/- 0.40 nmol/L (p less than 0.01).",Digoxin-verapamil interaction: reduction of biliary but not renal digoxin clearance in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2007320/),[nM] / [l],1.15,248135,DB00661,Verapamil
,2007320,biliary clearance,"The biliary clearance of digoxin decreased by 43%, from 187 +/- 89 to 101 +/- 55 ml/min (p less than 0.05), in the presence of verapamil, whereas the renal clearance was unaffected (153 +/- 31 versus 173 +/- 51 ml/min; difference not significant).",Digoxin-verapamil interaction: reduction of biliary but not renal digoxin clearance in humans. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2007320/),[ml] / [min],187,248136,DB00661,Verapamil
,2007320,biliary clearance,"The biliary clearance of digoxin decreased by 43%, from 187 +/- 89 to 101 +/- 55 ml/min (p less than 0.05), in the presence of verapamil, whereas the renal clearance was unaffected (153 +/- 31 versus 173 +/- 51 ml/min; difference not significant).",Digoxin-verapamil interaction: reduction of biliary but not renal digoxin clearance in humans. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2007320/),[ml] / [min],101,248137,DB00661,Verapamil
,2007320,renal clearance,"The biliary clearance of digoxin decreased by 43%, from 187 +/- 89 to 101 +/- 55 ml/min (p less than 0.05), in the presence of verapamil, whereas the renal clearance was unaffected (153 +/- 31 versus 173 +/- 51 ml/min; difference not significant).",Digoxin-verapamil interaction: reduction of biliary but not renal digoxin clearance in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2007320/),[ml] / [min],153,248138,DB00661,Verapamil
,2007320,renal clearance,"The biliary clearance of digoxin decreased by 43%, from 187 +/- 89 to 101 +/- 55 ml/min (p less than 0.05), in the presence of verapamil, whereas the renal clearance was unaffected (153 +/- 31 versus 173 +/- 51 ml/min; difference not significant).",Digoxin-verapamil interaction: reduction of biliary but not renal digoxin clearance in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2007320/),[ml] / [min],173,248139,DB00661,Verapamil
,31747844,peak plasma concentration,"The results showed that verapamil could significantly increase the peak plasma concentration (from 146.9 ± 10.17 to 193.97 ± 10.53 ng/mL), and decrease the oral clearance (from 14.69 ± 4.42 to 8.09 ± 3.03 L/h/kg) of oridonin.",Influence of verapamil on the pharmacokinetics of oridonin in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31747844/),[ng] / [ml],146.9,253865,DB00661,Verapamil
,31747844,peak plasma concentration,"The results showed that verapamil could significantly increase the peak plasma concentration (from 146.9 ± 10.17 to 193.97 ± 10.53 ng/mL), and decrease the oral clearance (from 14.69 ± 4.42 to 8.09 ± 3.03 L/h/kg) of oridonin.",Influence of verapamil on the pharmacokinetics of oridonin in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31747844/),[ng] / [ml],193.97,253866,DB00661,Verapamil
,31747844,oral clearance,"The results showed that verapamil could significantly increase the peak plasma concentration (from 146.9 ± 10.17 to 193.97 ± 10.53 ng/mL), and decrease the oral clearance (from 14.69 ± 4.42 to 8.09 ± 3.03 L/h/kg) of oridonin.",Influence of verapamil on the pharmacokinetics of oridonin in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31747844/),[l] / [h·kg],14.69,253867,DB00661,Verapamil
,31747844,oral clearance,"The results showed that verapamil could significantly increase the peak plasma concentration (from 146.9 ± 10.17 to 193.97 ± 10.53 ng/mL), and decrease the oral clearance (from 14.69 ± 4.42 to 8.09 ± 3.03 L/h/kg) of oridonin.",Influence of verapamil on the pharmacokinetics of oridonin in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31747844/),[l] / [h·kg],8.09,253868,DB00661,Verapamil
,31747844,efflux ratio,"The Caco-2 cell transwell experiments indicated that verapamil could decrease the efflux ratio of oridonin from 1.67 to 1.15, and the intrinsic clearance rate of oridonin was decreased by the pre-treatment with verapamil (40.06 ± 2.5 vs. 36.09 ± 3.7 µL/min/mg protein).",Influence of verapamil on the pharmacokinetics of oridonin in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31747844/),,1.67,253869,DB00661,Verapamil
,31747844,efflux ratio,"The Caco-2 cell transwell experiments indicated that verapamil could decrease the efflux ratio of oridonin from 1.67 to 1.15, and the intrinsic clearance rate of oridonin was decreased by the pre-treatment with verapamil (40.06 ± 2.5 vs. 36.09 ± 3.7 µL/min/mg protein).",Influence of verapamil on the pharmacokinetics of oridonin in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31747844/),,1.15,253870,DB00661,Verapamil
,31747844,intrinsic clearance rate,"The Caco-2 cell transwell experiments indicated that verapamil could decrease the efflux ratio of oridonin from 1.67 to 1.15, and the intrinsic clearance rate of oridonin was decreased by the pre-treatment with verapamil (40.06 ± 2.5 vs. 36.09 ± 3.7 µL/min/mg protein).",Influence of verapamil on the pharmacokinetics of oridonin in rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31747844/),[μl] / [mg·min],40.06,253871,DB00661,Verapamil
,31747844,intrinsic clearance rate,"The Caco-2 cell transwell experiments indicated that verapamil could decrease the efflux ratio of oridonin from 1.67 to 1.15, and the intrinsic clearance rate of oridonin was decreased by the pre-treatment with verapamil (40.06 ± 2.5 vs. 36.09 ± 3.7 µL/min/mg protein).",Influence of verapamil on the pharmacokinetics of oridonin in rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31747844/),[μl] / [mg·min],36.09,253872,DB00661,Verapamil
,9210977,systemic clearance,"After intravenous administration the systemic clearance of R-verapamil was significantly greater than that of S-verapamil; 34.9 +/- 7 against 23.7 +/- 3.7 mL min-1 kg-1 (mean +/- SD), respectively.",Pharmacokinetics of the enantiomers of verapamil after intravenous and oral administration of racemic verapamil in a rat model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210977/),[ml] / [kg·min],34.9,254464,DB00661,Verapamil
,9210977,systemic clearance,"After intravenous administration the systemic clearance of R-verapamil was significantly greater than that of S-verapamil; 34.9 +/- 7 against 23.7 +/- 3.7 mL min-1 kg-1 (mean +/- SD), respectively.",Pharmacokinetics of the enantiomers of verapamil after intravenous and oral administration of racemic verapamil in a rat model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210977/),[ml] / [kg·min],23.7,254465,DB00661,Verapamil
,9210977,clearance,"After oral administration, the clearance of R-verapamil was significantly greater than that of S-verapamil, 889 +/- 294 against 351 +/- 109 mL min-1 kg-1, respectively.",Pharmacokinetics of the enantiomers of verapamil after intravenous and oral administration of racemic verapamil in a rat model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210977/),[ml] / [kg·min],889,254466,DB00661,Verapamil
,9210977,clearance,"After oral administration, the clearance of R-verapamil was significantly greater than that of S-verapamil, 889 +/- 294 against 351 +/- 109 mL min-1 kg-1, respectively.",Pharmacokinetics of the enantiomers of verapamil after intravenous and oral administration of racemic verapamil in a rat model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210977/),[ml] / [kg·min],351,254467,DB00661,Verapamil
,9210977,apparent oral bioavailability,"The apparent oral bioavailability of S-verapamil was greater than that of R-verapamil, 0.074 +/- 0.031 against 0.041 +/- 0.011, respectively.",Pharmacokinetics of the enantiomers of verapamil after intravenous and oral administration of racemic verapamil in a rat model. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210977/),,0.074,254468,DB00661,Verapamil
,9210977,apparent oral bioavailability,"The apparent oral bioavailability of S-verapamil was greater than that of R-verapamil, 0.074 +/- 0.031 against 0.041 +/- 0.011, respectively.",Pharmacokinetics of the enantiomers of verapamil after intravenous and oral administration of racemic verapamil in a rat model. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210977/),,0.041,254469,DB00661,Verapamil
,11996822,C(max),"For buccal formulation the average values of C(max) and AUC(0-24 h) for verapamil were much higher than for the reference Staveran tablets and amounted to 51.28 and 320.23 ng/ml h, respectively.",Pharmacokinetics of verapamil and its metabolite norverapamil from a buccal drug formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996822/),[ng] / [h·ml],51.28,256007,DB00661,Verapamil
,11996822,AUC(0-24 h),"For buccal formulation the average values of C(max) and AUC(0-24 h) for verapamil were much higher than for the reference Staveran tablets and amounted to 51.28 and 320.23 ng/ml h, respectively.",Pharmacokinetics of verapamil and its metabolite norverapamil from a buccal drug formulation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996822/),[ng] / [h·ml],320.23,256008,DB00661,Verapamil
,9547706,flow rate,"At a flow rate of 1.5 ml min-1, a complete analysis was completed in less than 6 min.",Simplified reversed-phase HPLC method with spectrophotometric detection for the assay of verapamil in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9547706/),[ml] / [min],1.5,256381,DB00661,Verapamil
,9547706,Recoveries,Recoveries for the same drug concentrations from spiked rat plasma ranged from 85.6-93.0% (n = 8).,Simplified reversed-phase HPLC method with spectrophotometric detection for the assay of verapamil in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9547706/),%,85.6-93.0,256382,DB00661,Verapamil
,9547706,limit of detectability,The limit of detectability was about 0.1 microgram ml-1.,Simplified reversed-phase HPLC method with spectrophotometric detection for the assay of verapamil in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9547706/),[μg] / [ml],0.1,256383,DB00661,Verapamil
,16832615,bioavailability,"The predicted bioavailability of the p.o. 25, 50, 100 and 400 mg doses of talinolol was 64, 76, 85, 94%, respectively.",In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16832615/),%,64,256572,DB00661,Verapamil
,16832615,bioavailability,"The predicted bioavailability of the p.o. 25, 50, 100 and 400 mg doses of talinolol was 64, 76, 85, 94%, respectively.",In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16832615/),%,76,256573,DB00661,Verapamil
,16832615,bioavailability,"The predicted bioavailability of the p.o. 25, 50, 100 and 400 mg doses of talinolol was 64, 76, 85, 94%, respectively.",In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16832615/),%,85,256574,DB00661,Verapamil
,16832615,bioavailability,"The predicted bioavailability of the p.o. 25, 50, 100 and 400 mg doses of talinolol was 64, 76, 85, 94%, respectively.",In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16832615/),%,94,256575,DB00661,Verapamil
,16832615,EC50,"For all simulations, EC50 was 114 nM and E0 was 83 bpm.",In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16832615/),nM,114,256576,DB00661,Verapamil
,16832615,E0,"For all simulations, EC50 was 114 nM and E0 was 83 bpm.",In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16832615/),bpm,83,256577,DB00661,Verapamil
,24370612,AUC/dose,"The pharmacokinetic parameter estimations of ROC showed AUC/dose of 563 μg min/mL, total clearance of 2.5 mL/min/kg, volume of distribution at steady state of 190 mL/kg and mean residence time of 83 min.",Analysis of rocuronium in human plasma by liquid chromatography-tandem mass spectrometry with application in clinical pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24370612/),[min·μg] / [ml],563,257382,DB00661,Verapamil
,24370612,total clearance,"The pharmacokinetic parameter estimations of ROC showed AUC/dose of 563 μg min/mL, total clearance of 2.5 mL/min/kg, volume of distribution at steady state of 190 mL/kg and mean residence time of 83 min.",Analysis of rocuronium in human plasma by liquid chromatography-tandem mass spectrometry with application in clinical pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24370612/),[ml] / [kg·min],2.5,257383,DB00661,Verapamil
,24370612,volume of distribution at steady state,"The pharmacokinetic parameter estimations of ROC showed AUC/dose of 563 μg min/mL, total clearance of 2.5 mL/min/kg, volume of distribution at steady state of 190 mL/kg and mean residence time of 83 min.",Analysis of rocuronium in human plasma by liquid chromatography-tandem mass spectrometry with application in clinical pharmacokinetics. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24370612/),[ml] / [kg],190,257384,DB00661,Verapamil
,24370612,mean residence time,"The pharmacokinetic parameter estimations of ROC showed AUC/dose of 563 μg min/mL, total clearance of 2.5 mL/min/kg, volume of distribution at steady state of 190 mL/kg and mean residence time of 83 min.",Analysis of rocuronium in human plasma by liquid chromatography-tandem mass spectrometry with application in clinical pharmacokinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24370612/),min,83,257385,DB00661,Verapamil
,24555505,total area under the plasma concentration-time curve from zero to infinity (AUC),"In addition, the total area under the plasma concentration-time curve from zero to infinity (AUC) of the vitexin plus verapamil group and of the normal saline group was 44.9 and 39.8 μgċ min/mL, respectively.","Hepatic, gastric, and intestinal first-pass effects of vitexin in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24555505/),[min·μgċ] / [ml],44.9,257787,DB00661,Verapamil
,24555505,total area under the plasma concentration-time curve from zero to infinity (AUC),"In addition, the total area under the plasma concentration-time curve from zero to infinity (AUC) of the vitexin plus verapamil group and of the normal saline group was 44.9 and 39.8 μgċ min/mL, respectively.","Hepatic, gastric, and intestinal first-pass effects of vitexin in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24555505/),[min·μgċ] / [ml],39.8,257788,DB00661,Verapamil
,1969949,binding,The binding of verapamil was ca 85%.,Influence of lignocaine on plasma protein binding and pharmacokinetics of verapamil in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1969949/),%,85,258238,DB00661,Verapamil
,30173622,maximum concentration (Cmax),"The results showed that when the rats were pretreated with verapamil, the maximum concentration (Cmax) of puerarin increased from 683.7 ± 51.2 to 933.5 ± 75.8 ng/mL (p < 0.05), and the area under the concentration-time curve from zero to infinity (AUC0-inf) also increased from 3687.3 ± 444.6 to 5006.1 ± 658.6 μg·h/L (p < 0.05).",Effects of verapamil on the pharmacokinetics of puerarin in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30173622/),[ng] / [ml],683.7,258495,DB00661,Verapamil
,30173622,maximum concentration (Cmax),"The results showed that when the rats were pretreated with verapamil, the maximum concentration (Cmax) of puerarin increased from 683.7 ± 51.2 to 933.5 ± 75.8 ng/mL (p < 0.05), and the area under the concentration-time curve from zero to infinity (AUC0-inf) also increased from 3687.3 ± 444.6 to 5006.1 ± 658.6 μg·h/L (p < 0.05).",Effects of verapamil on the pharmacokinetics of puerarin in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30173622/),[ng] / [ml],933.5,258496,DB00661,Verapamil
,30173622,area under the concentration-time curve from zero to infinity (AUC0-inf),"The results showed that when the rats were pretreated with verapamil, the maximum concentration (Cmax) of puerarin increased from 683.7 ± 51.2 to 933.5 ± 75.8 ng/mL (p < 0.05), and the area under the concentration-time curve from zero to infinity (AUC0-inf) also increased from 3687.3 ± 444.6 to 5006.1 ± 658.6 μg·h/L (p < 0.05).",Effects of verapamil on the pharmacokinetics of puerarin in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30173622/),[h·μg] / [l],3687.3,258497,DB00661,Verapamil
,30173622,area under the concentration-time curve from zero to infinity (AUC0-inf),"The results showed that when the rats were pretreated with verapamil, the maximum concentration (Cmax) of puerarin increased from 683.7 ± 51.2 to 933.5 ± 75.8 ng/mL (p < 0.05), and the area under the concentration-time curve from zero to infinity (AUC0-inf) also increased from 3687.3 ± 444.6 to 5006.1 ± 658.6 μg·h/L (p < 0.05).",Effects of verapamil on the pharmacokinetics of puerarin in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30173622/),[h·μg] / [l],5006.1,258498,DB00661,Verapamil
,30173622,efflux ratio,The Caco-2 cell transwell experiments indicated that verapamil could decrease the efflux ratio of puerarin from 1.90 to 1.19 through inhibiting the activity of P-gp.,Effects of verapamil on the pharmacokinetics of puerarin in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30173622/),,1.90,258499,DB00661,Verapamil
,30173622,efflux ratio,The Caco-2 cell transwell experiments indicated that verapamil could decrease the efflux ratio of puerarin from 1.90 to 1.19 through inhibiting the activity of P-gp.,Effects of verapamil on the pharmacokinetics of puerarin in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30173622/),,1.19,258500,DB00661,Verapamil
,3937500,bioavailabilities,"The bioavailabilities of bepridil, diltiazem and nifedipine are of the order of 40 to 60%; those of verapamil and nicarpidine are lower, 10-20% and 15-30%, respectively.",[Clinical pharmacology of calcium inhibitors]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3937500/),%,40 to 60,259217,DB00661,Verapamil
,3937500,bioavailabilities,"The bioavailabilities of bepridil, diltiazem and nifedipine are of the order of 40 to 60%; those of verapamil and nicarpidine are lower, 10-20% and 15-30%, respectively.",[Clinical pharmacology of calcium inhibitors]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3937500/),%,10-20,259218,DB00661,Verapamil
,3937500,bioavailabilities,"The bioavailabilities of bepridil, diltiazem and nifedipine are of the order of 40 to 60%; those of verapamil and nicarpidine are lower, 10-20% and 15-30%, respectively.",[Clinical pharmacology of calcium inhibitors]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3937500/),%,15-30,259219,DB00661,Verapamil
,3937500,volumes of distribution,"Protein binding is high but does not interfere in the distribution; the volumes of distribution of bepridil, diltiazem and verapamil are large (4-5 l/kg); those of nifedipine and nicardipine are smaller (l l/kg).",[Clinical pharmacology of calcium inhibitors]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3937500/),[l] / [kg],4-5,259220,DB00661,Verapamil
,3937500,halflives,"The halflives of diltiazem, nifedipine, nicardipine and verapamil are short (1 to 5 hours); those of bepridil and perhexiline are longer (2 to 3 days).",[Clinical pharmacology of calcium inhibitors]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3937500/),h,1 to 5,259221,DB00661,Verapamil
,3937500,halflives,"The halflives of diltiazem, nifedipine, nicardipine and verapamil are short (1 to 5 hours); those of bepridil and perhexiline are longer (2 to 3 days).",[Clinical pharmacology of calcium inhibitors]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3937500/),d,2 to 3,259222,DB00661,Verapamil
,2475688,Peak BP reduction,"Peak BP reduction with 240 mg q.i.d. SR (6 h postdose) or 80 mg t.i.d. IR (4 h postdose) averaged 28/18 and 23/20 mm Hg, respectively.","Comparative efficacy, safety, and kinetics of immediate- and slow-release verapamil in hispanic patients with essential hypertension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2475688/),,28,259223,DB00661,Verapamil
,2475688,Peak BP reduction,"Peak BP reduction with 240 mg q.i.d. SR (6 h postdose) or 80 mg t.i.d. IR (4 h postdose) averaged 28/18 and 23/20 mm Hg, respectively.","Comparative efficacy, safety, and kinetics of immediate- and slow-release verapamil in hispanic patients with essential hypertension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2475688/),,23,259224,DB00661,Verapamil
,2475688,Peak PR prolongation,Peak PR prolongation averaged 43 ms for SR and 56 ms with IR.,"Comparative efficacy, safety, and kinetics of immediate- and slow-release verapamil in hispanic patients with essential hypertension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2475688/),ms,43,259225,DB00661,Verapamil
,2475688,Peak PR prolongation,Peak PR prolongation averaged 43 ms for SR and 56 ms with IR.,"Comparative efficacy, safety, and kinetics of immediate- and slow-release verapamil in hispanic patients with essential hypertension. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2475688/),,56,259226,DB00661,Verapamil
,25567760,entrapment,"Results indicated that the entrapment, mean size and zata potential of VLX - SLN was 74.9 ± 3.0 %, 186.3 ± 69.26 nm and -22.8 ± 7.78 mv, respectively.",Increased brain uptake of venlafaxine loaded solid lipid nanoparticles by overcoming the efflux function and expression of P-gp. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567760/),%,74.9,259877,DB00661,Verapamil
,25567760,mean size,"Results indicated that the entrapment, mean size and zata potential of VLX - SLN was 74.9 ± 3.0 %, 186.3 ± 69.26 nm and -22.8 ± 7.78 mv, respectively.",Increased brain uptake of venlafaxine loaded solid lipid nanoparticles by overcoming the efflux function and expression of P-gp. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567760/),nm,186.3,259878,DB00661,Verapamil
,25567760,zata potential,"Results indicated that the entrapment, mean size and zata potential of VLX - SLN was 74.9 ± 3.0 %, 186.3 ± 69.26 nm and -22.8 ± 7.78 mv, respectively.",Increased brain uptake of venlafaxine loaded solid lipid nanoparticles by overcoming the efflux function and expression of P-gp. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25567760/),mv,-22.8,259879,DB00661,Verapamil
,11282217,M/B(obs),M/B(obs) was near 15.,Pharmacokinetics of verapamil in lactating rabbits. Prediction of verapamil distribution into rabbit milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11282217/),,15,260633,DB00661,Verapamil
,2262922,plasma half lives,"A toxicokinetic study performed in two cases showed plasma half lives of 7.9 and 13.2 hours, total body clearances of 425 and 298 ml/min.",[Acute verapamil poisoning. 6 cases. Review of the literature]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2262922/),h,7.9,260960,DB00661,Verapamil
,2262922,plasma half lives,"A toxicokinetic study performed in two cases showed plasma half lives of 7.9 and 13.2 hours, total body clearances of 425 and 298 ml/min.",[Acute verapamil poisoning. 6 cases. Review of the literature]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2262922/),h,13.2,260961,DB00661,Verapamil
,2262922,total body clearances,"A toxicokinetic study performed in two cases showed plasma half lives of 7.9 and 13.2 hours, total body clearances of 425 and 298 ml/min.",[Acute verapamil poisoning. 6 cases. Review of the literature]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2262922/),[ml] / [min],425,260962,DB00661,Verapamil
,2262922,total body clearances,"A toxicokinetic study performed in two cases showed plasma half lives of 7.9 and 13.2 hours, total body clearances of 425 and 298 ml/min.",[Acute verapamil poisoning. 6 cases. Review of the literature]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2262922/),[ml] / [min],298,260963,DB00661,Verapamil
less,3675692,detection limit,The sensitivity of the procedure (detection limit less than 1 ng/ml) is suitable for pharmacokinetic studies after therapeutic doses.,Determination of verapamil and norverapamil in human biological material. Investigation of plasma concentrations after oral administration of two different verapamil formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3675692/),[ng] / [ml],1,260964,DB00661,Verapamil
,19530072,apparent influx clearance,The apparent influx clearance of [(3)H]naloxone across the BBB was 0.305 mL/min/g brain.,Blood-brain barrier transport of naloxone does not involve P-glycoprotein-mediated efflux. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19530072/),[ml] / [brain·g·min],0.305,261249,DB00661,Verapamil
,19530072,apparent elimination half-life,[(3)H]naloxone was eliminated from the brain with an apparent elimination half-life of 15.1 min after microinjection into the parietal cortex area 2 regions of the rat brain.,Blood-brain barrier transport of naloxone does not involve P-glycoprotein-mediated efflux. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19530072/),min,15.1,261250,DB00661,Verapamil
,19530072,apparent efflux clearance,"The apparent efflux clearance of [(3)H]naloxone across the BBB was 0.152 mL/min/g brain, which was calculated from the elimination rate constant (4.79 x 10(-2) min(-1)) and the distribution volume in the brain (3.18 mL/g brain).",Blood-brain barrier transport of naloxone does not involve P-glycoprotein-mediated efflux. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19530072/),[ml] / [brain·g·min],0.152,261251,DB00661,Verapamil
,19530072,elimination rate constant,"The apparent efflux clearance of [(3)H]naloxone across the BBB was 0.152 mL/min/g brain, which was calculated from the elimination rate constant (4.79 x 10(-2) min(-1)) and the distribution volume in the brain (3.18 mL/g brain).",Blood-brain barrier transport of naloxone does not involve P-glycoprotein-mediated efflux. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19530072/),1/[min],4.79 x 10(-2),261252,DB00661,Verapamil
,19530072,distribution volume,"The apparent efflux clearance of [(3)H]naloxone across the BBB was 0.152 mL/min/g brain, which was calculated from the elimination rate constant (4.79 x 10(-2) min(-1)) and the distribution volume in the brain (3.18 mL/g brain).",Blood-brain barrier transport of naloxone does not involve P-glycoprotein-mediated efflux. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19530072/),[ml] / [brain·g],3.18,261253,DB00661,Verapamil
,6473899,B max,Specific binding of digoxin was documented in the renal slices with B max of 42.34 pmol/gr and Kd of 7.6 pmol/gr.,Characteristics of the digoxin-quinidine and digoxin-verapamil interactions in the rat kidney. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6473899/),[pM] / [gr],42.34,261949,DB00661,Verapamil
,6473899,Kd,Specific binding of digoxin was documented in the renal slices with B max of 42.34 pmol/gr and Kd of 7.6 pmol/gr.,Characteristics of the digoxin-quinidine and digoxin-verapamil interactions in the rat kidney. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6473899/),[pM] / [gr],7.6,261950,DB00661,Verapamil
,6473899,maximal concentration,Further increase in verapamil concentration resulted in additional reduction in digoxin uptake; the maximal concentration used (42 microM) caused 60% decrease in uptake (p less than 0.0001).,Characteristics of the digoxin-quinidine and digoxin-verapamil interactions in the rat kidney. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6473899/),μM,42,261951,DB00661,Verapamil
,19820718,hepatic,"After id administration of 3 mg/kg omeprazole, the hepatic and intestinal extraction ratio was 57.18%+/-2.73% and 54.94%+/-1.85%, while the value was 59.29%+/-3.14% and 54.20%+/-1.53% after given 6 mg/kg, respectively.",Involvement of cytochrome P450 3A4 and P-glycoprotein in first-pass intestinal extraction of omeprazole in rabbits. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820718/),%,57.18,263616,DB00661,Verapamil
,19820718,hepatic,"After id administration of 3 mg/kg omeprazole, the hepatic and intestinal extraction ratio was 57.18%+/-2.73% and 54.94%+/-1.85%, while the value was 59.29%+/-3.14% and 54.20%+/-1.53% after given 6 mg/kg, respectively.",Involvement of cytochrome P450 3A4 and P-glycoprotein in first-pass intestinal extraction of omeprazole in rabbits. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820718/),%,59.29,263617,DB00661,Verapamil
,19820718,intestinal extraction ratio,"After id administration of 3 mg/kg omeprazole, the hepatic and intestinal extraction ratio was 57.18%+/-2.73% and 54.94%+/-1.85%, while the value was 59.29%+/-3.14% and 54.20%+/-1.53% after given 6 mg/kg, respectively.",Involvement of cytochrome P450 3A4 and P-glycoprotein in first-pass intestinal extraction of omeprazole in rabbits. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820718/),%,54.94,263618,DB00661,Verapamil
,19820718,intestinal extraction ratio,"After id administration of 3 mg/kg omeprazole, the hepatic and intestinal extraction ratio was 57.18%+/-2.73% and 54.94%+/-1.85%, while the value was 59.29%+/-3.14% and 54.20%+/-1.53% after given 6 mg/kg, respectively.",Involvement of cytochrome P450 3A4 and P-glycoprotein in first-pass intestinal extraction of omeprazole in rabbits. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19820718/),%,54.20,263619,DB00661,Verapamil
,26316707,effective permeability coefficient (P eff),"The results showed that the effective permeability coefficient (P eff) and apparent permeability coefficient of ECH were 0.83×10(-6)-3.23×10(-6) cm/s and 2.99×10(-6)-9.86×10(-6) cm/s, respectively.",Enhancement of absorption and bioavailability of echinacoside by verapamil or clove oil. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26316707/),[cm] / [s],0.83×10(-,263748,DB00661,Verapamil
,26316707,apparent permeability coefficient,"The results showed that the effective permeability coefficient (P eff) and apparent permeability coefficient of ECH were 0.83×10(-6)-3.23×10(-6) cm/s and 2.99×10(-6)-9.86×10(-6) cm/s, respectively.",Enhancement of absorption and bioavailability of echinacoside by verapamil or clove oil. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26316707/),[cm] / [s],3,263749,DB00661,Verapamil
,26316707,apparent permeability coefficient,"The results showed that the effective permeability coefficient (P eff) and apparent permeability coefficient of ECH were 0.83×10(-6)-3.23×10(-6) cm/s and 2.99×10(-6)-9.86×10(-6) cm/s, respectively.",Enhancement of absorption and bioavailability of echinacoside by verapamil or clove oil. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26316707/),[cm] / [s],2.99×10(-6,263750,DB00661,Verapamil
,26316707,apparent permeability coefficient,"The results showed that the effective permeability coefficient (P eff) and apparent permeability coefficient of ECH were 0.83×10(-6)-3.23×10(-6) cm/s and 2.99×10(-6)-9.86×10(-6) cm/s, respectively.",Enhancement of absorption and bioavailability of echinacoside by verapamil or clove oil. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26316707/),[cm] / [s],9.86×10(-6),263751,DB00661,Verapamil
,21757611,efflux ratio,"Two P-glycoprotein (P-gp) inhibitors, verapamil and cyclosporine A, substantially decreased the efflux ratio of Rh2s from 28.5 to 1.0 and 1.2, respectively, in Caco-2 cells.",Enhancement of oral bioavailability of 20(S)-ginsenoside Rh2 through improved understanding of its absorption and efflux mechanisms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21757611/),,28.5,264320,DB00661,Verapamil
,21757611,efflux ratio,"Two P-glycoprotein (P-gp) inhibitors, verapamil and cyclosporine A, substantially decreased the efflux ratio of Rh2s from 28.5 to 1.0 and 1.2, respectively, in Caco-2 cells.",Enhancement of oral bioavailability of 20(S)-ginsenoside Rh2 through improved understanding of its absorption and efflux mechanisms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21757611/),,1.0,264321,DB00661,Verapamil
,21757611,efflux ratio,"Two P-glycoprotein (P-gp) inhibitors, verapamil and cyclosporine A, substantially decreased the efflux ratio of Rh2s from 28.5 to 1.0 and 1.2, respectively, in Caco-2 cells.",Enhancement of oral bioavailability of 20(S)-ginsenoside Rh2 through improved understanding of its absorption and efflux mechanisms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21757611/),,1.2,264322,DB00661,Verapamil
,21757611,oral bioavailability,"In the A/J mice, the oral bioavailability of Rh2s (0.94% at 5 mg/kg and 0.52% at 20 mg/kg) was substantially increased by P-gp inhibitor to 33.18 and 27.14%, respectively.",Enhancement of oral bioavailability of 20(S)-ginsenoside Rh2 through improved understanding of its absorption and efflux mechanisms. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21757611/),%,0.94,264323,DB00661,Verapamil
,21757611,oral bioavailability,"In the A/J mice, the oral bioavailability of Rh2s (0.94% at 5 mg/kg and 0.52% at 20 mg/kg) was substantially increased by P-gp inhibitor to 33.18 and 27.14%, respectively.",Enhancement of oral bioavailability of 20(S)-ginsenoside Rh2 through improved understanding of its absorption and efflux mechanisms. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21757611/),%,0.52,264324,DB00661,Verapamil
,21757611,oral bioavailability,"In the A/J mice, the oral bioavailability of Rh2s (0.94% at 5 mg/kg and 0.52% at 20 mg/kg) was substantially increased by P-gp inhibitor to 33.18 and 27.14%, respectively.",Enhancement of oral bioavailability of 20(S)-ginsenoside Rh2 through improved understanding of its absorption and efflux mechanisms. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21757611/),%,33.18,264325,DB00661,Verapamil
,21757611,oral bioavailability,"In the A/J mice, the oral bioavailability of Rh2s (0.94% at 5 mg/kg and 0.52% at 20 mg/kg) was substantially increased by P-gp inhibitor to 33.18 and 27.14%, respectively.",Enhancement of oral bioavailability of 20(S)-ginsenoside Rh2 through improved understanding of its absorption and efflux mechanisms. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21757611/),%,27.14,264326,DB00661,Verapamil
,16765142,volume of distribution,"Mean volume of distribution values for 5 young healthy volunteers (age range, 21-27 years) and 5 elderly healthy volunteers (age range, 59-68 years) were 0.62+/-0.10 and 0.73+/-0.07, respectively (P=.03).",Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16765142/),,0.62,264995,DB00661,Verapamil
,16765142,volume of distribution,"Mean volume of distribution values for 5 young healthy volunteers (age range, 21-27 years) and 5 elderly healthy volunteers (age range, 59-68 years) were 0.62+/-0.10 and 0.73+/-0.07, respectively (P=.03).",Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16765142/),,0.73,264996,DB00661,Verapamil
,16765142,activity index,The activity index of P-gp activity in CD3-positive leukocytes was 2.88+/-0.77 in young volunteers and 1.76+/-0.58 in elderly volunteers (P=.02).,Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16765142/),,2.88,264997,DB00661,Verapamil
,16765142,activity index,The activity index of P-gp activity in CD3-positive leukocytes was 2.88+/-0.77 in young volunteers and 1.76+/-0.58 in elderly volunteers (P=.02).,Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16765142/),,1.76,264998,DB00661,Verapamil
,9190842,apparent oral clearances,"After separate administration, the apparent oral clearances of both enantiomers were similar [(R), 15.1 +/- 9.9 liters/min; (S), 11.0 +/- 6.0 liters/min], indicating that gallopamil first-pass metabolism is not stereoselective.",Pharmacokinetics and pharmacodynamics of the enantiomers of gallopamil. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9190842/),[l] / [min],15.1,265693,DB00661,Verapamil
,9190842,apparent oral clearances,"After separate administration, the apparent oral clearances of both enantiomers were similar [(R), 15.1 +/- 9.9 liters/min; (S), 11.0 +/- 6.0 liters/min], indicating that gallopamil first-pass metabolism is not stereoselective.",Pharmacokinetics and pharmacodynamics of the enantiomers of gallopamil. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9190842/),[l] / [min],11.0,265694,DB00661,Verapamil
,9190842,apparent oral clearance,"After coadministration, the apparent oral clearance of each enantiomers decreased [(R), 5.9 +/- 2.8 liters/min; (S), 5.8 +/- 2.66 liters/min], suggesting that a partial saturation of first-pass metabolism occurs because the dose was twice as high than for the single enantiomers.",Pharmacokinetics and pharmacodynamics of the enantiomers of gallopamil. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9190842/),[l] / [min],5.9,265695,DB00661,Verapamil
,9190842,apparent oral clearance,"After coadministration, the apparent oral clearance of each enantiomers decreased [(R), 5.9 +/- 2.8 liters/min; (S), 5.8 +/- 2.66 liters/min], suggesting that a partial saturation of first-pass metabolism occurs because the dose was twice as high than for the single enantiomers.",Pharmacokinetics and pharmacodynamics of the enantiomers of gallopamil. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9190842/),[l] / [min],5.8,265696,DB00661,Verapamil
,27876352,oral bioavailability (F),The oral bioavailability (F) of VER in rats was calculated as 0.02 ± 0.01 and was significantly increased to 0.45 ± 0.24 by the pre-treatment with ABT.,Quantitative analysis of pharmacokinetic profiles of verapamil and drug-drug interactions induced by a CYP inhibitor using a stable isotope-labeled compound. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27876352/),,0.02,266528,DB00661,Verapamil
,27876352,oral bioavailability (F),The oral bioavailability (F) of VER in rats was calculated as 0.02 ± 0.01 and was significantly increased to 0.45 ± 0.24 by the pre-treatment with ABT.,Quantitative analysis of pharmacokinetic profiles of verapamil and drug-drug interactions induced by a CYP inhibitor using a stable isotope-labeled compound. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27876352/),,0.45,266529,DB00661,Verapamil
,30096386,Ki,"Among the CV drugs screened, simvastatin and lovastatin were shown to inhibit the liver metabolism of sinomenine with Ki values of 13.00 and 25.83 μM, respectively.",Co-administration with simvastatin or lovastatin alters the pharmacokinetic profile of sinomenine in rats through cytochrome P450-mediated pathways. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30096386/),μM,13.00,270253,DB00661,Verapamil
,30096386,Ki,"Among the CV drugs screened, simvastatin and lovastatin were shown to inhibit the liver metabolism of sinomenine with Ki values of 13.00 and 25.83 μM, respectively.",Co-administration with simvastatin or lovastatin alters the pharmacokinetic profile of sinomenine in rats through cytochrome P450-mediated pathways. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30096386/),μM,25.83,270254,DB00661,Verapamil
,33962179,flow rate,"The isocratic mobile phase composed of acetonitrile: trifluoroacetic acid: 10 mM ammonium formate (100 : 0.1 : 0.1, v/v/v) at a flow rate of 0.3 mL/min was applied.",Rapid and sensitive LC-MS/MS method for the enantioanalysis of verapamil in rat plasma using superficially porous silica isopropyl-cyclofructan 6 chiral stationary phase after SPE: Application to a stereoselective pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33962179/),[ml] / [min],0.3,272552,DB00661,Verapamil
,23999035,bioavailability,The aim of the present study was to develop and characterize chitosan mucoadhesive microspheres of verapamil hydrochloride (VRP) for intranasal delivery as an alternative to oral VRP which suffers low bioavailability (20%) due to extensive first pass effect.,Bioavailability enhancement of verapamil HCl via intranasal chitosan microspheres. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23999035/),%,20,272960,DB00661,Verapamil
,23999035,bioavailability,The bioavailability study demonstrated that the nasal microspheres exhibited a significantly higher bioavailability (58.6%) than nasal solution of VRP (47.8%) and oral VRP solution (13%).,Bioavailability enhancement of verapamil HCl via intranasal chitosan microspheres. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23999035/),%,58.6,272961,DB00661,Verapamil
,23999035,bioavailability,The bioavailability study demonstrated that the nasal microspheres exhibited a significantly higher bioavailability (58.6%) than nasal solution of VRP (47.8%) and oral VRP solution (13%).,Bioavailability enhancement of verapamil HCl via intranasal chitosan microspheres. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23999035/),%,47.8,272962,DB00661,Verapamil
,23999035,bioavailability,The bioavailability study demonstrated that the nasal microspheres exhibited a significantly higher bioavailability (58.6%) than nasal solution of VRP (47.8%) and oral VRP solution (13%).,Bioavailability enhancement of verapamil HCl via intranasal chitosan microspheres. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23999035/),%,13,272963,DB00661,Verapamil
,2735930,maximal concentration,"At this dose, the maximal concentration in plasma was 24 microM, with rapid elimination such that plasma concentrations reported to modulate resistance in vitro (approximately 5-10 microM) were maintained for less than 60 min.",Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735930/),μM,24,273488,DB00661,Verapamil
,2735930,T1/2,"In small intestine, 8-fold greater levels of VCR were determined 24 hr after VCR administration, and this was associated with in increase in T1/2 for elimination from 350 to 913 min.",Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735930/),min,350,273489,DB00661,Verapamil
,2735930,T1/2,"In small intestine, 8-fold greater levels of VCR were determined 24 hr after VCR administration, and this was associated with in increase in T1/2 for elimination from 350 to 913 min.",Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735930/),min,91,273490,DB00661,Verapamil
,2735930,T1/2,"In small intestine, 8-fold greater levels of VCR were determined 24 hr after VCR administration, and this was associated with in increase in T1/2 for elimination from 350 to 913 min.",Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2735930/),min,3,273491,DB00661,Verapamil
